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ABSTRACT 
This thesis describes pharmacogenetic studies of CYP2D6, CYP2CI9, and CYPIA2, 
cytochrome P450 enzymes involved in the metabolism of antipsychotics and antidepressants. 
The hypotheses are that low enzyme activity is associated with a high incidence of adverse 
effects of metabolised drug, while high enzyme activity is associated with therapeutic 
resistance. I developed a novel long-PCR assay for the identification of CYP2D6 ultrarapid 
metabolisers (UMs). I investigated CYP2D6 genotype-phenotype correlations in French 
subjects and in elderly British Caucasians, and found that genotyping for CYP2D6*6 was 
necessary to identify all poor metabolisers (PMs) in French Caucasians, and that the elderly 
British subjects had a slightly lower mean CYP2D6 activity than the values in younger 
Caucasian studies. The association between CYP2D6 UM status and therapeutic resistance to 
typical antipsychotics (TAs) and between number of functional CYP2D6 genes and adverse 
effects of TAs was investigated in case-control studies, which showed the surprising finding of 
a trend for an association between response to TAs and UM status, and between number of 
functional CYP2D6 genes and tardive dyskinesia. This may reflect the relatively high 
proportion of subjects prescribed haloperidol in these studies. Conversely, a study in a sib pair 
and a twin pair was suggestive of an association between CYP2D6 poor or intermediate (IM) 
metaboliser status and a -high incidence of adverse effects, and the conversion of a genotypic 
IM status to a phenotypic PM status through the prescription of thioridazine. The association 
between CYP2D6 and CYP2C19 gene dosage and response to tricyclic antidepressants was 
investigated: I did not find any CYP2D6 UMs amongst the treatment-refractory subjects, but 
found a significant association between CYP2D6 inhibition by concomitant medication and 
response and adverse effects, and between CYP2C19 gene dosage and clinical response. I 
performed mutation screening of the CYPIA2 5' flanking region (identifying three novel SNPs) 
and functional characterisation of two of these, as well as sequencing of a BAC clone that 
generated novel 5' flanking CYPIA2 sequence, including the identification of possible 
polymorphic sites. I investigated the association between CYPIA2 SNPs and response to 
clozapine, and found an association between female gender and response, and a trend for an 
association with one of the 5' flanking SNPs that I had characterised. Finally, in a CYPIA2 
null-mouse study, I demonstrated that CYPIA2 is the major determinant of clozapine 
clearance, and the results suggested that individuals with a relatively low CYPIA2 activity 
might well be more susceptible to adverse effects of clozapine including sedation and seizures. 
In conclusion, the activity of these polymorphic cytochromes would appear to influence the 
clinical response to metabolised drugs, but further larger prospective studies in this field are 
warranted, including the study of interactions between cytochrome P450 genotype and 
pharmacodyamic genetic factors (eg drug transporters and receptors), as well as open system 
pharmacogenornic approaches. 
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for his assistance with scanning in figures. And last, but not least, I would like to thank 
my supervisors: Dr Ai Makoff, Dr DA Collier, and Prof RW Kerwin. 
21 
STATEMENT CONCERNING CONJOINT WORK 
CHAPTER THREE: PHARMACOGENETIC ASSOCIATION STUDIES 
3.1 Genotype-phenotype correlation studies 
3.1.2 French Caucasians 
I performed all the DNA extractions and genotyping for CYP2D6 alleles *3-5 for this 
study, in addition to developing the novel long-PCR assay for the identification of 
CYP2D6 ultrarapid metabolisers. For the latter, I received some assistance with primer 
design (from Alan G Gough), but developed the protocol and optimised the conditions 
unassisted, validating the assay with samples provided by Maýa-Liisa Dahl (Sweden). 
The dextromethorphan phenotyping was performed in France by the collaborating 
group (Marc-Antoine Croeq, Luc-Andr6 Granier, and Jean-Paul Macher). Kopal 
Tandon performed CYP2D6*6 genotyping on the two individuals with genotype- 
phemnotype discrepancy, under my supervision. I performed all the data analysis. 
Michael Gill was involved in a supervisory capacity in the early stages of this project, 
and latterly Robert W Kerwin, Andrew J Makoff, and David A Collier (RWK, AJM, 
and DAC). 
3.1.3 UK Caucasians 
I assisted in the design and collection of this sample, consenting the volunteers, 
collecting relevant clinical details, and scoring the General Health Questionnaire. I 
performed DNA 
3.2.3 CYP2D6 UM status and failure to respond to TAs 
I performed all the genotyping for this study, receiving only advice from Christoph 
Sachse regarding the conditions extractions, genotyping for CYP2D6 alleles *3-5 and 
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CYP2D6 gene amplification. Kopal Tandon performed the CYP2D6*2 genotyping and 
(on one sample) the CYP2D6*6 genotyping under my supervision. The debrisoquine 
phenotyping was performed by Mahesh Patel at St Bartholomew's Hospital. I analysed 
all the data. M4rk Kinirons and Vivien Maskrey from the Clinical Age Research Unit at 
King's College London were also involved in sample collection. 
for one assay (the CYP2D6*4 x2 assay). Janet Munro, Padraig Wright and Shubalade 
Smith were involved in collection of the clinical sample and in clinical ratings. Pak C 
Sham provided some statistical advice. 
3.2.4 Number of functional CYP2D6 genes and adverse effects of TAs 
3.2.4.1 Sib pair and twin study 
I performed clinical interviews, administered debrisoquine for phenotyping, and 
performed the genotyping for CYP2D6 alleles *3-5. Maria Arranz assisted in the early 
stages of optimising the CYP2D6*4 assay. Kopal Tandon performed the CYP2D6*2 
and CYP2D6*6 genotyping under my supervision. The phenotyping was again 
performed by Mahesh Patel. I analysed the data, identified genotype-phenotype 
discrepancies, and designed and supervised the subsequent work. Mark Taylor was 
involved in sample collection, and Robin M Murray in a supervisory capacity in 
addition to my three supervisors (RWK, AJM, and DAC). 
3.2.4.2 Case-control study 
I performed CYP2D6*3-5 genotyping, CYP2D6 gene amplification identification, and 
the data analysis, with some assistance in the statistical analysis from Jing Hua Zhao. 
Padraig Wright, Shubalade Smith, and Janet Munro were all involved in sample 
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collection, and Robin M Murray in a supervisory capacity in addition to RWK, AJM, 
and DAC. 
3.3 Tricyclic antidepressants (TCAs) and CYP2D6 and CYP2C19 
I collected the clinical samples, performed the clinical ratings (under the supervision of 
Stuart Checkley), and the genotyping for CYP2D6 and CYP2C19 variants in this study, 
other than the CYP2D6*2 and CYP2D6*6 genotyping, which was done by Kopal 
Tandon. The phenotyping was performed by Mahesh Patel (other than the phenotyping 
of two samples, which was performed by Gunnel Tybring's laboratory in Sweden) and 
I performed all the data analysis, with some statistical advice from Jing Hua Zhao. 
3.4 Clozapine and CYPlA2 
I developed the PCR-RFLP assay for the T-3591G SNP (which I had characterised, see 
below), and genotyped for this variant in the sample. Eva Tsapakis performed the 
CYPIA2 C-164A PCR-RFLP assay under my supervision. I conducted the data 
analysis, with some statistical assistance from Jing Hua Zhao. Janet Munro was 
involved in the sample collection. 
CHAPTER FOUR: CYPlA2 NOVEL MUTATION SCREENING AND 
FUNCTIONAL CHARACTERISATION 
I performed the genome walking, PCR sequencing, PCR-RFLP analysis, direct 
sequencing from a BAC clone, cloning of PCR products, site-directed mutagenesis, and 
transient transfections. Andrea Sapone assisted me in the early stages of the PCR 
sequencing, and Hani Zaher and Guillermo Elizondo were both involved in the 
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generation of the BAC clone. Catherine Bryant and Janet Munro were involved in the 
collection of clinical samples, and Frank J Gonzalez and Linda Quattrochi, were 
involved in a supervisory capacity. 
CHAPTER FIVE: CLOZAPINE PHARMACOKINETICS AND 
PHARMACODYNAMICS STUDIED WITH CYPlA2-NULL MICE 
I performed the pharmacokinetic study in the mice, optimising the protocol so that the 
clozapine dose and the timing of blood sampling was such that meaningful data would 
result. Takafami Sakai and Hani Zaher taught me how to handle the mice, Michael W 
Jann performed the HPLC analysis, Kim Wolff and Jing Hua Zhao gave advice 
regarding data analysis, and Frank J Gonzalez was involved in a supervisory capacity. 
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February 4,2000 
TO WHOM IT MAY CONCERN: 
Dr. Katherine J. Aitchison spent nine months in my laboratory in 1998-1999, performing 
studies on CYP I A2. I was her direct supervisor, but her work was largely carried out 
independently. Her project was developed from her own ideas and used a number of 
resources available in my laboratory. Dr. Aitchison's research involved a number of 
techniques. These included PCR sequencing, genotyping using a PCR-RFLP assay that 
she developed, direct sequencing from a bacterial artificial chromosome (BAC) clone, 
and pharmacokinetic studies with clozapine using wild-type and CYP I A2-null mice. It 
should be noted that she performed all of the above techniques herself, having been 
assisted in the early stages of the PCR sequencing by Dr. Andrea Sapone, and having 
been taught how to handle the CYPIA2-null mice by Drs. Hani Zaher and Takafurni 
Sakai. Drs. Hani Zaher and Guillermo Elizondo performed the initial stages of screening 
a human BAC library in order to identify a CYPIA2-positive BAC clone and Dr. 
Aitchison confirmed the presence of the CYPIA2 gene by PCR and by direct sequencing 
of the BAC clone. During her studies in the NCI, Dr. Aitchison demonstrated a high level 
of skill in the laboratory and a keen insight into areas of research that am of great medical 
importance in drug therapy. I am convinced that she will be highly successful as an 
independent investigator at her current institution. 
Sincerely. 
Frank J. Goýjz, Ph. D. 
Chief, Laboratory of Metabolism 
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To Whom It May Concem: 
Dr Katherine J. Aitchison spent 4 months in my laboratory* (from 
March 1999 to July 1999) performing studies on CYPIA2. ý Dr., 
Aitchiso 
,n came 
to my laboratory to conduct studies of genetic 
mutations that 'she identified in the 5'flanking region of the human 
CYPlA2 gene. These studies, comprised' mutation characterization 
(including cloning), genotyping using a PCR-RFLP technique, site- 
directed mutagenesis, and functional studies' using transient 
transfections. She performed all of these techniques herself, 
including optimization of' conditions where nec __ ry essa . The wild type construct (pLlA2N, containing the Nflanking"iequence of 
CYPIA2 proximal to a luciferase reporter gene) used for the - 
transient transfections had already been created (Postlind et al., 
1993), but site-directed mutagenesis was employed by, Dr, Aitchison 
to create the mutant constructs. Sequencing was ý periormed: by the 
Core Sequencing facility - at the University of Colorado Health 
Sciences Center. I supervised Dr Aitchison's 'expirim'ental work 
during her time in, myý laboratory; however, for the most part, Dr. 
Aitchison worked. independently. Fwas quite impressed by how 
quickly she learned and implemented the'advanced molecular 
techniques required for the success of this project. Her productivity 
during this relatively short time in my laboratory set an excellent 
standard for my lab personnel. 
Sincerely, 
Linda C. Quattrochi, Ph. D. 
Associate Professor, Medicine 
University of Colorado Health 'S' iý-n-ceis", ý ', Ce , nterý 
Denver, Colorado 80262 
The University of Colorado Health Sciences Center is votninitted to, equal cýpornuiity and affinnative action 
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ABBREVIATIONS 
AIMS Abnormal Involuntary Movements Scale 
ANCOVA Analysis of covariance 
bd twice daily 
BNF British National Formulary 
bp base pair 
BSA Bovine serum albumin 
CARU Clinical Age Research Unit 
CG Circle Grow (agar) 
CYPIA2 cytochrome P450 IA2 
CYP2C19 cytochrome P450 2C19 
CYP2D6 cytochrome P450 2D6 
dATP deoxyadenosine 5'-triphosphate 
dCTP deoxycytosine 5'-triphosphate 
df degrees of freedom 
DHPLC denaturing high performance liquid chromatography 
dGTP deoxyguanidine 5'-triphosphate 
df degrees of freedom 
DIP drug-induced parkinsonism 
DMF demthylformamide 
DMSO dimethylsulphoxide 
DNA deoxyribonucleic acid 
dNTPs deoxynucleotide triphosphates 
DSM-IIIR Diagnostic and Statistical Manual of Mental Disorders, third edition, 
revised 
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dTTP deoxythymidine 5'-triphosphate 
EDTA ethylenediamine teta-acetic acid 
EM extensive metaboliser 
GAS Global Assessment Scale 
GHQ General Health Questionnaire 
GST Glutathione S-transferase 
HGMP Human Genome Mapping Project 
ICD-10 International Classification of Diseases-10, Classification of Mental and 
Behavioural Disorders 
IM inten-nediate metaboliser 
IPTG isopropyl-P-D-thiogalactoside 
LB Luria-Bertani (medium/agar) 
Min minute(s) 
MR metabolic ratio 
NAT2 N-acetyltransferase 2 
NIH National Institutes of Health 
PCR polymerase chain reaction 
PM poor metaboliser 
prn as required 
qds four times daily 
RDC Research Diagnostic Criteria 
RE restriction endonuclease 
RFLP restriction fragment length polymorphism 
RNA ribonucleic acid 
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RT room temperature 
sd standard deviation 
SNP single nucleotide polymorphism 
SPSS Statistical Package for the Social Sciences 
TA typical antipsychotic 
TCA tricyclic antidepressant 
TCDD 2,3,7,8- tetrachlorodibenzo-P-dioxin 
TBE Tris-borate EDTA 
tds threelimes daily 
TE Tris-EDTA buffer 
TEMED N, NN', N'-tetraethylethylenediamine 
Tris Tris-(hydroxyrnethyl)aminomethane 
TD tardive dyskinesia 
UDPGT UDPglucuronyltransferase 
Um ultrarapid metaboliser 
UV ultraviolet (light) 
WRSP Webster's Rating Scale for parkinsonism 
X-Gal 5-bromo-4-chloro-3-indolyl-p-D-galactoside in DMF 
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CHAPTER ONE 
PHARMACOGENETICS OF PSYCHOTROPIC DRUG METABOLISM 
1.1 Definition of pharmacogenetics 
The first major psychotropic agents to be introduced for the treatment of psychiatric 
disorders were lithium (Cade, 1949) and chlorpromazine (Delay et al., 1952). Soon 
after their introduction, it became evident that there was marked interindividual 
variation in therapeutic doses of these, and although this was likely to be due to a 
complex interplay of multiple factors, it was proposed that genetic factors were 
partially responsible for this interindividual variation (Motulsky, 1957; Kalow, 1992). 
The study of the factors that were genetic in origin was defined as pharmacogenetics by 
Vogel (1959). The initial definition was relatively narrow: the study of heritable 
differences in the metabolism and activity of exogenous agents such as drugs or 
environmental toxins. More recently, this has been understood as comprising the study 
of variations in the coding or regulatory regions of genes that lead to interindividual 
variability in drug effect (efficacy) or in adverse effect profile (toxicity), but can also 
include benign differences such as the ability to taste certain chemicals (e. g. 
phenylthiourea, Kalow, 1992). Pharmacogenetics therefore includes the study of both 
pharmacodynamic genetic factors (affecting drug response at the site of action, i. e. 
target organ, e. g. at the level of receptor binding), and pharmacokinetic genetic factors 
(affecting drug absorption, metabolism, and excretion, e. g. cytochrome P450 enzymes 
in the liver) (Aitchison et al., 2000c; Masellis et al., 2000). 
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There arc various clinical, bchavioural, or physiological indicators of drug response in 
psychiatry at the level of the target organ, such as changes in severity of clinical 
symptoms as measured by standardiscd rating scales (e. g. the Hamilton Depression 
Rating Scale, Hamilton, 1967), changes in neuropsychologicAl measures (e. g. deficits 
in working memory), or changes in endophenotypes, such as physiological gating 
mechanisms (e. g. pre-pulse inhibition). In animal studies, changes in b6havioural 
responses or physiological gating mechanisms may be used. 
In the US, in 1994, adverse drug reactions (ADRs) were between the fourth and sixth 
leading cause of death (ahead of pneumonia and diabetes mellitus), causing 106,000 
deaths amongst hospitalised patients (Lazarou et al., 1998). It is therefore important 
that advances in the field of pharmacogenetics are made in order to reduce the 
morbidity and mortality associated with ADRs. ADRs are also associated with 
prolongation of hospital stay (Chou et al., 2000). Advances in pharmacogenetics and in 
the application of knowledge gained should have significant health economic 
consequences. 
1.2 Evidence for heritability of drug effect 
The first indication of heritability of drug effect was provided by Angst (1961), who 
observed concordance of response to imipramine among relative pairs with depression. 
This was soon followed by a more detailed report by Pare and colleagues (Pare et al., 
1962). They examined the records of 170 patients who had been treated with 
antidepressant drugs (imipramine or a monoamine oxidase inhibitor (MA01)), mostly 
in the context of controlled trials. Twelve first-degree relatives had also been treated 
with a drug from one of these two classes. Treatment effects were concordant in all 
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proband-relative pairs (for response in 5 and non-response in 7). The authors also 
observed a tendency for the same patient to respond (or not respond) to a drug of the 
same class on repeated administrations (13 out of 17 patients consistent for MAOI and 
7 out of 9 consistent for imipramine). 
In 1967, Sj6qvist and colleagues observed a very large (36-fold) variation in the steady- 
state plasma concentrations of the tricyclic antidepressant (TCA) desipramine in a 
small group of patients on a standard dose (Sj6qvist et al., 1967). The importance of 
genetic factors in determining the steady-state levels of the TCA nortriptyline was then 
shown in twin and family studies (Alexanderson et al., 1969,1973; Asberg et al., 
1971a), and was similarly shown in a twin study of the kinetics of amobarbital 
(Endrenyi et al., 1976). 
in a -new series of patients, Pare and Mack (1971) again observed concordance of 
response to antidepressants of the same class among first-degree relative pairs (10 out 
of 12 pairs). O'Reilly et al. (1994) reported a family multiply affected with major 
depressive disorder, four of whom did not respond to either TCAs or various new 
generation antidepressants, but did subsequently respond to the monoamine oxidase 
inhibitor, tranylcypromine. 
Franchini et al. (1998) analysed 45 pairs of first-degree relatives consisting of a 
proband (with recurrent major depression or bipolar affective disorder) who had twice 
responded to fluvoxamine treatment of major depression and a relative who had been 
treated with the same drug. Thirty relative pairs (67%) were concordant for good 
response to fluvoxamine as compared to 50% expected by chance, with an excess of 
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bipolar patients arnong the relatives of subjects concordant for fluvoxamine response. 
The same group also described evidence for mendelian (oligogenic) mode of 
transmission of bipolar disorder in families with good fluvoxamine response (Serretti et 
al., 1998). 
A recent study of trcatrncnt-rcsistant depression in which data on various possible 
factors influencing response was collected noted that the only covariatc that reached 
significance in terms of influencing whether an individual was responsive or resistant 
to antidepressant therapy was family history of affcctive disorder (Smith, personal 
communication). 
With respect to antipsychotic response, Vojvoda et al. (1996) reported a set of 
monozygotic twins, each with a DSM-IV diagnosis of schizophrenia, who were 
concordant for treatment-refractoriness to various typical antipsychotic agents, but who 
had a positive response to clozapine. Furthermore, a. heritable component to 
antipsychotic response has been demonstrated by studies with mouse strains (Dains et 
al., 1996), and indicated by a human family study (Sautter et al., 1993), and studies 
indicating differential response to antipsychotics in different ethnic groups 
(Frackiewicz et al., 1997; Aitchison et al, 2000c). 
There are a series of studies that have examined the role of genetic factors in response 
to lithium (for reviews see Alda, 1999; Alda, in press). Several (Mendlewicz el al., 
1973; Smeraldi et al., 1984; Grof et al., 1994), but not all (Coryell et al., 2000), studies 
have found that a positive family history of bipolar disorder is associated with lithium 
response. Other studies have reported familial concordance of lithium response 
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(McKnew et al., 1981; Grof et al., 2000). Smcraldi et al. (1984) found evidence for a 
major gene effect in the families of responders, which was shown to be consistent with 
an autosomal recessive mode of inheritance by Alda and colleagues (1994,1997). 
There is, however, a relative paucity of studies investigating the heritability of drug 
response, and there are several reasons for this (Aitchison & Gill, 2002). Firstly, the 
phenotype to be measured is a transient, temporary trait, the response or adverse effects 
being elicited only in the presence of the drug. This means that it may well be difficult 
to find e. g. other family members or co-twins who are also taking the drug in question 
at the same time as the proband being investigated. If a family member has taken the 
same drug at some time in the past, it may be possible to perform a retrospective 
clinical assessment of their response or adverse effects, but this may be subject to recall 
bias or inaccuracy, etc. Secondly, the range of psychotropic medication available on 
the market has changed radically over the last 50 years, and continues to develop 
rapidly, so that what was available to a clinician treating a family member 30 years ago 
may be very different from the range of choices now available. Of note, the drug in the 
study of O'Reilly and colleagues (1994) was tranylcypromine, which due to its 
stimulant action is now regarded as the most hazardous of the monoamine oxidase 
inhibitors, and is rarely prescribed in the UK. Similarly, even if there are two or more 
family members simultaneously affected by a particular psychiatric disorder, the 
variety of available drugs for the treatment of psychiatric disorders means that the 
affected members may be prescribed different drugs, especially if they are 
geographically separated. Thirdly, in a study of families multiply affected with 
psychiatric illness, the precise disorder may vary amongst different family members, 
due to the polygenic nature of complex diseases, and the phenomena of incomplete 
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penetrance (Farmer et al., 1987) and pleiotropy. Pleiotropy refers to genes segregating 
within a family, but apparently causing different phenotypes (e. g. bipolar disorder, 
depression, and schizophrenia segregating in the same family). These factors may 
clearly lead to variation in the psychotropic agents being employed. Fourthly, 
polypharmacy, i. e. the use of more than one psychotroPic agent simultaneously (e. g. a 
mood stabiliser plus an antidepressant), is common these days, and this may lead to 
further difficulties in finding family members who are being treated only with a 
particular drug. 
As good prospective data are hard to collect for the reasons outlined above, many 
phannacogenetic studies to date have relied on retrospective collection of data 
regarding treatment history (including response and adverse effect profile to all current 
and previous agents used). From these, there is now a body of evidence indicating that 
genetic variation in activity of drug-metabolising enzymes has therapeutic and 
toxicological consequences (Bertilsson & Dahl, 1996; Bertilsson & Dahl, 1997; 
Ingelman-Sundberg et al., 1999; Kalow, 1999, Wolf et al., 2000; Ozdemir et al., 2001; 
Kirchheiner et al., 2001). Papers reviewed in the above are discussed in more detail in 
relevant sections of this thesis. 
1.3 Phase I and phase 11 drug metabolism 
Hepatic drug metabolism usually comprises two phases: phase I (oxidative 
metabolism . ), and phase 11 (conjugation). In phase Ia metabolite with a functional 
group (e. g. a hydroxyl group) is formed, enabling the conjugation reaction in phase II 
to occur. The phase I reactions are mediated principally by the Wochrome P450 
(CYP) enzymes, as well as others including the flavin monooxygenases (FMOs). 
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Several drugs (e. g. morphine) undergo direct phase II metabolism. Examples of phase 
II conjugation reactions include the addition of a glucuronic acid (by 
UDPglucuronyltransferases), a glutathione group (by glutathione S-transferases), or 
acetate (by N-acetyltransferases), or sulphate (by sulphotransferases). The phase I 
reactions in general take place in the endoplasmic reticulum, whilst most phase II 
reactions take place in the cytosol. This thesis focuses on phase I enzymes, notably 
three of the cytochrome P450s: CYP2D6, CYP2CI9, and CYPlA2. I have also 
included CYP3A isoforms in this Introduction, as these are the most abundant hepatic 
isoforms, and hence impact upon metabolism through other routes, and other CYP2C 
isoforms, as the genes encoding these are in the same gene cluster as the gene encoding 
CYP2CI9. 
1.4 Cytochrome P450s 
1.4.1 Characteristics of the superfamily 
The CYP enzymes are haem-thiolate membrane-bound proteins (Omura & Sato, 
1964a). The haern group is a protoporphyrin IX molecule and an iron atom, and acts as 
the prosthetic group for the CYP apoprotein. When the haern iron is in its reduced 
form (Fe 2+ ) and bound to carbon monoxide, and subjected to spectroscopy, maximal 
light absorption is seen at 450 mn - this feature is the basis for the P450 name and can 
also be used to measure the total CYP content of a given tissue in solution (Omura & 
Sato; 1964a, 1964b). 
CYP nomenclature is based on degree of amino acid homology between different 
members of this superfamily of enzymes (Nelson et al., 1996; Daly et al., 1996a; see 
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also websites: httD: //www. imm. ki. se/CYPalleles. 
http: //www. dmelson. utmem. edu/human. p450s .A CYP gene is named starting with 
the italicised CYP, followed by an Arabic number signifying the P450 family, an upper 
case letter signifying the gene subfamily, and another Arabic number for the individual 
gene (e. g. CYP2D6). The same sequence of letters and numbers is used in non- 
italicised form to represent the corresponding gene products (i. e. mRNA, protein, etc. ). 
A P450 protein sequence from one gene family is defined as having: 5 40% amino acid 
identity to a P450 protein from any other family, although there are exceptions to this 
(Nelson et al., 1993). In a given family, there is >40% amino acid sequence homology 
between the members. 
The extent of metabolism of a drug by a given CYP isoform is determined by both the 
affinity of the isoform for the substrate, and the relative abundance of the particular 
CYP in comparison to the other CYP isoforms in the tissue concerned. Shimada and 
colleagues (1994) estimated the relative content of various CYPs in human liver (Table 
1-1), with 72% of the total CYP content being accounted for by the 7 isoforms or 
subfamilies studied. From this it can be seen that CYP2D6, for example, is a relatively 
low-abundance CYP in the liver. However, it has a relatively high affinity for a wide 
variety of substrates (both drugs and toxins, see below). By contrast, CYP3A is 
relatively high in abundance, but has a lower affinity for some of the CYP2D6 
substrates. CYP2D6 therefore often functions as a high affinity, low capacity enzyme, 
which is more important at low substrate concentrations, while with higher doses or 
multiple dosing, enzymes such as CYP3A4, which is high capacity and may be low 
affinity, may play a more important role (Aitchison et aL, 2000c; Brosen & Gram, 
1998). 
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However, the study of Shimada and colleagues (1994) omitted some CYPs (e. g 
CYPIAI), and, moreover, further CYPs have since been identified. These are likely to 
account for the remaining 28% unaccounted for in the original study. 
Table 1.1 Relative content of individual CYP isoforms determined 
immunohistochemically in relation to total CYP content in human liver microsomes 
(values are means ± S. D. from 30 Japanese and 30 Caucasian liver samples, from 
Shimada et al., 1994) 
CYP isoform % of total CYP 
CYP I A2 12.7 ± 6.2 
CYP2A6 4.0 ± 3.2 
CYP2B6 0.2 ± 0.3 
CYP2C 18.2 ± 6.7 
CYP2D6 1.5 ± 1.3 
CYP2EI 6.6 ± 2.9 
CYP3A 28.8 ± 10.4 
CYPs are also found extrahepatically. For example, CYP3A4, CYP3A5 and CYPIA2 
are found in the intestine (Li et al., 1998; Kuehl et al., 2001). CYPIAI is expressed in 
extrahepatic organs including prostate, mammary gland, intestine, thymus, colon, 
adrenal, lung, and testis (Shimada et al., 1992,1994,1996; loannides et al., 1990). 
CYPIBI, an enzyme with substrate specificity overlapping that of CYPIAI and 
CYPIA2, but with different catalytic activity for these substrates (characteristic 
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substrate: 17poestradiol), is expressed (at least at the level of mRNA) in many 
extrahepatic tissues including brain, heart, lung, intestine, testis, ovary, uterus, kidney, 
prostate, mammary gland, pituitary, thymus, spleen, and adrenal (Sutter et al., 1994; 
Walker et al., 1995), with particularly high levels in the kidney, prostate, uterus, and 
mammary gland (Shimada et al., 1996). In addition to the liver and intestine, CYP3A5 
is expressed in kidney, lung, and polymorphonuclear leucocytes (Kuehl et al., 2001). 
Studies of brain P450 have indicated that the total P450 abundance is approximately 1- 
10% of hepatic P450. Brain CYPs are implicated in local drug metabolism (e. g. it has 
been shown that rat brain 2D18 is capable of demethylating imipramine - Kawashima 
et al., 1996; Thompson et al., 1998), neurosteroid metabolism (notably CYP3A, IBI, 
and CYP17 isoforms), neurotransmission (CYP2D6 is found in association with the 
dopamine transporter, and is inhibited by the dopamine reuptake inhibitor GBR-12935 
- Britto & Wedlund, 1992; Niznik et al., 1990 Hiroi et al., 1997), and neurotoxicity 
(CYPIA2 is able to oxidise dopamine to aminochrome, which may lead to the 
formation of reactive intermediates, Segura-Aguilar, 1996; Segura-Aguilar et al., 
1997). However, although there have been some studies of human brain CYPs (Voirol 
et'aE, 2000; Miksys et al., 2002; for reviews see Kalow & Tyndale, 1992 and 
Ravindranath, 1998), the relative abundances, distributions, and substrate affinities of 
most brain CYPs remain to be defined. Furthermore the brain CYPs may differ from 
their hepatic counterparts: Thompson et al. (1998) reported novel cDNA clones 
isolated from rat brain which differed from the liver isoforms in their 5' and 3'- 
untranslated regions (UTRs). They commented that these differences could lead to 
differential catalytic activities, and, furthermore that this indicated differential 
regulation of CYP gene expression between liver and brain (e. g. rat 2D 18, which has a 
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longer 3'-UTR than 2D4, is highly expressed in the brain, negligibly in the liver, 
Thompson et al., 1998). It has been suggested that regional distribution of CYP 
isoforms in the brain may be of considerable relevance for the pharmacogenetics of 
psychotropic agents (Miksys et al., 2000). Hedlund et al. (1996) showed that brain 
P450 was significantly induced by clozapine (especially 2D4), in tenns of protein 
expression, but not by haloperidol. 
Another interesting and relatively understudied facet of CYP genetics is developmental 
regulation of CYP gene expression. Multiple P450 forms have been isolated from liver 
microsomes of human foetuses, CYP3A7 being a foetus-specific and major form 
(Kitada et al., 1985). A foetal CYPIA that differs from CYP1A2 has been purified 
(Kitada et al., 1991); in the single neonatal liver sample examined by Shimada et al. 
(1994), a very low level of CYPIA2 was found, indicating that CYPlA2 expression 
may be increased developmentally (between the neonate and the adult). CYPIBI was 
found in foetal heart, brain, lung, and kidney by Shimada et al. (1996). 
1.4.2 Substrates of cytochrome P450s 
The P450 gene superfamily is ancient, the ancestral gene having existed before the time 
of prokaryote/eukaryote divergence, with CYPs being implicated in basic life functions 
such as calcium ion and electrolyte balances, and, cell division (Nebert, 1997). Drug 
metabolising enzymes (DMEs) including CYPs are involved in ligand-modulated 
regulation of transcription of genes effecting growth, differentiation, apoptosis, cellular 
homeostasis, and neuroendocrine functions (Nebert, 1994; Nebert, 1997). 
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The 'substrates of the CYPs are therefore manifold, including substances found 
naturally in the environment (xenobiotics) or the human body, with prescribed 
medications being only "fortuitously" metabolised. A summary of substrates of 
polymorphic human CYPs relevant to drug metabolism is provided in Table 1.2. Many 
enzymes show overlapping substrate specificity, and only the major routes of 
metabolism are shown. Substances may also exert considerable inhibitory effect at a 
given isoform, without being metabolised by that enzyme (e. g. quinidine in the case of 
CYP2D6). 
1.5 Genetic variation in CYP activity 
1.5.1 CYP2D6 
1.5.1.1 Genetic polymorphism of CYP2D6 
1: ký 
The debrisoquine/sparteine polymorphism. was discovered independently by research 
teams led by R. L. Smith and M Eichelbaurn in the late 1970's (Silas et al., 1977; Idle et 
al., 1978; Idle & Smith, 1979; Eichelbaurn et al., 1979). Smith noticed that the 
antihypertensive agent debrisoquine caused an unexpectedly high incidence of side 
effects, and hypothesised that an underlying genetic variation in the way in which 
,II 
different individuals metabolised the drug might be responsible for the high incidence 
of undesirable responses. He and three laboratory colleagues took the standard 
prescribed dose, an Id measured the levels of metabolites in their urine. Smith became 
hypoýtensive and his urinary 4-hydroxy metabolite of debrisoquine was 18-fold less than 
that of his colleagues. They then screened a larger group of subjects, and poor 
metabolisers of debrisoquine, as they were termed, were found to represent 6% of a 
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metabolisers, based on their debrisoquine metabolic ratio (ratio of urinary debrisoquine 
to 4-hydroxydebrisoquine in an 8-hour urine sample following ingestion of the probe 
drug debrisoquine). Similarly, Eichelbaum and colleagues described the sparteine-NI- 
oxidation polymorphism, inherited in an autosomal recessive manner, and being 
controlled by "similar if not identical genetic factors" as the debrisoquine 
hydroxylation polymorphism (Eichelbaum et al., 1979; Bertilsson et al., 1980). Figure 




Figure 1.1 Chemical structure of debrisoquine; the arrow indicates the site of the 
polymorphic hydroxylation. 
In ýa series of parallel investigations (Gough et al., 1990; Hanioka et al., 1990; 
Kagim6to et al., 1990), a primary mutation at the DNA level associated with the poor 
metaboliser phenotype was described: a G1934A substitution at the 3' end of intron 3, 
resulting in an altered splice acceptor site, and hence a premature stop codon in the 
MRNA sequence, predicting a protein of 181 amino acids instead of 497. This turned 
out to be the commonest genetic variation in CYP2D6 associated with the PM 
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phenotype (Heim & Meyer, 1990; Broly et al., 1991; Dahl et al., 1992; Marez et al., 
1997), and is now termed CYP2D6*4, although many others have subsequently been 
discovered. On the website where novel alleles are submitted, there are now 43 
CYP2D6 alleles, with several of these having subtypes (e. g. CYP2D6*4A, *4B, *4C, 
*4D, *4E, *4F, *4G, *4H, *4J, *4K, *4L; http: //www. imm-ki. se/CYPalleles, searched 
23'd July 2002, page updated by Mikael Oscarson 3 rd July 2002). CYP2D6 now 
represents one of the most extensively studied monogenic variations in drug 
metabolism (Nebert, 1999; Sj6qvist, 1999). 
CYP2D6 exists as part of a polymorphic gene cluster on chromosome 22ql3.1, which 
includes two pseudogenes, followed by the coding CYP2D6 sequence, oriented in the 
same direction 5' to 3' on a contiguous region of about 45 kb (Gonzalez et al., 1988; 
Gough et al., 1993; Kimura et al., 1989; Gaedigk et al., 1991; Heim & Meyer, 1992). 
The pseudogenes are CYP2D8P and CYP2D7, the latter also existing in variant forms 
(CYP2D7AP and CYP2D7BP). CYP2D8P is a pseudogene with many features typical 
, 
of pseudogenes (Kimura et al., 1989), while the key difference in CYP2D7 as 
compared to CYP2D6 is aT insertion at position 137 of exon 1, leading to a disrupted 
reading frame (Kimura et al., 1989). Both pseudogenes show a high degree of 
homology with CYP2D6, the degree of homology between CYP2D7 and CYP2D6 
obviously being greater than that between CYP2D8P and CYP2D6. 
The multiple allelic variants in CYP2D6 have been seen to correlate with four different 
levels of CYP2D6 activity: ultrarapid metabolisers (UM), extensive metabolisers (EM), 
intermediate metabolisers (IM), and poor metabolisers (PM) (Sachse et al., 1997), 
which leads to a variation of up to 1000-fold in CYP2D6 activity (Bertilsson et al., 
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1992; Meyer & Zanger, 1997). PMs, IMs, and UMs are defined below; the rest of the 
population are termed EMs. 
Poor metabolisers are homozygous for non-functional CYP2D6 alleles, i. e. alleles that 
do not give rise to the expression of any active CYP2D6 protein. Such alleles include 
CYP2D6*3 (an A deletion at position 2637 leading to a disrupted reading frame; 
Kagimoto et al., 1990), CYP2D6*4 (described above), and CYP2D6*5 (a complete 
deletion of the CYP2D6 coding sequence, Gaedigk et al., 1991; Steen et al., 1995), 
which are the commonest non-functional CYP2D6 alleles in Caucasians. 
Intermediate metabolisers are either homozygous for alleles associated with reduced 
but not absent CYP2D6 activity (e. g. CYP2D6*10 or CYP2D6*17), or have one 
reduced activity allele or one non-functional allele, or one reduced activity allele and 
one non-functional allele (Sachse et al., 1997; 1998). The majority with a debrisoquine 
MR in the moderate range (3.0-12.6) fit into the latter category (Sachse et al., 1998). 
Ultrarapid metabolisers have extra copies of a functional CYP2D6 gene in tandem due 
to gene amplification events (Johansson et al., 1993; Johansson et al., 1996), with 
between 2 and 13 copies of the gene being found in such individuals, most commonly 2 
copies (gene duplication). Three individuals (members of the same family) with 13 
copies of a functional CYP2D6 gene have been described (Johansson et al., 1993). 
Recently, it has been suggested that not all CYP2D6 UMs have gene 
duplications/amplifications, but that allelic variants could be associated with increased 
catalytic activity. Lovlie et al. (2001) suggested that CYP2D6*35 could be associated 
with increased catalytic activity; however, functional studies of CYP2D6*35 expressed 
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in yeast did not indicate increased catalytic activity as compared to wild-type enzyme 
(Allorge et al., 2001). Nonetheless, the authors commented that the CYP2D6 promoter 
polymorphism (-1584C>G) in linkage disequilibrium. with the single nucleotide 
polymorphisms (SNPs) of CYP2D6*35, might possibly be associated with increased 
catalytic activity. Given the organisation of the CYP2D gene cluster, it has also been 
hypothesised that CYP2D7 might be active in some individuals, and hence, in 
combination with an active CYP2D6, lead to an ultrarapid metaboliser phenotype 
(Lovlie et al., 2001). However, Lovlie and colleagues (2001) sequenced CYP2D7 exon 
1 from. 17 subjects selected for relatively low debrisoquine MRs (13 UMs and 4 EMs), 
who were negative for CYP2D6 duplications, and all subjects were homozygous for the 
137T insertion. Interestingly, CYP2D71CYP2D6 chimeric alleles (CYP2D6*13 and 
CYP2D6*16, the former with exon I and part of intron 1 of CYP2D7, the rest of the 
gene originating from CYP2D6, and the latter with breakpoints between the end of 
-I exon 
7 and the start of exon 9 in the respective genes, have been described (Panserat et 
al., 1995; Daly et al., 1996b). I 
The frequency of the different CYP2D6 allelic variants varies between different ethnic 
groups (Aitchison et al., 2000c). In Caucasian populations, the frequency of PMs is 5- 
10% (Sachse et al., 1997; Marez et al., 1997), while in Black Africans the frequency is 
0-8% (Woolhouse et al., 1985; Masimirembwa et al., 1996a, 1996b), in African- 
Americans the frequency is 3.7% (Leathart et al., 1998), and in Orientals (Chinese, 
Japanese, and Koreans having been studied) the frequency is approximately 1% 
(Nakamura et al., 1985; Lou et al., 1987; Horai et al., 1989; Sohn et al., 1991; Du et 
al., 1990; Bertilsson et al., 1992). In addition, a lower population mean enzyme 
activity has been observed in Chinese, Zimbabweans, and Ghanaians as compared to 
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Caucasians. The low PM frequency in Orientals is caused mainly by the very low 
incidence of the CYP2D6*4 mutant allele, the allele which is associated with absent 
enzyme activity and accounts for about 66% of PM alleles in Caucasians (Marez et al., 
1997). The lower population mean enzyme activity has been attributed to the relatively 
high frequency of CYP2D6*10 in the Chinese, and of CYP2D6*17 in the Ghanaians 
and Zimbabweans, both of which alleles being associated with diminished but not 
absent CYP2D6 activity, and known as intermediate metabolising alleles (Johansson et 
al., -, 1994; Lee et al., 1994; Masimirembwa et al., 1996b; Droll et al., 1998). The 
CYP2D6*10 allele is a C188T substitution in exon 1, leading to a Pro34Ser change in a 
highly conserved region, and is associated with a 10-fold reduction in catalytic activity 
in vivo (Johansson et al., 1994). The CYP2D6*17 allele also occurs at a greater 
frequency in African-Americans (Leathart et al., 1998). In addition, a further allele that, 
occurs with relatively high frequency (20%) in Black populations has been identified: 
CYP2D6*29 (Wennerholm et al., 2001), which is associated with reduced catalytic 
activity for debrisoquine (63% of wild-type activity in vitro). 
Dahl et aL (1995b) compared findings in a pilot study on Koreans, Chinese, and 
Japanese, and found that the frequency of CYP2D6*]OA and CYP2D6*IOB was 
somewhat lower among the Koreans than among the Chinese or Japanese. Therefore 
findings from one ethnic group may not be applicable to another geographically close 
and apparently similar ethnic group. Canadian Native Indians are descendants of North 
Asian populations, and have been found to resemble Chinese in terms of PM frequency, 
but to lack the shift towards a lower mean enzyme activity (Nowak et aL, 1997). This 
was seen, to be due to a lower frequency of the CYP2D6*3 and CYP2D6*4 mutant 
alleles relative to Caucasians, and a lower frequency of CYP2D6 *10 compared with the 
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Chinese. Similarly, a relatively low frequency of CYP2D6*10 has been found in the 
South-Amerindian population of Chile (Munoz et al., 1998). This genefic drift has 
been interpreted as possibly due to a founder effect, mitochondrial DNA sequence 
variations revealing that these two groups of Amerindians were derived from a small 
number of maternal lineages (Bailliet et al., 1994), or due to genetic selection pressures 
by dietary or other environmental factors. Middle Eastern populations show a very l6w 
frequency of CYP2D6 PMs, resembling Orientals rather than Caucasians in 
phenotyping studies (reviewed in Price Evans et al., 1995). 
A further factor to be considered amongst individuals of lower CYP2D6 activity is that 
in Black African populations, individuals who appear to be PMs when tested with one 
drug may not be PMs when tested with another drug, the two drugs both being 
metabolised similarly by CYP2D6 in Caucasians (Woolhouse et al., 1985; Sommers et 
al., 1989; Lennard et al., 1992; Simooya et al., 1993). This has been suggested to be 
due to either the presence of an as yet unidentified CYP2D6 variant with differential 
. substrate specificity, or due to 
interethnic variations in conjugation and/or renal tubular 
transport. 
At the other end of the spectrum of enzyme activity, the frequency of UMs also differs 
markedly between different ethnic groups, being 0.8-2% in Danes or Swedes (Dahl et 
al., 1995a; Bathum et al., 1998), 3.6% in Germans (Sachse et, al., 1997), less than 5% 
(Masimirembwa, et al., 1993; Masimirembwa et al., 1996a) in Black Zimbabweans, 7% 
in Spaniards (Agdndez et al., 1995), 20% in Saudi Arabians (McLellan et al., 1997), 
and 29% in Ethiopians (Aklillu et al., 1996). 
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1.5.1.2 Clinical relevance of CYP2D6 polymorphism 
Genotype-phenotype correlation studies indicate that the number of functional CYP2D6 
genes predicts drug and metabolite concentrations in the plasma: DaMn et al. (1998) 
showed that following a single oral dose of 25 mg nortriptyline to Caucasian volunteers 
known to have 0,1,2,3, and 13 functional copies of CYP2D6, the concentration of 
nortriptyline was inversely related to the number of copies of CYP2D6, while the 
concentration of 10-hydroxynortriptyline (formed from nortriptyline in a reaction 
catalysed by CYP2D6) was directly related. The oral clearance of perphenazine and 
zuclopenthixol in patients on continuous treatment was also shown to be significantly 
predicted by CYP2D6 genotype (Jerling et al., 1996). 
It would therefore be intuitively logical that if PMs were at increased risk for drug 
toxicity during treatment with standard doses, then UMs might need doses higher than 
the normal therapeutic range in order to gain beneficial clinical effect. There is some 
evidence in support of this hypothesis, which is discussed in further detail in Chapter 3. 
For prodrugs that require activation by CYP2D6 (e. g. codeine), PM phenotype is 
associated with treatment resistance (Cleary et al., 1994; Sindrup & Brosen, 1995), and 
reduced capacity for codeine abuse. Chou et al. (2000) have estimated that the annual 
cost of treating patients at extremes of CYP2D6 activity (PMs and UMs) is a mean of 
4000-6000 US dollars greater than for the CYP2D6 IMs and EMs, with the duration of 
hospital stay being prolonged for PMs. 
There have also been studies of CYP2136 and disease association, notably Parkinson's 
Disease and lung cancer. Meta-analysis of the literature is consistent with CYP2D6 PM 
status being associated with a small increase in risk of Parkinson's Disease (McCann et 
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al., 1997; Christensen et al., 1908; Rostami-Hodjegan et al., 1998). Subsequent studies 
have, however, yielded conflicting results, with positive associations being mainly 
found for the CYP2D6*4 allele (Atkinson et al., 1999; Bon et al., 1999; Stefanovic et 
al., 2000), although not invariably (Harhangi et al., 2001), and not for other PM/IN4 
alleles (Sabbagh et al., 1999; Nicholl et al., 1999; Joost et al., 1999; Ho et al., 1999; 
Maranganore et al., 2000). It has been suggested that the apparent CYP2D6*4 effect is 
an age-related artefactual association (Payami et al., 2001). 
Meta-analyses of the data for lung cancer indicate that the CYP2D6 PM phenotype is 
associated with a small decrease in the risk of lung cancer, which is not, however, held 
up -in studies based on CYP2D6 genotyping (Rostami-Hodjegan et al., 1998; 
Benhamou et al., 1999). 
There is some evidence that CYP2D6 PM status may be associated with anxious 
personality traits (Llerena et al., 1993b; Peter Joyce, personal communication 2 nd July 
2002). - Given the colocation with the dopamine transporter, there may be an as yet 
unidentified endogenous brain substrate for CYP2D6- 
1.5.2 CYP2C enzymes 
1.5.2.1 CYP2C genetics 
Four members of the human CYP2C subfamily have been identified: CYP2C8, 
CYP2C9, CYP2C 18, and CYP2C 19 (Goldstein et al., 1994); their genes form a cluster 
at chromosome lOq24. Of these, the role of CYP2Cl9 in the metabolism of 
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psychotropic drugs has been most extensively studied; relevant substances include: 
amitriptyline, imipramine, clomipramine, moclobemide, citalopram, diazepam, and 
desmethyldiazepam (Bertilsson & Dahl, 1996), as well as clozapine, olanzapine, 
propranolol, and phenytoin to lesser extents. Four SSRIs (fluoexetine, sertraline, 
paroxetine, and citalopram) all inhibit CYP2C19 and may also be metabolised by this 
enzyme. CYP2C18 lies distal to CYP2C19 on chromosome 10, is 85.7% homologous to 
CYP2C19, and shows similar substrate specificity towards diazepam (Jung et al., 
1997), phenytoin (Krecic et al., 1995; BaJpai et al., 1996), and omeprazole (Karam et 
al., 1996). Furthermore, Mamiya et al. (1998) found cosegregation of poor metaboliser 
mutations of CYP2Cl9 and CYP2CIS, indicating that CYP2Cl8 may not be able to 
take over from CYP2Cl9 in individuals deficient in CYP2Cl9. CYP2C9 was shown 
by Hashimoto and colleagues (1996) to play a greater role than CYP2Cl9 in the 
metabolism of phenytoin, and the Leu 359 allele, which is present in the heterozygous 
state in 3.4% of Han Chinese subjects (Wang et al., 1995), was seen to be associated 
with a 40% reduction in the Vmax for phenytoin. 
The incidence of poor metabolisers (PMs) of CYP2Cl9 in different populations has 
been reviewed (Price Evans et al., 1995; Bertilsson, 1995; Persson et al., 1996; 
Goldstein et al., 1998). There is substantial interethnic variation: the frequency of PMs 
is 2-5%, in, Caucasians, 2% in Saudi Arabians, 4% in Black Zimbabweans, 5% in 
Ethiopians, 
. 
13% in Koreans, 15-17% in Chinese, 21% in Indians, and 18-23% in 
Japanese.. Indeed, when the square root of the PM frequency (representing the total 
frequency of mutant CYP209 alleles) is plotted versus longitude, an increase in this 
value versus longitude may be seen, with an increment in the value occurring between 
Saudi Arabia and Bombay (Price Evans et al., 1995). 
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There are 2 wild-type CYP2C19 alleles (CYP2C19*IA and CYP2C]9*IB, i. e. with 
enzyme activities within the normal range), and seven defective alleles that are 
responsible for the PM phenotype (Goldstein et al., 1998; hn: //www. imm. ki. se/CYPalleles 
searched 23d July 2002, page updated 15'h February 2000 by. Mikael Oscarson). The 
most common defective allele is CYP2Cl9*2A (a G681A substitution in exon 5, which 
creates an aberrant splice site, previous name for this allele, ml). A variant of this 
allele, CYP2C]9*2B, contains a G276C substitution in exon 2 which creates a GIU92Asp 
change; this allele comprises 15% of the CYP2C19*2 allele in Caucasians, but was not 
observed in 53 Japanese CYP2Cl9*2 alleles, studied. The two CYP2Cl9*2 alleles 
account for 86% of PM alleles in Caucasians and 69-87% in Orientals. The second 
major defective allele is CYP2C]9*3 (a G636A mutation in exon 4, which creates a 
premature stop codon, previous name for this allele, m2); this comprises 13-3 1% of PM 
alleles in Oriental populations and 1.5% in Caucasians. A third PM allele, CYP209*4 
(an A-ýG mutation in the initiation codon), accounts for 3% of Caucasian PM alleles. 
CYP2C19*5 (a C1297T mutation in exon 9 which results in an Arg433Trp change in the 
haern binding region) accounts for 1.5% of Caucasian PM alleles and is rare in 
Orientals. CYP2C19*6 (a G395A base substitution resulting in an Arg132GIn coding 
change in exon 3) and CYP2CJ9*7 (a GT->GA mutation in the donor splice site of 
intron 5) each account for a further 1.5% of Caucasian PM alleles. CYP209*8 (a 
T359C substitution resulting in a Trpl2oArg change in exon 3) is a relatively recently 
characterised, rare defective allele. The products of CYP2C]9*6 and CYP2C]9*8 
show reduced catalytic activity (2% and 9% of wild-type S-mephenytoin hydroxylase 
activity, respectively); the other mutants are associated with failure to express active 
CYP2CI9. CYP2C]9*2A and CYP209*3 have both been identified in an Ethiopian 
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population, and found to account for all the PM alleles in the 114 individuals studied 
(Persson et al., 1996). 
1.5.2.2 Clinical studies of CYP2C19 and CYP2C9 
Mephenytoin (Figure 1.2) and omeprazole have been used as probe drugs in studies of 
CYP2C19 activity. In single-dose studies, the clearance of orneprazole has been found 
to be higher in CYP2Cl9 EMs than PMs in Caucasians, Chinese, and Koreans, with the 
clearance in Caucasian EMs being significantly higher than that in both Chinese and 
Korean EMs (Bertilsson, 1995). After multiple doses of omeprazole, the mean areas 
under the plasma concentration-time curve for the parent drug indicated that 
heterozygous individuals had a reduced rate of metabolism as compared to 
homozygous EMs. It has therefore been hypothesised that the difference in clearance 
between Caucasians and Orientals is due to the relatively high proportion of 




Figure 1.2 Chemical structure of mephenytoin; the arrow indicates the site of the 
polymorphic hydroxylation 
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In the case of diazepam, the clearance is significantly lower in Caucasian and Korean 
CYP2Cl9 PMs than EMs (Bertilsson, 1995). However, in Chinese, no significant 
difference between the elimination half-life of 8 EMs and 8 PMs was found, and the 
mean clearance in the whole group was relatively low as compared to Caucasians. It 
has been suggested that among the 8 Chinese EMs, 7 with a relatively low diazepam 
clearance might be heterozygous, which would explain the low overall clearance and 
the lack of significant difference between the EM and PM groups. Alternatively, 
differences in the contribution of CYP3A4 to diazepam pharmacokinetics in the 
different ethnic groups could explain the different findings. Like CYP2D6, CYP2Cl9 
often functions as a high-affinity, relatively low capacity enzyme, which is more 
important at low drug doses. With higher doses, multiple-dosing, or in the case of 
CYP2Cl9 deficiency, the high capacity enzyme CYP3A4 (Table 1.1) increases in its 
contribution to overall drug clearance. Schmider et al (1996) have calculated that even 
with single doses, approximately . 
60% of diazepam clearance is Cyp3A4-dependent. 
The relatively high incidence of low CYP3A4 activity in Chinese may therefore 
contribute to the low mean diazeparn clearance, and, if polymorphisms in CYP3A4 and 
CYP2Cl9 do not cosegregate, could c: ontribute towards the lack of a significant 
difference between diazeparn clearance in S-mephenytoin PMs and EMs. It has been 
noted that "many Hong Kong physicians routinely prescribe smaller diazeparn doses 
for. Chinese than for white Caucasians" (Kumana el al., 1987); this tradition is 
consistent with the lower clearance found experimentally. 
An association between CYP2C9 polymorphisms and warfarin dose requirement and 
risk of bleeding complications has been described (Aithal et al., 1999). CYP2C9 
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catalyses the conversion of S-warfarin to inactive 6-hydroxy and 7-hydroxy 
metabolites, and there are 2 allelic variants, CYP2C9*2 and CYP2C9*3, which show 
less than 5% and approximately 12% of wild-type CYP2C9 activity respectively (Rettie 
et al., 1994; Haining et al., 1996; Crespi et al., 1997). Genotyping for the CYP2C9*2 
and CYP2C9*3 alleles in a group of patients with a low warfarin dose requirement (1.5 
mg or less), a group of randomly selected warfarin clinic controls, and 100 healthy 
population controls was conducted. This showed an odds ratio of 6.21 (95% 
confidence interval, or CI 2.48-15.6) for individuals with a low warfarin dose 
requirement having one or more CYP2C9 low activity alleles compared with the 
normal population. Patients in the low-dose group were more likely to have difficulties 
at the time of induction of warfarin therapy, including prolongation of length of 
inpatient admission when compared with the clinic control group (odds ratio 5.97,95% 
CI 2.26-15.82), and had an increased risk of major bleeding complications when 
compared to this group (rate ratio 3.68,95% Cl 1.43-9.50). Pre-prescribing genotyping 
might therefore identify individuals more likely to have problems on induction, and 
lead to altered dose escalation procedures for these patients. In addition, the likely 
increased risk of major bleeding complications (in general later in the course of 
therapy) might lead either to increased monitoring of these clients, or a careful 
assessment of the risk-benefit ratio. The CYP2C9*3 allele has also been shown to be 
associated with reduced clearance of phenytoin and tolbutamide (a hypoglycaemic 
agent) (Miners et al., 1998). 
56 
1.5.3 CYPlA2 
; 1.5.3.1 Variation in CYPlA2 activity 
There is wide interindividual variation in CYP I A2 activity (Kalow and Tang, 199 1 a), 
which in most studies has been demonstrated to be trimodally or bimodally distributed 
(Butler et al., 1992; Lang et al., 1994; Nakajima et al., 1994; Schrenk et al., 1998; Ou- 
Yang et A, 2000). This would appear to support the existence of genetic 
polymorphism in CYP1A2. Indeed, in a family study, the pattern of CYPIA2 activity 
in 8 pedigrees was consistent with genetic polymorphism at a single gene locus, with 
autosomal dominant transmission (Nakajima et al., 1994). 
At least., some of the interindividual variability in CYPlA2 activity is, however, 
explicable by enviromnental factors. The enzyme is inducible by various dietary 
substances, -drugs, and toxins. This includes cruciferous vegetables 
(Cruciferae, 
otherwise known as brassica, including broccoli, cauliflower, cabbage, watercress, and 
radishes), , heterocyclic amines, polycyclic aromatic hydrocarbons (e. g. 3- 
methylcholanthrene), and heterocyclic aromatic hydrocarbons (including 2,3,7,8- 
tetrachlorodibenzo-p-dioxin, or TCDD), caffeine, cigarettes, paracetamol, omeprazole, 
and carbamezepine (Aitchison et al., 2000a; Rost et al., 1994; Parker et al., 1998). 
I CYP I A2 may be inhibited by lutein (found in leafy green vegetables, Le Marchand et 
al., 1997), apiaceous vegetables (including parsnips, celery, and herbs such as dill and 
parsley; Lampe et al., 2000), grapefruit juice (Fuhr et al., 1993), oestrogens and 
pregnancy (Knutti et al., 1981; Rietveld et al., 1984; Abernethy and Todd, 1985; 
Vistisen et al., 1992; Le Marchand et al., 1997), quinolone antibiotics (Fuhr et al., 
1992), fluvoxamine (Brosen et al., 1993), and, in smokers, heavy ethanol consumption 
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(Rizzo et al., 1997). Nonetheless, Le Marchand and colleagues (1997) showed in a 
study of 90 subjects of various ethnic backgrounds in Hawaii that 73% of the variance 
remained unexplained after taking into account the major environmental contributors to 
the-variance. In a larger study (N=786 Caucasians), Tantcheva-Poor et al. (1999) 
found that 63% of the overall variation remained unaccounted for after analysis for the 
major covariates (e. g. coffee consumption). This finding points to the existence of 
other factors, such as genetic polymorphisms, as contributors to the variation in 
CYPIA2 activity. There is also evidence of interethnic variation in CYPIA2 activity 
(Section 4.1.2). 
Nonetheless, the polyinorphisms that have been identified to date in CYP1A2 would 
not appear to account for the apparent frequency of CYPIA2 poor metabolisers, seen in 
the bimodal distributions. There are several possible reasons for this, including 
polymorphism in regulatory regions, and in other genes that may interact with 
CYPIA2. Indeed, in a study of caffeine N-3-demethylation (an index of CYPIA2 
activity) in the mouse using quantitative trait methodology, Casley et al. (1999) showed 
that 62% of the variance was accounted for by 3 loci, on murine chromosomes 1,4, and 
9, the last colocalising with the murine CYPIAj locus. This points to the contribution 
of loci other. than CYPIA2 to indices of CYPIA2 activity, and is discussed in further 
detail in section 4.6. 
1.5.3.2 Clinical relevance of variation in CYP1A2 activity 
CYPIA2 plays a major role in the metabolism of many commonly used drugs, 
including chlorpromazine, trifluoperazine, clozapine, ý olanzapine, tertiary amine 
tricyclic antidepressants (amitriptyline, imipramine, and clomipramine), zopiclone, 
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tacrine, paracetamol, xanthines (caffeine, theophylline, aminophylline), and lignocaine 
(Imaoka et al., 1990; Aitchison et al., 2000c). It is also involved in the metabolism of 
the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), which produces 
a parkinsonian syndrome in man (Coleman et al., 1996), and in the activation of 
arylamines and heterocyclic amines implicated in the genesis of colon and bladder 
cancer (McManus et al., 1990; Boobis et al., 1994; Eaton et al., 1995; Hammons et al., 
1997). 
There have been several in vitro studies investigating the role of Cyps in clozapine 
metabolism, which have indicated involvement of CYPIA2, but been inconsistent as to 
the relative importance of CYPIA2 and the precise role of CYPIA2 in the generation 
of the two major metabolites (Eiermann et al., 1997; Linnet and Olesen, 1997; Tugnait 
et al., 1999). This is discussed in further detail in Section 5.1.1. Interestingly, very low 
plasma clozapine levels despite high doses, in association with very high CYPlA2 
activity, have been described (Bender et al., 1998). It is therefore possible that, 
analogous to the variability of CYP2D6, there exist individuals with CYPlA2 
ultrarapid metaboliser status. 
The most important pathways for olanzapine metabolism are CYPlA2, flavin- 
containing monoxygenase 3, and N-glucuronidation, with minor pathways including 
CYP2D6 and CYP2CI9 (Ereshefsky, 1996). Olanzapine clearance is increased in 
males (by about 30%) and in smokers, and decreased in the elderly, all of which are 
consistent with the involvement of CYPlA2. Evidence for the contribution of 
CYPIA2 to the pharmacokinetics of typical antipsychotics includes the effect of 
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smoking: smoking increases the clearance of fluphenazine and haloperidol by 100% 
and at least 50% respectively in an affected population. 
1.5.4 CYP3A4 
1.5.4.1 Variation in CYP3A activity 
Human CYP3A activities reflect the heterogeneous expression of at least three CYP3A 
family members: CYP3A4, CYP3AS, and CYP3A7. The three genes coding for these 
enzymes are adjacent to each other on chromosome 7q2l, together with two 
pseudogenes, CYP3AP1 and CYP3AP2 (Finta et al., 2000, in the order CYP3A4- 
CYP3AP2-CYP3A7-CYP3API-CYP3A5). Functional CYP3A4 is found in most adults, 
with a 10- to 40-fold variation in its expression. CYP3A7 is predominantly expressed 
in foetal life; however, some people express CYP3A7 mRNA into adulthood (Schuctz 
et al., 1994). Kuehl and colleagues (2001) have shown that CYP3A5 may comprise at 
least 50% of total hepatic CYP3A, in individuals that have at least one CYP3A5*1 
(wild-type) allele. There are two common allelic variants, CYP3A5*3 and CYP3A5*6, 
which both cause alternative splicing and protein truncation, resulting in the absence of 
functional CYP3A5. Kuehl and colleagues (2001) also showed interethnic variation in 
expression of CYP3A5, CYP3A5 being expressed in 60% of the livers of African 
Americans, as compared with 33% of Caucasian livers. 
CYP3A4 is present in the liver and small intestine, and can be induced, inhibited, or 
inactivated by drugs as well as environmental factors including food substances 
(Aitchison et al., 2000c). Interpopulation variation in activity may therefore arise not 
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only secondary to intrinsic variation in enzyme activity, but also secondary to the effect 
of environmental agents. 
Nifedipine is a cardiovascular drug that is metabolised by CYP3A4 and has been used 
as a probe drug to investigate CYP3A4 activity in different populations. It has been 
shown that South Asians (from the Indian subcontinent) oxidise nifedipine at a 
significantly slower rate than Caucasians (Ahsan et al., 1991; Ahsan et al., 1993), 
resulting in sustained haemodynamic changes. In the first study by Ahsan and 
colleagues, the South Asians had retained their original dietary practices, whereas the 
Caucasians consumed a typical Western diet. The effect of diet was studied in 6 
Caucasians by giving them an Indian diet for 3 days prior to the administration of 
nifedipine; no significant difference in any of1he pharmacokinetic parameters was 
detected. Similarly, the N-demethylation of codeine, which is catalysed by an enzyme 
of the CYP3A subfamily, occurs at a significantly slower rate in Chinese as compared 
to Caucasians (Yue et al., 1989). Interestingly, Chinese have also been shown to have 
a significantly lower mean codeine N-demethylation activity as compared to Japanese 
(Yue et al., 1995). 
Twin and repeated drug administration studies have indicated that genetic factors play a 
prominent role in the regulation of CYP3A4 expression (Penno et al., 1981; Ozdemir et 
al., 2000). An A to G point mutation has been found in the nifedipine specific element 
(NFSE) at position -289 in the CYP3A4 promoter (CYP3A4*]B, Rebbeck el al., 1998), 
which has been shown to have a high frequency in African-Americans, and a low 
frequency in Caucasians and Taiwanese (Sata et al., 2000). This allele was proposed to 
be associated with altered catalytic aptivity; however, functional studies performed by 
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Westlind et al. (1999) were not consistent with this. Kuehl et al. (2001) showed that 
there was linkage disequilibrium between CYP3API *I and CYP3A4*IB in African 
Americans, and as there was an association between CYP3API *1 and high levels of 
CYP3A5 expression, postulated that it was CYP3A5 genotype that was the ma* Jor 
determinant of CYP3A functionality. 
1.5.4.2 Clinical relevance of variation in CYP3A activity 
6YP3ýk 
enzymes play a role in the metabolism of many typical antipsychotics, 
sertindole, and clozapine, in addit. ion to many other prescribed medications and steroids 
(Table 1.2, and Ereshefsky, 1996). Drugs and food substances may act on the 
CYP3A4/5 present in the small intestine as well as that present in the liver. Indeed, the 
effect of a given agent on the hepatic and intestinal CYP3As may differ. For example, 
consumption of some furanocourmarins present in grapefruit juice can cause 
inactivation of enterocyte CYP3A4 while having no detectable effect on liver CYp3A4 
activity (Watkins, 1998). Conversely, some oral drug regimens have been shown to 
increase, liver CYP3A4 activity while having no effect on small bowel CYP3A4. It 
appears that some drugs (including benzodiazepines) undergo substantial first pass 
metabolism by enterocyte CYP3A. 
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Table 1.3 CYP3A inhibitors (modified from Aitchison et al., 1999c) 
SSRIs (fluoxetine, fluvoxamine), SNRls (venlaflaxine, nefazodone) 
Steroids (oral contraceptives, prednisolone, tamoxifen, etc. ) 
Antibiotics (erythromycin, troleandomycin, clarithromycin, isoniazid) 
Antifungals (ketoconazole, itraconazole, clotrimazole) 
AntiHIV drugs (ritonavir, zidovudine) 
Analgesics (e. g. dextropropoxyphene) 
Anaesthetics ( e. g. midazolarn, lidocaine) 
Cardiac drugs (nifedipine, verapamil, diltiazern) 
Immunosuppressants (cyclosporin, vinblastine) 
Bromocriptine 
Cimetidine 
It has been shown that CYP3A4 is responsible for the back oxidation of reduced- 
haloperidol to haloperidol and also for the N-dealkylation of haloperidol (Pan el al., 
1998; Fang et al., 1997). A negative correlation between clinical response and 
reduced-haloperidol levels or reduced-haloperidol/haloperidol ratios has been observed 
-. III 
(Bareggi et al., 1990); hence individuals with higher CYP3A4 activity could respond 
better to haloperidol than those with lower CYP3A4 activity. In a study on newly 
hospitalised Chinese patients with schizophrenia, Lane and colleagues found that those 
who experienced EPS had significantly higher reduced haloperidol concentrations and 
reduced haloperidol/haloperidol ratios than the other patients (Lane et al., 1997). A 
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trend towards higher haloperidol concentrations was also found in the EPS group. 
This would be consistent with individuals with lower CYP3A4 activity being more 
vulncrable to EPS. 
CYP3A4 is readily induced by carbarnazepine; for most typical antipsychotics twice as 
much antipsychotic is required to achieve the same plasma concentration in the 
presence of carbamazepine as in the absence of carbamazepine (Ereshefsky, 1996). 
This interaction is relevant for the treatment of schizoaffective psychoses. Many other 
substances (mostly metabolised at least partially by CYP3A) inhibit metabolism by the 
CYP3A enzymes. Clozapine toxicity has been reported after the coadministration of 
one such inhibitor, erythromycin (Funderburg et al., 1994). Individuals who are 
CYP2D6 poor metabolisers or who are in receipt of drugs that inhibit CYP2D6 
metabolism would be expected to be at increased risk of effects secondary to drug 
interactions at CYP3A4, and vice versa. 
1.6 Gene-environment interaction causing variation in CYP activity 
There are several factors that may interact with genotype, increasing interindividual 
variation in CYP activity and leading to intraindividual variation in the same. These 
include drug-drug interactions, and the effects of dietary components or toxins (such as 
tobacco constituents), nutraceuticals, aging, and disease. Several have already been 
mentioned above, but will be covered in more detail below. 
I 
1.6.1 Drug-drug interactions 
Interactions with other psychotropic medications and/or non-psychotropic medications 
may occur (Table 1.2), and have been extensively reviewed (Lin & Lu, 1998; 
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Greenblatt et al., 1999; Fang & Gorrow, 1999; Tanaka & Hisawa, 1999; Flockhart & 
Oesterheld, 2000). Treatment with a potent CYP2D6 inhibitor (e. g. paroxetine or 
quinidine) may render an individual that is genotypically a CYP2D6 EM 
phenotypically a CYP2D6 PM. Indeed, even less potent CYP2D6 inhibitors, especially 
when administered chronically, may have this effect. Spina et al. (1991) showed that 
the proportion of subjects who were phenotypically CYP2D6 PMs increased on typical 
antipsychotic monotherapy, and Llerena et al. (1993a, 2001) showed that typical 
antipsychotic and antidepressant treatment was associated with CYP2D6 PM 
phenotype, in individuals that were genotypically EMs. This effect may persist after 
cessation of administration of the relevant drug (depending on its half-life), and hence 
should be considered by prescribing clinicians when changing a patient's treatment 
regime (Alfaro et al., 2000). It is possible to predict whether or not two drugs are likely 
to interact with each other at a given CYP if the following is known: a) which CYP 
isoform(s) are mainly responsible for the metabolism of the drugs b) the relative 
contribution of these CYPs to the total metabolism of the drugs c) the relative affinities 
of the drugs for these CYPs and d) the relative concentrations of the drugs in the tissue 
of, interest (e. g. hepatocytes) (Andersson, 1996). If two drugs are significantly 
metabolised by the same CYP, they will often competitively inhibit each other, the 
metabolism of the drug with lower affinity for the enzyme being inhibited to a greater 
degree. Multiple CYPs may also be involved in such interactions, such that the net 
effect of the interactions may be difficult to predict, especially if there is induction of 
one CYP and inhibition of another. Many substances inhibit CYP3A enzymes at 
clinically used doses (Table 1.3). Coadministration of valproate and carbarnazepine 
leads, to increased formation of an epoxide metabolite of carbarnazepine due to a 
complex interaction resulting from inhibition of CYP3A by valproate and induction of 
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CYP3A by carbamazepine. In such cases, phenotyping, if necessary using a cocktail of 
probe drugs to simultaneously evaluate multiple CYP activity (Streetman et al., 2000), 
may yield data that are both clinically informative and useful for pharmacogenetics, as 
drug interaction effects may confound the interpretation of pharmacogenetics studies 
(Meyer et al., 1996). 
1.6.2 Nutraceutical effects 
Many cultures have for centuries used herbal remedies and dietary constituents for the 
treatment of various conditions (e. g. Chinese herbal medicine; Milne, 1999), and there 
is now increasing interest in the Western world in these substances. However, it has 
become clear that these substances may affect the CYP system, leading to drug-drug 
interactions just like any other pharmacologically active agent. 
For example, St John's Wort (extract of Hypericum peforatum) induces CYP3A, which 
may reduce the efficacy of protease inhibitors (e. g. indanavir, Piscitelli et al., 2000), 
oral contraceptives (Ernst, 1999), and immunosuppressants such as cyclosporin (Mai et 
al., 2000; Ruschitzka et al., 2000). Possible mechanisms for this effect include 
enhanced transcriptional activity of the steroid X receptor, also known as the pregnane 
X receptor, a nuclear receptor involved in CYP3A induction (Wentworth et al., 2000; 
Moore et al., 2000), and increased P-glycoprotein activity (a transmembrane protein 
that extrudes drugs from cells and is responsible for resistance to drug treatment, 
encoded by the gene MDR], multiple drug resistance gene 1; Johne et al., 1999). 
Similarly, garlic supplementation may decrease the concentration of the antiviral 
saquinavir (a CYP3A and P-glycoprotein substrate, Piscitelli et al., 2001), an effect that 
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may persist for more than 10 days after cessation of garlic supplementation taken twice 
daily for 3 weeks. 
1.6.3 Dietary effects 
Substances ingested as part of the diet without. intention of any nutraceutical effect may 
also affect CYP activity. In addition to the effects already detailed, isothiocyanate- 
containing vegetables (e. g. watercress) can inhibit CYP2EI (Kim & Wilkinson, 1996), 
organosulfur compounds present in garlic in animal model and in vitro studies inhibit 
CYP2EI and induce CYPIA, CYP3A, and phase II enzymes (Brady et al., 1991; Haber 
et al., 1994; Kwak et al., 1994,1995; Reicks et al., 1996), althoUgh this effect is 
unlikely to be relevant to the amounts of garlic or garlic products consumed in the diet 
(Wilkinson, 1997). Grapefruit juice components may inhibit and reduce intestinal 
CYP3A expression by selective post-translational downrcgulation of enterocyte 
CYP3A4 (Bailey et al., 1998), and in some cases CYPIA (Bailey et al., 1994; Dresser 
et al., 2000), leading to large variation in bioavailability of CYP3A substrates. In 
addition, vitamins and spices have been implicated in altering drug metabolising 
enzyme (DME) activity (Wilkinson, 1997). 
1.6.4 Influence of aging 
From the third decade of life onwards, both liver blood flow and volume decline 
I inearlyo'ver time, reducing to 20-40% of maximum by 80-90 years of age (Dumas et 
al., 1990), accompanied by'a reduction in clearance by the hepatic 'cytochromes 
CYP3A4/5, CYPIA2, CYP2C9, and CYP2C18/19 (Kinirons & Crome, 1997). For 
drugs that exhibit significant first-pass hepatic metabolism in young subjects, their 
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clearance in older subjects may be significantly affected by this phenomenon. There are 
no data on changes in intestinal CYP activity with aging. 
1.6.5 Influence of disease 
Acute inflammation, infection, and surgery may affect the metabolism of drugs and 
toxins (Wooles & Borzelleca, 1966; Renton & Mannering, 1976; Brockmeyer et al., 
1998; Shedlofsky et al., 1994, Gidal et al., 1996). The effects of inflammation or 
infection on CYP activity are thought to be due to stimulation of the cellular immune 
response, including via interleukins 1 and 6 and tumour necrosis factor (Renton, 2000; 
Watkins et al., 1995; Haas, 2000). In HIV-infected individuals taking no medications 
known to alter DME activity, it was recently shown that CYP3A and CYP2D6 
activities were reduced by 30-90%, with 25% of infected individuals showing 
genotype-phenotype discrepancy for CYP2D6 (Gotzkowsky et al., 2000). This 
indicates that genotype-based pharmacogenetics assessments may have limited utility 
in HIV-infected individuals. Similarly, liver disease, especially cirrhosis, may affect 
D, ME activity (Vessell, 1984; George et al.,. 1995; Wilkinson, 1997; Adedoyin et al., 
1998; Bechtel et al., 2000). 
1.7 Ethical considerations pertinent to pharmacogenetics 
Ethical considerations pertinent to pharinacogenetics have been highlighted by 
Spallone and Wilkie (1999,2000) and include the following (Aitchison & Gill, 2002). 
Firstly,. what are the costs to the individual of population segmentation based on 
pharmacogenetic profile? For example, what might the psychological consequence be 
to someone to realise that they were excluded from a given treatment, e. g. clozapine, 
which is arguably the most effective antipsychotic to date? An individual might prefer 
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to take the risk of agranulocytosis and have haernatological monitoring, depending on 
the magnitude of the risk, whereas a pharmaceutical company might not be prepared to 
take that risk: the risks acceptable to an individual and to a company might differ 
significantly. Similarly, to continue with this example, an effective treatment for 
agranulocytosis might be developed at some point in the future, and, if that were to 
happen, would the pharmaceutical company remove the exclusion from the particular 
population subgroup deemed to be at high risk of agranulocytosis, or would they 
consider that the possible associated risks or costs were for them still too high? 
A related question is the likely size of the population subgroups resulting from 
population segmentation. The size of the groups resulting from a profile designed to 
predict drug efficacy are likely to be significantly larger than those designed to predict 
drug toxicity. Pharmaceutical companies might well be keen to identify relatively large 
subgroups likely to respond well to a given drug, but will it be cost-effective for a drug 
company to market a diagnostic test for a small percentage of individuals at risk of drug 
toxicity; what will be the threshold percentage, threshold cost of the test, and threshold 
severity of the potential ADR? With the economics of drug development already 
constrained to the point that many approved drugs never recover their development 
costs, it is unlikely that any pharmacogenetic strategies that require any significant 
increase in the scope or cost of drug development will be adopted by the industry. It 
has therefore been said that the challenge, then, for pharmacogenetics and 
pharmacogenomics is to invent and implement the novel technologies that can meet 
drug development's needs (Ledley, 1999). 
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Secondly, there are ethical considerations regarding informatics. There is the question 
of informed consent, when the current knowledge base regarding pharmacogenomics is 
relatively poor. What exactly does one tell the patient or volunteer that one is 
consenting for a study or clinical trial? To consent for a pharmacogenomics study 
requires a much broader consent provision than a pharmacogenetics study, the latter 
tending to involve specific candidate genes, the function of which one could make an 
attempt at explaining; the former requires consent for analysis of markers whose 
functional effect may not be known, and the possible consequences to the individual of 
having a particular known genetic marker profile in the future may be very difficult to 
predict. Some drug companies are making efforts to address these issues in written 
information provided to both investigators and patients in pharmacogenetics studies 
that are part of clinical trials (Spallone & Wilkie, 1999). 
Then there is the question of protecting confidentiality for those about whom medical 
data is collected, relevant to any genetic study, and not unique to pharmacogenetics or 
pharmacogenomics; collaborations with pharmaceutical companies or biotechnology 
companies may render the issue particularly pertinent. There are three methods of 
handling data in order to enhance or ensure confidentiality (Spallone & Wilkie, 2000): 
anonymity, encoding, and encryption. Data is anonymous if all information capable of 
identifying the individual to whom the data relates has been removed and destroyed. 
I 
Further information pertaining to that individual may then never be added to the 
6. 
appropriate record in the database. Data is encoded if a serial number or other code is 
attached to the data and a key to this is held elsewhere. Encoded data might be 
effectively anonymous to the research team working on it (e. g. laboratory research 
workers), if they did not have access to the key, but the data would not be truly 
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anonymous, as someone would be able to link the two. Encoding would allow 
updating of an individual's record, e. g. in the course of a longitudinal study. 
Encryption means turning the data into meaningless strings of numbers or letters, which 
are only decipherable by someone with the key. This latter method may be useful not 
so much for reasons of confidentiality towards the subject as for reasons of commercial 
security, ' to prevent unauthorised access by rivals to commercially significant 
collections of data. For pharmacogenetics and phannacogenornics studies, in which it 
may be necessary to link detailed clinical information with genetic data, encoding 
would seem the most appropriate method of preserving subject confidentiality. This 
allows further clinical data to be incorporated in the database in time should research 
indicate that analysis with respect to other clinical variables might be informative. In 
the case of truly anonymised data, the sample can only be used once, then discarded, 
which may, of course, represent the loss of a potentially highly valuable genetic 
resource. 
Finally, in terms of ethical considerations for pharmacogenetics/genomics, 
commercialisation, issue of intellectual property, and patent regimes for biotechnology 
may affect the doctor-patient relationship, which is vulnerable at a time when new 
partnerships developing between academia and industry may blur the boundaries 
between public and private interest. The involvement of industry in pharmacogenetics 
may constrain academic freedom, or restrict the use of any diagnostic tests resulting 
from the pharmacogenetics research, or restrict access to important resources including 
genetic sequencing databases and DNA banks. The latter has been a concern regarding, 
for exampl6, the deCODE-sponsored databank in Iceland (Spallone & Wilkie, 2000). 
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All of the above should be considered when designing a pharmacogenetics study. All 
research reported in this thesis has been approved by the relevant Ethics Committees. 
1.8 Aims of this thesis 
This thesis describes pharmacogenetic studies of CYP2D6, CYP2Cl9, and CYPlA2, 
cytochrome P450 enzymes involved in the metabolism of antipsychotics and 
antidepressants. The hypotheses were that low enzyme activity would be associated 
wi, th,, a high incidence of adverse effects of metabolised drug, while high enzyme 
activity would be associated with therapeutic resistance. 
Chapter 3 describes a couple of genotype-phenotype correlation studies for CYP2D6, 
iý 11 .. 
followed by a number of genetic association studies of CYP2D6, CYP2Cl9, and 
CYPIA2 and antidepressant and antipsychotic treatment response, including adverse 
effects. The aim of the first genotype-correlation study was to investigate the degree of 
genotype-phenotype correlation in French subjects, through genotyping for the 
CYP2D6*3-5 and gene duplication alleles. The aim of the second genotype-phenotype 
correlation study was to investigate the, degree of CYP2D6 genotype-phenotype 
correlation in an elderly sample, in order to ascertain whether due to age, a relative 
genotype-phenotype discrepancy developed. 
The general aim of the genetic 
'association 
studies was to determine whether or not 
there was an association between cytochrome P450 genotype or phenotype 
IýIýI-I 
(specifically, that of CYP2D6, CYP2CI9, or CYPIA2, or a combination thereof) and 
clinical response to treatment with antipsychotics and antidepressants. In the first 
reported genetic association study, I tested the hypothesis that patients with 
schizophrenia who were refractory to treatment with typical antipsychotics would be 
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more likely to be ultrarapid metabolisers, as compared with patients who responded to 
typical antipsychotics. In the next set of genetic association studies, I report 
investigation of putative association between CYP2D6 metaboliser status and 
susceptibility to adverse effects of antipsychotics. In a genetic association study of 
antidepressant treatment, there were several aims, including testing-of the hypothesis 
that CYP2D6 ultrarapid metaboliser status would be associated with therapeutic 
resistance to treatment, that low CYP2D6 activity would be associated with a high 
incidence of adverse effects, and that CYP2CI9 activity would also influence both 
clinical response and adverse effects. In the last genetic association study reported in 
Chapter 3, the aim was to investigate the association between CYPlA2 polymorphism 
and response to clozapine. 
Chapter 4 reports -mutation screening and functional studies of the 5' flanking region of 
CYPIA2. Given the indication that factors including genetic polyrnorphism in CYPIA2 
could contribute to CYPlA2 variability and the negative finding of Nakajima et al. 
(1994), my aim was to screen the 5' flanking region of CYPIA2 further upstream than - 
3470 bp, ' to see whether or not a functional polymorphism, which could affect the 
inducibility of CYP I A2, could be found. 
In Chapter 5, pharmacokinetic and pharmacodynamic studies of clozapine in CYPlA2- 
null mice are reported. The literature available at the time of this work was 
inconclusive regarding the contribution of CYPIA2 to clozapine metabolism. My aim 
was to use the CYPIA2 -/- mouse in order to investigate the in vivo contribution of 
CYPIA2 to clozapine pharmacokinetics. In addition, I used the CYPIA2 -/- mouse as 
a model for low CYPlA2 activity in man, through the use of behavioural ratings, 
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aiming to draw conclusions regarding the pharmacodynamic 'effects of clozapine in 
individuals relatively deficient in CYPlA2 activity. 
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CHAPTERTWO 




2.1.1.1 French Caucasians / volunteers 
A sample of 154 normal French male volunteers were recruited as part of a Phase II 
clinical trial (M-A Crocq and J-P Macher, Centre Hospitalier Specialise, 68250 
Rouffach, France). Forty-six also consented to phenotyping for CYP2D6 activity using 
dextromethorphan (see below). 
2.1.1.2 UK Caucasians 
A, sample of 74 UK volunteers were recruited by the Clinical Age Research Unit, 
King's College London (S Jackson, M Kinirons, and C Bryant). Recruitment was from 
a, variety of sources, including referral from medical practitioners, advertisement in 
local libraries and retired elderly people's day centres, and by word of mouth from 
existing volunteers. For each volunteer, the following information was ascertained: 
ethnicity,, past psychiatric history, past medical history, alcohol intake, level of 
smoking, and current medication. In addition, the 28-itern General Health 
Questionnaire (GHQ, Goldberg & Hillier, 1979, using the simpler "GHQ scoring 
method, " 0-0-1-1) was administered. No volunteers gave a history of psychiatric illness 
and 4 had a GHQ greater than or equal to 5 (the threshold score 4/5 correlating with 
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psychiatric "caseness, " Goldberg & Hillier, 1979). Forty-three of these volunteers 
were eligible for and consented to phenotyping with debrisoquine. 
2.1.1.3 Taiwanese 
One hundred and twenty-five nonnal Taiwanese volunteers (all Han Chinese) were 
recruited (J-D Huang, Department of Pharmacology, College of Medicine, National 
Cheng Kung University, Tainan, Taiwan), and blood samples were taken for DNA 
analysis. 
2.1.1.4 Black Americans 
One hundred and four American subjects of African descent were collected (W. E. 
Evans, Pharmaceutical Department, St Jude Children's Research Hospital, 332 North 
Lauderdale, Memphis, Tennessee 38101-0318, USA), and blood samples taken for 
DNA analysis. 
2.1.2 Patients 
2.1.2.1. Patients treated with typical antipsychotics 
Sixty-six Caucasian subjects with DSM-IIIR schizophrenia were collected (P. Wright, 
South London and Maudsley NHS Trust). They were receiving treatment with typical 
antipsychotics (32% haloperidol decanoate, 25% fluphenazine decanoate, 22% 
flupenthixol decanoate) at doses equivalent to at least 100 mg chlorpromazine daily for 
at least 12 months prior to the date of assessment. All were examined for the presence 
of tardive dyskinesia (TD) using the Abnormal Involuntary Movements Scale (AIMS, 
US Department of Health, Education, and Welfare, 1974). A Research Diagnostic 
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Criteria (RDC) diagnosis of probable TD was made if subjects scored 2 or more in 2, or 
3 or more in one of the 7 body areas assessed (Schooler and Kane, 1982). A further 
assessment using the AIMS was made between 2 and 6 weeks after the initial 
assessment, and persistent TD was confirmed if the above criteria were still fulfilled. 
In addition, all subjects were examined for the presence of drug-induced parkinsonism 
(DIP) using Webster's Rating Scale for Parkinsonism (WRSP). A diagnosis of DIP 
was made if a score of 2 (moderate slowness) or greater on the bradykinesia item, along 
with a combined score of 3 or greater on the rigidity and tremor items was reached 
(Metzer et al., 1989). Six Caucasian patients with schizophrenia were also collected by 
S. Smith (South London and Maudsley NHS Trust), and rated for TD and DIP. 
2.1.2.2. Affected twin pair and affected sib pair 
One affected twin pair and one affected sib pair was collected (M. Taylor, R. M. 
Murray). The twins were 31 years at time of sampling, had a diagnosis of 
schizophrenia, and had both suffered adverse effects on a variety of antipsychotics 
(including extrapyramidal side effects or EPSE on typical antipsychotics, and 
neutropenia on clozapine). The sib pair was two brothers, 29 years and 23 years of age, 
both with schizophrenia, with an unaffected sister and unaffected parents. Both 
brothers had suffered EPSE on typical antipsychotics and neutropenia on risperidone. I 
administered the debrisoquine for phenotyping the twins, brothers, brothers' sister and 
parents (Lennard et al., 1977), and took blood samples for DNA analysis. I also 
reviewed the medical records in order to ascertain a full medication history, and 
interviewed each subject. 
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2.1.2.3 Patients treated with clozapine 
Two hundred and forty-six patients treated with clozapIne In the UK were collected 
(R. W. Kerwin and J. Munro, South London and Maudsley NES Trust). All of these 
patients were resistant to treatment with typical antipsychotics, and had a diagnosis of 
schizophrenia or schizoaffective disorder (clozapine prescribing restrictions in the UK, 
UK Clozaril Patient Monitoring Service). Prescribing consultants provided data 
regarding whether their patients were refractory to typical antipsychotics, intolerant of 
typical antipsychotics, or both refractory and intolerant of typical antipsychotics. Out of 
the 246 patients on clozapine, there were a total of 220 (89.4 %) who were refractory, 
11 (4.5%) who were intolerant, and 15 (6.1%) who were refractory an(l intolerant to 
typical neuroleptics. The standard definition of treatment-refractory schizophrenia has 
been provided by Kane et al. (1988): (1) at least 3 periods of treatment in the preceding 
5 years with antipsychotics (from at least 2 different chemical classes) at doses 
equivalent to or greater than 1000 mg/day of chlorpromazine for a period of 6 weeks, 
each without significant symptomatic relief, and (2) no period of good functioning 
within the preceding 5 years. Data regarding which typical antipsychotics had been 
prescribed were not available. However, the most commonly prescribed typical 
antipsychotic prior to switching to clozapine in the UK for the period during which our 
sample was collected was halopendol (Novartis, personal communication). Seventy- 
nine were female (32.1%), one hundred and sixty-seven male (67.9%). The mean age 
was 39.0 years (range 19-81 years, SD 10.57). 
In addition, information was collected from the psychiatrists prescribing clozapine 
regarding each patient's global level of response to clozapine, categonsing the response 
into I of 4 categories: improved a lot (Category 1); improved a little (Category 2); 
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showed no improvement (Category 3); and inadequate information available (Category 
4). 
2.1.2.4 Patients treated with tricyclic antidepressants 
I collected a sample of 49 patients with ICD-10 (World Health Organisation, 1992) 
depressive disorder (n = 41) or bipolar affective disorder (n = 8) in receipt of tricyclic 
antidepressant treatment, ascertaining the following information: ethnicity, age, alcohol 
intake (units/week), level of cigarette smoking (cigarettes per day), and current and 
previous treatment regime, and previous levels of tricyclics and their demethylated 
metabolites on previous treatment regimes. These patients were phenotyped for 
CYP2D6 status using the debrisoquine test (Lennard et al., 1977, see below). I also 
performed Hamilton Depression Rating Scale ratings (HDRS, Hamilton, 1967; Guy, 
1976), scoring patients prospectively for their severity of depression after a course of at 
least 6 weeks of tricyclic antidepressant (post-treatment score), and retrospectively for 
their pre-treatment score by interview at the post-treatment point with corroborative 
information from clinical records (I was trained in the use of the HDRS by Prof S 
Checkley). In addition, I rated the patients for adverse effects of the tricyclics using a 
modified version of the scales described by Asberg et al. (1970) and Ziegler et al. 
(1978). Subjects were rated for the following adverse effects on a 0-3 severity scale (0 
= absent, I= mild, 2= moderate, 3= severe): dry mouth, drowsiness, blurred vision, 
headache, constipation, nausea or vomiting, disturbance of micturition, interference 
with sexual function, palpitations, orthostatic symptoms, vertigo, sweating, tremor, 
disorientation, and weight gain. In their study of nortripytline plasma levels nad 
subjective side effects, Ziegler et al. (1978) found that eight of the above items (dry 
mouth, blurred vision, constipation, disturbance of micturition, orthostatic symptoms, 
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vertigo, sweating, and tremor) correlated more consistently with nortriptyline level, 
The 8-item corrected adverse effect score (total of score for these 8 items) was 
therefore also derived. Blood samples for DNA analysis and for serum levels of 
tricyclics and their N-demethylated metabolites were also taken. 
2.1.3 Mice 
A line of CYPIA2-null (-/-) mice were produced as described (Pineau et al., 1995, 
Buters et al., 1996), and were already available at the time of commencement of my 
study. In brief, a mouse CYPIA2 cDNA probe was used to isolate a 129/SV mouse 
genomic DNA clone, and disruption of CYPlA2 in this clone was generated by , 
inserting the NEO gene (phosphoribosyltransferase II, confers resistance to the 
, antibiotic G418) at a unique Hind III site in the second exon (first coding exon). A 
Herpes simplex virus thyinidine kinase (HSV-TK) expression cassette was added to 
allow the use of ganciclovir for negative selection of homologous recombinant clones. 
Target vectors were linearised and used for electroporation into JI embryonic stem 
cells (isogenic to 129/SV), cultured on y-irradiated G418-resistant mouse primary 
fibroblasts, and G418 *and ganciclovir resistant colonies were picked 6 days later. 
Restriction analysis and PCR were used to characterise positive clones and determine 
NEO orientation, and embryonic stem cells from one clone were in ected in to the 
blastocoel cavity of 3.5-day C57BL/6N embryos. Embryos were transferred into 
pseudopregnant NIH Swiss foster mothers. Chimeric males were generated that gave 
germ-line transmission of the targeted allele. Homozygous mutant mice (-/-) were 
obtained by heterozygous (+/-) matings. Animal genotyping was carried out by 
Southern blot analysis of tail DNA. 
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In my study, I used wild-type mice of the same (129/SV) genetic background as the 
CYPlA2 4- mice. These two strains have been previously characterised in detail by 
Buters et al. (1996), who showed that all parameters that might affect pharmacokinetic 
studies were not significantly different in the two strains. Specifically, they showed 
that renal function (as measured by creatinine), liver function (bilirubin, alanine 
transaminase, aspartate transaminase), protein binding (albumin), and the expression of 
other cytochrome P450s did not differ between the 2 strains. 
All mice were kept in a barrier facility with 2 ppm chlorinated water, autoclaved food, 
and bedding under a 12h light-dark cycle, 40% humidity, with free access to food and 
water. The animals were fasted for 12 hours prior to dosing and for the duration of the 
experiment, but allowed water ad libitum throughout. I conducted pilot studies in order 
to determine the dose of clozapine that would produce detectable pharmacokinetic data 
without inducing toxicity in the mice, and also the time points at which samples should 
be taken for meaningful pharmacokinetic data to result. For this purpose, a total of 28 
wild type mice and 19 CYPIA2 -/- mice in a total of 11 pilot studies were used, 
employing doses of clozapine ranging between 5 and 25 mg/kg, and taking blood 
samples at various time points up to 480 min post injection of clozapine. For the final 
experiment, four male CYPIA2 -/- and four male wild-type animals were used. These 
8 mice had all been born 81 days prior t6the day of the pharmacokinetic study. 
2.1.4 Ethical Committee approval 
All studies, involving human subjects were approved by the South London and 
Maudsley NES Trust (Bethlem and Maudsley Hospitals) and Institute of PsY'Chiatry 
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Ethical Committee (Research), or local ethics committees, as appropriate. The mice 
study protocol was approved by the Animal Care and Use Committee of the National 
, Cancer Institute (National Institutes of Health, Bethesda, MD, USA). 
2.2 LABORATORY METHODS 
The composition of buffers and other experimental reagents is described in Table 2.1. 
2.2.1 CYP2D6 phenotyping 
2.2.1.1 Debrisoquine phenotyping 
Debrisoquine is an antihypertensive agent which is no longer licensed for prescription, 
but which has been well described as a CYP2D6 probe, CYP2D6 catalysing the 
formation of 4-hydroxydebrisoquine in vivo (Evans et al., 1980). For debrisoquine 
phenotyping, subjects were instructed to empty their bladder, take, a 10 mg dose of 
debrisoquine (Declinax 0, Roche Products Ltd. ) before retiring, then collect any urine 
passed during the subsequent 8 hours in the collection bottle provided, rising exactly 8 
hours after retiring, and emptying their bladder on rising into the bottle provided. They 
were also instructed to avoid alcohol on the day that they performed the debrisoquine 
test, and not to eat anything for 2 hours prior to taking the debrisoquine. In addition, all 
subjects who had a history of liver disease were excluded. Two 30-ml aliquots of the 
unne samples from each subject were made and frozen at -200C for later analysis; the 
concentrations of debrisoquine and 4-hydroxydebrisoquine in one of these were 
determined by flame-ionisation gas chromatography with minor modifications of the 
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Table 2.1 ExDerimental reagents 
gent Composition 
Reag Comments 
Nonidet P40' An octylphenol-ethylene oxide 
condensate containing an 
average of 9 moles of ethylene 
oxide per mole of phenol 
Proteinase K 20 mg/ml stock solution, use in 
reaction at 50 pg/mI 
Store stock solution at -200C, 
digest at 37-560C 
Proteinase K buffer 






(Nucleon 11 Kit) 
Triton X- 100 
Reagent B 
(Nucleon 11 Kit) 
0.0 1M Tris (pH 7.8), 0.005 M 
EDTA, 0.5% SDS 
Dissolve 100 g SDS in 900 ml 
H20. Heat to 680C to assist 
dissolution. Adjust the pH to 
7.2 by adding a few drops of 
concentrated HCL Adjust the 
volume to II with H20- 
A mask should be wom when 
weighing SDS and the weighing 
area and balance should be 
wiped down after use, because 
the fine crystals of SDS disperse 
easily. There is no need to 
sterilise 10% SDS. 
Dissolve 12 1.1 g Tris base in 
800 MI H20. Adjust the pH to 
the desired value by adding 
concentrated HCI (for pH 7.4, 
use approximately 70 ml HCI, 
pH 7.6, use 60 ml HCI, pH 8.0, 
use 42 ml HCI). 
Mix equal amounts of phenol 
and chloroform, and equilibriate 
by extracting several times with 
0.1 M Tris-CI (pH 7.6-8.0), or 
buy equilibriated mixture. Store 
under an equal volume of 0.0 1 
M Tris-CI (pH 7.6-8.0), at 40C 
in dark glass bottles. 
The pH of Tris solutions is 
temperature-dependent and 
decreases approximately 0.03 
pH units for each I OC increase 
in temperature. For example, a 
0.05 M solution has pH values 
of 9.5,8.9, and 8.6 at 50C, 250C, 
and 370C respectively. 
Phenol is highly corrosive, so 
safety glasses must be used, and 
all manipulations conducted in a 
hood. Any areas of skin coming 
into contact with phenol should 
be rinsed with a large volume of 
water and washed with soap and 
water. 
10 mM Tris-Cl (pH 8.0) 
I mM EDTA (pH 8.0) 
10 mM Tris-Cl 
320 mM sucrose 
5 MM MgC]2 
I% Triton X- 100 
Adjust to pH 8.0 using IM 
NaOH /concentrated HCI, and 
autoclave. 
Polyoxyethylene-p- 
isooctylphenol, a nonionic 
detergent 
400 mM Tris-Cl 
60 mM EDTA 
150 mM NaCl 
1% SDS 
Store dark, at RT, can be used to 
substitute for Nonidet P40 in 
many applications 
Adjust to pH 8.0 using IM 
NaOH, prior to adding the 
EDTA. Autoclave prior to 
adding the SDS. 
5x TBE 270 g Tris Base ' Make up to 5 litres with distilled 
137.5 g Borate, 14.8 g EDTA deionised H20 
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Table 2.1 Experimental reagents (continued) 
PCR-grade H20 Distilled deionised water, Or: water filtered using a 
filtered through 0.2 M filters MilliQ-Plus system 
Ethidiurn bromide (10 mg/ml) Dissolve Ig ethidiurn bromide 
in 100 ml H20 for several hours 
on magnetic stirrer (or buy 
solution at this concentration). 
LB medium (I litre) 10 g Bacto-tryptone 
5g Bacto-yeast extract, 10 9 
NaCl 
LB agar (350 ml) 1.5 g Bacto-tryptone 
1.75 g Bacto-yeast extract 
3.15 g NaCl, 5.25 g Bacto-agar 
6x Loading buffer 11 0.25% bromophenol blue 
0.25% xylene cyanol FF 
15% Ficoll (Type 44, 
Pharmacia) 
6x Loading buffer 111 0.25% bromphenol blue 
0.25% xylene cyanol FF 
30% glycerol 
3M Sodium acetate Dissolve 408.1 g sodium 
acetate-31-120. Adjust the pH 
with glacial acetic acid, then 
adjust the volume to II with 
H20- 
TEMED NNN', N'- 
tetramethylethylenediamine 
Sequencing loading buffer 5: 1 deionised formamide 
to 25 mM EDTA (pH 8.0), with 
blue dextran (50 mg/ml) 
IPTG Isopropylthio-fl-D-galactoside 
(MW 238.8 g). Dissolve 2g 
IPTG in 8 ml distilled H20- 
Adjust the volume to 10 ml with 
distilled H20, and sterilise by 
filtration through a 0.2 pm filter. 
Store at RT in dark bottle. 
Ethidium bromide is a powerful 
mutagen, and appropriate 
precautions should be taken. 
Make up to I litre with distilled 
deionised H20, then autoclave. 
Make up to 350 ml with distilled 
deionised H20, then autoclave 
for 60 min. 
Store at room temperature 
Store at 40C 
Dispense into aliquots and 
sterilise by autoclaving. 
TEMED is a catalyst for the 
polyrnerisation of acrylamide 
when used with ammonium 
persulphate. Store well-sealed, 
dry, and dark, at RT. 
Store at -200C 
Dispense the solution into I ml 
aliquots, and store at -200C. 
X-gal 5-Bromo4-chloro-3-indolyi-p- Wrap tube in foil and store at - 
D-galactoside. Dissolve in 200C. (Not necessary to sterilise' 
dimethylformamide to make a by filtration. ) 
20 mg/ml stock solution in a 
glass or polypropylene tube. 
SOC medium 2% Tryptone, 0.5% Yeast Store at -200C 
Extract, 10 mM NaCl, 2.5 mM 
KCI, 10 mM MgC12,20 mM 
glucose (dextrose) 
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method of Lennard et aL (1977), i. e. boiling for 15 min instead of incubating for 16 
hours, and the use of a capillary column instead of a packed column. This assay was 
performed by M. Patel (St Bartholomew's Hospital); the second sample was stored for 
second analysis should this be required. 
The debrisoquine metabolic ratio (NlRdebrisoquine) was defined as the ratio of the 
concentrations of debrisoquine to 4-hydroxydebrisoquine in the urine sample. The limit 
of detection was I pg/ml, and subjects with no detectable metabolite were also classed 
a-s PMs. The intra- and interassay coefficients of variation (CV) for measurement of 
debrisoquine spiking the urine with 4 pg/ml, were 7.21% and 7.33% respectively. The 
corresponding values for 4-hydroxydebrisoquine were 7.97% and 9.98% respectively. 
Each assay was run with a control of known CYP2D6 intennediate metaboliser status 
(MRdebrisoquine 4-6). 
2.2.1.2 Dextromethorphan phenotyping 
Dextromethorphan phenotyping, using a 30 mg dose of dextromethorphan and an 8- 
hour overnight urine collection was performed similarly. The concentrations of 
dextromethorphan and its O-demethylated metabolite, dextrorphan, in a 30 ml aliquot 
were determined by high performance liquid chromatography (Chen et al., 1990), with 
the - analysis being performed by collaborators at the Centre Hospitalier Specialis6. The 
dextiomethorphan metabobolic ratio (MR) was defined as the ratio of the urinary 
concentrations of dextromethorphan to dextrorphan. 
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2.2.2 Isolation of DNA 
2.2.2.1 DNA extraction from peripheral leucocytes 
Blood (5-9 ml) was collected in potassium EDTA tubes and stored at -700C until use. 
Two methods of DNA extraction were used: phenol/chlorofonn (with proteinase K), 
and the Nucleon BACC3 kit for genomic DNA extraction (Tepnel Life Sciences PLC, 
Manchester, UK). The former was used for the samples collected earlier in this study, 
and the latter for the later samples, as it is a quicker method, more easily adaptable for 
the processing of considerable numbers of samples. The composition of all solutions 
used is given in Table 2.1. 
Phenollchloroform extraction of genomic DNA 
Blood samples were thawed at room temperature, and decanted into 50 ml Falcon 
tubes. Distilled deionised H20 at 40C was added to 40 ml, and the tubes placed on ice. 
Cells were then pelleted by centrifugation at 2,000 g for 10 min, resuspended in 25 ml 
0.1 % Nonidet P40, and pelleted for a second time by centrifugation at 3,250 rpm for 
10 min. This pellet was resuspended in 10 ml Proteinase K buffer. To this was added 
25 gl proteinase K at 20 mg/ml (for protein digestion), then 0.5 ml 10% SDS (to lyse 
the nuclear membranes), the latter slowly, drop by drop, swirling the contents of the 
tube, until a viscous solution resulted. ' This was then incubated overnight at 370C. 
Tubes were then placed on ice again, 5 ml phenol at pH 7.8 (equilibriated with 
Tris. HCl pH 8.0) was added, the tubes were placed on a rotary shaker for 5 minutes, 
then centrifuged at 2,000 g for 5 minutes. The upper (aqueous) layer was then 
removed, to this was added 5 ml phenol at pH 7.8 and 5 ml chloroform, and the shaking 
and centrifugation steps were repeated as above. The aqueous layer was removed a 
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second time, and, either a phenol: chloroform extraction, or only chloroform extraction 
(5 ml) was repeated. The DNA was then precipitated using 2.5 times the volume of 
absolute'ethanol at -200C, recovered using a flamed Pasteur pipette, air dried, and 
rinsed in 1 ml 70% ethanol at 40C. Depending on the yield, DNA was then 
resuspended in 50-200 ýLl of TE, left overnight at 40C to dissolve, and then stored at - 
200C prior to quantification. 
Nucleon BA CC3 kit extraction ofgenomic DNA 
Blood was thawed as above, decanted into 15 ml Falcon tubes, and 14 ml Reagent A 
was added. Tubes were handshaken for 2 minutes, then placed on a rotary shaker for 5 
minutes, then centrifuged at 2,800 g for 8 minutes (to lyse the red cells and then pellet 
all cells). To the pellet was added I ml Reagent B, and this was vortexed vigorously 
until the pellet was completely dispersed (to lyse the leucocytes). To this was added 
250 gl of 5M sodium perchlorate, the mixture was swirled and placed on a rotary 
shaker for 10 minutes, and then in a water bath at 630C for 25 minutes (effecting 
deproteinisation). To extract the DNA, Iml of chlorofonn at -200C was added, the 
mixture swirled, and centrifuged at 2,000 g for 2 minutes. In order to facilitate 
I 
separation of the upper DNA-containing aqueous phase from the lower organic phase, 
200 ýtl of Nucleon II resin (a silica-based suspension) was added, and the tubes spun 
again at 2,000 g for 2 minutes. DNA was then precipitated by adding the upper 
aqueous layer to 2.5 ml absolute ethanol at -200C, and recovered, washed, dissolved, 
and stored as above. 
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Quantification of DNA 
The. concentration of the DNA in TE solution was measured using a UV 
spectrophotometer. The absorbance at 260 nm allows quantification of DNA, using the 
following equation: 
[DNA] in ýLg/ml = OD260 xXx dilution factor 
where X is 50 for double-stranded DNA, and the dilution factor is that used for diluting 
the samples for reading in the spectrophotometer cuvette. A dilution factor of 20 was 
used (5 pl of sample diluted in 100 pl TE), with the result that the above equation 
simPlifies to: 
[DNA] in ýtg/rnl = OD260 X 1000 
i. e. [DNA] in pg/pl = OD260 
In addition, the UV spectrophotometer readings were used to estimate the purity of the 
sample. The OD280 is a measure of the protein content, a ratio of the OD260 to OD280 Of 
at least 1.8 indicating DNA of a high degree of purity; ratios of 1.6 and above were 
regarded as acceptable. After quantification, aliquots of the DNA samples at 100 ng/ýtl 
(in sterile TE) were made. 
2.2.2.2 Isolation of DNA from agarose gels 
The QIAEX H agarose gel extraction kit was used (designed for the extraction of 40 bp 
to 50 kb DNA fragments from 0.3-2.0% agarose gels). The DNA band of interest was 
excised from the gel using a clean scalpel and weighed in a 1.5 ml eppendorf tube. To 
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this was added 3 volumes of Buffer QX1 (containing a high concentration of chaotropic 
salt to disrupt the hydrogen bonds between the sugars in the agarose), then 10 ýtl of 
QIAEX II suspsension (containing glass powder to adsorb the DNA), then the 
eppendorf was inverted to mix contents, and incubated at 500C for at least 10 minute, 
with mixing of contents by hand every 2 minutes in order to keep the QIAEX 11 in 
suspension. The adsorption of DNA to QIAEX II is only efficient at pH c: 7.5, so once 
the gel had dissolved, the pH was checked (using pH paper), and if the pH was >7.5,10 
pl of 3M sodium acetate (pH 5.0) was added and the mixture incubated at room 
temperature for a further 10 minutes. The sample was then centrifuged at 10,000 g for 
30 s, the pellet resuspended in 500 ýd of buffer QX1 by vortexing, and then 
recentrifuged (to remove residual agarose contaminants). The pellet was then 
resuspended in 500 ýtl of Buffer PE by vortexing, and recentrifuged, with this step 
being repeated (to remove residual salt contaminants) At these last 3 stages, it is 
important to remove all traces of supernatant. The pellet was then air-dried at room 
temperature until it became white (usually approximately 15 minutes), following which 
the DNA was eluted by the addition of 20 [d of 10 mM Tris. HCI pH 8.5, resuspending 
the pellet by vortexing, incubating for 5-10 minutes at room temperature, and retrieving 
the supernatant after centrifugation. 
2.2.2.3 Isolation of BAC DNA 
The BAC clones were stored in E. coli cells at -700C, and grown up by seeding into 
conical flasks containing 250 ml. of LB medium with chloramphenicol at 12.5 pgIml 
(the latter to increase yield in the presence of the ColEI replication origin), and 
incubating overnight in a shaking incubator at 370C. The bacteria were harvested by 
centrifugation at 2,400 g for 10 min, and the BAC DNA extracted by use of the 
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QIAGEN Plasmid Maxi kit (Qiagen Ltd., Crawley, UK), see Table 2.2 for composition 
of reagents. 
The bacterial pellets were first resuspended in 10 ml Buffer PI (in plastic centrifuge 
tubes), then 10 ml Buffer P2 was added, and the tubes inverted 10 times to mix 
contents, resulting in a viscous solution, which was incubated at RT for 5 min. To this 
was added 10 ml chilled Buffer P3, followed by immediate but gentle mixing of the 
tube contents by inversion 10 times, and incubation on ice for 20 min. Tubes were then 
centrifuged at at least 20,000 xg for 30 min at 40C, and whilst this was being 
conducted, Qiagen-tip 500s were equilibriated by applying 10 ml buffer QBT, and 
allowing the column to empty by gravity-assisted flow. The supernatant was then 
filtered (filters supplied in syringes in the kit), allowing the filtrate to pass into the 
Qiagen tips, entering the resin by gravity flow. The Qiagen tips were then washed 
twice with 30 ml Buffer QC (this step removes contaminants), again allowing the 
buffer to pass through the tip by gravity flow. The DNA was then eluted with 15 ml 
Buffer QF into glass centrifuge tubes, and precipitated with 0.7 volumes isopropanol at 
RT by centrifugation at at least 15,000 xg for 30 min at 40C. The DNA pellet was then 
washed in I ml of 70% ethanol, then recentrifuged, this step being repeated up to 3 
times, especially if not all of the pellet was recovered from the glass centrifuge tube 
initially. The BAC DNA was then dissolved in an appropriate volume of TE, overnight 
at 40C, and concentration estimated by running I [d on a 1% agarose gel together with 
standard DNA of known concentration. 
2.2.2.4 Isolation of plasmid DNA 
Single colonies containing plasmid DNA were picked from the sample plates, seeded in 
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Table 2.2 Experimental Materials - Qiagen Plasmid Purification Buffers 
Reagent Composition Comments 
Buffer P1 50 mM Tris. Cl, pH 8.0 Use Tris base, adjust pH to 8.0 
(resuspension buffer) 10 mM EDTA with HCI, store at 40C after the 














200 mM NaOH, 1% SDS Store at RT 
3.0 M potassium acetate, pH 5.5 Store at RT, or 40C 
750 mM NaCl 
50 mM MOPS, pH 7.0 
15 % isopropanol 
0.15% Triton X- 100 
Store at RT, sterilise by 
filtration 
IM NaCl 
50 mM MOPS, pH 7.0, 
15% isopropanol 
1.6 M NaCl 
50 mM Tris. Cl, pH 8.5 
15% isopropanol 
1.6 M NaCl 
50 mM MOPS, pH 7.0 
15 % isopropanol 
100 mM NaCl 
10 mM Tris-Cl, pH 8.0 
1 mM EDTA 
Store at RT, sterilise by 
filtration 
Store at RT, sterilise by 
filtration 
Store at RT, sterilise by 
filtration 
Store at RT 
to 5ml Circle Grow (BIO 101, Inc, Vista, CA, USA) medium with ampicillin at 50 
ng/ml (for plasmids containing the ampicillin resistance gene, so that plasmids could be 
selected for ampicillin resistance), and placed in a 370C shaking incubator at 225 rpm 
overnight. 
IThe 
following day, 100 ml of Circle Grow medium with 50 ng/ml 
ampicillin was seeded with 500 pl of the 5 ml culture, and placed in the 370C shaking 
incubator again at 225 rpm for 16 hours. The next day, plasmid was harvested from the 
culture using QlAGEN-tips 500 (Maxi), following the same plasmid purification 
protocol as above, except that I found that in order to produce high quality plasmid, it 
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was necessary to vortex the pellet briefly in the first step, to perform a second 
centrifugation step (recentrifuging at 20,000 xg for 15 min at 40C after the first 
centrifugation at 20,000 x g), to perform a second wash with 70% ethanol at the end, 
and to ensure that the pellet was dry (translucent) before redissolving in TE pH 7.5 
(100 [11). 
2.2.3 PCR techniques 
2.2.3.1 Standard Iýngth PCR 
Primer-mediated enzymatic amplification of DNA was first described by Saiki et aL 
(1985), and was named the polymerase chain reaction by Mullis et aL (1986,1987). It 
is a technique for amplifying in vitro a segment of DNA that lies between two regions 
of known sequence, commencing with primers '(oligonucleotides) of sequence 
complementary to opposite strands of the knowm sequence, at opposite ends of the 
target region to be amplified. The DNA is amplified exponentially by a series of 
repeated cycles of denaturation of template, primer annealing, and extension of 
sequence beginning with the annealed primers by a DNA polymerase. The extension 
product of one cycle of the PCR reaction serves as the template in the next cycle, 
causing an exponential accumulation of the product. It is theoretically possible to 
achieve a 107 fold amplification in 30 rounds of thermal cycling. The efficiency of a 
PCR amplification can be calculated using the following formula: 
N= No (1+eff)' 
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Where N= number of end products, No = number of starting targets (I gg of human 
genomic DNA =1.4-3 X 105 copies of a single-copy gene), n= number of cycles, and 
eff mean efficiency of a cycle. For example, with an efficiency of 85%, 20 cycles 
will give 220,000-fold amplification. 
The DNA polyinerase used for standard length PCR (<5 kb) was Taq, a thermostable 
DNA polymerase purified from the thermophilic bacterium, Yhermus aquaticus, and 
produced by the expression of a modified form of the Taq DNA polymerase gene 
cloned in E coli (Lawyer et al., 1989). This is a 94 kDa protein that has a ti/2 of 
approximately 40 minutes at 950C, possesses 5'-3' exonuclease activity, but lacks 3-5' 
exo nuclease activity, and extends at a rate of 2-4 kb per minute at 720C. The fidelity of 
Taq is less than or equal to I in 10-50,000 nucleotides (Eckert & Kunkel, 1991), and is 
affected by reaction conditions (e. g. high magnesium concentrations reduce the fidelity 
I 
of Taq). 
The primer sequences were designed either by hand, using certain guidelines (e. g. a 
"GC clamp" at the 3' end, Le. aG or aC at the 3' end of the sequence, may increase 
specificity of annealing), or using the programme PRIMER (Lincoln et al., 1991), and 
all primer sequences can be found within the relevant chapters of this thesis. Primers 
that were designed by hand were tested for suitability using web-based tools for 
identification of likelihood of secondary structure formation, Le. inter-primer 
dimers/oligomers or intra-primer hairpins (e. g. that available via Operon Technologies, 
Inc. on the website http: //operon. com). The Tn, (melting temperature) of each primer 
was calculated using the following formula for primers of at least 10 bases: 
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T. = 81.5 + 16.6(log[molarJ+])+41(#G+#C)/primer length -675/primer length 
Where the molar J+ is the concentration of monovalent cations and is 0.05 M for PCR 
(see below), and #G is sum of the number of Gs, and #C the sum of the number of Cs 
in the primer. For primers of less than 10 bases, the following formula is adequate: 
(#G + #Q x4+ (#A + #T) x2 
Primer pairs were designed such that their T,,, s were similar, and chosen such that in 
general the %GC (i. e. 100 x (#G +#C/priffier length)) was close to 50%, or if the region 
to be amplified was such that primers with less than 50% GC had to be used, then the 
length of the primer was increased. Sources for the primers included Oswel DNA 
Service, GibcoBRL, Operon Technologies, Inc., and Genset. Primers in excess of 30 
base pairs were HPLC-purified. The annealing temperature (see below) was initially 
set at 50C below the mean Tn of the primer pair. 
Various thermal cyclers were used for the PCRs (e. g. Perkin Elmer Thermal Cycler, 
Perkin Elmer 2400, Biometra TRIO-Thermoblock, MJ Research DNA Engine Tetrad), 
and the cycling conditions varied slightly depending on the cycler used, and again, 
specific conditions (annealing temperatures, etc. ) are given in the relevant chapters of 
the thesis. In general, the cycling conditions included an initial denaturation step of 930- 
950C for up to 3 min, in order to denature genomic template, followed by 25-35 cycles 
of denaturation at 930C for 30s to I min, annealing at 50-650C depending on the primer 
Tms for 10 s-I min, and elongation at 720C for 1-3 minutes. Slightly lower 
temperatures and slightly shorter time periods were chosen for the later model cyclers 
(employing a more -rapid ramping system). The length of the elongation step was 
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chosen according to the length of the amplicon expected, at I minutes per kb. Finally, a 
terminal elongation step of 720C for 7 minutes was performed, in order to increase the 
number of full-length products, since in the final rounds of amplification the amount of 
enzyme may become limiting and lead to the production of partially elongated 
products. The reaction was then cooled tO'40C. 
The primers were used together with 50-100 ng genomic DNA in a total reaction 
volume of 25-100 ýtl, containing 10 mM Tris. HCl pH 8.3,50 MM KCI, 0.001% (w/v) 
gelatin, 1-3 MM MgC12,, 0.2 mM each dNTP, 0.2-0.5 ýM each primer, 1-2.5 U Taq, and 
made up to the total reaction volume with PCR-grade water (Table 2.1). The mixture 
of the Tris. HCI, KCI, and gelatin was supplied as a 10 x concentrate ("PCR buffen 
together with the Taq supplied by manufacturers (a variey of manufacturers were used 
during the course of the work for this thesis, including Applied Biosystems (Perkin- 
E, lmer) and Bioline, most of the work being conducted using Ampli Taq supplied by 
Applied Biosystems). A negative control (PCR-grade water of equal volume to that 
used of the genomic DNA sample) was included for each set of PCR reactions, in order 
to ensure that no contamination had entered the reactions. The reaction conditions for 
each primer pair were initially set at 1.5 111M M902 and 0.2 ýLm each primer, and if 
yield or specificity was inadequate with this, then optimisation of the reaction was 
conducted, according to the following principles: 
I Increasing the annealing temperature closer to the Tm of the primers enhances 
specificity of annealing, and reducing the length of the time at the annealing 
temperature may reduce the likelihood of extension occurring from a misprimed 
event (i. e. where the primer has annealed to a sequence that it is not exactly 
complementary to). 
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2 Reducing the number of cycles may also increase the specificity. In general, 25 
cycles should be sufficient, and the lowest cycle number that results in an 
adequate amount of PCR product for subsequent applications should be used. 
3A "hot start, " Le. not allowing Taq to have contact with the full complement of 
reagents until the reaction temperature is at least 800C, increases the specificity 
of the reaction, and can be achieved by techniques such as the use of 
I 
AmpliWaxTm (Pcrkin-Elmcr, UK, sce below). Similarly, a "pscudohotstart, " i. e. 
heating the thermal cycler to 900C before adding the reagents, may also achieve 
'. ', -. - this. , 
4-ý Increasing the M902 concentration may increase the yield, but will tend to 
reduce the specificity. The magnesiwn concentration affects primer annealing, 
strand dissociation temperatures of the template and PCR product, formation of 
primer-dimer artefacts, and Taq activity and fidelity. 
5 ý,, ý "Reducing the dNTP concentration reduces the likelihood of extending 
,, misincorporated nucleotides (Innis et al., 1988). The use of nucleotide stocks 
:: ýý Ahat have been subjected to multiple freeze-thaw cycles should be avoided. 
6 
_, ý- , 
Increasing the primer concentrations may promote mispriming and increase the 
probability of generating primer-dimers. 
7 Increasing the amount of Taq above 2.5 U per reaction may lead to the 
accumulation of non-specific products. However, an inadequate amount of Taq 
(e. g. <1 U) may lead to the plateau phase of the PCR reaction (at which 
amplification of target sequences is no longer exponential) being reached before 
the end of the PCR programme, especially for cycle numbers greater than 25. 
As the cycle number increases, there may eventually be less than one molecule 
of -Taq per primer-template complex, which will 'contribute to the plateau 
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phenomenon, yielding less than full length product, which is then unable to 
serve as intact template for further rounds of amplification. The use of an 
autosegment extension as part of the cycling programme (where the 
denaturation time is extended in later cycles) can delay the plateau effect. 
8 The use of cosolvents (up to 15% glycerol, 5-10% DMSO, or 0.05-0.5% 
TweenR 20) may enhance the denaturation GC-rich targets, and improve the 
yield, especially of relatively long targets (see below). 
Usually optimisation by trying alternative annealing temperatures (e. g. 20C-IOOC above 
and below the mean T.. of the primers) and alternative M902 concentrations (within 
the ranges of 1-3 mM) was sufficient to produce pure product of adequate yield. 
2.2.3.2 Long PCR 
Although it is possible to produce amplicons of 5-15 kb with Taq, the reported yields 
are low, so where the target length of DNA was at least 3 kb, the technique known as 
"long PCR7 was used. This refers to a series of modifications of standard PCR, first 
described by Cheng et aL (1994) and Barnes (1994), including: 
2 Two-temperature thermal cycling (one temperature for denaturation, and 
another temperature for both primer annealing and strand -extension), with a 
denaturation step at no higher than 940C in order to minimise DNA damage, 
and annealing/extension at 680C. The high annealing temperature minimises the 
formation of products from secondary priming sites. Primers that are 20-23 
oligomers of 52-60% G+C content in general are successful with a 680C 
annealing and extension temperature. An annealing/extension time of 5 min is 
sufficient for products of up to approximately 9 kb, with times of up to 30 min 
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being necessary for targets of up to 40 kb, and including an autosegment 
extension of 15-20 s per cycle for the later cycles. A hot-start method also 
minimises undesirable primer interactions, and can either be achieved through 
the use of a "pseudohotstart" (as described above), or through the use of 
Ampliwax. Tm Ampliwax beads are specially fonnulated wax beads of an 
appropriate size that melt at 80OC; in the use of Ampliwax, a lower layer of long 
PCR reagents (long PCR buffer, dNTPs, primers and Mg(OAc)2) is added to the 
tubes first, followed by a wax bead, the wax is then melted by placing the tubes 
in a thermal cycler for 5 minutes at 800C and then cooled to room temperature, 
following which the upper layer of long PCR reagents are added (more long 
PCR buffer, long PCR enzyme, and target DNA). The reactions are then placed 
in the cycler, and during the first cycle of amplification, the wax melts, allowing 
the 2 layers to mix, with the result that the long PCR enzyme has the full 
conditions necessary for its function once the reaction is at at least 800C. The 
melted wax then serves as a vapour barrier for the reset of the amplification (for 
older cyclers that do not use a heated lid protocol). 
3 The addition of a small amount of a thermostable DNA polymerase that has 3' 
to 5' exonuclease in addition to the primary polymerase greatly improves yield 
(Bames, 1994). The 3'-5' exonuclease activity acts as a. 'ýproofreader, " 
removing any mismatched nucleotides and permitting the predominant 
polymerase activity to complete the strand synthesis. One such mixture of 
enzymes is rTth + VentR , marketed by Applied Biosystems (Perkin Elmer) in 
, ., their 
GeneAmp XL PCR kit; another is Taq + Pwo marketed by Boehringer 
Mannheim in their Expand Long Template PCR kit, where Ventý and Pwo are 
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the 2 proofreading enzymes. I used both of these kits, for different long PCR 
applications. 
4' The addition of cosolvents as well as th e proofreading enzyme greatly improves 
yield. Cosolvents may increase the thermal stability of the polymerase, and 
effectively lower melting and strand separation temperatures (2.5-30C per 10% 
glyerol), thus facilitating denaturation of the template and increasing the 
specificity of primer annealing. Cheng et A (1994) demonstrated that for long 
PCR, the use of more than one cosolvent (e. g. DMSO with glycerol) was more 
effective than one, and the buffers in the GeneAmp XL and Expand Long 
Template PCR kits both contain more than one cosolvent (tricine, DMSO, and 
glycerol in the former in addition to potassium acetate, concentrations not given 
by manufacturer; and in the latter: 20 mM Tris. HCl pH 7.5,100 mM KCI, 1 
mM dithiothreitol, 0.1 mM EDTA, 0.5% (v/v) TweenR 20,0.5% (v/v) NonidetR 
P40,50% glycerol (v/v), and 1.75 MM M902). The use of the Tricine buffer 
enhances the activity of Mh, but Tris. HCI is better for Taq, while lower K+ 
concentrations, and the use of KOAc rather than KCI also enhance the yield. 
For my first experiments with long PCR, I used the GeneAmp XL PCR kit, and the 
control X DNA and X primers supplied with the kit. I was able to successfully generate 
a 20.8 kb amplicon, following the manufacturer's instructions. Specifically, the 
reaction conditions were: 0.01 pg, % DNA, Ix XL Buffer, 0.2 mM dNTPs, 0.4 pM each 
primer, 1.1 mM Mg(OAC)2, and 4U Mh XL in a final total reaction volume of 100 gl 
having done the two-layer technique with AmpliWax as described above. The cycling 
conditions (in a Perkin Elmer DNA Thermal Cycler) were: 930C for 1 min; 16 cycles of 
930C for I min, 680C for 10 min; 12 cycles of 930C for I min, 680C for 10 min with a 
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15 s increment per cycle; and a terminal elongation step of 720C at 10 min, followed by 
cooling to 40C. 
I then applied this technique to the amplification of the intergenic segments between 
CYP2D8P, CYP2D7P, and CYP2D6, in order to generate a PCR that was capable of 
detecting extra copies of CYP2D6 (CYP2D6 gene amplification). For this purpose, 
sequence comparison of CYP2D8P, CYP2D7P, and CYP2D6 was undertaken, and 
primers were designed from regions of complete homology in exons 9 and 1. The 
forward primer was designed from the forward sequence of exon 9 near its 3' end, 
sequence: 5'-CTTTGTGCTGTGCCCCGCTAG-3. ' The reverse primer was designed 
from - the reverse sequence of exon. 1, near its 5' end, sequence 5'- 
GTCCACCAGGAGCAGGAAGAT-3'. Primers were used at concentrations of 0.2 
pM, with 300 ng genomic DNA, and reaction conditions and cycling parameters were 
otherwise as for the amplification of the X DNA. This produced a successful result, 
with the generation of 2 amplicons, representing the CYP2D8P-CYP2D7P and the 
CYP2D7P-CYP2D6 intergenic segments. Figure 2.1 shows the 2D locus with 
intergenic products expected for different allelic variants. Optimisation of the reaction 
was then conducted, using different amounts of genomic template (Figure 2.2), which 
demonstrated that 400 ng of genomic DNA gave the best results with this protocol. I 
then performed this PCR on the 163 French subjects, which demonstrated that in one 
subject, of very low dextromethorphan MR (0.002), there was an extra band, 
corresponding to a CYP2D6-CYP2D6L intergenic segment (Figure 2.3), of length 
approximately 8.5 kb (Aitchison et al., 1995a). I also performed restriction analysis of 
the long-PCR products (Figure 2.4). The 4.8 kb 2D8P-2D7 fragment was cleaved 
twice by Xba I, giving fragments of 0.7,1.9, and 2.2 kb. Only I site was expected from 
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the map given in Kimura et d (1989), but on checking the Xba I sites in the known 
sequence (Genbank accession number M33387) using the HGMP sequence analysis 
tools, the 2 sites were confinned, with positions as shown in Figure 2.1. The 4.8 kb 
fragment was also cleaved once by EcoR 1, as expected, giving fragments of 1.8 and 
3.0 kb, while the 9.5 kb 2D7P-2D6 fragment was also cleaved only once by EcoR 1, 
giving fragments of 7.9 and 1.6 kb. I also further verified the methodology of this 
technique through the testing of a positive control, kindly supplied by Dr Marja-Liisa 
Dahl (Karolinska Institute, Huddinge University Hospital, Sweden), which was 
previously described as having results on pulse field gel electrophoresis consistent with 
13 copies of CYP2D6 (Johansson et al., 1993). Figure 2.5 shows the results of my 
CYP2D intergenic long PCR on this subject, showing that the band corresponding to 
the CYP2D6-CYP2D6L intergenic segment has a very high intensity, consistent with 
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Figure 2.2 Optimisation of CYP2D intergenic long-PCR technique: the effect of 
increasing template concentration. Lanes 1-8 have 0.1,0.2,0.3,0.4,0.5,0.6,0.8, and 









Figure 2.3 Agarose gel electrophoresis of products of novel long-PCR for the 
identification of CYP2D6 gene amplification. Subjects of lanes 2 and 3 are extensive 
metabolisers; in lane 4 is the result for an ultrarapid metaboliser (clextromethorphan 










Figure 2.4 Agaorse gel electrophoresis of novel CYP2D6 long-PCR products and 
restriction enzyme digests of products (0.6% agarose). Lane I shows wild-type 
banding (4.8 and 9.5 kb), lane 2 the extra band of 8.5 kb in subject with 
dextromethorphan MR of 0.002. Lane 3 shows Xba I digest of products in lane 1, and 







Figure 2.5 Agarose gel electrophoresis of products of novel CYP2D6 long-PCR assay, 
showing increased intensity of 8.5 kb amplicon in subject known to have 13 copies of 
CYP2136 (lane 3), as compared to extensive metabolisers (lanes I and 2) and the 
ultrarapid metaboliser with dextromethorphan MR of 0.002 (lane 4). In lane 5 is aX 
DNAJEco RI + Hind III ladder. DNA from subject with 13 copies of CYP2D6 kindly 
supplied by Marja-Liisa Dahl. 
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However, during the time of my PhD work, another group also published a long PCR 
method for the identification of CYP2D6 amplification events (Lovlie et al., 1996), and 
as their work was more thorough than mine, including Southern blot analysis of 
subjects and sequencing of the intergenic product, for later analyses, I used the 
methodology of this group, with minor modifications. For this I used the Expand Long 
Template PCR System (Boehringer Mannheim, UK), as this system (not requiring 
AmpliWax) lends itself more easily to the analysis of large numbers of samples. 
Primers 5'-TCCCCCACTGACCCAACTCT-3' (cyp-17) and 51- 
CACGTGCAGGGCACCTAGAT-3' (cyp-32) were used in a final volume of 25 pl 
including 2.5 pl Boehringer buffer 1,4.5 pI of a2 mM solution of each dNTP, 0.5 pI of 
each primer (10 ptM solutions), and 0.25ýd of Boehringer enzyme mix (TaqlPwo). 
Cycling conditions were modified as follows: initial denaturation for 2 min at 940C; 35 
cycles of 930C for 10 s, WC for 30 s and 680C for 5 min; followed by an elongation 
step of 68*C for 7 min. 
Long PCR methodology was also used for the identification of the CYP2D6*5 allele as 
described by Steen et al. (1995), using primers 5'-ACCGGGCACCTGTACTCCTCA- 
3' and 5'-GCATGAGCTAAGGCACCCAGAC-3' and the GeneAmp XL PCR kit. 
PCR was perfonned using AmpliwaXR beads to facilitate a hot start in a 100 gI reaction 
volume with 200 ng genomic DNA, lxXL reaction buffer, 0.2 mM each dNTP, 0.3 tiM 
each primer, 1.1 mM Mg(OAC)2 and 2U of the rTthNentR DNA polymerase mixture. 
Cycling conditions were: initial denaturation at 930C for Imin; 35 cycles at 930C for I 
min, '650C for 30 s, 680C for 5 min; and a final elongation at 720C for 10 min. 
Duplications of non-functional alleles (e. g. CYP2D6*4) have been described, and 
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therefore, if cases were positive on both the CYP2D6*4 and the duplication assays, they 
were further tested to determine whether the null or the wild type allele was duplicated 
as described by Sachse et al. (1997): a further duplication assay was perfonned with 
primers as described by Johansson et al. (1996), giving a lOkb amplicon in cases 
positive for a duplication, which was then subjected to a nested PCR followed by 
digestion with Hph I (Figure 2.6). The primers for the Johansson et al. assay were 5'- 
GCCACCATGGTGTCTTTGCTTTC-3' and 5'-ACCGGATTCCAGCTGGGAAATG- 
3', and I modified the conditions by performing the assay with the Expand Long 
Template PCR System, using a total reaction volume of 25 PI with 2.5 ýLl of Boehringer 
buffer 1,4.5 til of a 2mM solution of each dNTP, 0.5 pl of each primer (10 ýLM 
solutions), 0.37 [LI of the TaqlPwo enzyme mix, and 200 ng of genomic DNA. Cycling 
conditions were: initial elongation of 940C for 2 min; 10 cycles of 930C for 10 s, 600C 
for 30 s, 680C for 12 min; 20 cycles of 930C for 10 s, 600C for 30 s, and 680C for 12 
min with a 15 s increment per cycle; and a terminal elongation step of 680C for 7 min. 
The product of this reaction was then diluted 1: 5 and subjected to nested PCR using 
primers 5'-TCAACACAGCAGGTTCA-3' and 5'-CTGTGGTTTCACCCACC-3'. 
The reactionvolume was 65 pl, containing 10 mM Tris-HCI pH 8.3,50 mM KCI, 1.5 
MM M902,0.160 mM each dNTP, 0.1 pM each primer, and 0.2 U AmpliTaq. The 
cycling conditions were: initial elongation at 940C for 2 min, 25 cycles of 940C for 30 
s, 580C for 10 s, 720C for 1 min, and a final elongation step of 720C for 7 min. The 
products were digested with Hph I and separated on a 3% agarose gel (see below). 
2.2.4 Agarose gel electrophoresis 
0.7-3% (w/v) agarose gels were prepared by adding the appropriate weight of agarose 












Figure 2.6 Agarose gel electrophoresis of Hph I digests for CYP2D6*4x2 analysis. 
Subjects in lanes 2 to 5 are all positive for this variant, while the subject in lane 6 has a 
gene duplication that is not CYP2D6*4. y2 (is CYP2D6 wt/wt on the CYP2D6*4 assay, 
and positive for a gene duplication event on the Lovlie et al., 1996 assay). In lane I is a 
I kb ladder (Life Techologies, Inc., bp). 
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microwave oven. (For identification of long PCR products or restriction digests, gels 
of 0.7-1.0 % were used; for standard length PCR products, 1% gels were used; and for 
products of restriction digests of standard length PCR products, 3% gels were used. ) 
Ethidium. bromide (10 mg/ml) was then added to a final concentration of 0.5 pg/ml, and 
the agarose cooled to approximately 700C on a magnetic stirrer. Ethidiurn bromide is a 
dye that intercalates between the base pairs of DNA, and fluoresces under LIV 
radiation, thereby enabling visualisation of the DNýk. The cooled agarose was poured 
into a gel mould, with casting combs to generate an appropriate number of wells, 
allowed to solidify at 40C, then placed in an electrophoresis tank containing 1x TBE. 
Samples were loaded into the wells, having mixed them with an appropriate volume of 
6x loading buffer. For agarose gel electrophoresis of long PCR products, it was found 
that loading buffer II (with Ficoll) gave a better result. For most other applications, 
loading buffer III was used. An appropriate size marker (100 bp or lkb ladder for 
standard length PCR or PCR-RFLP analysis, X Hind III or 2, Hind III/EcoR I for long 
PCR) was loaded in addition to the samples. The gel was electrophoresed at an 
appropriate voltage/cm (negatively charged DNA migrates towards the positive 
electrode) until the required separation had been achieved, and then photographed 
under UV light. 
2.2.5 RFLP analysis 
Restriction endonucleases (REs) are enzymes purified from bacteria that cut DNA at 
specific recognition sequences (often palindromic in forrii, e. g. GTTAAC, the sequence 
on one strand being the same as that on the other in the reverse direction). This property 
can be used in mapping (e. g. confirmation of the identity of long PCR products), or in 
identification of polymorphic sites in a sequence. Restriction fragment length 
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polymorphism (RFLP) refers to variations in lengths of DNA produced by digestion 
with a particular RE owing to the presence/absence of the RE site in that particular 
region of DNA from different individuals. PCR-RFLP analysis refers to the generation 
of a PCR product that contains a polymorphic site from a number of different 
individuals, followed by restriction digestion of the products, in order to identify which 
individuals carry the variant site. The polymorphic site is a single nucleotide 
polymorphism (SNP) within the RE recognition sequence so that the enzyme either 
cuts or fails to cut according to the presence/absence of the SNP. Examples of such 
PCR-RFLP analyses performed include the CYP2D6*4 and CYP1A2 T-359IG 
identification. If the SNP to be identified does not alter a restriction site, mutagenic 
primers can be designed, which introduce a restriction site overlapping the position of 
the sequence change. An example of such an analysis is the CYP2D6*3 assay. 
PCR products were incubated with the appropriate RE, the RE buffer as supplied by the 
manufacturer, and, if indicated by the manufacturer, BSA to a final concentration of 
100 pg/ml. In general 5-10 U of RE were used for up to 20 pl of PCR product,. but for 
the case of Mbo II digestion (identification of the T-3591G SNP), a series of assays 
determined that 1.5 U gave best results (for up to 20 pl PCR product). The incubation 
'temperatures were as recommended by the manufacturer, and conducted in an 
incubator set at the appropriate temperature (e. g. 370C) or a Hybaid oven (for the 
higher temperatures, e. g. 600C for BstN I). 
2.2.6 Genorne walking 
"Genome walking" is a technique for peforming serial PCR of genomic segments from 
a region of known sequence into a region of unknown sequence. Primers were designed 
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for use with the GenomeWalkeJm Kit (Clontech Laboratories, Inc., CA, USA) in order 
to generate genomic sequence further 5' than the 5' flanking sequence of CYPIA2 that 
had been published to date (the aim being to search for functional mutations in the 5' 
flanking region beyond -3.4 kb (counting +1 as the start of translation), which was the 
point at the most 5' of CYPIA2 to which Nakajima et al., 1994 had screened). The 
GenomeWalker Kit provides a means of "walking" upstream or downstream in 
genomic DNA from a known sequence. The kit contains five "libraries" of uncloned 
genomic DNA fragments, produced by digestion of pure samples of high molecular 
weight genomic DNA by five different REs, EcoR V, Sca I, Dra I, Pvu II, and Ssp I, 
and which are then ligated to a 5'-extended 48-bp adaptor sequence (Figure 2.7). The 
process involves a 2-stage, or nested PCR, the primary PCR reaction utilising adaptor 
primer 1 (API) provided in the kit, and a gene-specific primer designed by the 
researcher. The 5' adaptor sequence has no binding site for the API primer, and an 
API binding site can therefore only be generated by polymerase-mediated extension 
from the gene-specific primer. In the secondary PCR reaction, the product of the first 
reaction is diluted and used as the template, with primers nested adaptor primer (AP2) 
and the nested gene-specific primer designed by the researcher (the nested gene- 
specific primer being further in the direction being travelled, e. g. further 5' in the 
known sequence). This generally produces a single, major PCR product from at least 4 
out of the 5 libraries, and each of the 5 DNA fragments, which begin at the known 
sequence at the 5' end of the first gene-specific primer and extend into unknown 
adjacent genomic DNA, can then be analysed. The kit uses long PCR technology, and 
recommends the use of the rTth supplied in the GeneAmp XL kit, but I compared the 
results with this and with the TaqlPwo supplied in the Expand Long Template PCR kit, 
and found that the results with the TaqlPwo were better. The gene-specific primers are 
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Genome Walker Adap to 
Srf I 
mui sari Sma IlXm aI 
5'- OTAATACOACTCACTATAGGGCACOCOTOOTCOACOOCCCOGOCTGOT-3' 
3'-H2N-CCCOACCA-PO4-5' 
AdIptor primer I LAP I& 22-me--r) Nested AdalDtor vrimer 2 (AP2-. 19-mer) 
5'-GTAATACGACTCACTATAGGGC-3' 3'-ACTATAGGGCACGCOTGOT-3' 
Figure 2.7 Structure of the Genome Walker adaptor and adaptor primers. The adaptor 
is ligated to both ends of the genomic DNA fragments in all five Genome Walker 
"libraries" supplied with the kit. The arnine group on the lower strand of the adaptor 
blocks extension of the 3' end of the adaptor-ligated genomic fragments, and thus 
prevents formation of an API. binding site on the general population of fragments. The 
design of the adaptor and adaptor primers is critical for. the suppression PCR effect; the 
Tms of API and AP2 are 590C and 710C (from the GenomeWalker Kit user manual, 
Clontech). 
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recommended to be 25-28 nucleotides in length, with a G/C content of 40-60%, T 
greater than 680C, and 3' sequence that is not complementary to the 3' ends of the 
adaptor primers. In both cycling reactions, "touchdown" PCR is employed, involving 
using an annealing/extension temperature that is several degrees higher than the T. of 
the primers during the initial PCR cycles, in order to increase specificity of annealing. 
The annealing/extension temperature is then reduced to slightly below the primer T,,, 
for the remaining PCR cycles. Positive control gene-specific primers, specific for the 
human tissue-type plasminogen activator (tPA) locus, are supplied with the kit. 
A primer specific for the known 5' flanking region of CYPIA2, towards the end of the 
published sequence (Quattrochi and Tukey, 1989), and GenBank sequence U02993), 
was designed for use in the primary reaction: cyplabrl, 5'- 
GGTTAGGTGCCATTCTCGTCACATC-3', using the recommended constraints 
regarding primer choice (as above). This primer was used in the primary PCR reaction 
as per the manufacturer's instructions, using the following cycling conditions in a MJ 
Research tetrad PCR machine (as the manufacturer recommended for a Perkin-Elmer 
GeneAmp PCR 9600 cycler, with the addition of an initial denaturation step for 2 min): 
initial denaturation at 940C for 2 min; followed by 7 cycles of 940C for 2 s, 720C for 3 
min; followed by 32 cycles of 940C for 3 s, 670C for 3min; and ending with a terminal 
elongation step of 670C for 4 min. A pseudohotstart was used, placing the samples in 
the block when it had reached 800C. The reaction products were run on a 1.5% agarose 
gel, and a clean band was seen in the lane from library number 3 (Dra I library). A 
second, nested, gene-specific primer was designed further 5', cyplabr2,. 5'- 
GTGCGTGTCAGGTCTCTTCACTGTA-3', and used together with AP2 with the 
products from each of the libraries in the first PCR reaction, with the following cycling 
114 
conditions (again, MJ Research machine, minor modifications to the protocol given by 
the manufacturer for use in a 9600 cycler): initial denaturation at 940C for 1.5 min; 
followed by 5 cycles of 940C for 2 s, 720C for 3 min; followed by 20 cycles of 940C for 
3 s, 670C for 3 min; and ending with a terminal elongation step of 670C for 4 min. 
Again, a pseudohotstart was performed by placing the samples in the block once it had 
reached 800C. This time bands were seen in the lanes from all libraries on the agarose 
gel, with the bands being particularly clean in the lanes of libraries 2 and 4 (Sca I and 
Pvu II libraries, Figure 2.8). These second PCR products were purified using 
QIAquick PCR purification (see below), and sequenced directly using 60-90 ng of 
purified PCR product, standard cycle sequencing with primer cyplabr2, ABI PRISM 
Dye Terminator Cycle Sequencing Ready Reaction Kit (see below), and an ABI 377 
DNA sequencer. 
2.2.7 Techniques relating to automated sequencing 
2.2.7.1 PCR product purirication 
PCR products were purified using the QIAquick PCR Purification Kit (Qiagen Ltd., 
UK), to eliminate the primers, dNTPs, salts and polymerase from the PCR reaction. 
Five'volumes of buffer PB (containing chaotropic salts; the composition of the 
individual buffers is not given by the manufacturer) were added to 1 volume of PCR 
product and mixed by vortexing. The mixture was applied to a QlAquick spin column 
within a2 ral collection tube and centrifuged at 13,000 rpm (>10,000 x g) in a 
microcentrifage for 1 min (all centrifuge steps were conducted at this speed). During 
this step, the DNA adsorbs to the silica-gel membrane within the column (DNA 












Figure 2.8 Agarose gel electrophoresis of products of secondary PCR using the 
GenorneWalker kit and primers cyp I abr2 and AP2. Lane 1: Eco RV library; lane 2 Sca 
I library; lane 3: Dra I library; lane 4: Pvu 11 library; lane 5: Ssp I library; lane 6: 
negative control; lane 7: positive control supplied with kit, lane 8: lkb ladder (Gibco 
BRL, Inc., kb). 
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addition of buffer PB), whilst the excess PCR reagents flow through to the collection 
tube and are discarded. The DNA bound to the silica-gel was then washed by the 
application of 0.75 ml of buffer PE, followed by centrifugation for 1 min. The flow- 
through was discarded, and the spin column centrifuged for 3 min to remove residual 
buffer (the manufacturer's instructions were for I min here, but I found that 3 min 
produced better results). The spin column was then placed in a clean 1.5 ml 
microcentrifuge tube. In order to elute the DNA, 25 pl buffer EB (10 mM Tris. Cl, pH 
8.5) was applied to the centre of the QIAquick membrane, the column was allowed to 
I 
stand for 3 min, and then spun at 13,000 rprq for 3 min (again, this represents minor 
modifications of the protocol given by the manufacturer). (For the work conducted at 
NIH, USA, the Wizard PCR Preps DNA purification system was used, which works on 
similar principles. ) 
2.2.7.2 Automated sequencing 
2.2.7.2.1 Cycle sequencing of PCR products 
Cycle sequencing using fluorescently-labelled terminators is a rapid and convenient 
method for performing enzymatic extension reactions for DNA sequencing. The ABI 
PrismTM dRhodamine cycle sequencing ready reaction kit (Applied Biosystems, Perkin 
Elmer) contains the sequencing enzyme 4mpliTaq DNA polymerase FS, dye 
terminators, dNTPs, M902, and buffer pre-mixed in a single tube which is stored at - 
200C until use. The concentration of purified PCR product was first estimated by 
running I gl on a 1% agarose gel (I gl purified product, I gl 6x loading buffer, and 3 
ýtl Tris, the latter to enhance the result using a low sample volume), alongside standards 
of known concentration (e. g. a plasmid, pTET, of known concentration, supplied by A. 
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J. Makoff, or DNA Quantitation Standards, GibcoBRL), judging concentration of the 
PCR product by comparision, by eye. For PCR products of less than I kb, 30-90 ng is 
suitable for cycle sequencing, and so the above rough estimation is sufficiently 
accurate. (The amount of PCR product required for good results on cycle sequencing 
depends on the length; products of 1-2 kb, and greater than 2 kb require 100-200 ng and 
200-ý00 ng respectively. ) The following sequencing reaction was then set up for each 
sample: 6 ýtl terminator ready reaction mix, x pl PCR product equivalent to 30-90 ng, I 
pl of sequencing primer at 3.2 pM, and PCR-grade H20 to make the total volume up to 
20 pl. Alternatively, in order to conserve the expensive terminator ready reaction mix, 
reactions with half total volume were set up, using half the above quantities, except for 
the terminator ready reaction mix at 4 ýtl. If the Perkin Elmer DNA Thermal Cycler 
was used, the reactions were set up in 0.5 ml microcentrifuge tubes, and overlaid with 
40 gl mineral oil, with cycling conditions of 25 cycles of 960C for 30s, 500C for 15 s, 
and 600C for 4 min, preceded by a 950C for 3 min during which the samples were 
added to the machine once it had reached 950C, and followed by a 40C hold. If the 
Perýin Elmer 9600 cycler was used, reactions were set up in 96-well plates, and the 
heýted lid option was employed, with the following cycling 'conditions: 25 cycles at 
960C for 10 s, 500C for 5 s, 600C for 4 min, followed by a 40C hold (following the 
manufacturer's instructions). 
2.2.7.2.2. Cycle sequencing of BAC clones 
Direct sequencing of BAC clones was similarly performed using cycle sequencing. If 
the dRhodamine cycle sequencing ready reaction kit was employed, then the following 
protocol was used: 22 [d of BAC DNA at 2 ýtg/ýtl, 16 ýd of terminator ready reaction 
mix, with 2 ýd of primer at 3.2 pmol/pl, and cycle sequencing conditions of. 50 cycles 
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of 950C for 30 s, 50-550C (depending on primer Tn) for 20 s, and 600C for 4 minutes. 
Or, alternatively, the ABI PrismTm BigDye Terminator Kit was used, with the following 
protocol: 8 [il BAC DNA to give a final amount of 1-1.5 pg, 8 P1 Big Dye terminator 
mix, I pl of primer at 25 pmol/pl, and 3 [d of PCR-grade H20. The cycling conditions 
employed for the latter were the same as with the dRhodamine kit, with 550C for 20 s 
as the second step producing good results with the primers used. It was found that a hot 
start was not required for BAC sequencing, and results were best when only 1.5-2.0 PI 
of sequencing buffer was used per sample. 
2.2.7.2.3 Preparation of samples for the sequencer 
2.2.7.2.3.1 Column purification 
In order to eliminate unincorporated fluorescent dideoxynucleotides (that would 
produce background fluorescence on the sequencing gel), the extension products of the 
cycle sequencing reaction were purified prior to loading on the sequencing gel. For the 
work conducted at NIH, USA, a column purification method was used, employing 
eit her Centri-sep columns or columns made by Edge Biosystems, Inc (Gaithersburg, 
MD, USA). The protocol for the latter was as follows: the supplied unit (cartridge and 
microtube) were placed in a microcentrifuge and centrifuged at 750 xg for 1 min (= 3.0 
x 1000 rpm on an Eppendorf microcentrifuge). If the Thermal Cycler had been used, 
the products of the cycle sequencing reaction were then de-oiled (by decanting the 
samples on to parafilm, and lifting up the parafilm carefully so that the samples ran 
down the parafilm, leaving the oil behind, and recovering the de-oiled sample). The 
cartridge was then transferred to a clean microtube (provided with the kit), and the 
sample added to the centre of the gel surface. The cap of the microtube was then 
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closed and the tube with contents centrifuged at 750 xg for 2 min. The eluate was then 
retained, and dried (by placing in a speedivac for 45 min). Samples were then prepared 
for loading on the sequencing gel by the addition of 4 ýtl sequencing buffer, followed 
by centrifugation, placing in an eppendorf shaker for 15 minutes, and denaturing by 
heating to 950C for 5 min with immediate cooling on ice. 
2.2.7.2.3.2 Ethanol precipitation 
For the work that was conducted in the UK, the extension products were purified by 
ethanol precipitation. To a 1.5 ml microcentrifuge tube, 2 ýd of 3M sodium acetate at 
pH 4.6 and 50 gl 95% ethanol was added. The sample (de-oiled as above, if necessary) 
was added to this, the mixture vortexed, and then left at RT for 20 min to precipitate the 
DNA. The microcentrifuge was then centrifuged at 13,000 rpm for 20 min (with the 
hinge of the microcentrifuge to the periphery, so that the position of the DNA 
precipitate can be located to the bottom of the microcentrifuge tube, beneath the hinge), 
and the supernatant carefully aspirated. The pellet was then respun, and the rest of the 
supernatant carefully removed. The resulting pellet was then rinsed with 250 gl of 
75% ethanol, vortexed briefly, and recentrifaged at 13,000 rpm for 10 min. At this 
point all the ethanol was then carefully removed. The pellet was then dried, either by 
leaving to dry in air at RT for at least 30 min, or by drying in a microcentrifage with 
the microcentrifage lid cut off. Samples were then prepared for loading on the 
sequencing gel as above. 
2.2.7.2.4 Use of the ABI Prism 377 DNA fluorescent sequencer 
Electrophoresis on the ABI Prism 377 DNA fluorescent sequencer was conducted 
according to the manufacturer's protocol (Applied Biosystems, Perkin Elmer). In 
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summary, a 38-well denaturing polyacrylamide gel (4.25%, with 35 [LI TEMED) was 
poured in between the sequencing plates, taking care to exclude air bubbles, left to set, 
excess gel was removed, and the comb was inserted to a depth of approximately 3 mm. 
The, plates with gel were then placed in the sequencer, scanned for background 
fluorescence, the tanks in the sequencer were filled with Ix TBE buffer, and a pre-run 
at 480C for 30 min was conducted. The prepared samples (1.8 or 2 pl) were then loaded 
into each well, loading every other well initially, and electrophoresing the gel for 2 min 
prior to loading the remaining samples. Electrophoresis was then conducted for 7 
hours., Raw data for each sample was generated and analysed using the ABI 377XL 
collection (v2.4) and Sequencing Analysis (v. 3.2) software. The resulting 
electropherograms were analysed by hand and by use of software packages including 
MacVector (Oxford Molecular Limited, Oxford, UK), Hitachi MacDNASIS Pro 
version 3.4 (Novex, San Diego, CA), and GeneTool lite version 1.0 (DoubleTwist, Inc., 
CA, USA). 
2.2.8 Techniques using DNA cloning 
2.2.8.1 Cloning and sequencing of PCR products 
PCR products chosen for cloning were cloned using the TA Cloning Kit (Invitrogen 
Corporation, Carlsbad, CA, USA). The principle of the TA Cloning Kit is that Taq 
polymerase has a non-template-dependent activity which adds a single deoxyadenosine 
(A) to the 3' ends of the PCR product; the linearized vector (pCR2.1) supplied with the 
Kit has single 3' deoxythyrnidine (T) residues, therefore allowing efficient ligation of 
the PCR inserts with the vector. The vector also contains a lac promoter and IacZ(x 
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fragment (encoding the first 146 amino acids of P-galactosidase) for the "blue-white 
screening" method of identification of colonies containing the PCR insert (white 
colonies containing the insert). The site of insertion into the vector is in between the 
lac promoter and the lacZ(x fragment. The vector also contains a T7 priming site and 
M 13 forward and reverse priming sites, to facilitate sequencing of an insert. 
For the use of this technique, I found that it was important to end the PCR cycling 
reaction with a final 7-10 minute extension step, but even with this, if the sample was 
more than 24 hours old when cloned, the Y-A overhangs were readded as follows: to 
25 ýLl of PCR product was added 5 ýtl of 10 x PCR reaction buffer from the kit 
(contains M902 to a final concentration of 2.5mM), I pl lOmM dATP (to a final 
concentration of 0.2mM), 0.5 pl Taq (5U/pl Life Technologies, Inc, Gaithersburg, MD, 
USA), and 18.5 gl of PCR-grade water, and incubation at 720C for 10 min followed by 
cooling to RT-was conducted. The procedure for TA cloning into the vector pCR2.1 
was then followed as per the manufacturer's instructions (except that 3 ligation 
reactions were set up, see below). The following formula was used to estimate the 
amount of PCR product needed to ligate with 50 ng (20 fmoles) of pCR2.1 vector: 
X ng PCR product = (Y bp 6R product)(50 ng pCR2.1 vector) 
(size in bp of the pCR2.1 vector: approx 3900 bp) 
Three ligation reactions were then set up as follows, one with a ratio of vector to insert 
of 1: 1 (ng: ng), one with a ratio of 1: 3, and one with no insert (as a control): x Al PCR 
product (corresponding to the correct ng PCR product, calculated as above), I ýd 10 x 
ligation buffer (supplied in the. kit), 2 ýLl pCR2.1 at 25 ng/ýtl, I pl T4 DNA ligase, 
(equivalent to 4 Weiss units, or 240 cohesive end units), and sterile water to a total 
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volume of 10 ýd. The ligation reaction was then incubated at 140C in a water bath 
ovemight. 
Instead of the competent cells recommended in the TA Cloning Kit, the lab's own 
competent cells were used (I conducted these experiments in Denver, Colorado; the 
cells were made by Linda Quattrochi's staff; E. coli strain MN 522, which work best 
with pBluescript derived plasmids). These cells express the lac repressor, which will 
repress transcription from the lac promoter, unless IPTG is added. Plates of Circle 
Grow (CG) and LB agar containing 50 [tg/ml of ampicillin were wanned at 370C for 10 
min, then 80 gl of 20 mg/ml X-Gal and 40 gl 100 mM IPTG was spread evenly onto 
the plates using a sterile spreader, and allowed to diffuse into the plates by incubating 
at 370C for a further 20-30 min. The reaction tubes containing the ligations were then 
centrifuged briefly and placed on ice. The competent cells were thawed on ice, and 2 
pl of each ligation reaction was pipetted directly into the competent cells, and mixed by 
stirring gently with a pipette tip., The vials were then incubated on ice for 30 min (and 
the remainder of the ligation reactions stored at -200C), following which they were heat 
shocked for exactly 30 s in a 420C water bath, then placed on ice for 2 min. At this 
point 250 ýtl SOC medium at RT (Table 2.1) was added, and the vials were shaken 
horizontally at 370C for I hour at 225 rpm in a rotary shaking incubator. The vials with 
the transformed cells were then placed on ice. They were plated out on to the prepared 
plates as follows: 50 ýtl and 200 gI from each transformation reaction was plated on to 
each prepared CG and LB plate respectively (as CG agar tends to give a higher density 
of growth). A control transformation using pUC 18 (1 ýtl of pUC 18 diluted to 10 pg/gl) 
was also conducted. Once the liquid was absorbed, plates were incubated at 370C for 
18 hours, then shifted to 40C for 273 hours to allow for proper colour development. 
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Blue and white colonies were obtained, and also some white colonies with blue centres 
as the insert was shorter than 500 bp and therefore achieved only partial disruption of 
IacZ in some cases. The protocol for colony lysis and PCR was then followed from the 
PCR-Trap manual (GenHunter Corporation, Nashville, TN, USA). On the back of each 
plate, each colony to be analysed (white or white with blue centre) was numbered, and 
then picked with a sterile toothpick and placed in 50 pI colony lysis buffer in a 
microcentrifuge tube. The tubes were then incubated at 950C for 10 min, centrifuged 
for 2 min to pellet the cell debris, and the supernatant was transferred to a clean tube 
and used immediately for PCR analysis or stored at -200C. Primers M13R (5'- 
CAGGAAACAGCTATGAC-3') and T7 (5'-TAATACGACTCACTATAGGG-3') 
were used at a final concentration of 0.2 ýM in a total reaction volume of 20 ýd with 2 
ýLl of colony lysate, 20 ýM dNTPs, Ix PCR buffer including M902 (concentration not 
given by manufacturer), and IU Taq. Cycling conditions were as follows: initial 
denaturation at 940C for 30 s; 30 cycles of 940C for 30 s, 500C for 30 s, 720C for 45 s; 
and, a terminal elongation step of 720C for 7 min. PCR products were then analysed on 
a 3% agarose gel, with those positive for an insert being clearly identifiable (being 264 
bp or 273 bp longer than the negative clones for the products of the cyplabr2-M5 and 
M3-M4 PCRs respectively). One of the samples cloned in this way (Black American 
sample number 9) generated four positive clones thus identified, which were subjected 
to standard cycle sequencing using T7 as a sequencing primer. The second sample 
cloned in this way (Black American sample number 43) generated 35 colonies positive 
for an insert. As this sample had already been identified to be heterozygous for the T- 
359IG substitution, which generated an Mbo II restriction site, we were able to screen 
these PCR products using Mbo II digestion (using 10 pl PCR product, 1.5 U Mbo 11, 
124 
and making up the volume to a total volume of 50 ýtl with 34.7 [il PCR-grade water). 
Products of colony PCR which digested with Mbo 11 and products which did not were 
then subjected to sequencing, again using T7 as a sequencing primer. 
2.2.8.2 Site-directed mutagenesis 
Site-directed mutagenesis was performed using the QuikChangeTm Site-directed 
mutagenesis kit (Stratagene Inc., La Jolla, CA, USA) on the pLIA2N plasmid that had 
already been constructed by LQ. This plasmid is approximately lOkb in length 
(double-stranded), and contains a Kpn I fragment of CYPIA2 (-3201/+53) proximal to a 
luciferase reporter gene (Postlind et al., 1993; Figure 2.9). (This plasmid also contains 
an SV40 promotor and a neomycin resistant gene, which were not necessary for the 
purpose of transient transfections, but this plasmid was used as it was already in LQ's 
possession and had been previously used to generate stable transfectants. ) The 
QuikChangeTm site-directed mutagenesis method can be used to make point mutations, 
switch amino acids, and delete or insert single or multiple amino acids in a double- 
stranded plasmid, generating mutants with an efficiency of at least 80%, using 
PfuTurboTm DNA polymerase (which has a 6-fold higher fidelity than Taq DNA 
polymerase). Two primers containing the desired mutation are extended during 
temperature cycling by PfuTurbo DNA polymerase, generating a mutated plasmid with 
staggered nicks (Figure 2.10). The product of cycling was then treated with Dpn I 
(target sequence 5'-Gm6ATC-3'), which is specific for methylated and hemimethylated 
DNA, and therefore digests the parental (non-mutant) DNA, selecting for mutation- 
containing synthesised DNA. The nicked vector DNA incorporating the desired 
mutations is then transformed in to Epicurian Coli XLI-Blue supercompetent cells. 
The small amount of the starting DNA template required to perform this method, the 
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high fidelity of the PfuTurbo DNA polymerase, and the low number of PCR cycles all 
contribute to the high mutation cfficiency and decreased potential for random mutations 
during the reaction. 
Site-directed mutagenesis to create the T-3591G mutation was performed with primers 
SDMlF (5'- 
CCTGTAATTTAATTT=AAGTTTGAAGAAAACATTAAAAATAAAAAG-3') 
and SDMlR (5'- 
CTTTTTATTTTTAATG=CTTCAAACTTAAAAAAATTAAATTACAGG-3'), 
where the underlined nucleotides are the sites in the primers that differ from the wild- 
type sequence, and constraints regarding primer design were followed as in the 
manufacturer's instructions. Reaction conditions were as in the manual (with 125 ng 
of each primer and 1 pl of Pfu (2.5 U/ýtl) set up in thin-walled PCR tubes and overlaid 
with 30 pl of mineral oil), 4 different reactions being set up, using 5 ng, 10 ng, 20 ng, 
and30ngofplasmid. Cycling conditions were: initial denaturation of 950C for 30 s; 18 
cycles of 950C for 30 s, 550C for 1 min, and 680C for 20 min; followed by cooling to 
40C. Cycling conditions for the control reaction were as in the manual (Le. initial 
denaturation of 950C for 30 s; 12 cycles of 950C for 30 s, 550C for 1 min, 680C for 12 
min; followed by cooling to 40C). When the products were run on a 1% agarose gel, a 
clean band was visible in the lanes of the 20 ng and 30 ng reactions. DpnI digestion of 
thes e products was then carried out as per the manual, and Epicurian Blue cells 
transformed as per the manufacturer's instructions. For the creation of XgaMTTG 
plates (for the control and pUC18 reactions), 50ýtl of 20mg/ml Xgal (in DMF) was 















Figure 2.9 Schematic map of the pLIA2N expression vector, containing a Kpn I 
fragment of CYPIA2 (-3201/+53), that includes exon 1 (black box), no intronic 
sequence, and 3201 bases of human CYP1A2 5' flanking sequence, proximal to a 
luciferase reporter gene. The start of transcription is indicated by +1 and the consensus 
TATAA sequence is indicated. The coordinate, 2065, corresponds to the unique Hind 
III site of the pSVO fector (De Wet et al., 1987) and coordinates in bold correspond to 
the location of the restriction sites in the published sequence of SV40 (Buchman et al., 
1981). From Postlind et al. (1993). 
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Figure 2.10 Overview of the QuikChange TM site-directed mutagenesis method (from 
the QuikChangeTm Site-Directed Mutagenesis Kit Instruction Manual). 
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theplates. All 500 gl of the sample reactions were plated onto CircleGrow (BIO 101, 
Inc, Vista, CA) agar plates with ampicillin at 50 ng/ml, and the pUC 18 control reaction 
was plated in NZY+ broth as per the manual. Plates were then incubated at 370C for 16 
hours. Approximately 1000 colonies resulted on the sample plates, with the control 
plates showing a mutagenesis efficiency of approximately 95 %, and the pUC 18 plates 
revealing a high transformation efficiency (>108 cfu) with >98% having the blue (P- 
gal+) phenotype. Single colonies were then picked from the sample plates, and plasmid 
DNA isolated as described above (using ampicillin). DNA was then quantified using a 
spectrophotometer (absorbance at 260 mn). 
Following creation of the mutant plasmid by the above procedure, the plasmid was 
subjected to sequencing using primer M3. Sequencing confirmed correct introduction 
of the mutation, and absence of any other differences in DNA sequence from the parent 
plasmid. Sequence comparison was undertaken with the programme Hitachi 
MacDNASIS Pro version 3.4 (Novex, San Diego, CA). This plasmid was then termed 
SDMI. 
Site-directed mutagenesis to create the G-3595T mutation was performed in a similar 




time, reactions were set up using 10 ng, 20 ng, 30 ng, and 40 ng of plasmid, and clear 
bands resulted from each, using the same cycling conditions as for the creation of 
SDMI. The 10 ng reaction was used for DpnI digestion, and 1.5 pl of DpnI was used 
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(as the PCR product was of greater intensity than for SDMI, and I wanted to ensure 
complete digestion of parent plasmid). Transformation and plasmid preparation was 
then undertaken as for SDMI, and, again, sequencing was performed with primer M3 
to ensure correct introduction of the mutation. The resultant plasmid was termed 
SDM2. 
A third site-directed mutagcnesis reaction was performed in order to create a double 
mutant, with both the T-3591G and the G-3595T substitutions, using primers SMD3F (5'- 
CTATATTGTATCCTGTAATTTAATTT=AA. TTTT-GAAGAAAAC-3') and 
SDM3R (5'- 
GTTTTCTTCAAAATTAAAAAAATTAAATTACAGGATACAATATAG-3'). This 
time the transformation reactions were split into 2 before plating, and fewer, larger 
colonies resulted. Plasmid preparation and confirmation of mutagenesis by sequencing 
were then conducted as for SDMI, and the resultant, correctly mutated plasmid was 
termed SDM3. 
2.2.9 Transient transfections 
HepG2 cells were seeded at 1.25 x 105 /Ml in 6-well plates in complete growth medium 
with 10% serum. The complete growth medium consisted of Dulbecco's Modified 
Eagle Medium and F-12 Nutrient Mix in a 1: 1 ratio (DMEM/F12,1: 1, GIBCO BRL, 
Life Technologies), with 10 mM Hepes, 100 U/mI penicillin, and 100 ug/mI 
streptomycin. Cells were grown up for 24 hours at 370C under 5% C02, and transfected 
the next day with 2pg plasmid and 0.5 jig CMVP (ClonTcch Laboratories Inc., Palo 
Alto, CA), using lipofectamine reagent (Life Technologies, Inc., Gaithersburg, MD, 
USA), with a 1: 8 ratio (mass: mass) of DNA: Iipofectamine and -OPTI-MEM I (Life 
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Technologies, Inc., Gaithersburg, MD, USA) as the serum-free medium. The CMVP 
plasmid expresses P-galactosidase from the human cytornegalovirus immediate early 
gene promotor. For each transfection, a minimum of eight 6-well plates were set up, 2 
being transfected with pLlA2N, 2 with SDMI, 2 with SDM2, and 2 with SDM3 (and 
each being cotransfected with the P-galactosidase plasmid). The DNA, lipofcctamine, 
and OPTI-MEM solution was incubated at room temperature for 1 hour to allow 
complexes to form, the cells were overlaid with I ml of complex-containing solution per 
well, and the plates were incubated at 370C under 5% C02 for 5 hours. The complex- 
containing solution was then removed, and replaced with Iml prewarmed 10% A2. 
The next day the medium was replaced with fresh complete medium, and at 40 hours 
post transfection 1 plate for each plasmid was treated with lOnM TCDD (a CYP I A2 
inducer), and for the other plate the medium was replaced with fresh complete medium. 
Sixty hours post transfection, the cells were harvested for luciferase activity, using a 
Luciferase Assay System with Reporter Lysis Buffer (Promega Corporation, Madison, 
WI, USA), 200ýtl Reporter Lysis Buffer per well. The lysates were cleared by 
centrifugation for 2 min at 40C, and 20 ýLl of cleared lysate was then assayed for 
luciferase activity using a Lumat LB9501 luminometer (Berthoid, Sci West, Arvada, 
- CO, USA). The remaining cleared lysates were then frozen at -700C. The next day the 
lysates were assayed for P-galactosidase activity using the P-galactosidase Enzyme 
Assay System with Reporter Lysis Buffer (Promega Corporation, Madison, WI, USA), 
using a microtitre plate (Nalge NUNC International, Naperville, IL, USA) for the 96- 
well format and preparing a standard curve using the P-galactosidase supplied. Lysates 
(50 gl, undiluted) and standards were assayed in duplicate. After the addition of Assay 
2x Buffer, plates were incubated at room temperature for 15 min before the first 
absorbance reading in a plate reader at 410 mn, with 490 mn as a comparative 
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wavelength. Serial readingswere then taken every 15 min until an hour after the first 
reading (so that the best linear standard curve could be elicited).. 
2.2.10 Studies with wild-type and CYP1A2-nulI mice 
2.2.10.1 Study design 
Human and mouse CYPIA2 resemble each other closely in cDNA derived amino acid 
sequence (Kimura et al., 1984; Jaiswal et al., 1987) and in catalytic activity (Aoyama et 
al., 1989). Given the inconsistencies in the conclusions of previous studies regarding 
the contribution of CYPIA2 to clozapine metabolism (Section 5.1), my aim was to use 
the CYPIA2 -/- (null) mouse in order to investigate the in vivo contribution of CYP 1 A2 
to clozapine pharmacokinetics. In addition, I used the CYPIA2 -/- mouse as a model 
for individuals with relatively low CYPIA2 activity, through the use of behavioural 
ratings aiming to draw conclusions regarding the pharmacodynamic effects of 
clozapine in such individuals. 
Clozapine was purchased from Sigma Chemicals Co. (St Louis, MO, USA), and 
desmethylclozapine and clozapine N-oxide from Research Biochemicals International 
(Natick, MA, USA). All other chemicals were of analytical-grade, available from 
commercial sources. A clozapine solution of lmg/ml was made (clozapine powder was 
dissolved in O. lM HCI, neutralised to pH 5-6 with IM NaOH, and made up to lmg/ml 
with deionised distilled water). All mice were weighed, and at time = 0, a dose of 10 
mg/kg clozapine was given intraperitoneally. I was taught how to administer 
intraperitoneal injections to the mice by Dr Takafumi Sakai (a visiting fellow at Dr 
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Gonazelez's laboratory during the same time period that I was there). Eight sequential 
blood samples (each approximately 50 [d) per mouse were then taken by tail blood 
sampling at 5,15,30,60,120,240,360, and 480 min post injection (the injection times 
of the mice were approximately 20 min apart for ease of sampling). The method of tail 
blood sampling was by sequential clipping of the tail (2-3 mm of tail being cut at each 
interval), followed by cauterisation to stop bleeding. The blood was collected in 
heparinised tubes (Sarstedt Ltd, Leicester, UK), and stored at -800C until analysis. 
Behavioural parameters (degree of drowsiness, motor incoordination) were recorded at 
each time point. After the last sample had been taken, the mice were killed by carbon 
dioxide asphyxiation. 
2.2.10.2 Behavioural effects ratings 
In the pilot studies, I noticed that clozapine at the dose administered caused drowsiness 
and motor impairment in the mice. I therefore devised a scale for the rating of these 
eff6cts (Table 2.3), based on repeated observations of characteristic motor and 
behavioural changes of wild-type and CYPIA2 -/- mice during pilot studies with 
clozapine. Mice were scored at each time point, just before tail blood sampling. 
2.2.10.3 HPLC analysis 
Clozapine, desmethylclozapine, and clozapine N-oxide in the blood samples were 
analysed by HPLC with UV detection at 254 mn as described (Volpicelli et al., 1993), 
by Prof Michael W. Jann (Mercer University Pharmacy Practice, Atlanta, GA, USA). 
The recovery from control rat serum at 500 ng/ml of clozapine, 500 ng/ml of 
desmethylclozapine, ' and 100 ng/ml of clozapine N-oxide was 78%, 84%, and 62% 
respectively (N =6 samples). A standard assay curve was completed and repeated six 
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tinýes using 7 data points for clozapine of known concentrations in the range 10 ng/ml 
to 
, 1ý1000 ng/ml 
(r2 = 0.996). The lower limit of detection was 5.0 ng/ml for clozapine, 
ill 
desmethylclozapine, and clozapine N-oxide, and the interassay and intraassay 
coefficients of variation (CV) were 8.2% and 5.0% respectively for all tbree substances. 
3.3 Data analysis 
ý. Data analysis was conducted using SPSS version 8.0 for Windows (Statistical Package 
I for the Social Sciences, Chicago, IL, USA), Epilnfo version 6.0 (Centers for Disease 
. ontrol and Prevention, USA and World Health Organization, Switzerland), Solo Table 
rable 2.3 Scale for rating behavioural effects of clozapine in mice 
Clozapine behavioural effects ratings in mice 
Drowsiness 
0 Fully alert 
I Eyes half closed at rest 
2 Eyes closed at rest, but easily rousable 
3 Eyes closed at rest, difficult to rouse 
Motor impairment 
L0 Normal posture at rest, move normally in cage on handling 
I Mild splaying of legs at rest, movements slowed and jerky, mild reduction in struggle on handling 
2 Moderate splaying of legs at rest, little movement in cage, moderate reduction in struggle on handling 
3 Prominent splaying of legs at rest (sprawled), no movement in cage, minimal struggle on handling 
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. Power Analysis (BMDP Statistical Software, Los Angeles, CA, USA), NCSS 2000 
(Statistical analysis and data analysis software, Kaysville, UT, USA), and Axum 
version 5.0 (MathSoft, Inc., Cambridge, MA, USA). AP value of less than 0.05 was 
interpreted as significant unless a Bonferroni correction was being applied. 
2.3.1 Calculation of metabolic ratios and phenotype assignment 
The debrisoquine MR (MRDBQ) was defined as the molar ratio of the concentrations of 
debrisoquine to 4-hydroxydebrisoquine in an 8-hour overnight urine collection 
(Maghoub et al., 1977). The cut-off points between different phenotypes are defined 
by the antimodes on a log-normal distribution of the MRs (i. e. a plot of the frequency 
versus logarithinjo of the MR). In Caucasians, the cut-point between CYP2D6 
extensive metabolisers (EMs) and poor metabolisers (PMs) is usually defined as 12.6 
(Evans et al., 1980; Steiner et al., 1985), although other antimodes have been described 
(7.28 by Evans et al., 1983, on reanalysis of their original data, or 5.42 by the sarne 
authors in a separate group of 215 British white subjects, and 4.48 in a study of 127 
unrelated Spaniards by Henthorn et al., 1989). However, the numbers of individuals 
with MRs within the range 4.48-12.6 is predicted to be small, so a very small number 
of individuals would be alternatively classified with a different choice of cut-point 
(Henthorn et al., 1989). Moreover, in the most comprehensive genotype-phenotype 
association study conducted in Caucasians (Sachse et al., 1997), the antimode of 12.6 
correctly classfied all PMs. I 
The ultrarapid metaboliser (UM) phenotype has been defined as an MRDBQ less than 
0.20 (Dahl et al., 1995a). However, as has been noted by Lovlie and colleagues (2001), 
this cut-off point is arbitrarily defined, and some studies (e. g. Johansson et al., 1996) 
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define UMs as those with MRDBQ < 0.15.1 have similarly analysed my data using both 
alternative, cut-points, determining the genotype-phenotype correlations. The EM 
phenotype (including intermediate metabolisers, or IMs) corresponds to MRDBQ iying 
between the cut-points for UMs and PMs. 
Similarly, the dextromethorphan MR is defined as the molar ratio of the urinary 
concentrations of dextromethorphan to dextrorphan, with NlRdextromethorphanl'ý03 defining 
CYP2D6, PMs (Schmid et al., 1985; Larrey et al., 1987). A genotype-phenotype 
correlation study in 456 German Caucasians phenotyped with dextromethorphan found 
that the mean MRdextromahorphan values (with 95% confidence limits of the mean) for 
individuals genotyped as having none, one, two, or three functional CYP2D6 genes 
were 1.902 (1.392-2.598), 0.009 (0.007-0.012), 0.003 (0.002-0.003), and 0.002 (0.001- 
0.005) respectively (Sachse et al., 1997). 
2.3.2 Association analysis 
2.3.2.1 Genotypic distribution 
In the case of CYP2D6 analysis, genotyping was conducted to identify 3 non-functional 
alleles (CYP2D6*3, CYP2D6*4, and CYP2D6*5), and also the gene duplication event, 
and further assays (see section 2.2.3.2) were also performed, in order to identify 
duplications of non-functional alleles (e. g. CYP2D6*4 duplications). It was therefore 
possible to identify the number of functional CYP2D6 genes, or CYP2D6 gene dosage, 
where this figure varied between 0 and 3, with'a value of zero corresponding to 
homozygosity for a non-functional allele (including duplications thereof), a value of 1 
indicating possession of one copy of an active (wild-type) allele, a value of 2 indicating 
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2 copies of an active (wild-type) allele, and 3 indicating at least 3 copies of an active 
CYP2D6 allele. Where cases were positive on the duplication assay but negative for 
non-functional alleles, they were assumed to be heterozygous for the duplication allele, 
not homozygous, as in the paper by Johansson et al. (1996) zero out of 17 UM cases 
(debrisoquine MR <0.15) were homozygous for a duplication event. PMs correspond to 
those with a CYP2D6 gene dosage of 0, and UMs to a gene dosage of at least 3 (up to 
13 according to the work of Johansson et al., 1993; 1996). SPSS was used to generate 
tables with numbers of subjects with each value of gene dosage, for the different 
subsets of subjects within a study (e. g. individuals with or without tardive dyskinesia, 
or TD). From these tables, the data were collapsed into 2x2 contingency tables for entry 
into EpiInfo, as follows: 
With Disease Without Disease 
I 1ý ":, ,11 
(e. g. With TD) (e. g. Without TD) 
With exposure, 
(e. g. CYP2D6 PM status) 
Without "posure 
(e. g. CYP2D6 
I 
non-PMs) 
These tables were then analysed (using EpiInfo) by X2 , or, if the number in individual 
cells was less than 5, by Fisher's exact test. EpiInfo also generates odds ratios (ORs), 
with 95% confidence limits (Cornfield or exact) of these. 
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Forý'the, genotyping study involving CYP2C19 (tricyclic antidepressant, or TCA 
response), the number of functional CYP2C19 genes was calculated similarly, except 
that for this locus, there are not known gene duplication events, so the number of 
functional genes varies between 0 and 2 (0 homozygous for non-functional allele, I 
heterozgous for non-functional allele, 2 homozygous wild-type). For EpiInfo, 
analysis was conducted using the recessive model, appropriate here for a gene coding a 
metabolic enzyme. 
With. the genotyping study involving the T-3591G CYPlA2 promoter mutation, the 
functional effect of this mutation is not known. The genotypic distribution in 
individuals of different ethnic groups was calculated, and X' analysis using EpiInfo was 
conducted 'comparing homozygous mutant versus all others (recessive model), or 
heterozygous plus homozygous mutant versus wild-type (dominant model). 
In all the genotyping studies, the genotypic distribution was tested for deviation from 
Hardy-Weinberg equilibrium using the'X 2 test using the programme HWE (Utility 
programs for analysis of genetic linkage, J. Ott, 1999). If a population with a bi-allelic 
system with two alleles (A and a) of frequencies p and q respectively is in Hardy- 
2 Weinberg equilibrium, the frequencies of each genotype (AA, Aa, and aa) are p, 2pq, 
and q2, respectively, and remain stable over successive generations. However, the 
Hardy-Weinberg equilibrium holds exactly only for large populations in which there is 
random mating and in which there is no selection, mutation, or migration. Deviation 
from any of these conditions can alter allele frequency in a population and lead to an 
increase or decrease in allele frequencies from one generation to another (Gelehrter et 
al., 1998). 
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2.3.2.2 Allelic distribution 
Similarly, SPSS was used to generate the frequencies of the allelic variants identified in 
the sample groups tested, and the numbers of subjects of each type of allelic variant (in 
the ý case 'of CYP2D6, wild-type, versus non-functional, versus functional gene 
duplication) were generated from the genotypic tabulation. From such tables, 2x2 
contingency tables were derived, and EpiInfo was used to perform a 7,2 or Fisher's 
exact test as appropriate, with OR and 95% confidence limits, with the exposure 
categories being those subjects with and without the allelic variant type of interest (e. g. 
non-functional allele). 
2.3.2.3 Testing for interactional effects 
For the TCA response study, the combined effect of CYP2D6 and CYP2CI9 activity 
was analysed by two different ways: 
I. --A simple model, assuming additive effect of number of CYP2D6 and CYP2C 19 
genes: creating a new variable by multiplying the number of CYP2D6 and 
number of CYP2C19 functional genes together, and analysing for association 
with clinical response, etc. 
The creation of a variable (combined CYP2D6 and CYP2CI9 index) 
approximating to the combined effect of these CYP2D6 and CYP2CI9 
, activities as reflected in the serum level data: (the inverse of the dose corrected 
, combined TCA level) x (the dernethylation index), see Section 3.3.2. 
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2.3.2.4 Bonferroni correction 
A Bonferroni adjustment was applied where there was multiple testing, i. e. cc, the 
significance level, was set as 0.05 divided by the number of independent tests 
performed (Bland & Altman, 1995). 
2.3.3 Regression analysis 
2.3.3.1 Logistic regression 
Logistic regression with a dichotomised variable as the dependent variable (e. g. 
dichotomised response to TCA, responders being defined as those with a Hamilton 
Depression Rating Scale score of 15 or less after at least 6 weeks of treatment with 
TCA) Was conducted using SPSS, controlling for independent confounding variables, 
with the variable of interest (e. g. number of functional CYP2D6 genes) as the main 
independent variable of interest. The output including the regression coefficient, 
signfiCance value, and Wald statistic (the ratio of the square of the regression 
coefficient to the square of the standard deviation; the Wald statistic is calculated by 
the programme for the variables in the model to determine whether or not a variable 
should be removed), was then tabulated. 
2.3.3.2 Multiple regression 
Multiple linear regression was si I milarly conducted using SPSS, using a linear variable 
(e. g. percentage change in Hamilton Depression Rating Scale score) as the dependent 
variable, controlling for independent confounding variables (e. g. other concomitant 
medications that inhibit CYP2D6), with the main variable of interest (e. g. CYP2D6 
gene dosage) being again the main independent variable. 
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2.3.4 Estimation of sample power 
Estimations of sample power were calculated using Solo Power Analysis and NCSS. 
2.3.4.1 Power of Chi-squared test 
; iThe power of the Chi-squared test for a given sample was calculated using Solo Power 
A, nalysis, inputting the sample size, appropriate degrees of freedom, and different effect 
sizes. Tor example, the sample of 246 clozapine-treated patients has a power of 1.0 
(allelic or genotypic comparison, one degree of freedom) at the P<0.05 level to detect 
a medium effect size (w = 0.3) for the X2 test between the intolerant and non-intolerant 
!I 
I groups (Cohen, 1977). With a smaller effect size (w = 0.2), the power remains high at 
0.99 (allelic) or 0.88 (genotypic). 
2.3.4.2 Power of logistic regression analysis ' 
The power of logistic regression analysis ý of a given sample was calculated using 
NCSS, entering values for the relevant variables based on the study results. For 
example, for the study on TD, pO = base proportion, i. e. fraction of the sample affected, 
equal to 0.18 of the sample of 72 rated for probable TD, cc, or the significance level, 
was set at 0.05, the odds ratio was 4.86, and Rý was 0.0469 W being calculated by 
linear regression of gene dosage onto the other variables), giving a power of 0.999. 
2.3.5 Analysis of transfection data 
The transfection data were analysed using Instat Biostatistics (Graph Pad, Intuitive 
Software for Science, San Diego, CA, USA), and SigmaStat 2.0 (SPSS Inc., Chicago, 
IL., USA). A Bartlett's test for homogeneity of variances was initially performed, 
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which indicated that non-parametric analysis should be used. The Kruskal-Wallis test 
.1 
J, was used, with a post-hoc Dunn's Multiple Comparisons Test to compare the results of 
,.. I 
ýach of the groups of transfections versus the wild-type. The mean fold induction for 
,c ach transfection experiment performed for the 4 plasmids was similarly analysed using 
'the Kruskal-Wallis test. 
2.3.6 Analysis of pharmacokinetic data 
Pharmacokinetic data were calculated using the equation: 
Cl =Dx F/ AUC 
in which Cl is whole blood clearance, D is doses of clozapine, AUC is the area under 
the curve, and F is the fraction absorbed or bioavailability (model independent 
pharmacokinetics). The AUC was calculated using the linear trapezoidal rule using C= 
0 and t=0 and was extrapolated to infinity using Axum 5.0. The half-life of clozapine 
in blood was calculated by linear regression of the In transformed blood concentrations. 
The percentage of the clozapine clearance mediated by CYPlA2 (%ClcypIA2) in wild- 
type mice was estimated by the following relationship: 
%CICYPIA2 ý-- (Clw-t- Cl-/-)/Clw-t 
in which Cl, t is the wild-type clozapine clearance and Cl_/_ is the clozapine clearance in 
the, CYPlA2 -/- mice. This simple relationship was used as it had already been 
established that the CYPIA2 4- and wild-type mice lines did not differ from each other 
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in parameters (such as liver function) that could affect the pharmacokinetics of 
clozapine (Buters et al., 1996). 
Statistical analyses comparing the parameters in the wild-type versus the CYPIA2 -/- 
mice were conducted using SPSS. Although all the parameters measured would be 
expected to show a normal distribution, non-parametric testing (the Mann-Whitney U- 
test) was chosen because there were only 4 mice per group, and hence non-parametric 
testing was more appropriate and more stringent. 
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CHAPTER THREE 
PHARMACOGENETIC ASSOCIATION STUDIES 
3.1 CYP2D6 Genotype-phenotype correlation studies 
3.1.1 Introduction 
3.1.1.1 Previous CYP2D6 genotype-phenotype correlation studies 
Early CYP2D6 genotype-phenotype correlation studies include those of Daly et al. 
(1991) and Broly et al. (1991). These studies used phenotyping with debrisoquine and 
genotyping using Southern blotting with restriction fragment length polymorphism 
analysis (RFLP) as well as PCR-based methods for detecting the CYP2D6*3, 
CYP2D6*4, CYP2D6*5, and in the latter case, CYP2D6*9 variants (then known as 
CYP2D6A, CYP2D6B, CYP2D6D, and CYP2D6C respectively). Using these 
techniques, Broly et al. reported identification of at least 95% of mutant poor 
metabolising alleles: 96.4% of individuals were correctly predicted, 100% of the 
extensive metabolisers, and 86% of the poor metabolisers. A similar study by Graf et 
aL (1992) used only allele-specific PCR amplification (methodology of Heim & Meyer, 
1990), for CYP2D6*3, CYP2D6*4, and CYP2D6*9, and reported 97.5% correct 
classification of EMs, and 75% correct classification of PMs (with no CYP2D6*9 
alleles being detected). Studies in Black Africans revealed a dissociation between 
dcbrisoquine, sparteine, and mctoprolol metabolic ratios (Lennard et al., 1992; 
Masimirembwa et al., 1996a), and a higher median value for the metabolic ratio as 
compared with Caucasians, which was later found to be due to the presence of the 
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CYP2D6*17 allele in this ethnic group (Masimirembwa et al., 1996b). The relatively 
high frequency of the CYP2D6*17 allele in individuals of African origin was 
confirmed in a detailed analysis of debrisoquine phenotype-CYP2D6 genotype in 
American Caucasians and African-Americans reported by Daly and colleagues 
(Leathart et al., 1998). 
In recent years, many different CYP2D6 alleles have been identified, with the result 
that. there are now (http: //www. imm. ki. se/CYPalleles, searched 23rd July 2002, page 
updated by Mikael Oscarson 3rd July 2002) a total of 43 identified CYP2D6 alleles, 17 
major alleles (with subtypes) identified as having complete lack of activity, 7 alleles 
with reduced activity, and several allelic variants for which the functional consequence 
has not yet been defined (see Section 1.5.1.1). These variants include SNPs, deletions, 
and CYP2D67PICYP2D6 hybrid alleles produced by unequal crossover events (the 
latter including CYP2D6*13 and CYP2D6*16, Daly et al., 1996b). In addition, 
duplications or amplifications of CYP2D6*1, CYP2D6*2, and-CYP2D6*4 have been 
described. The most up-to-date information on CYP2D6 alleles can be found on the 
website. 
A landmark genotyping-phenotyping correlation study was that of Sachse et al. (1997), 
in . which 589 unrelated German volunteers were phenotyped with either 
dextromethorphan (456) or debrisoquine (133), and genotyped for CYP2D6 alleles *I- 
*16, as well as for gene duplication events, ý including discrimination of which allele 
was duplicated. Observed CYP2D6 genotypes were grouped into those denoting none, 
one, two, or three functional alleles, and significant differences (P < 0.001) were 




(mean MR = 0.003), one (mean MR = 0.009), and no functional alleles 
(mean MR = 1.902), and between carriers of one versus two (P < 0.001) or three (P < 
0.01) functional alleles. 
In another study by Marez et aL (1997), several novel variants were characterised by 
single strand conformation polymorphism (SSCP) analysis, but as noted by Sachse and 
colleagues (1997,1998), most of the variants were very rare, and determination of the 
CYP2D6 alleles lacking in activity (*3-*6) that are common in Caucasians, together 
with assays for CYP2D6 gene duplication should be sufficient for a highly reliable 
prediction of CYP2D6 phenotype amongst the EM, IM, and PM categories. 
There has been one other large phenotyping study of French Caucasians (Laforest et 
al., 2000, performed after I commenced my, study). This was a CYP2D6 genotype- 
phenotype - study in lung cancer patients and hospital controls, genotyping for 
CYP2D6*3-5 and *16, and gene amplification events, ý, and phenotyping with 
dextromethorphan. In this study, genotypes corresponding to UM, EM, HEM 
(heterozygous EM/PM), and PM status were detected in 4.7%, 62.6%, 25.3%, and 
6.4% of the controls. The CYP2D6*4 allele frequency in the controls was 0.149 (allele 
frequencies of the other alleles not given). There was 93.8% concordance (121/129 
controls) between the genotypic and phenotypic determinations, with two genotypic 
PMs for whom the dextromethorphan MR was below 0.3, and two genotypic EMs that 
were phenotypically determined as PMs., Phenotypically, the frequency of PMs was 
8.5%., 
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3.1.1.2 Aims of these studies 
My French Caucasian sample consisted of 154 male general population volunteers, 
prior to participation in a Phase II Clinical Trial. 
The aims of the study were: 
I To genotype the volunteers, in order to identify individuals homozygous for 
n -f -type (EMs), so on unctional alleles (PMs), and individuals homozygous wild 
that these individuals could participate in the Phase II trial. 
2 ;-- To investigate the degree of genotype-phenotype correlation in the sample, 
,, through genotyping for the CYP2D6*3-5 and gene duplication alleles. At the 
time of the study, there, were no genotype-phenotype studies in French 
Caucasians. 
3ý To use the long-PCR assay that I developed to identify the frequency of 
individuals positive for a CYP2D6 duplication/amplification event in the 154 
male volunteers, and to compare the results of this assay with that of the long- 
PCR assay for CYP2D6 gene duplication developed by Lovlie et al., 1996. 
The UK Caucasian sample was recruited by the Clinical Age Research Unit, King's 
College London, and consisted largely of volunteers of at least 60 years of age. The aim 
0f this studywas to investigate the degree of CYP2D6 genotype-phenotype correlation 
in an ý elderly sample, in order to ascertain whether due to age, the CYP2D6 
metabolising capacity (and hence phenotype) was reduced, and hence a relative 
genotype-phenotype discrepancy developed. 
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3.1.2 French. sample 
3.1.2.1, Methods 
One hundred and fifty-four male French volunteers taking no prescribed medication 
were enlisted for the study (Section 2.1.1.1). Of these, one hundred and thirty-six were 
Caucasian, 17 of North African descent, and 1 was Black African in origin. The mean 
age was 26.15 years (sd 4.15, range 19-39 years). 
DNA was extracted from blood collected in EDTA tubes using the Nucleon II kit (now 
marketed as the Nucleon BACC3 kit, see Section 2.2.2.1), and genotyping for 
CYP2D6*3-5, and gene amplification events undertaken. A subset of this sample, 
c onsenting to phenotyping and with no contraindications (N = 46) were phenotyped 
with dextromethorphan (Section 2.2.1.2). 
CYP2D6*4 and CYP2D6*5 are the most common and next most common null alleles 
respectively; analysis for CYP2D6*4, CYP2D6*5, and CYP2D6*3 would be predicted 
to detect 90 to 95% of null alleles in a European Caucasian population (Heim et al., 
1990; Broly et al., 1991; Dahl et al., 1992). The CYP2D6*3 and CYP2D6*4 point 
I mutation alleles were detected by PCR followed by restriction enzyme digestion as in 
the method of Smith et al., 1992, with minor modifications. For the CYP2D6*3 assay, 
pnmers 5'-ATGAGCTGCTAACTGAGCCC-3' and 5- 
CCGAGAGCATACTCGGGAC-3' were used in a total reaction volume of 25 [tI with 
the'buffer typical for standard length PCR arnplification (Section 2.2.3.1), with 3 mM 
M9029 0.2 mM each dNTP, 0.25 pM each primer, and 1.25U AmpliTaq (Perkin- 
Elmer, 'UK). Cycling conditions were: initial denaturation at 940C for 3 min, 30 cycles 
148 
at 950C for I min, 600C for 30 s, and 720C for I min, followed by final elongation at 
720C for 10 min. PCR products were digested using Hpa II, and analysed on a 3% 
agarose gel, together with a lkb ladder (Gibco BRL). For the CYP2D6*4 assay, I used 
primers 5'-GCCTTCGCCAACCACTCCG-3' and 5- 
AAATCCTGCTCTTCCGAGGC-3' and the same reaction conditions and cycling 
conditions as for CYP2D6*3, except that a M902 concentration of 1.5 mM was used. 
PCR products were digested with Bst NI and analysed on a 3% agarose gel. The 
CYP2D6*5 gene deletion allele was assayed by long-PCR using the GeneAmp XL 
PCR kit (Perkin Elmer, UK) by the method of Steen and colleagues (1995), as 
described in Section 2.2.3.1. Figures 3.1,3.2, and 3.3 show representative results of 
assays for CYP2D6*3, CYP2D6*4, and CYP2D6*5. 
CYP2D6 gene amplification was detected by the long-PCR method of Lovlie et al., 
1996 (Section 2.2.3.2), and for the forty-six cases that were phenotyped, the long-PCR 
assay that I developed for CYP2D6 gene amplification was also used (Section 2.2.3.2). 
The results were analysed using SPSS for Windows, EpiInfo Version 6 and Axum 5.0 
(Section 2.3). 
3.1.2.2 Results 
Nine out of 154 subjects (5.8%) were genotyped as PMs (having no functional 
CYP2D6 alleles). The relationship between dextromethorphan metabolic ratio and 
CYP2D6 genotype for the 46 individuals that were phenotyped is shown in Figure 3.1 
(antimode = 0.3, i. e. MR > 0.3 defining PMs, and MR -5 0.3 defining EMs and UMs). 











Figure 3.1 Agarose gel electrophorcsis of Hpa 11 digests for CYP2D6*3 analysis. The 
subject in lane I is lieterozygous for the CYP2D6*3 allele, the subjects in lanes 2-4 are 










Figure 3.2 Agarose gel electrophoresis of Bst NI digests for CYP2D6*4 analysis. 
Subjects in lanes 2,5, and 6 are wild-type, subjects in lanes 3 and 4 are heterozygous 
for CYP2D6*4, and the subject in lane 7 is homozygous for CYP2D6*4. In lane I is a 








Figure 3.3 Agarose gel electrophoresis of long-PCR products for CYP2D6*5 analysis. 
The subject in lane I is positive for CYP2D6*5, in lane 3 is a positive control (supplied 
by Dr A Daly), and in lane 4 is a XlHind III ladder (Gibco BRL, Inc., kb). 
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I 
for the Caucasian subset (N = 44) was 0.483 (sd 1.97). It is clear in Figure 3.4 that two 
out of 46 cases were genotypically EMs (heterozygous EMs), but phenotypically PMs- 
There is also one outlier in genotypic category 2 (i. e. CYP2D6*11*1), with an MR of 
0.070 (logoMR = -1.15). 
These two cases were genotyped using the combined CYP2D6*6 and *4 allele assay 
(methodology described by Sachse et al., 1997), and found to be *41*6 genotype. No 
I 
cases were genotypic PMs and phenotypic EMs. With the *6 results there is a 100% 
concordance between the genotyping and the phenotyping results in terms of 
classification of PMs (Figure 3.5). Without the *6 results, there was 95.6 % 
concordance between the genotyping and the phenotyping results, with the sensitivity 
of the'genotyping being 100% and the specificity 95.2% (calculated with the 
phenotyping result representing the "actual" condition, and the genotyping result the 
"te_sf' condition). Interestingly, Laforest et al. (2000) did not genotype for CYP2D6*6, 
and had only 93.8% concordance between their genotyping and phenotyping results. 
This suggests that it is necessary to genotype for CYP2D6*6 in order to identify all 
PMs in French Caucasians. 
Table, 3.1 gives the numbers and percentages of cases detected in the Caucasians from 
my study with 0,1,2, or 3 functional genes, in comparison to the data of Sachse et al. 
(1997), Leathart et al. (1998), and Laforest et al. (2000). The percentages of cases in 
my study are seen to be similar to those of both of these two groups of investigators, 
-and to lie within the 95% confidence limits given by Sachse et al. (1997). Moreover, 
statistical comparison using the X2 test (3 degrees of freedom), between my data and the 
raw data of these other investigators reveals that my data do not differ significantly in 
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distribution from that of Sachse et al. Q2=1.85, P=0.60), or Leathart et al. (X 2 
1.99, P=0.58), or Laforest et al. (X2 = 1.30, P=0.73). 
The mean dextromethorphan MRs for the different genotypic categories and for 
subjects with 0,1, or 2 functional (active) CYP2D6 genes is given in Table 3.2, with 
comparative data from Sachse et al. (1997). (There were no individuals with 3 
functional genes amongst the forty-six who were phenotyped. ) If the outlier in 
genotypic category 2 is excluded, then the mean MR for subjects with 2 functional 
copies of CYP2D6 is the same as those in the study reported by Sachse et al. (1997). 
The mean MR for subjects with I functional CYP2D6 gene in my study (0.028) is 
higher than that for the same group of subjects in Sachse et al. (1997), i. e. 0.009, and is 
outside the 95% confidence limits reported by Sachse et al. (0.007-0.012). 
The frequencies of CYP2D6 alleles *3-5 and gene amplification in the whole sample, 
and in the Caucasian and African subsets are shown in Table 3.3. The genotypic 
distributions were in Hardy-Weinberg equilibrium for all the CYP2D6 variants tested, 
in the whole sample, and Caucasian and African subsets. The allele frequencies of the 
Caucasians in my sample are seen to be similar to the results of Sachse et al. (1997), 
while the subjects of African descent have a lower frequency of CYP2D6*3 (no alleles 
detected) and CYP2D6*4, and a higher frequency of the gene amplification event (4 out 
of the total of 18, i. e. 22.2%, of non-Caucasian cases were all *]/*] genotype and 
positive for the gene amplification). The allele frequency of the *6 allele is not given 
for my French sample as only the two individuals with genotype-phenotype 
discrepancy were genotyped for *6. The allele frequency of CYP2D6*6 in the 589 
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French males S2 German Caucasian 
C YP2D6 genotype N Mean MR (sd) N Mean MR (sd) 
*1x21*4 1 0.002 
26 0.006 (0.013) 
Z2 functional genes 27 0.006 (0.013) 246 0.003 (0.002 - 0.003) 
12 functional genes, 26 0.003 (0.003) 
excluding outlier 
*11*3 1 0.050 
11 0.02 (0.031) 
*421*1 1 0.090 
Y-1- functional gene 13 0.028 (0.035) 165 0.009 (0.007 - 0.012) 
*31*4 2 2.075 (0.163) 
*41*4 2 1.225 (0.728) 
*61*4 2 7.08(8.09) 
10 functional genes 6 3.46(4.60) 33 1.902 (1.392 - 2.598) 
Table 3.2 Dextromethorphan MRs (metabolic ratios) corresponding to different 
I 
genotypic groups, for forty-six French male volunteers (section 3.1.2), ' and four 
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Figure 3.4 CYP2136 phenotype (dextromethorphan metabolic ratio) versus CYP2D6 
genotypic category for 46 French male volunteers, without the *6 data (where I= 
*lx2l*4,2 = *]/*], 3= *11*3,4 = *11*4,5 = *4x2l*], 6= *31*4, and 7= *41*4). The 
dotted line marks a metabolic ratio of 0.3 (antimode, MRs greater than 0.3 
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Figure 3.5 CYP2D6 phenotype (dextromethorphan metabolic ratio) versus CYP2D6 
genotypic category for 46 French male volunteers, with the *6 data (where I= *lx2l*4, 
2= *]/*], 3= *11*3,4 = *11*4,5 = *4x2l*]. 6= *31*4, and 7= *4,1*4, and 8= *41*6). 
The dotted line marks a metabolic ratio of 0.3 (antimode, MRs greater than 0.3 
phenotypically defining poor metabolisers). 
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in the 5 89 Gennan Caucasians reported by Sachse et aL (1997) was 0.0093. 
There was 100% concordance between the results for my long-PCR assay for CYP2D6 
gene amplification and the modified version of the Lovlie et al. (1996) assay in the 46 
samples tested. Furthermore, the results of my assay were consistent with an allele 
with only one extra copy of the CYP2D6 gene (see Section 2.2.3.2). 
3.1.2.3 Discussion I 
Without genotyping for CYP2D6*6, there was a relatively high concordance between 
the genotyping and phenotyping results (95.6%), consistent with concordance figures 
reported by other investigators (93.4-100%, reviewed in Laforest et al., 2000). With 
the *6 results (together with *3-5 and gene amplification analysis), the concordance 
was 100%. The percentages of cases with 0,1,2, or 3 functional genes was not 
. significantly different from those in the studies of Sachse et al. (1997), Leathart et al. 
--ý, Iý (2000), or Laforest el al. (2000). The allele frequencies in the Caucasians of my 
sample were also similar to those of Sachse et al. (1997), while the pattern of 
frequencies seen in the subjects of African descent was similar to those in the study of 
Leathart et al. (1998), with a lower frequency of CYP2D6*3 and *4 in the subjects of 
African origin. 
However, the mean dextromethorphan MR for the French Caucasians in this sample 
(0-483) was higher than the mean dextromethorphan MR for the German Caucasian 
sample reported by Sachse and colleagues (0.143), the mean MR for subjects with 1 
functional gene (0.028) was also higher than that reported by Sachse et al. (0.009), and 
there was one outlier in terms of phenotype corresponding to *]/*] genotype. The 
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increased overall mean dextromethorphan MR and increased mean MR for subjects 
with 1 functional CYP2D6 gene may either be an artefactual finding due to the 
relatively small sample size, or represent an increased incidence of CYP2D6 alleles that 
may be associated with reduced CYP2D6 activity (e. g. CYP2D6*2, which I did not 
assay for -in this sample, and which may be associated with reduced CYP2D6*2 
activity; compare with the effect of the CYP2D6 *10 and *17 alleles on the mean MR in 
Orientals and individuals of African origin, section 1.5.1.1). Alternatively, to explain 
both this and the I outlier, there is the possibility that the volunteers were taking non- 
prescribed medications (e. g. cough remedies) that were CYP2D6 inhibitors. In the case 
of. the, *]/*] outlier, although the MR value is outside the 95% confidence limits of the 
MR values for subjects with this genotype in the study of Sachse et al. (1997), it is not 
0 utside, the range seen in that study. This individual is a Caucasian, and further 
genotyping of this subject is in progress. -- 
Sachse et al. (1997) explored the functional effect of alleles CYP2D6*2, *9, and *10 by 
comparison of the metabolic ratios corresponding to different allelic combinations, and 
found significant differences (P < 0.001) between PM/PM, and all other combinations, 
and between., IM/PM and EM/EM, EMAM, and MIA Comparison of genotypes 
including the CYP2D6*2 allele with those including the wild-type allele *1 showed a 
higher mean dextromethorphan MR comparing *21*4 and *11*4 (P, < 0.0 1), and a trend 
for a higher mean MR comparing *21*2 with *]/*l. In the phenotyping, the antimode 
was 0.3 -for the dextromethorphan and 12.6 for the - debrisoquine test, and all 8 
individuals - phenotyped, as debrisoquine PMs were genotyped as PMs. In the 
dextromethorphan group, one individual had an MR of 0.47, and was genotypically 
heterozygous, ý and individuals with the *21*4 genotype had MRs non-significantly 
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higher than 0.3. This is consistent with the debrisoquinc test discriminating better than 
the dextromethorphan between poor and intermediate metabolisers, as Sachse et al. 
(1998) note. In the latter study, 47 phenotypically intermediate metabolisers as defined 
by a dextromethorphan ratio greater than 0.1 were re-phenotyped with debrisoquine, 
and genotyped by Xba I RFLP analysis and PCR-RFLP tests for CYP2D6 alleles *1- 
*16. One *11*2 carrier, and 10 carriers of only one functional CYP2D6 allele had a 
I 
debrisoquine MR ranging from 1.50 - 15.3, with the one individual having an MR 
greater than 12.6 having a dextromethorphan MR less than 0.3 (0.12), and no additional 
mutations being found on sequencing. The remaining 36 out of 47 individuals all had a 
I. 11 
debrisoquine MR greater than 12.6 and had no active CYP2D6 allele. However, of note 
(see section 3.1.3.3), the findings of Zanger et al. (2001) suggest heterogeneity within 
alleles positive for the characteristic CYP2D6*2 R296C substitution in that alleles with 
the G variant of the -1584C>G promoter SNP may have relatively high activity, 
whereas only those positive for both the R296C and the C variant at the promoter site 
are intermediate metabolising in terms of activity. 
There was 100% concordance between the results of my long-PCR assay for the 
ýý ,I". . 
T, ý 
detection of CYP2D6 gene amplification, and the results of the Lovlie et al. (1996) 
assay with primers cyp-17 and cyp-32 (i. e. my assay and the Lovlie et al., 1996 assay 
gave the same results in terms of identifying individuals with gene amplification). This 
demonstrates the validity of my assay. Moreover, I have shown that the number of 
functional CYP2D6 genes on the allele that has been amplified can be estimated (Figure 
2.5). Given that individuals with 3,4,5, and 13 copies of the CYP2D6 locus on one 
allele have been described (Johansson et al. 1996; Aklillu et al., 1996), this assay may 
t 1. ýI! 
well be useful to differentiate such individuals, who might be expected to be 
ý Iýt I' ''I - 
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particularly refractory to treatment with drugs that were significantly metabolised by 
CYP2D6 (e. g. tricyclic antidepressants), or sensitive to drugs that were activated by 
CYP2D6 (e. g. codeine). It is possible that the assay developed by Lovlie and 
colleagues might also be able to estimate copy number; further work should include 
comparison of the results of both assays on individuals of CYP2D6 gene copy numbers 
2,3,4,5, and 13. 
The higher frequency of the gene amplification in the subset of subjects of African 
descent is consistent with the results of Aklillu et al. (1996), who reported that 29% of 
Ethiopians were UMs, but differs from the results of Leathart et al. (1998), who 
reported 12/246 (4.9%) of African-American individuals were heterozygous for a 
CYP2D6 gene duplication allele. Of my French subjects of African descent, 17 were of 
North African origin, I was Black African. The North Africans might be more 
ethnically similar to the Ethiopians, and hence my results are consistent with the above. 
Further study is warranted in British and French individuals of African origin. 
II%I! 
3.1.3 UK Caucasians 
3.1-3.1 Methods 
A sample of 74 UK volunteers were recruited by the Clinical Age Research Unit, 
King's College London (Section 2.1.1.2), 32 males and 42 females. Of these, 67 were 
of age at least 60 years (elderly), 65 of whom were Caucasian, 29 were male, and 38 
female. The mean age for those above 60 years was 71.31 years (sd 5.74, range 61-84 
years). Of the total sample of 74, two were non-Caucasian in ethnicity (Caribbean). 
Forty-three volunteers were eligible for and consented to debrisoquine phenotyping. 
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The methodology for genotyping and data analysis (Section 3.1.2.1.1) and phenotyping 
was as described (Section 2.2.1.1). 
3.1.3.2 Results 
The relationship between debrisoquine metabolic ratio and CYP2D6 genotype is shown 
in Figure 3.6 (antimode = 12.6, i. e. MR > 12.6 defining PMs). The mean debrisoquine 
MR for the 67 elderly was 5.67 (sd 15.3, range 0-70, where a value of zero means that 
only the metabolite was detected); the mean debrisoquine MR in the study by Sachse et 
aL (1997) was somewhat lower, 3.54 (calculated from Figure 2B in the paper). 
From Figure 3.6 it can be seen that one out of 43 cases was genotypically an EM 
(heterozygous EM, *11*5), but phenotypically a PM. This individual was genotyped as 
wild-type on the *3 and *4 assays (i. e. it was possible to generate amplicons from the 
CYP2D6 locus), and therefore cannot be homozygous for a CYP2D6*5 deletion allele. 
This one case of genotype-phenotype discrepancy is negative on assay for CYP2D6*6 
and is being subjected to mutation screening by Dr K Tandon under my supervision, 
using denaturing high performance liquid chromatography (O'Donovan et al., 1998). 
No cases were genotypic PMs and phenotypic EMs. This gives an overall 97.7% 
concordance between the genotyping and the phenotyping results, with the sensitivity 
of the genotyping being 100% and the specificity 97.4% (calculated on the assumption 
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Figure 3.6 CYP2136 phenotype (debrisoquine metabolic ratio) versus CYP2D6 
genotypic category for 40 UK volunteers (where I= *lx2l*], 2= *]/*/, 3= *11*4,4 = 
*11*5,5 = *41*4,6 = *41*5), metabolic ratios of zero excluded. The dotted line marks 
a metabolic ratio of 12.6 (antimode, MRs greater than 12.6 phenotypically defining 
poor metabolisers). 
Table 3.1 gives the numbers and percentages of cases with 0,1,2, or 3 functional genes 
detected in the Caucasians from my study, and the elderly subset, in comparison to my 
data from the study on French subjects detailed above, and the data of Sachse et al. 
(1997), Leathart el al. (1998), and Laforest et al. (2000). The percentages of cases in 
the elderly subset lie within the 95% confidence limits given by Sachse ef al. (1997), 
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except in the case of 1 functional gene, for which my percentage of cases detected is 
just, above the upper 95% confidence limit. Statistical comparison between the data 
from the elderly subset (N = 65), and that of the French Caucasians, and the raw data of 
Daly, and colleagues, Laforest and colleagues and Sachse and colleagues reveals that 
the distribution of subjects with 0,1,2, and 3 functional genes is not significantly 
different between'the data for the elderly subset and the data of Sachse et al. (X 2=2.79, 
P=0.42), or my French Caucasians (X2 = 2.87, P=0.41), but there is a trend towards a 
higher percentage of individuals with 1 functional gene in the elderly Caucasian group 
as compared with the American Caucasian group Q26.52, P 0.09), similar to the 
comparison with the data of Laforest et al. (X2 = 5.65, P=0.13). 
The mean debrisoquine MRs for the different genotypic categories and for subjects 
with 0, ', 1,2, or 3 functional (active) CYP2D6 genes is given - in Table 3.4, including the 
values if the outlier in genotypic category 4 is excluded. The corresponding values for 
'debrisoquine MRs are derived from the data of Leathart et al. (1998), and it can be seen 
that my results fall within the ranges reported by Leathart and colleagues. Sachse et al. 
(1998') report a range for debrisoquine MR corresponding to no active CYP2D6 genes 
of 17.1-249, for I functional gene 1.11-11.8, and the mean for 1 or 2 functional genes 
from the graphical presentation of the data in Sachse et al., 1997 is approximately 1.44 
and approximately 0.46 respectively. My results therefore also fall within the ranges 
reported by previous investigators, but the mean MR for subjects with one functional 
CYP2D6 gene is higher in my study than in that of Sachse et al. or Daly and co- 
workers. 
The frequencies of CYP2D6 alleles *3-5 and gene amplification in the whole sample, 
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UK Caucasians' American Caucasians 2 
CYP2D6 genotype N Mean (sd) N Mean (range) 
*lx2l*l (3 gene copies) 3 0.58(0.79) 6a 0.54 (0.14 - 14.8) 
*1/*1 (2 gene copies) 21 1.10(l. 22) 154 b 0.54 (0.02 - 51) 
*11*4 - 11 2.45(2.40) 
*11*5 2 16.82 (23.47) 
El functional gene 13 4.66(8.93) 69 1.55 (0.24 - ; 0.36) 
11 'functional gene, 12 2.26(2.38) 
excluding one outlier 
*41*4 4 58.24 (17.65) 
*4ý*5 1 70.00 
10 functional genes 5 60.59 (16.16) 18 48.91 (5.45 - 244) 
Table 3.4 Debrisoquine metabolic ratios corresponding to different genotypic 
categories, for UK Caucasians (section 3.1.2), ' and American Caucasians reported by 
Leathart et al. (1998) .2 
'Subjects with 3 gene copies, allelic combination not given, 
b 
subjects with 2 gene copies, allelic combination not given; means calculated from In 
values reported 
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and in the elderly subset are shown in Table 3.3. The allele frequencies of the 
Caucasians in my sample are seen to be similar to the results for the French and 
German Caucasians, except that in the elderly UK Caucasians no CYP2D6*3 was 
detected. The genotypic distributions for CYP2D6 alleles *3-*5, and the gene 
duplication allele were all in Hardy-Weinberg equilibrium 
3.1.3.3 Discussion 
In this study, there was 97.7% concordance between the genotyping and the 
phenotyping results. This is consistent with the findings of previous investigators, 
which have indicated that both phenotyping and genotyping may not be 100% accurate 
in the identification of true PMs (Griese et al., 1998; Leathart et al., 1998). 
The mean debrisoquine MR (5.67) in the elderly sample (British Caucasians of at least 
60 years) is somewhat higher than the mean debrisoquine MRs in two previous sets of 
data on Caucasian volunteers (Daly et al., 1991, mean debrisoquine MR less than 1.0 
for N= 73 volunteers; Sachse et al., 1997, mean debrisoquine MR 3.54 for 133 
debrisoquine-phenotyped German Caucasians). It is difficult to calculate whether or not 
the difference between the mean MR in this study does differ significantly from the 
mean MR in the Sachse et al. (1997) study owing to the raw data not being reported in 
the latter study. There was a trend towards an increased percentage of heterozygous 
individuals in the elderly Caucasians as compared to the American Caucasians studied 
by Daly and colleagues (Leathart et al., 1998; mean age of sample not given), and the 
sample of Laforest et al. (mean age 55.0 years). However, this trend was not seen in 
comparison with my French young (mean age 26.15 years) Caucasian sample, and the 
sample of Sachse et al. (mean age 40 years in males, 48 years in females). This 
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relatively high overall mean debrisoquine MR may reflect the relatively high mean MR 
for subjects with one functional CYP2D6 gene. This could either reflect the presence of 
an intermediate metabolising allele (e. g. CYP2D6*2) in my elderly cases with relatively 
high frequency, or reduced CYP2D6 activity in the heterozygous state due to an age- 
related reduction in CYP2D6 hepatic capacity. If the latter were the case, then this 
would be the first study to report results consistent with this, Kinirons and Crome 
(1997)-having noted reduction in other hepatic cytochrome P450s (CYP3A4/5, 
CYPIA2, CYP2C9, and CYP2CI8/19) with increasing age, but not having observed a 
reduction, in CYP2D6 capacity. 
It is also of note that there were 4 individuals in this study with debrisoquine MR < 
0.20: three with MRs of zero (i. e. only the metabolite detected, genotypes *lx2l*], 
*]/*I, and *11*4), and one with an MR of 0.15 (genotype *11*4). The Lovlie et al. cyp- 
17/cyp-32 assay hence detected only one out of these 4 individuals as being positive for 
a gene amplification event. 
A study of 61 unrelated Swedish subjects with debrisoquine MR less than 0.2 revealed 
CYP2D6 amplification in 14 (23%), and of those with MR less than 0.1,40% had 
CYP2D6 amplification (Dahl et al., 1995a). The authors therefore concluded that there 
must'be variation in CYP2D6 other than gene amplification to account for high 
CYP2D6 activity. This was then followed up by Lovlie et al. (2001), who screened 13 
UMs and 4 EMs for variants in exon I and flanking sequences of CYP2D7P, and the 
promoter region and 5' coding sequence of CYP2D6. (The above region of CYP2D7P 
was selected as CYP2D7P has an insertion of a single T at position 137 in exon 1, 
leading to a disrupted reading frame, which classifies it as a pseudogene - the 
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hypothesis was that gene-conversion events could have converted CYP2D7 back to a 
CYP2D6-like sequence, giving an allele effectively equivalent to CYP2D6 duplication. ) 
All individuals tested were homozygous for the T137 insertion, but five variants from 
the 5'-end of CYP2D6 were selected for further analysis (representing most of the 
variation observed, based on estimated haplotypes) in a further 27 UMs and 77 EMs. 
Data analysis showed that the 31A allele of the 31G>A (ValjjMet) SNP was 
significantly more frequent in the UMs (P = 0.04), and one of the haplotypes with this 
variant constituting 23.5% of haplotypes in the UM group as opposed to 4.2% in the 
EM group (P = 0.03). However, the authors noted that the results were only of 
borderline significance and not corrected for multiple testing. Indeed, a subsequent 
functional study showed that the functional activity and level of expression of 
,, recombinant CYP2D6.3 5 (positive for the 31 G>A substitution) was comparable to that 
of wild-type enzyme (Allorge et al., 2001). 
Lovlie et A (2001) also found a non-significant over-representation of the G-allele of a 
1584C>G promoter polymorphism in the UM group, consistent with the findings of 
Zanger et aL (2001) that the -1584G variant was associated with significantly higher 
microsomal protein expression in liver biopsy samples. Therefore, it may not be 
sufficient to simply genotype for gene duplication/amplification events in order to 
identify UMs. 
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3.2 Typical antipsychotics CrAs) and CYP2D6 
3.2.1 Introduction 
CYP2D6 , contributes significantly to the pharmacokinetics of most typical 
antipsychotics (Dahl and Bertilsson, 1993). Up to 30% of patients with schizophrenia 
who are prescribed typical antipsychotics are treatment-resistant (Kane et al., 1988). 
The term treatment-resistant includes those who are treatment-refractory (show 
inadequate clinical response) and those who are treatinent-intolerant (exhibit adverse 
- responses). 
Two patients with CYP2D6 UM status have been described for whom tricyclic 
antidepressants at doses beyond the usual therapeutic range were required in order to 
achieve a therapeutic response (Bertilsson et al., 1993). One of these was first 
described by Bertilsson et al. (1985): a depressed patient with a very low debrisoquine 
MR (0.07), in whom nortriptyline doses up to 300-500 mg daily (the British National 
Formulary, or BNF, recommended maximum dose being 150 mg) were required to 
reach plasma levels of nortriptyline within the therapeutic range. Hydroxylation of 
nortriptyline to 10-hydroxynortriptyline (the major metabolic pathway of nortriptyline) 
is catalysed by CYP2D6 (Mellstr6m et al., 1981; Nordin et al., 1985), and 
concentrations of 10-hydroxynortriptyline 3 times higher than normal were observed in 
this patient. The same group later showed that this patient carried a duplication of 
CYP2D6 (Bertilsson et al., 1993), and also reported another patient with CYP2D6 gene 
duplication in which a clomipramine dose of 225 mg yielded a clornipramine level of 
150 nM and desmethylclomipramine less than 100 nM, both much lower than expected, 
and required 300 mg (BNF maximum 250 mg) of clomipramine to produce an adequate 
171 
clinical response. A third patient has been described with extremely rapid metabolism 
of mianserin (also metabolised by CYP2D6), in which 13-fold amplification of 
CYP2D6 was found. There is a case report of the impact of CYP2D6 UM status on the 
metabolism of risperidone (Guzey et al., 2000). However, when I began my study, 
there were no systematic case-control studies of the effect of CYP2D6 UM status on 
response to antidepressants or antipsychotics. 
Treatment with typical antipsychotics can result in a variety of adverse effects. If these 
are severe, this may result in intolerance, and hence the need to change to an atypical 
antipsychotic, such as clozapine. The adverse effects that are most likely to cause 
typical antipsychotic intolerance are extra-pyramidal side-effects (EPS). These 
include: drug-induced parkinsonism, dystonia, dyskinesia, and akathisia, with acute and 
tardive variants of the last three (Bames, 1992). 
Druý-induced parkinsonism (DIP) resembles idiopathic Parkinson's disease, which is 
characterised by the triad of bradykinesia, rigidity, and tremor, except that 
- asymmetrical distribution and the classical pill-rolling tremor are less common in the 
drug-induced' form (Lishman, 1998). Tardive dyskinesia (TD) is an abnormal 
involuntary movement disorder caused by sustained exposure to antipsychotics, 
characterised by orofacial dyskinesia and choreoathetoid movements of the tnmk and 
limbs. 'Risk factors for TD include: high lifetime antipsychotic exposure, especially to a 
high dopamine D2-receptor potency antipsychotic, the presence of movement disorder 
" i' (both subtle movement disorder prior to treatment, and acute EPS, especially drug- 
induced parkins. onism), negative symptoms, cognitive impairment, diabetes, alcohol or 
drug abuse, and, in most studies, age (Wolf el al., 1983; Kane et al., 1986; Woerner et 
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al., 1991; Caliguiri et al., 1991; Waddington, 1995a; van Os et al., 1997; Muscettola et 
al., 1993 and 1999). Indeed, a recent study indicates that the prevalence of involuntary 
movements approaches 100% over a lifetime trajectory for individuals with 
schizophrenia chronically medicated with typical antipsychotics (Quinn et al., 2001). 
An association between CYP2D6 PM status and concentration-dependent adverse 
effects of typical antipsychotics, such as sedation, postural hypotension, and 
antimuscarinic side-effects, has been found (Spina et al. 1992). Meta-analysis of the 
literature has revealed that CYP2D6 PM status is associated with a small increase in 
risk of IParkinson's 
Disease (McCann et al., 1997; Christensen et al., 1998; Rostami- 
Hodjegan, et al., 1998). Subsequent studies have, however, yielded conflicting results, 
with positive, associations being mainly found for the CYP2D6*4 allele (Atkinson et 
al., 1999; Bon et al., 1999; Stefanovic et al., 2000), although not invariably (Harhangi 
et al., 2001), and not for other PM/IM alleles (Sabbagh et al., 1999; Nicholl et al., 
1999; Joost et al., 1999; Ho et al., 1999; Maraganore et al., 2000). It has been 
suggested that the apparent CYP2D6*4 effect is an age-related artefactual association 
(Payami et al., 2001). Some studies (Armstrong et al., 1997; Andreassen et al., 1997; 
i 
Kapitany et, al., 1998; Ohmori et al., 1998; Vandel et al., 1999; Scordo et al., 2000; 
Topic et al., 2000), but not all (Arthur et al., 1995; Hamelin et al., 1999; Ohmori et al., 
1999), have found associations between CYP2D6 metaboliser status and antipsychotic 
intolerance or EPS including DIP and/or TD. 
3.2.2 Aims 
1 -, I To test the hypothesis that patients with schizophrenia who were refractory to 
treatment with typical antipsychotics would be more likely to be ultrarapid 
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, metaboliscrs, as compared with patients who responded to typical 
antipsychotics. (If the hypothesis were confirmed, it could form the rationale 
,-, for a pre-prescribing genotyping assay to predict patients who would be less 
likely to respond well to typical antipsychotics at standard doses, and therefore 
assist the process of clinical dose finding and/or the more rapid progression of 
such patients on to an atypical antipsychotic not subject to the CYP2D6 
polymorphism. ) 
2 Given some indication of an association between CYP2D6 metaboliser status 
and susceptibility to adverse effects of antipsychotics, especially DIP and TD, 
, but inconsistency in the findings, my aim was to clarify the nature of the 
apparent associations found. In addition, my studies differ from that of most 
previous authors in that I genotyped not only for non-functional alleles, but also 
for the presence of gene duplication/amplification (i. e. UM status), which 
allowed me to determine whether or not there were associations with the 
number (N = 0-3) of functional CYP2D6 genes. 
3.2.3 CYP2D6 UM status and failure to respond to TAs 
This study has already been published (Aitchison et al., 1999b). 
3.2.3.1 Methods 
Two hundred and forty-six patients treated with clozapine, resistant to treatment with 
typical antipsychotics, were collected (R. W. Kerwin and J. Munro, South London and 
Maudsley NHS Trust). Of these, 235 were refractory to typical antipsychotic treatment, 
and were used in this study (see section 2.1.2.3 for sample details). The comparison 
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group, non-refractory to TAs, comprised 73 patients from the Maudsley and Bethlern 
Royal Hospitals NHS Trust. Of these, 66 were collected by P. Wright, and 7 were 
collected by Dr S. Smith (Section 2.1.2.1). Six of the seven subjects had a clinical 
diagnosis of schizophrenia or schizoaffective disorder, the seventh had severe 
depressive disorder with psychotic features. Six had been treated with the equivalent of 
100 mg chlorpromazine daily, while the remaining patient received 15 mg flupenthixol 
decanoate fortnightly, the equivalent of approximately 75 mg chlorpromazine daily. As 
the -patients were treated with a variety of antipsychotics, we converted all the 
prescriptions to chlorpromazine equivalents according to BNF guidelines, in order to 
assess whether or not there was a relationship between the magnitude of the dose and 
the CYP2D6 genotype. 
Ethical Committee approval was obtained for the study on all subjects, and, as there 
were Insufficient numbers of non-Caucasians in the sample for the analysis to be 
informative, all non-Caucasians were excluded. 
DNA was extracted from blood collected in EDTA tubes using the Nucleon II kit, and 
CYP2D6 gene amplification was detected by the long-PCR method of Lovlie et al., 
1996 (Section 2.2.3.2). As cases had been described in which there are extra copies of a 
non-functional or null CYP2D6 allele (Lovlie et al., 1996; Masimirembwa et al., 1993; ' 
Sachse et al., 1997), it was necessary to assay for non-functional CYP2D6 alleles as 
well as for the presence of a gene amplification event in order to confirm ultrarapid 
metaboliser status. I therefore assayed for the CYP2D6*3, CYP2D6*4, and CYP2D6*5 
null alleles, which would be predicted to detect 90 to 95% of null alleles in a European 
Caucasian population (Heim et al., 1990; Broly et al., 1991; Dahl et al., 1992). The 
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methodology for CYPM03-5 genotyping and the gene amplification assay by the 
modified version of the LovIie et al. (1996) assay was as described in Section 3.1.2.1.1. 
Two cases were positive on both the CYP2D6*4 and the gene amplification assays. 
These were further tested to determine whether the null or the wild type allele was 
duplicated as described by Sachse et aL, (1997; Section 2.2.3.2): a further gene 
amplification assay was performed with primers as described by Johansson et al. 
(1996), giving a lOkb amplicon. in cases positive for a gene amplification, which was 
then subjected to a nested PCR followed by digestion with Hph I. 
The results were analysed using SPSS for Windows and EpiInfo Version 6 (Section 
2.3). 
3.2.3.2 Results 
CYP2D6 genotype and deduced phenotype for the 235 subjects refractory to treatment 
with typical antipsychotics versus the 73 responsive to typical antipsychotics are given 
in Table 3.5. Of the 235 treatment-refractory subjects, 4 (1.7%) cases were positive on 
the duplication assay. However, two cases yielded'a CYP2D6*41wt result with the 
CYP2D6*4 assay and a positive result with the duplication assay; these caseg were 
found to represent duplications of the CYP2D6*4 allele. As these cases possessed only 
one functional copy of CYP2D6, they were deduced to be phenotypically equivalent to 
heterozygous null cases and hence EMs, not UMs. Therefore only 2 out of 235 cases 
(0.9%) were positive for duplication of a wild type allele. In contrast, of the sample of 
73 non-refractory patients, 3 (4.1%) were positive for the duplication assay, of which 
none were positive for the null alleles tested. The results were therefore in the opposite 
direction to that predicted by our hypothesis, but they did not reach significance: 
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Fisher's exact test was performed, comparing the presence or absence of UM status in 
the 2 clinical groups, which gave a 2-tailed P value of 0.091. (Chi square was not 
appropriate here, with the number of cases being less than 5; with Fisher's exact test 
the 1 -tailed and 2-tailed P values were identical, but the value is reported as 2-tailed as 
the i6sults were in the opposite direction to that predicted by the hypothesis). 
Table 3.6 shows the distribution of the alleles with allele frequencies in the 2 clinical 
groups, with the results being reported under the assumption that the duplication allele 
is present in the heterozygous state. If this allele were present in a homozygous state in 
all cases in which it was found, then the frequencies of the wild type and null alleles in 
the treatment-refractory group would be unchanged, while that of the duplication allele 
would be doubled at 0.0085; the frequencies of the wild type, null, and duplication 
alleles in the non-refractory group would be 0.71,0.25, and 0.041 respectively. 
However, as in the paper by Johansson el al. (1996) none of their cases with a 
duplication allele were homozygous for this variant, I assumed that all of the cases are 
heterozygous. The frequencies of the CYP2D6*4, CYP2D6*5, and CYP2D6*3 alleles 
respectively in the sample of 235 and 73 were: 0.223,0.024, and 0.018 (in the sample 
of 235), and 0.219,0.02, and 0.02 (in the sample of 73). Comparing the presence or 
absence of the duplication allele in the 2 groups, Fisher's exact test gave a 2-tailed P 
value of 0.10 (Table 3.6). 
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Table 3.5 CYP2D6 genotype and deduced phenotype in subjects refractory to 
treatment with typical antipsychotics and non-refractory to treatment with typical 
antipsychotics; numbers of cases given with percentages in parentheses 
EM PM um 
(wt/wt) or (wt/mut) (mut/mut) (dup of wt) 
Refractory to TAs (n = 235) 220 (93.6) 
Non-refractory to TAs 67 (91.8) 
(n = 73) 
13 (5.5) 2 (0.9)* 
3 (4.1)* 
TAs, typical antipsychotics, wt, wild type, mut, non-functional mutant or null allele 
(includes 2 duplications of mut in the EM group), dup of wt, duplication of wild type 
allele. *Two-tailed P-value for presence or absence of UM status in refractory versus 
non-refractory group = 0.09 (Fisher's exact test); odds ratio = 0.2,95% confidence 
limits 0.02-1.80 
178 
Table 3.6 Distribution of CYP2D6 alleles in the treatment-refractory and non- 
refractory groups; allele numbers given, with frequencies in parentheses. The 
CYP2D6*4 x2 allele is included in the null alleles 
Wild type Null Duplication of wild type 
Refractory to TAs 343(0.73) 97 (0.26) ,2 (0.0043)* 
Non-refractory to TAs 103(0.72) 37(0.26) 3 (0.021)* 
TAs, typical antipsychotics. *Two-tailed P-value for presence or absence of duplication 
allele in refintory versus non-refractory groups = 0.10 (Fisher's exact test); odds ratio 
0.21,95% confidence limits 0.02-1.88. 
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3,. 2.3.3 Discussion 
I'did not find an excess of ultrarapid metabolisers in subjects refractory to treatment 
, ýyith 
typical antipsychotics. On the contrary, only, 2 out of 235 (0.9%) treatment- 
refractory cases were positive for duplication of a wild-type allele, while 3 out of 73 
I 
ýi 
(4.1%) non-refractory cases were genotyped as ultrarapid metabolisers. This gives a 
trend (P = 0.091, Fisher's exact test) towards an excess of ultiarapid metabolisers in the 
non-refractory group of patients. However, both percentages are within the range for 
ultrarapid metabolisers in Caucasian populations (Agdndez et al., 1995; Jerling et al., 
1994; Dahl et ah, 1995a; Sachse et al., 1997). Two cases of CYP2D6*4 duplication 
were found, which is the second time this has been reported in Caucasians, Sachse and 
colleagues (1997) having provided the first report. 
The results demonstrate that ultrarapid hydroxylation by CYP2D6 of typical 
antipsychotics is not a major cause of failure to respond to treatment with these agents. 
There are at least 5 possible explanations for this surprising result. Firstly, I could have 
failed to find a significant result when there . is in, fact a significant association of 
ultrarapid - hydroxylation either, with treatment-refractory status (the direction of the 
original hypothesis), or with treatment non-refractory status (the direction of the trend 
found). The odds ratio (OR) for UM status, counting the treatment-refractory group as 
the "diseased state" and the non-refractory group as the "non-diseased state, " was 0.2, 
with exact lower and upper 95% confidence limits of 0.02 and 1.8 respectively (Table 
3-5)., This means, that ultrarapid metaboliser status is less associated with being 
treatment-refractory than with being non-refractory, with the range extending to being 
more associated with treatment-refractory. Of note the 2 patient sample groups are 
unequal in size; if. we had had as many in the treatment non-refractory group and the 
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percentage of ultrarapid metabolisers in this group had remained the same as in my 
current findings, then I would have found 10 ultrarapid metabolisers in the non- 
refractory group, which would have given a chi square of 5.47, ap value of 0.019, and 
an OR of 0.19, with exact lower and upper limits of 0.02 and 0.92 respectively. In this 
ýenario a significant result in the opposite direction to our original hypothesis would 
have been found. 
, 
'§econdly, in both of my groups of subjects, the dose of antipsychotic was titrated by ]ihe 
prescribing consultants according to clinical effect. This could obscure any 
inharmacogenetic effects, Le. ultrarapid metabolisers could be receiving doses above or 
at the upper, end of the normal prescribed range, and then respond as if they were 
extensive metabolisers. However, for the non-refractory group one of the patients with 
CYP2D6 duplication was on only 30mg flupenthixol decanoate 2 weekly (equivalent to 
15. Omg chlorpromazine daily, Le. a low dose). 
Thirdly, although CYP2D6 is known to contribute to the pharmacokinetics of many 
typical antipsychotics (Dahl and Bertilsson, 1993), the specific contribution is different 
for different antipsychotics, and other cytochromes are involved. CYP2D6 is involved 
in the first pass metabolism and systemic elimination of perphenazine (Dahl-Puustinen 
et al., 1989); and the systemic elimination of zuclopenthixol (Dahl et al., 1991). For 
these drugs; high CYP2D6 activitymould be expected to lead to lower serum levels of 
the drugs, " and hence possible therapeutic resistance. Although inhibition studies 
demonstrated that CYP2D6, is likely to be , 
involved in the metabolism of 
chlorpromazine (Inaba et aL, '1985; Spina et al., 1991), Muralidhan and colleagues 
(1996) showed that CYP2D6 makes a relatively minor contribution to the large 
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interindividual variability seen in plasma chlorpromazine levels. 
II 
The systemic elimination of haloperidol has been shown by Llerena and colleagues 
(1992) to be dependent on CYP2D6 activity, and although early reports showed that 
CYP2D6 catalysed the oxidation of reduced haloperidol back to haloperidol 
(Chakraborty et al., 1989; Tyndale et al., 199 1), other work was not consistent with this 
(Young et al., 1993), and recent reports (Fang et al., 1997; Pan et al., 1998) have 
demonstrated that CYP3A4 is the primary enzyme involved in this step in the 
metabolic pathway. The steps in the metabolism of haloperidol in which CYP2D6 is 
involved are at present unclear, but, consistent with the results of Llerena and 
colleagues (1992), Nyberg et al. (1995) showed that a CYP2D6 poor metaboliser had 
higher concentrations of plasma haloperidol throughout a4 week treatment period with 
haloperidol decanoate as compared with 7 CYP2D6 extensive metabolisers. Although 
none of the subjects in the study of Nyberg et al was an ultrarapid metaboliser, it would 
be'logical to assume that a UM would have low plasma haloperidol levels. Suzuki and 
colleagues (1997) studied the correlation between CYP2D6 genotype and steady-state 
plasma concentrations (C,, ) of haloperidol and reduced haloperidol in a group of, 50 
Japanese patients with schizophrenia. They found that the mean C. of haloperidol was 
si gnificantly higher (p<0.05) in the patients with I mutant allele compared to those 
with no mutant alleles, and that the mean C,, of reduced haloperidol was significantly 
higher (p<0.05) in the patients with 1 or 2 mutant alleles compared to those with no 
mutant alleles. They therefore suggested that the Cs of reduced haloperidol was more 
dependent upon CYP2D6 activity than the C,, of haloperidol. However, although they 
did not find a significant -difference between the mean Cs, of haloperidol in patients 
with 2 mutant alleles compared to those with no mutant alleles, it is of note that in this 
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study, the patients with 2 mutant alleles were either homozygous for the CYP2D6*10 
allele (n = 4), which is associated with reduced but not absent CYP2D6 activity, or 
were compound heterozygotes for the CYP2D6*10 and CYP2D6*5 alleles (n = 2). 
Hence no patient actually had 2 CYP2D6 null alleles. Lane et al. (1997) examined the 
relationship between CYP2D6 phenotype (as measured by 
dextromethorphan/dextrorphan metabolic ratio) and haloperidol disposition in 18 newly 
hospitalised Chinese patients with schizophrenia. Despite the fact that no PMs were 
found in this study, significant correlations between the metabolic ratio and plasma 
haloperidol concentration, reduced haloperidol concentration, and reduced 
I haloperidol/haloperidol ratios were found. In a preliminary report of a larger study, 
Schmidcr et aL (1998) invcstigatcd thcrapeutic drug m9nitoring data in 178 paticnts 
versus CYP2D6 genotype and found that PMs had significantly higher reduced 
I haloperidol but not haloperidol concentrations compared to patients with I or no 
'- mutant alleles. The suggestion of Suzuki et al. (1997) that CYP2D6 affects reduced 
haloperidol levels at steady-state to a greater extent than haloperidol levels might 
therefore be correct. However, Suzuki et al. also suggested, based on the work of 
,i Tyndale and colleagues (1991), that CYP2D6 catalyses the oxidation of reduced 
haloperidol back to haloperidol. As already outlined above, more recent work is not 
consistent with this (Young et al., 1993; Fang et al., 1997; Pan et al., 1998), although 
the precise step in the metabolism of reduced haloperidol in which CYP2D6 is involved 
is at present unclear. Young et al. (1993) showed that reduced haloperidol was the 
preferred form in the plasma after the administration of a single dose of either 
haloperidol or reduced haloperidol to healthy volunteers. A negative correlation 
between clinical response and reduced haloperidol levels or reduced 
haloperidol/haloperidol ratios has been observed (Bareggi et al., 1990); it is possible 
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that ultrarapid metabolisers of CYP2D6 could have lower reduced haloperidol levels 
and hence a better clinical response. This would be consistent with the trend that we 
have found for an excess of UMs in the non-refractory group. However, Lane et al. 
(1997) did not find a correlation between response and reduced haloperidol levels, 
r- educed -haloperidol/haloperidol ratios, or haloperidol levels. This is consistent with 
analyses by other authors (Chang et al., 1992; Altarnura, et al., 1993). 
In the case of thioridazine, CYP2D6 catalyses the formation of mesoridazine, a 
metabolite with antipsychotic activity (von Bahr et al., 1991), and may be involved in 
the, generation" of another active metabolite, sulphoridazine. Extensive metabolisers 
have been' shown to have higher peak levels of mesoridazine and sulphoridazine than 
poor metabolisers, after a single oral dose, with lower levels of thioridazine. The total 
serum concentrations of substances with antipsychotic activity at steady-state will be 
determined by the relative magnitudes of the equilibrium constants of all the reactions 
in the metabolic pathway; these equilibrium constants and the relative antipsychotic 
potencies of the different active metabolites are unknown. It is therefore difficult to 
predict the effect of ultrarapid metaboliser status on clinical response to thioridazine. 
Both of our groups of patients had been treated with various typical antipsychotics; it is 
therefore possible that I failed to show a correlation in one direction oý the other as 
effects with some antipsychotics versus other antipsychotics cancelled each other out. 
Furthermore, it is possible that some patients in the treatment-refractory group were 
treated with agents whose levels are not significantly affected by CYP2D6 genotype 
(such as chlorpromazine). However, I would emphasise that a significant result would 
be unlikely to be obscured by either of the above possibilities as the numbers of 
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individuals with duplications is very low in both the treatment-refractory and non- 
refractory groups. It is also of note that the subject on zuclopenthixol who is a UM is 
clinically stable on a low dose. 
Fourthly, several of the above studies (especially those on normal volunteers) were 
single-dose pharmacokinetic analyses; single dose effects may differ markedly from 
those seen at steady-state in a situation of pharmacological adaptation (Grahame-Smith, 
1997). However, the work of Nyberg et al. (1995), Suzuki et al. (1997), Lane et al. 
(1997), ' and Schmider et al. (1998) was conducted on patients at steady-state. 
Furthermore, Jerling et al. (1996) conducted a study on patients during continuous 
treatment and CYP2D6 genotype was shown to significantly predict the oral clearance 
of perphenazine and zuclopenthixol (patients with 2 CYP2D6 null alleles having a 
significantly lower clearance than those with one or no mutant alleles). 
Finally, other factors may contribute towards non-response to medication, including 
non-compliance, pharmacodynamic factors, other biological factors, and psychosocial 
factors. Non-compliance occurs in up to 50% of patients on neuroleptics (Bebbington et 
al.,, 1995). Pharmacodynamic factors have been implicated in the clinical response to 
clozapine, an atypical antipsychotic (Arranz et al., 1995); it may be that other 
pharmacodynamic factors (e. g. D2 receptor variants) are involved in the response to 
typical antipsychotics. Lieberman and colleagues (1996) and Van Os et al. (1996) have 
reviewed predictors of outcome in psychotic illness and concluded that factors such as 
longer duration of untreated illness, and structural brain abnormality on CT or MRI 
predict unfavourable outcome, while living in a low "expressed emotion7 environment 
is one of the predictors of a favourable outcome. 
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I did not find an association between ultrarapid metaboliser status and being treatment- 
refractory to typical antipsychotics. On the contrary, I found a trend towards an 
association between UM status and being non-refractory to TAs, which could have 
reached significance had the non-refractory group been equal in size to the refractory 
group. 
Nonetheless, I have not excluded the possibility that UM status could lead to failure to 
respond to a standard dose of some TAs and other drugs metabolised at least partially 
by CYP2D6, e. g. risperidone. In the case of risperidone, there has been a report 
describing two individuals treated with risperidone (4 mg/day) who had a lack of 
therapeutic ý response and lower than, expected concentrations of risperidone for that 
dose, and who were found to be ultrarapid metabolisers on genotyping (Giizey el al., 
2000). ý However, Gflzey and colleagues note that the concentration of 9- 
hydroxyrisperidone (which also has antipsychotic activity) was as expected or only 
slightly, lower than, expected, so that the concentration of the active moiety (i. e. 
risperidone plus 9-hydroxyrisperidone) would only be slightly lower, but not 
considerably lower than expected (see also Scordo et al., 1999). The authors also note 
that they were not able to identify the exact number of copies of the active allele (using 
the assay developed by Lovlie et al., 1996). 
I did not genotype for the -1584C>G promoter SNP (Section 3.1.1.1), which may also 
be associated with UM status. However, as only 0.5% to 7% of Caucasians are UMs, 
unless, UM , status were associated with the psychotic illnesses for which the 
antipsychotics were prescribed (in this study, mainly schizophrenia), then as treatment 
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resistance occurs in up to 30% of cases of schizophrenia, then this factor would be 
unlikely to account for the majority of cases of treatment resistance. In summary, my 
data are not consistent with UM status being a major cause of failure to respond to 
typical antipsychotics, but are consistent with UM status being weakly associated with 
response to TAs, especially in the case of haloperidol. 
3.2.4 Number of functional CYP2D6 genes and adverse effects of TAs 
3.2.4.1 Sib pair and twin pair 
3.2.4.1.1 Methods 
The subjects were as described in section 2.1.2.2. The sib pair and twin pair had 
suffered intolerance to a variety of antipsychotics, the details of their adverse responses 
being surnmarised in Table 3.7. 
The twins were monozygotic. There were no other siblings, and no other family 
member with any psychiatric or medical condition. Neither twin had ever used alcohol 
or illicit drugs. 
, 
TNyin I (Dý4A number 2134) first saw a psychiatrist in October 1988, aged 25, after she 
had become increasingly paranoid and withdrawn. Later she described passivity 
phenomena and third person auditory hallucinations. She was diagnosed as suffering 
from paranoid schizophrenia, and treated with trifluoperazine 10mg. After 10 days this 
treatment was discontinued due to. "spasms" and profuse sweating. Perphenazine was 
then tried but this produced a rash and akathisia, and also could not be tolerated. During 
187 
Table 3.7 Summary of adverse effects of antipsychotics experienced by twin pair and 
sib pair 
u ject Antipsychotic(s) Date Adverse effect 
Twin 1 (2134) Trifluoperazine 10 mg 1988 "Spasms" and profuse sweating 
Perphenazine 1988 Rash and akathisia 
Sulpiride 200 mg + chlorpromazine 75 mg 1989 Orthostatic hypotension 
Pimozide 4 mg 1990 Parkinsonism and dystonia 
Fluphenazine decanoate 12.5 mg 1991 Dystonia (right limb) 
Haloperidol 20 mg 1991 Oculogyric crisis 
Clozapine 150 mg 1991-94 Orthostatic hypotension, 
neutropenia 
Twin 2 (2135) Chlorpromazine 75 mg + sulpiride 400 mg 1989 Orthostatic hypotension, 
akathisia, dystonia 
Trifluoperazine 80 mg 1990 Dystonia and dyskinesia 
Haloperidol 9 mg 1990 Parkinsonism and orofacial 
dyskinesia 
Clozapine 300 mg 199 1294 Neutropenia , 
Risperidone 1994 Diarrhoea and vomiting 
Loxapine 1994 Headaches 
Fluphenazine 3 mg 1994 Nil, but ineffective 
Pimozide 4 mg 1994 Dystonia (lower limbs) 
Thioridazine 40 mg 1994 Parkinsonism 
Sib 1 (2007) Trifluoperazine 10 mg 1986 Dystonia (upper limb) 
Chlorpromazine 400 mg + sulpiride 400 mg 1987 Orthostatic hypotension 
Pimozide 4 mg 1 1988 Akathisia 
Trifluoperazine 12 mg spansules 1988 Dystonia and akathisia 
Risperidone 1993 Neutropenia and dystonia 
Thioridazine 300 mg + sulpiride 400 mg 1994 Postural hypotension and 
impotence 
Sib 2 (2206) Chlorpromazine 1993 Nil 
Sulpiride 800 mg 1994 Orofacial dyskinesia, neutropenia 
Risperidone 4 mg 1994 Oversedation, neutropenia, 
dystonia 
Trifluoperazine 1995 Nil 
the next year she was treated with sulpiride 200mg and chlorpromazine 75mg daily, 
which was associated with orthostatic hypotension. In July 1990 trifluoPerazine 10mg, 
with procyclidine, was reintroduced as she had become catatonic. She was unable to 
tend for herself, and virtually immobile. There was little improvement so pimozide 4 
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mg was added in December 1990. This resulted in dystonia and parkinsonism. In view 
of the, multiplicity of problems twin 1 was admitted to hospital and tried on 
fluphenazine decanoate 12.5 mg. However this led to an acute limb dystonia. 
Haloperidol 20 mg resulted in an oculogyric crisis, so in July 1991 clozapine was 
I started. This also resulted in orthostatic hypotension, but treatment with clozapine 150 
mg was continued as she was felt to have made a better clinical response than she had 
made to any other antipsychotic up until that time. Unfortimately, after a succession of 
"amber" results (i. e. relatively low neutrophil count), in May 1994 she developed a 
neutropenia and by March 1995 had again developed a neutropenia, with the result that 
clozapinehad to be withdrawn. Within three weeks she was in catatonic stupor which 
only resolved when clozapine was cautiously reintroduced. Later she was entered into a 
double-blind trial of sertindole. Unfortunately she lapsed once more into a catatonic 
state: prior Ao the commencement of active treatment. Finally, a combination of 
thioridazine and low-dose loxapine brought some normalisation of her mental state, 
enabling her to become self-caring even though she remained deluded and hallucinated. 
Twin 2 DNA number (2135) first became ill a year after, her sister, in 1989, aged 26. 
She had persecutory delusions and auditory and visual hallucinations. She also would 
collapse to the floor, shaking. She was treated with chlorpromazine'75 mg and sulpiride 
400 mg, and like her sister, had orthostatic hypotension on this combination, and also 
developed dystonia and akathisia. In 1990 trifluoperazine was tried, up to a maximum 
dose of 80 mg. This led to dystonic and dyskinetic movements, and was then 
substituted with haloperidol 9 mg, which led to orofacial dyskinesia and parkinsonism. 
In July 1991 twin 2, like her co-twin, was commenced on clozapine, titrating up to a 
dose of 300mg daily. Again, the clozapine seemed to help greatly but a worsening 
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neutropenia led to a "red alert" being given by the Clozaril Patient Monitoring Service 
in December 1993, and hence withdrawal of clozapine. In early 1994 twin 2 was 
prescribed risperidone and loxapine. The former led to diarrhoea and vomiting with 
subsequent weight loss, and the latter produced headaches. In March 1994 fluphenazine 
3. mg was tried, but deemed to be "not effective" by PT and her family after only a 
, month's trial. Following this, pimozide 4 mg was prescribed, but resulted in lower limb 
dystonias. By July 1994 thioridazine 40 mg was the only neuroleptic employed. The 
family maintained thioridazine "didn't work" and twin 2 complained of a stiff face. The 
responsible psychiatrist however felt clinically there was a partial response to 
thioridazine. In July 1995 she entered a double-blind trial of sertindole. As part of the 
trial, ' her psychopathology and any movement disorder were assessed using the PANSS 
(positive and negative symptom scale); Simpson-Angus scale (for extrapyramidal side 
effects);, and AIMS (abnormal involuntary movements scale). Her pre-treatment and 
post-treatment Simpson-Angus and AIMS scores were 6 and 0, and 9 and 0 
respectively. Her mental state also improved on the sertindole (pre-treatment PANSS 
score 50, post-treatment PANSS score 21), and she was discharged home on this 
medication. 
Sib 1 DNA number (2007) was 29 years, sib 2 DNA number (2206), 23 years at the 
time of sampling, and they had a sister at 27 years. Both sibs were diagnosed with 
schizophrenia. There was no other family history of mental disorder. 
Sib I was aged 20 when first seen by a psychiatrist, in 1986. A change in his behaviour 
had been noted for the previous 5 months, and at assessment he was deluded and felt to 
have symptoms of schizophrenia. He was also taking a variety of recreational drugs at 
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this time. Trifluoperazine 10 mg was prescribed, which produced an upper limb 
dystonia. After a period umnedicated he relapsed in July 1987, and was cornmenced on 
chlorpromazine to 400 mg daily with sulpiride 400 mg. Despite some orthostatic 
'hypotension, he showed some clinical improvement. Unfortunately, by December 1987 
he had again stopped his neuroleptic treatment. Pimozide 4 mg was then commenced, 
resulting in akathisia. After non-compliance again, trifluoperazine (12 mg spansules) 
was again prescribed, which resulted in an upper limb dystonia and akathisia. 
Nevertheless he remained on this treatment until April 1993, with only partial 
resolution of his psychotic symptoms, but another episode of self-hann at that time led 
to an involuntary admission. It was then that he was put on risperidone 4 mg, which 
resulted in limb dystonia and neutropenia (1.4 x 109/1). The haematologist consulted 
,- performed a bone marrow biopsy and felt this low count was because of neutrophil 
ý margination, rather than agranulocytosis. Eventually it was decided to change his 
medication, to, thioridazine 300 mg and sulpiride 400 mg daily. The thioridazine 
resulted in orthostatic hypotension and complaints of impotence, and so the dose was 
halved. Sib I has remained partially treated on this combination since.. 
Sib 2 (2206) first saw a psychiatrist in August 1993, aged 21, and it was noted that he 
had been behaving oddly for the previous 5 weeks. He also gave a history of excessive 
drug use, including ecstasy, cannabis, and, LSD. At assessment he was deluded and 
admitted to hospital involuntarily. He settled quickly on chlorpromazine, without any 
documented adverse events. However, he defaulted from follow-up or treatment after 
discharge, and when readmitted was started on sulpiride up to 800 mg daily. This had a 
good therapeutic effect, but his mother noticed him to be suffering from "writhing 
movements of the jaw" (i. e. orofacial dyskinesia), which sib 2 was unaware of. Routine 
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blood. testing revealed a progressive neutropenia, down to a level of 1.3 x 109/1. Bone 
marrow biopsy was not performed in this case, and eventually it was decided to change 
his medication to risperidone 4 mg, which was found to be oversedative, and resulted in 
a limb dystonia and a neutropenia of 1.4 x 109/1. Trifluoperazine was then commenced, 
which apparently was well tolerated, although after discharge he failed to comply, and 
remained untreated in the community. 
Debrisoquine phenotyping of the twins, the sib pair and their sister and parents was 
conducted as in section 2.2.1.1. Blood was collected for DNA analysis, and genotyping 
was performed for CYP2D6 alleles *3-5 and gene amplification, as described in 
sections 2.2.3.1, and 3.1.2.1. 
phenotype status. 
3.2.4.1.2 Results 
Genotyping was performed blind to debrisoquine 
When I analysed the results of the CYP2D6*3-5 and gene amplification genotyping, 
there was a gcnotypc-phcnotype discrepancy for 2134 and 2007. Under my supervision, 
Kopal Tandon had performed gcnotyping of the twins plus the sibs and their relatives 
for the CYP2D6*2 (as described by LovIie et al., 2001) and the *6 allele (as described 
by Sachse et al., 1997). 
The results of the debrisoquine phenotyping and CYP2D6 genotyping including the *2 
and *6 results and the medication being taken at the time of phenotyping are given in 
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Figure 3.7 Genograrn of family with 2 siblings affected with schizophrenia; results of 
debrisoquine phenotyping and CYP2D6 genotyping and given. NMD = no metabolite 
detected, PM = poor metaboliser, IM = intermediate metaboliser, EM = extensive 
metaboliser. 
3.2.4.1.3 Discussion 
Sib I and sib 2 are both genotyped as *21*4, but sib 1 is phenotypically a PM, sib 2 an 
IM. At the time of phenotyping, sib I was being prescribed 300 mg thioridazine daily. 
Llerena et al. (2001) demonstrated that thioridazine is a potent CYP2D6 inhibitor, 
confirming the earlier results of Spina et al. (1991), reporting that the effect of 
thioridazine dosage on debrisoquine hydroxylation phenotype was dependent on 
CYP2D6 genotype. All patients with homozygous wild type genotype treated with a 
dose of at least 150 mg/day were phenotypically PMs, while for patients with wt1*4 
genotype, a thioridazine dose of 50 mg/day was sufficient to convert phenotype to PM 
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(CYP2D6*2 was not assayed for in this study). The dose of 300 mg thioridazine should 
therefore be more than sufficient to convert the phenotype of sib I (genotype *21*4) to 
PM, and is likely to account for the difference in phenotype between sibs I and 2. 
Sib 1 may also have another mutation, on the same allele as the *2, inherited from his 
father (Figure 3.7, both siblings have inherited *4 from their mother), and which is 
associated with reduced or absent CYP2D6 enzyme activity. Sib 2, by contrast, would 
be postulated to have inherited the other *2 allele from the father, consistent with a *2 
allele with reduced enzyme activity as previously described. In the report by Sachse et 
al. (1998) on intermediate metabolisers, the mean MR for individuals of *21*4 
genotype was 4.40 (range 1.11 - 11.8). The debris. oquine MR for sib 2 is therefore 
entirely consistent with *21*4 genotype, especially as sib 2 was prescribed risperidone, 
which is also known to be metabolised by CYP2D6 (compare with the sister, who was 
-also genotyped as *21*4, but not on any prescribed medication at the time of 
phenotyping). 
In the case of the twins, twin 2 was taking sertindole (which is metabolised by 
CYP2D6) at the time of phenotyping, and was'genotyped as *21wt. This is consistent 
with the debrisoquine MR of 1.55. Twin I was taking thioridazine (600 mg daily) at 
th e time of phenotyping, and, again, thioridazine prescription is likely to account for 
the PM phenotype, especially as the total daily dose of thioridazine was high, and the 
twins are monozygotic. 
I 
Of note, phenotypically, both twins and the two siblings had low CYP2D6 activity (IM 
or PM). Genotypically, the sibs were *21*4 (i. e. had only one functional CYP2D6 
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allele, Le. the CYP2D6*2, which, as previously discussed, is usually associated with 
reduced activity), while the twins were *2Avt. The high incidence of adverse effects of 
typical antipsychotics may be due to the likely relatively low CYP2D6 activity 
conferred by these genotypes, rendering these individuals more susceptible to inhibition 
of CYP2D6 by psychotropic medications including antipsychotics. Zanger et al. (2001) 
reported that recombinantly expressed CYP2D6.2 was associated with one-third of the 
P450 content of recombinantly expressed CYP2D6.1. Spina et al. (1991) reported that 
there was an increased frequency (46.2%) of debrisoquine PM status in 91 patients with 
schizophrenia on neuroleptic monotherapy as compared with the frequency (7.5%) in 
67 umnedicated healthy controls, due to the inhibitory effect of the neuroleptics on 
debrisoquine metabolism. In addition, thioridazine was noted as a particularly potent 
CYP2D6 inhibitor; 50 mg thioridazine given to 8 healthy controls converted 4 of these 
(two IMs, two EMs) to PM phenotype. 
In this study, both sib 1 and twin I were being prescribed relatively high doses of 
thioridazine (300 mg and 600 mg daily respectively) at the time of phenotyping, and 
although they were genotypically the same as co-sib or co-twin, both of whom were 
phenotypically IMs, they were phenotypically PMs. The co-sib and co-twin at time of 
phenotyping were being prescribed risperidone 2 ing twice daily and sertindole 24 mg 
daily respectively. Risperidone is metabolised by CYP2D6 to 9-hydroxyrisperidone, 
and would, therefore be expected to, be a CYP2D6 inhibitor; sertindole is also 
metabolised at least partially by CYP2D6. A more definitive phenotype would have 
been obtained had it been possible to discontinue all medication in both members of the 
sib and twin pairs prior to phenotyping, but this was not clinically feasible. The 
genotype would be more definitive if genotyping for the -1584C>G promoter variant 
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were conducted, and this work is in progress. Although it is possible that sib 1 and the 
twins arc positive for mutations not yet identified, the inhibition by ihioridazinc is a 
sufficient explanation for the difference in phenotypes between each member of the 
two pairs. There is a history of penicillin sensitivity in both the twins; it is also possible 
that they also have another enzyme deficiency, related to the penicillin allergy, and that 
it is the relatively low CYP2D6 activity in combination with another possible enzyme 
deficiency that renders them particularly sensitive to the adverse effects of 
antipsychotics. 
Interestingly, Gill et al. (1997) described a case of a patient with schizophrenia who 
had suffered adverse effects with many different antipsychotics, awas, gcnotypcd as 
CYPM6*41ý4, and subsequently treated successfully with a very low dose of a typical 
antipsychotic (chlorpromazinc 50 mg daily). If the sibs and twins can be gcnotyped 
more dcfinitively, then this may provide data consistent with the report of Gill and 
colleagues. 
3.2.4.2 Case-control study 
3.2.4.2.1 Methods 
Two samples of patients were employed, for 3 case-control studies: a sample of 246 
paients treated with clozapine, for whom information was available regarding history of 
intolerance to TAs, and a sample of 72 patients scored for drug-induced parkinsonism 
(DIP) and tardive dyskinesia (TD). These samples are the same as those described in 
Sections 2.1.2.2,2.1.2.1,, and 3.2.3.1, except that one of the 7 subjects collected by Dr 
S. Smith was excluded from this study as there was insufficient clinical detail in order 
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to enable controlling for confounding variables in the DIP and TD studies. The design 
of the study was to compare CYP2D6 gene dosage in individuals with and without TA 
intolerance, with and without DIP, and with and without TD. 
Ethical Committee approval was obtained as above, and CYP2D6 genotyping was 
conducted as described in section 3.2.3.1. Data were analysed by Fisher's exact test or 
chi-squared test (as appropriate), comparing genotype and allele data in intolerafit 
versus non-intolerant groups, those with and without DIP, and those with and without 
TD. ý An addition, logistic regression (dependent variable: presence of typical 
antipsychotic intolerance, or DIP, or TD in respective studies) versus CYP2D6 gene 
dosage, controlling for potential confounding variables as appropriate (see below), and 
niUltiple linear regression analysis (dependent variable: total AIMS score) was 
conducted. Power analyses were performed using Solo Power Analysis and NCSS 
2000., 
3.2.4.2.2 Results 
Out of the 246 patients taking clozapine, there were a total of 26 who had a history of 
intolerance to typical antipsychotics (10.6%). Seventy-nine were female (32.1%), one 
hundred and sixty-seven male (67.9%). The mean age was 39.0 years (range 19-81 
years, SD 10.57). 
The CYP2D6 genotype, deduced phenotype and history of reason for resistance to 
typical antipsychotics in the 246 clozapine-treated patients is given in Table 3.9. 
Thirteen patients (5.3 %) were homozygous for non-functional alleles (mut1mut) and 
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Table 3.9 CYP2D6 genotype, deduced phenotype and history of reason for resistance 
to typical antipsychotics; numbers of cases are given with percentages in parentheses 
um EM EM ' PM 
(dup of wl) 







Refractory to TAs (n = 220) 2(0.9) 113(51.3) 93(42.3) 12 (5.4)' 
Intolerant to TAs (n = 11) 0(0) 5 (45.5) 
10(66.7) 
6(54.5) o(o), 
4(26.7) 1 (6.7)' 
0.10 0.08 
Intolerant and refractory to TAs (n = 15) 0(0) 
Frequency of intolerance 0 0.12 
TAs, typical antipsychotics; wt, wild-type; mut, non-functional mutant allele, Le. 
CYP2D6*3, CYP2D6*4, or CYP2D6*5 (includes 2 duplications of mut in the wtImut 
group); dup of wt, duplication of wild-type allele. Gene dosage refers to the number of 
functional CYP2D6 genes. 
ýTwo-tailed P-value for presence or absence of PM status in intolerant versus non- 
intolerant groups = 1.0 (Fisher's exact test); odds ratio = 0.69,95% confidence limits 
0.02-5.08. Chi-squared = 0.3, P=0.59 for presence or absence of non-ftinctional 
mutant'allele in intolerant versus non-intolerant groups; odds ratio = 0.83,95% 
confidence limits 0.38-1.68. 
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therefore classified as PMs; of these, 9 were homozygous for the CYP2D6*4 allele, 3 
were CYP2D6*41CYP2D6*5, and 2 were CYP2D6*41CYP2D6*3. The frequencies of 
the CYP2D6*4, CYP2D6*5, and CYP2D6*3 alleles were 0.223,0.024, and 0.018. Four 
cases were positive on the CYP2D6 gene duplication assay, but of these, 2 were found 
to represent duplications of CYP2D6*4. As these cases possessed only one functional 
copy of CYP2D6, they were deduced to be phenotypically equivalent to heterozygous 
mut cases and hence included in this group. Two cases (0.8%) were positive for 
duplication of a wild-type allele and hence classed as UMs. Cases heterozygous or 
homozygous wild-type were classed as EMs. The genotype frequencies were in Hardy- 
Weinberg equilibrium. 
As the PM phenotype results from homozygosity of CYP2D6 non-functional alleles 
(Daly et al., 1991), it is logical to analyse the genotyping data using a recessive model. 
I also grouped together those with a history of intolerance with those with a history of 
being both refractory and intolerant. As can be seen in Table 3.9, in progressing from 
the mut1mut (no functional CYP2D6 genes) to the wt/wt (2 functional CYP2D6 alleles) 
group, there appears to be a correlation between the frequency of intolerance to typical 
antipsychotics and the number of functional CYP2D6 genes. Logistic regression 
analysis, to determine whether or not there was a relationship between the number of 
functional CYP2D6 genes C'gene dosage") and the presence of typical antipsychotic 
intolerance, was therefore performed. The variable "gene dosage" was given a value of 
0 for the mut1mut genotype, I for the wt1mut genotype, 2 for the wtlwt genotype, and 3 
for cases positive for the duplication -Of a wild-type allele. As in the paper by Johansson 
et al. (1996), none of their cases with a duplication allele was homozygous for this 
variant, I assumed that the cases positive on the duplication assay were heterozygous 
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for the duplication allele. However, this analysis revealed no association between gene 
dosage and intolerance (Wald score = 0.23, P=0.63). Adding in age and gender as 
covariates did not change the results of the analysis significantly (Wald score = 0.25, P 
0.62). 
The CYP2D6 genotype and deduced phenotype with respect to the presence or absence 
of DIP is given in Table 3.10. Thirty-five out of 66 patients (53%) met the criteria for 
DEP. Thirty-six out of the 66 were male (54.5%), thirty were female (45.5%). The mean 
age was 41.5 years (range 19-87 years, SD 17.61), the mean age of those with DIP 
(41.5 years) not differing significantly from the mean age of those without DEP (41.6 
years). - Logistic regression analysis showed no association between DIP and gene 
dosage (Wald score 0.55, P=0.46). In addition, entering age, gender, and duration of 
treatment into the logistic regression as covariates revealed no significant association 
between these variables, and no significant change to the P value for gene dosage (age: 
Wald score 0.20, P=0.66; gender: Wald score 0.40, P=0.52; duration of treatment: 
Wald score 1.84, P=0.18; gene dosage: Wald score 0.66, P 0.42). 
The CYP2D6 genotype and deduced phenotype with respect to presence or absence of 
TD is given in Table 3.11. Thirteen out of 72 patients (18.1 %) met the criteria for RDC 
probable TD. Thirty-nine were male (54.20/o), thirty-three female (45.8%). The mean 
, age was 42.0 years (range 19-87 years, SD 17.3), and the mean duration of typical 
antipsychotic treatment was 142.9 months (range 14-396, SD 90.7). The frequencies of 
the CYP2D6*4, CYP2D6*5, and CYP2D6*3 alleles were 0.215,0.014, and 0.021 
respectively. Three out of 72 (4.2%) of cases were ultrarapid metabolisers, of which 
none was positive for the null alleles tested. The genotype frequencies were in Hardy- 
201 
Table 3.10 CYP2D6 genotype and deduced phenotype in 66 patients with DSM-IIIR 
schizophrenia, with and without drug-induced parkinsonism (DIP); numbers are given, 
with percentages in parentheses 
UM (dup of wt) EM (wtlwt) EM (wtlmut) PM (mutlmut) 
Gene dosage 3210 
DIP present (n = 35) '0(0) 21(60) 14(40) 0 (O)b 
DIP absent (n =3 1) 2(6) 14(45) 12(39) 3 (1 O)b 
Frequency of DIP 0 0.60 0.53 0 
-Ib 
Two-tailed P-value for presence or absence of, PM, status in those with and without 
DIP 0.1 (Fisher's exact test); odds ratio 0.00,95% confidence limits 0.00-2.10. Chi- 
squared = 1.46, P=0.23, for presence or absence of non-functional mutant alleles in 
those with and without DIP; odds ratio = 0.61,95% confidence limits 0.25-1.46. 
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Table 3.11 CYP2D6 genotype and deduced phenotype in patients with and without 
RDC probable tardive dyskinesia (TD); numbers of cases are given with percentages in 
parentheses 
UM (dup of wt) EM (wtlwt) EM (wilmut) PM (MUMmut) 
Gene dosage 3 2 1 0 
TD present (n = 13) 1(8) 9(69) 3(23) 0 (0y 
TD absent (n = 59) 2(3) 27(46) 27(46) 3 (5)' 
Frequency of TD 0.33 0.25 0.10 0 
cTwo I tailed P-value for presence or absence of PM status in patients with and without 
RDC probable TD = 1.0 (Fisher's exact test); odds ratio = 0.00,95% confidence limits 
0.00-11.37. Chi-squared = 3.07, P=0.08 for presence or absence of non-functional 
alleles'in patients with and without RDC -probable TD; odds ratio = 0.34,95% 
confidence limits = 0.06-1.23. 
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Weinberg equilibrium, and there was no significant difference between patients with 
and without RDC probable TD in the genotypic distribution. However, the allelic 
distribution revealed a trend towards a negative association between non-functional 
alleles, and RDC probable TD (P = 0.08). 
The results of the logistic regression (presence versus absence of probable TD, N= 72) 
and multiple regression analysis (versus total AIMS score) are given in Table 3.12. 
This revealed significant associations between the occurrence of RDC probable TD or 
total AIMS score and duration of antipsychotic treatment and DIP. There was also a 
significant association between gene dosage and RDC probable TD (P = 0.04, N= 72), 
with the direction of effect being an increase in the number of functional CYP2D6 
genes being associated with an increased risk of TD (odds ratio = 4.86). Similarly, 
there was a trend towards an association between gene dosage and total AIMS score of 
at least 6 (P = 0.06, N= 72, OR = 4.54). For 6 out of 72 subjects, there was 
information regarding the dose of antipsychotic; the mean dose, expressed in 
chlorpromazine equivalents, in those with TD (N = 2) was 375 mg, SD 318.20, and the 
mean dose in those without TD (N = 4) was 168.75 mg, SD 102.82. For these 6 
subjects there was also data available regarding anticholinergic medication, which was 
prescribed in I out of 4 cases without TD, mean dose 1.35 mg (procyclidine). 
Restricting the analysis to those subjects that had had a second assessment using the 
AIMS in order to confirm TD (N = 66, of whom 11, i. e. 16.7%, met the Research 
Diagnostic Criteria for persistent TD), there was a trend towards an association 
between gene dosage and RDC persistent TD (P = 0.14, odds ratio = 3.49). However, 
there was no association between gene dosage and total AIMS score for either the 
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In the sample of 246 clozapine-treated patients, there was no association between 
CYP2D6 PM status or number of functional CYP2D6 genes and a history of intolerance 
to typical antipsychotics. The sample has a power of 1.0 (allelic or genotypic 
comparison) at the P<0.05 level to detect a medium effect size (w = 0.30) for the X2 
test between the intolerant and non-intolerant groups (Cohen, 1977). With a smaller 
effect size (w = 0.2), the power remains high at 0.99 (allelic) or 0.88 (genotypic). My 
results are consistent with those of Hamelin et al. (1999), who genotyped 39 patients 
with, schizophrenia for 5 non-functional CYP2D6 alleles (CYP2D6*3, CYP2D6*4, 
CYP2D6*5, CYP2D6*6, and CYP2D6*7), and found that neither the one PM subject 
nor the EM heterozygotes differed statistically from EM homozygotes with respect to 
the number or severity of adverse drug reactions after at least 21 days of treatment with 
antipsychotics metabolised at least partially by CYP2D6 (mainly haloperidol and 
fluphenazine). 
These results are, however, contrary to those of Spina et al. (1992), Chou et al. (2000), 
and Topic et al. (2000). ý Spina et al. (1992) estimated CYP2D6 activity by phenotyping 
(with the debrisoquine hydroxylation test), rather -than by genotyping, and the 
phenotyping procedure was conducted after a minimum of one week after' 
discontinuation of antipsychotic medication. This may not have been long enough; 
many typical antipsychotics are CYP2D6 inhibitors, and hence'affect the phenotyping 
test (Spina et aL, 199 1, Llerena et al., ' 1993); and a minimum of 2 weeks for a washout 
period prior to phenotyping may be necessary, depending on the half-life of the drug 
involved. Hence at least some of the subjects, particularly those on higher doses of 
aýntipsychotics, who were apparently CYP2D6 PMs in the study of Spina et'al. (1992) 
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may in fact have been CYP2D6 EMs. The apparent correlation between concentration- 
dependent adverse effects of neuroleptics and CYP2D6 metaboliser status may then 
have 
, 
in fact reflected a correlation between the adverse effects and dose of 
antipsychotic. Chou et al. (2000) studied 100 patients on a variety of psychotropic 
agents at least partially metabolised by CYP2D6, rated them for adverse drug events 
including EPS (Simpson Angus Scale), and found a trend towards an inverse 
association. between adverse drug events and CYP2D6 gene dosage. However, their 
sample, was mixed (in terms of diagnosis and drug), and the association between 
adverse drug events and CYP2D6 gene dosage may be stronger in the case of 
antidepressants than in the case of antipsychotics (Chen et al., 1996; Aitchison et al., 
2001a; Section 3.3). Although Topic et al. (2000) found a positive association between 
homozygosity for CYP2D6 non-functional alleles and side effects of antipsychotics, 
they also found an overrepresentation of CYP2D6*4 in the subjects with schizophrenia, 
which is not consistent with previous findings (Spina et al. 1992; Dawson et al., 1994; 
Aitchison et al., 1999b; Hamelin et al., 1999). 
Similarly, I did not find an association between CYP2D6 PM status or number of 
fiinctional CYP2D6 genes and DIP. Although Arthur'et al. '(1995) showed a correlation 
between the debrisoquine metabolic ratio (MR) and the severity of EPS, only one of 6 
patients who wa's phenotypically a- PM was also genotypically a PM. ' The authors 
themselves 'comment that the apparent relationship between MR and EPS needs to be 
interpreted with caution due to the effect on the phenotype of the prescribed 
antipsychotics. Armstrong et al. '(1997) found that 4 out of the 5 CYP2D6 PMs (out of 
a total study population of 76) suffered from a movement disorder, as compared with 
42% of homozygous wild-type individuals and 46% of hetero'zygotes; however, 
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because the number of PMs was small, this difference did not reach statistical 
significance. Moreover, they grouped together patients with DIP and TD. Although 
Andreasson et al. (1997) found a non-significant tendency for PMs to have higher DIP 
ratings as compared to EMs, there was no significant difference in the frequency of the 
PM genotype among patients with or without DIP. Vandel et al. (1999) studied 65 
inpatients on a variety of psychotropics (tricyclic, SSRI, and/or antipsychotic) and 
found a, higher percentage of genotypes with no functional alleles in the group of 
patients with EPS as compared to those without EPS. However, again, this was a 
mixed sample (and the EPS were various, including dystonia and akathisia). Scordo et 
al. (2000) investigated the association between EPS (dystonia, parkinsonism, or TD) 
and, CYP2D6 genotype (including duplications) in 119 patients with schizophrenia 
treated with antipsychotics, and found no difference in the distribution of homozygous 
EM,, heterozygous EM, and UM between the 2 groups. However, all 4 PMs had a 
history of EPS. The authors concluded that PM genotype might be a predisposing 
factor for antipsychotic-induced EPS, but acknowledged the doubtful nature of this 
conclusion owing to the small number of PMs in the sample. - 
The failure to find a clear correlation between DIP and CYP2D6 PM status may firstly 
be due to the limited statistical power of the sample to detect a small effect size. The 
samPle, has a power of 0.93 (allelic comparison) or 0.68 (genotypic comparison) at the 
P<0.05 level to detect a medium effect size (w 0.30), but the power drops to 0.21 
(allelic) or 0.13 (genotypic) assuming an effect size of only 0.10. Similarly, the power 
of this sample for the logistic regression analysis is low (0.26, calculated using values 
of base proportion, i. e., percentage of cases with DEP = 0.53, OR = 1.39, N= 66, cc 
0.05, and Rý = 0.0248, NCSS 2000). Secondly, a significant association may have been 
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negated by clinical employment of the "neuroleptic threshold" (McEvoy, 1986), Le., 
titration of antipsychotic dose to the point where cogwheel rigidity discernible from 
baseline is detected. By this method, differential susceptibility to DIP would be 
obscured by dose titration, a higher incidence of DIP not being seen amongst CYP2D6 
PMs in our sample due to lower doses being employed. In support of this hypothesis is 
the finding of Andreasson et al. (1997) of a non-significant tendency for PMs to have 
higher DIP ratings as compared to EMs, and the finding by Arthur et al. (1995) that 
patients with the highest DIP ratings tended to have the lowest neuroleptic doses. In 
both of these studies the high DIP ratings may reflect failure to titrate down the 
neuroleptic dose to a sufficient extent in CYP2D6 PMs. Unfortunately, for our 66 
subjects rated for DIP, I know only that the typical antipsychotic dose was at least 100 
mg chlorpromazine equivalents, but not the actual dose, and, furthennore, have no 
information regarding concomitant medications including anticholinergics. I do, 
however, know that the most common typical antipsychotic prescribed in this group 
was haloperidol (32% of cases), ýnd that due to the complex involvement of CYP2D6 
in haloperidol metabolism, the direction of effect of CYP2D6 genotype on clinical 
response to haloperidol may be in the opposite direction to that with other 
antipsychotics metabolised by CYP2D6 (section, 3.2.3.3). Furthermore, Spina et al. 
(1991) showed that phenothiazine antipsychotics were more potent inhibitors of 
CYP2D6 than haloperidol. It may therefore be that an association between relatively 
low CYP2D6 activity and antipsychotic adverse effects is additionally more likely to be 
found with typical antipsychotics other than haloperidol because of this inhibitory 
effect. 
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The figure of 18% for persistent TD is in agreement with values reported by other 
authors (Kane et al., 1986; van Os et al., 1997; Muscettola et al., 1993). The finding 
of duration of antipsychotic treatment and DIP as risk factors for TD is also in 
accordance with other studies (Brandon et al., 1971; Richardson and Craig 1982; Wolf 
et al., 1983; Caliguiri et al., 1991; Salz et al., 1991; Muscettola et al. 1993; van Os et 
al., 1997). Given that most studies report an increased risk of emergence or severity of 
TD with older age (Kane et al., 1982a, 1982b; Kane et al., 1986; Waddington et al., 
1990; Morgenstern and Glazer, 1993; Muscettola et al., 1993; Jeste and Caligiuri, 
1993; Jeste et al., 1995; van Os et al., 1997, Segrnan and Lerer, 2002), the failure in 
this study to show an association between age and TD is surprising. However, other 
studies have also failed to show this association (Chouinard et al., 1986; Waddington et 
al., - 1995b). I also found no association between gender and persistent 
TD in the 
sample. Although many cross-sectional studies report a higher incidence of TD in 
females as opposed to males (Kane et al., 1986; Yassa and Jeste, 1992), most 
prospective studies have not found an association with gender, apart from van Os et al., 
1997, who found an association with male sex. 
I found a significant association between CYP2D6 gene dosage and probable TD (P = 
0.04), and a trend towards an association between gene dosage and total AIMS score of 
at least 6 for these cases (P = 0.06), a trend towards an association between gene 
dosage and p, ersistent TD (P = 0.14), but no association between gene dosage and total 
AIMS score. 
Arthur et al. (1995) studied 16 patients with TD, and found only one, CYP2D6 PM (by 
genotype) in this group, and did not find a correlation between CýTM6 phenotype and 
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AIMS score. Andreasson et aL (1997) genotyped 100 patients with schizophrenia for 
the CYP2D6 alleles CYP2D6*3-7, and found no significant difference in the frequency 
of CYP2D6 PMs in those with and without TD. However, they found a non-significant 
tendency for CYP2D6 PMs to have more severe TD ratings, and a trend towards a 
higher frequency of the PM genotype in patients with persistent TD (P = 0.08). 
Kapitany et aL (1998) genotyped 45 patients with schizophrenia for the CYP2D6 alleles 
CYP2D6*3-5, and the one PM did not have TD. However, a higher frequency of TD 
(81.3%) in individuals heterozygous for the non-functional alleles tested as compared 
with the'frequency (46.4%) in those homozygous wild-type was found. In addition, 
Kapitany'et al. (1998) found higher TD ratings in heterozygous individuals as 
compared to homozygous wild-type subjects. Ohmori, et al. (1998) genotyped 100 
Japanese patients with schizophrenia for the CYP2D6*3, CYP2D6*4, and CYPjD6*10 
alleles, ' and found a significant association between CYP2D6*10 genotype and total 
AIMS score (P = 0.014) and a modest association with TD occurrence (P = 0.051). 
However, the same group (Ohmori et al., - 1999) did not find an association between 
CYP2D6*2 genotype and either total AIMS score (P = 0.28) or TD occurrence (P 
0.10). They suggested that the reason for the'difference between their findings for the 
CYP2D6*10 and CYP2D6*2 alleles could be that the CYP2D6*2 allele codes for only 
slightly reduced CYP2D6 activity, while the CYP2D6*10 allele codes for moderately 
reduced enzyme activity (Sachse et al., 1997). In fact, the 31G>A (Val,, Met, exon 1) 
variant,, -, which is in allelic disequilibrium. with the mutations constituting the 
CYP2D6*2, allele (Marez et al., 1997) was overrepresented in ultrarapid metabolisers 
in the study by Lovlie and colleagues (2001), although, functional studies have not 
supported the 31 G>A substitution as being a cause of UM status (Allorge et al., 200 1). 
Furthermore, Lam et al. (2001) did not find an association between CYP2D6*10 
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genotype and TD in men, only finding an association in female patients with TD. The 
sample of Scordo et al. (2000) included 15 patients with TD; there was no difference 
between the mean AIMS scores between those homozygous EM's and those having at 
least one non-functional CYP2D6 allele. 
In the context of the above conflicting results, and the fact that the most commonly 
prescribed antipsychotic in the sample was haloperidol, my finding of a trend towards a 
positive association between the number of functional CYP2D6 genes and TD but lack 
of, association with total AIMS score is not too surprising. If the positive association is 
valid, one possible explanation for this would be that the metabolism of the typical 
antipsychotics (especially haloperidol) by CYP2D6 produces metabolites (or parent 
drug) that are associated with increased risk of TD, individuals with a greater number 
of -functional CYP2D6 genes producing more of such active moeities. The 
pharmacodynamic effects of most metabolites of typical antipsychotics have not been 
established, but in the case of thioridazine, for example, CYP2D6 catalyses the 
fonnation of mesoridazine, which has antipsychotic activity. Authors who have not 
found an association between TD and CYP2D6 PM status have previously suggested 
that this may be explained by CYP2D6 PMs having a low level of lifetime exposure to 
antipsychotics metabolised by CYP2D6 due to severe intolerance (Kapitany et al., 
1998). Similarly, one other possible reason for the trend towards a positive association 
between the number of functional CYP2D6 genes and TD is that the dose has been 
titrated initially to the "neuroleptic threshold", higher doses being employed for those 
with higher CYP2D6 activity. With multiple-dosing, especially at higher doses, the 
phenotype of those who are genotypically high in metaboliser status might become 
relatively low, especially if there is a delayed effect of the dose on the phenotype so 
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that a dose which is initially at the neuroleptic threshold exceeds the threshold at 
steady-state. The exceeding of the neuroleptic threshold at the steady-state in 
individuals who in the drug-nalve state had relatively high CYP2D6 activity and were 
therefore prescribed higher doses of antipsychotics might then be associated with the 
occurrence of TD. As already mentioned, information regarding the exact dose for the 
majority of the sample was unavailable. However, for the 6 subjects for which dose 
information was available, the mean antipsychotic dose was higher in the subjects with 
TD than those without, and the mean dose of anticholinergic medication was also 
higher' The latter finding is consistent with the results of previous investigators that 
indicate that anticholinergics may exacerbate TD in some cases (Kiloh et al., 1973; 
Gerlach & Thorsen, 1976; Burnett et al., 1980; Moore et al., 1980; Greil et al., 1984). 
Another cytochrome P450, CYPIA2, has recently been implicated in TD (Basile et aL, 
2000). ' However, more recent studies investigating a putative association between 
CYPIA2 and TD have been negative (Schulze et al., 2001; Tsapakis et al., 2002a). 
Other factors, e. g. -variation in the dopamine D3 receptor (Steen et al., 1997; Basile et 
al., 1999; Segman et al., 1999), and the 5-HT2A and 5-HT 2C receptors (Segman et al., 
2000; Segman et al., 2001; Segman & Lerer, 2002); may also contribute to a 
vulnerability to TD, possibly in interaction with phan-nacokinetic factors such as 
CYP2D6, CYP I A2, and CYP 17 (Segman et al., 2002). 
In conclusion, this study indicates that CYP2D6 PM status or number of functional 
CYP2D6 genes need not be, in isolation, a risk factor for intolerance to typical 
ý' i 
antipsychotics, or specifically drug-induced parkinsonism, or tardive dyskinesia. 
Differences between my findings and those of previous investigators may reflect the 
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relatively high percentage of cases prescribed haloperidol in my study and differences 
in prescribing practice. A study investigating all the candidate genes implicated so far 
in the genesis of tardive dyskinesia, performing a multivariate analysis, might prove 
fruitful. 
3.3 Tricyclic antidepressants (TCAs) and CYP2D6 and CYP2C19 
3.3.1 Introduction 
3.3.1.1 Cytochromes and TCA metabolism 
As early as 1967, it was observed that 11 patients on a standard dose of the TCA 
desipramine showed a 36-fold variation in the steady-state plasma concentrations 
achieved 'genetic factors in determining 
, 
(Sj6qvist et al., 1967), and the importance of 
the steady-state levels of the TCA nortriptyline was shown in twin and family studies 
I 
(Alexanderson et al., 1969, Asberg et al., 1971a, Alexanderson, 1973). It was 
subsequently shown that the steady-state concentrations of desipraminc and 
nortriptyline were related to CYP2D6 activity (Bertilsson and Aberg-Wistedt, 1983, 
Nordin et al., 1985), that the hydroxylation of the TCAs amitriptyline and 
clornipramine were also associated with polymorphic CYP2D6 activity (Balant-Gorgia 
et al., 1982; Balant-Gorgia et al., 1986), and that the 2-hydroxylation of imipramine 
cosegregated with CYP2D6 phenotype and genotype in a Danish study of the families 
of 18 CYP2D6 poor metabolisers (Madsen et al., 1996). In Chinese, the CYP2D6*10 
allele is seen to affect plasma levels of nortriptyline in a dose-dependent manner, with 
heterozygous individuals showing higher nortriptyline concentrations than homozygous 
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wild type, and *10 homozygotes showing the highest concentrations (Yue et aL, 1998). 
Dal6n et al. (1998) found a linear relationship between the clearance of nortriptyline 
and the 109 MRdebrisoquine and the number of functional CYP2D6 genes (for values of the 
latter of 0,1,2,3, and 13), and Morita et al. (2000) showed that the number of mutant 
I 
CYP2D6 alleles accounted for 41% of the variance in log (nortriptyline level corrected 
for dose and body weight). 
Other studies have demonstrated the involvement of CYP2Cl9, CYP2C9, CYP3A4, 
and CYPIA2 in TCA metabolism (reviewed in Jann and Cohen, 2000). An early in 
vitro study by Lemoine et A (1993), which did not include studies of CYP2CI9 or 
CYP2Cl8, demonstrated the involvement of CYPIA2 and CYP3A4 in imipramine N- 
demethylation. Similarly, Schmider et al. (1995) demonstrated the involvement of 
CYP3A isofonns in arnitriptyline dernethylation, and Spina et al. (1997a) and Wang et 
al. (1997) in in vivo inhibition studies, showed that CYP3A4 played a major role in 
imipramine N-demethylation. However, Koyarna et al. (1996) studied imipramine and 
desipramine concentrations in relation to CYP2CI9 phenotype (S-mephenytoin 
hydroxylation status), which showed'that the mean N-demethylation index was 
significantly less in the CYP2Cl9 poor metabolisers. The same group went on to 
perform a detailed in vitro study (Koyama et al., 1997), using hepatic microsomes of 
varying CYP2Cl9 activity (as determined by in vitro S-mephenytoin 4'-hydroxylation) 
and recombinant CYPs, and demonstrated that imipramine N-demethylation was 
catalysed by CYP2Cl9 and CYPlA2 (high affinity and low affinity components 
respectively), imipramine 2-hydroxylation is mediated by CYP2D6 and CYP2Cl9 
(high -affinity and low affinity components respectively), and that in individuals 
deficient in CYP2Cl9, CYPlA2 and CYP2D6 play a major role in imipramine N- 
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demethylation and 2-hydroxylation respectively. Among the recombinant human 
CYPs, CYP2Cl9,2CI8,2D6, IA2,3A4, and 2B6 in rank order catalysed the N- 
demethylation, whereas CYP2D6,2CI9, IA2,2CI8, and 3A4 catalysed the 2- 
hydroxylation. The delineation of the high and low affinity components came from 
analysis of the Kn, values. A later monoclonal antibody inhibition study by Yang and 
colleagues (1999) gave similar results, concluding that imipramine was metabolised to 
2-hydroxyimipramine by 2C19 and 2D6, and to desipramine by IA2,2CI8,2CI9, and 
2D6, with the contributions of the isoforms to desipramine formation varying for 2C 19 
(13-50%), 1A2 (23-41%), and 3A4 (8-26%). 
Olesen and Linnet (1997a; 1997b) showed that CYP2D6 is the major isoform involved 
in nortriptyline and amitriptyline 10-hydroxylation, with CYP2Cl9 and CYPlA2 being 
'involved in the demethylation of nortriptyline (CYP2Cl9 having the highest 
demethylation capacity), and CYP2Cl9 being the major enzyme responsible for the 
demethylation of amitriptyline. They also concluded that the relative affinities and 
capacities of the CYPs would predict that at toxic doses of amitriptyline, CYP3A4 
I -would play a dominant role in the metabolism. Consistent with the amitriptyline study 
was the work of Venkatakrishnan et al. (1998), using a combination of in vitro enzyme 
kinetic and chemical inhibition studies, which concluded that CYP2Cl9 (high affinity 
component) was the major anutnptyline N-demethylase at low (therapeutically 
relevant) amitriptyline concentrations, whereas CYP3A4 (low affinity component) was 
estimated to be more important at higher amitriptyline concentrations. Also consistent 
was the work of the same group (Venkatakrishnan et al., 1999), demonstrating that the 
10-hydroxylation of nortriptyline was conducted by CYP2D6 (high affinity component) 
and CYP3A4 (low affinity component), with the relative magnitude of the contribution 
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of the latter being only 20%. This indicates that CYP3A4 inhibition is unlikely to have 
a marked effect on nortriptyline hydroxylation; however, CYP3A4 may play a more 
significant role in CYP2D6 poor metabolisers or individuals prescribed drugs that 
induce CYP3A4. These studies were, however, in part contradicted by an in vitro 
inhibition study by Ghahrarnani et al. (1997), which concluded that Cyps 3A4,2C9, 
and 2D6 mediated the N-demethylation of amitriptyline, and did not find a role for 
CYP2CI9. An in vitro inhibition study of clomipramine concluded that its N- 
demethylation was mediated mainly by CYPIA2 and CYP3A4, and to a lesser extent 
by CYP2Cl9 (Wu et al., 1998). An in vivo study of levels of trimipramine and its 
metabolites in CYP2D6-, CYP2Cl9-, and CYP3A4/5-phenotyped patients was 
consistent with the involvement of CYP2D6 in the 2-hydroxylation of trimipramine, 
and CYP2C 19 in the dernethylation (Eap et al., 2000). 
The above studies may be summarised as showing that CYP2D6 catalyses 
hydroxylation of the parent TCA and N-demethylated metabolite, with CYP2Cl9 
contributing mainly to the N-demethylation of the parent TCA, with a low affinity 
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Figure 3.8 Initial steps in the metabolism of imipramine, with contributing cytochrome 
P450s shown (from Spina et al., 1997b) 
Several studies support the existence of a concentration-effect relationship for TCAs 
and/or their active metabolites (Ziegler et al., 1977a; Sj6qvist et al., 1980; Gram et al., 
1984;, Perry et al., 1987; Preskorn and Jerkovich, 1990). An early study linked high 
concentrations of nortriptyline with not only adverse effects, but also with decreased 
antidepressant effect (Asberg et al., 1971b). Subsequent reports have described 
concentration-dependent side-effects in individuals deficient in CYP2D6 treated with 
usual doses of TCAs due to the accumulation of the parent drug and/or active 
metabolites (Bertilsson et al., 1981; Sj6qvist and Bertilsson, 1984; Balant-Gorgia et al., 
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1989). There are interethnic differences in the distribution of various cytochrome P450 
alleles (Aitchison et al., 2000c), with, for example, Blacks showing a lower population 
mean CYP2D6 activity due to a high frequency of the CYP2D6*17 allele (see Section 
1.5.1.1; Masimirembwa et al., 1996b; Droll et al., 1998; Leathart et al., 1998). It has 
been reported that at comparable doses of TCA, Black patients achieve higher levels of 
TCA than Caucasians, and also have a faster rate of recovery from a depressive episode 
(Raskin et al., 1975; Ziegler et al., 1977b; Rudorfer and Robins, 1982). A prospective 
study found that CYP2D6 poor metabolisers attained the highest levels of desipramine, 
and had adverse effects necessitating dose reduction (Spina et al., 1997a). In a study 
including patients on TCAs, a trend towards an inverse correlation between the 
frequency of adverse drug events and number of functional CYP2D6 genes was found 
(Chou et al., 2000). 
Selective serotonin reuptake inhibitors, or SSRIs (e. g. paToxetine and fluoxetine, with 
paroxetine being a very potent inhibitor of CYP2D6), and the serotonin-noradrenaline 
reuptake inhibitor (SNRI) venlafaxine are also metabolised by CYP2D6 (Brosen, 
1993), and a higher frequency of inactivating CYP2D6 alleles has been found amongst 
patients with a history of an adverse reaction to TCAs, relevant SSRIs, and venlafaxine 
(Chen et al., 1996). Paroxetine is both a substrate for and an inhibitor of CYP2D6 
(Bourin et al., 2001), and Lam and colleagues (2002) described a subject with at least 
three functional CYP2D6 genes who had an undetectable concentration of paroxetine. 
Fluoxetine is also a relatively potent inhibitor of CYP2D6, and because of its longer 
half-life, this inhibitory effect lasts much longer than for other other SSRIs with 
CYP2D6 inhibitory activity (Liston et al., 2002). The major metabolite of quoxetine, 
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norfluoxetine, is a CYP3A inhibitor (Caccia et al., 1998). The major route of 
metabolism for citalopram is CYP2C 19 (Sindrup et al., 1993). 
At the other extreme of the metabolic spectrum, case reports have indicated an 
association between therapeutic resistance to antidepressant treatment and CYP2D6 
ultrarapid metabolisdr status (Bertilsson et al., 1993; Baumann et al., 1998; Lam et al., 
2002). 
Cases of combined cytochrome P450 isoform deficiency may lead to particularly 
marked adverse effects: Bluhm et al. (1993) describe a case report of an individual who 
was a CYP2D6 poor metaboliser, and a CYP2C19 intermediate metaboliser who had 
had a normal baseline ECG, but developed myocardial ischaernia with doses of 
desipramine within the usual prescribed range. Most studies investigating correlations 
between -. antidepressant effects and metaboliser status have studied one, with few 
studying 2 cytochrome P450s, or controlling for the presence of concomitant 
medications affecting CYP metaboliser status. 
3.3.1.2 Aims 
The aims'of this study involving patients treated with TCAs were to test the following 
hypotheses: 
1- . 'I . 
CYP2D6 ultrarapid metaboliser status is associated with -low levels of parent 
TCA plus demethylated metabolite, corrected for dose, and therapeutic 
ý , 'ý ý resistance to treatment. 
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2, ", Low CYP2D6 activity (due to the presence of at least one non-functional allele) 
is associated with high levels of parent TCA plus demethylated metabolite, and 
a high incidence of adverse effects. 
3 -, , Low CYP2C19 activity (due to the presence of at least one non-functional 
allele) is associated with high levels of the parent TCA, and low levels of the 
1ý 1. 
demethylated metabolite. This was hypothesised to result in a higher incidence 
of the effects consistent with the parent TCA, and a lower incidence of the 
, ..., 
effects consistent with the demethylated metabolite. 
4ý. Items I and 2 may be summarised as: the number of functional CYP2D6 genes 
is inversely associated with response to TCA and susceptibility to adverse 
. effects of TCA. 
5, The combination of relatively low CYP2D6 activity and low CYP2CI9 activity 
Was hypothesised to render an individual particularly susceptible to TCA 
adverse effects. 
3.3.2 Methods 
Details of the sample are given in Section 2.1.2.4. Preliminary analyses of this study 
have been reported (Aitchison et al., 2001a; Tandon et al., 2002b). Patients who 
consented and were not ineligible for phenotyping (e. g. concomitant antihypertensive 
treatment) were phenotyped for CYP2D6 status using the debrisoquine test (Lennard et 
al., 1977). Genotyping for CYP2D6 alleles *3-5 and gene duplication was undertaken 
as described (Aitchison et al., 1999b, also sections 2.2.3.1 and 3.2.3.1). Genotyping for 
CYP2, Cl 9 alleles *2 and *3 was undertaken as described by de Morais et al. (I 994a and 
1994b), with modifications to the protocol for *3 as described by Kubota et al. (1996), 
and employing a "hotstart" by the use of AmpliTaq Gold (Applied Biosystems). In 
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brief, for CYP2C19*2, primers 5'-AATTACAACCAGAGCTTGGC-3' and 5'- 
TATCACTTTCCATAAAAGCAAG-3' were used in a total reaction volume of 25 PI 
using Perkin-Elmer Buffer II (without magnesium), with 1.25 MM MgC12,0.06 mM 
each dNTP, 0.25 pM each primer, and MU AmpliTaq Gold (Perkin-Elmer, UK). 
Cycling conditions (on a MJ Research tetrad using 96-well plates) were: initial 
denaturation at 940C for 10 min (a long initial denaturation is required for AmpliTaq 
Gold); 38 cycles at 940C for 30 s, 580C for 30 s, and 720C for I min; followed by final 
elongation at 720C for 7 min. PCR products were digested using Sma I, and analysed 
on a 3% agarose gel. For CYP2C19*3 assay, primers 5'- 
AACATCAGGATTGTAAGCAC-3' and 5-TCAGGGCTTGGTCAATATAG-3' were 
used in a total reaction volume of 25 ýd using Perkin-Elmer Buffer II (without 
magnesium), with 1-5 MM M902,0.2 mM each dNTP, 0.2 ýM each primer, and 1.5U 
AmpliTaq Gold (Perkin-Elmer, UK). Cycling conditions (on a Perkin-Elmer Thermal 
Cycler using 0.5 ml eppendorf tubes) were: initial denaturation at 940C for 5 min; 40 
cycles at 940C for I min, 570C for 1 min, and 720C for 2 min; followed by final 
elongation at 720C for 5 min. PCR products were digested using Bam HI, and analysed 
on a 3% agarose gel. 
Association analysis, linear regression, and logistic regression analysis were conducted 
using EpiInfo version 6.0, and SPSS version 8.0, as described in sections 2.3.2 and 
2.3-3. 'Graphs were plotted using Axum 5.0, and power was calculated with Solo Power 
Analysis ,. In addition, the combined effect of CYP2D6 and CYP2Cl9 activity was 
analysed by two different ways: 
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3-, A simple model, assuming additive effect of number of CYP2D6 and CYP2CI9 
,: ýý, genes: creating a new variable by multiplying the number of CYP2D6 and 
- number of CYP2C19 functional genes together, and analysing for association 
with clinical response, etc. 
The creation of a variable (combined CYP2D6 and CYP2Cl9 index) 
approximating to the combined effect of these CYP2D6 and CYP2CI9 
activities as reflected in the serLun level data: (the inverse of the dose corrected 
%., combined TCA level) x (the dernethylation index). This was derived as follows: 
CYP2D6 activity is inversely proportional to the ([parent TCA] plus [demethylated metabolite])/ dose = 
I/dose corrected combined TCA level 
CYP2CI9 activity is proportional to the ratio of the [demethylated metabolite] to the [parent TCA) 
demethylation index 
Where [ ... ]denotes "concentration of'in pg/l 'I 
Hence CYP2D6 x CYP2CI9 activity is proportional to I/dose corrected combined TCA level x 
demethylation index. 
3.3.3 Sample characteristics 
Out of the 49 individuals recruited, one was excluded as there was no clear history of 
affective disorder (the TCA was being prescribed as analgesia), and another was 
excluded due to inadequate clinical data being available. Of the remaining 47, forty 
had a diagnosis of unipolar depression, and 7 bipolar affective disorder. Five did not 
have both pre- and post-treatment Hamilton Depression Rating Scale (HDRS) scores, 
but an overall measure of response as judged by the treating clinician. Of the 42 with 
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pr I e- and post-treatment HDRS ratings, II were non-responders (non-responders being 
defined as individuals with an HDRS score of at least 16 after at least 6 weeks of TCA 
treatment, Danish University Antidepressant Group, 1999), 31 were responders, giving 
a response rate of 74%. The mean pre-treatment HDRS was 25.56 (SD 4.70, range 13- 
36); the mean post-treatment HDRS was 12.52 (SD 6.23, range 1-24). If the whole 
sample was included, including those with merely dichotomised response based on 
clinician opinion, there were 13 non-responders out of a total of 47, giving a response 
rate, of 72%. Forty-two subjects had adverse effect scale ratings; the mean rating was 
7.29 (SD 5.01, range 1-20). The mean 8-item corrected total adverseeffect score (as in 
4-. 
Ziegler et al., 1978) was 4.88 (sd 3.35, range 0-13). Information on TCA level was 
available for 44 subjects; details of the TCA and concomitant prescribed medication for 
these 44 are given in Table 3.13. For details of CYP substrates, see Table 1.2. Binary 
variables for CYP2D6 and CYP2CI9 inhibition were created, where 0= no CYP 
inhibition, I= CYP inhibition by concomitant medication; Table 3.13 gives details of 
which medications were deemed to be CYP2D6 and/or CYP2C19 inhibitors. 
The mean age of subjects was 44.38 (SD 11.14, range 25-69 years), twenty-five (53.2 
per cent) were female, and twenty-four (5 1.1 per cent, smoking data was not available 
on one subject) were non-smokers. Thirty-seven subjects were Western European 
Caucasian, the rest were of varying ethnic origin (4 Mediterranean Caucasian, I mixed 
ýace, I Hispanic, 2 Indian, and 2 Afro-Caribbean). Thirty-four subjects consented to 
phenotyping with debrisoquine, and were not ineligible for phenotyping. For one 
individual, the phenotyping result was "no metabolite detected. " This individual was 
therefore assigned a poor metaboliser phenotype, and for the purpose of linear 
regression was assigned an MR of 15.00 (above all the other MR values and in the poor 
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Tricyclic antidepressant (rCA) Concomitant medication 
Amitriptyline 150 mg 
Dothiepin 175 mg 
Dothiepin 75 mg Chlorpromazinel 50 mg, 1.5 mg haloperidoll pm 
Amitriptyline 225 mg 
Amitriptyline 200 mg Trifluoperazinel 8 mg 
Amitriptyline 75 mg 
M2 10 mg Imipramine 300 mg Diazepa 
Amitriptyline 100 mg Lithium I g, chlorpromazinel 50 mg, temazepam 40 mg 
Lofepramine 70 mg 1,2 Amitriptyline 100 mg Lisinopril 2.5 mg, cimetidine 800 mg, aspirin 75 mg 
Amitriptyline 125 mg DiazepaM2 7.5 - 15 mg, diclofenac sodiUM2 150 mg, 
Amitriptyline 200 mg 
Imipramine 150 mg 
Lofepramine 140 mg 
Amitriptyline 100 mg 
Amitriptyline 100 mg 
Amitriptyline 100 mg 
Imipramine 200 mg 
Lofepramine 140 mg 
Amitriptyline 250 mg 
Lofepramine 70 mg 
Imipramine 100 mg 
Imipramine 75 mg 
Amitriptyline 150 mg 
Amitriptyline 150 mg 
Trimipramine 150 mg 
Amitriptyline 200 mg 
Amitriptyline 100 mg 
Lofepramine 140 mg 
Imipramine 150 mg 
Nortriptyline 50 mg 
Amitriptyline 50 mg 
Trimipramine 150 mg 
Trimipramine 100 mg 
Trimipramine 150 mg 
Trimipramine 300 mg 
Lofepramine 70 mg 
Trimipramine 125 mg 
Trimipramine 75 mg 
-Trimipramine 150 mg 
, Trimipramine 125 mp- 
propranolol'-2 80 mg 
Ranitidine 600 mg 
Carbamazepine 400 mg 
Lithium 600 mg, atenololl 50 mg, thioridazinel 50 mg 
Insulin 
Paracetamol up to 6 mg daily, omeprazole2 prn 
Lithium 600 mg 
Indapamide 2.5 mg, Captopril 100 mg 
Nifedipine 40 mg, thioridazinel 100 Mg, codydramoll up to 4 
tablets daily 
Carbamazepine 400 mg 
Fluoxetinel 20 mg, chlorpromazinel 50 mg, cocodamoll 4 
tablets daily 
Chlorpromazinel 50 mg, lithium 1200 mg 
Thyroxine 100 micrograms, zopiclone 7.5 mg 
Haloperidoll 5 mg, lisinopril 5 mg 
Haloperidoll 5 mg, lisinopril 5 mg 
Zopiclone 7.5 mg 
Indomethacin 75 mg, amlodipine 5 mg 
Trimipramine 75 mg Cimetidinel- 2 800 mg, diltiazem180 mg, captopril 50 mg, 
zimovane 7.5 mg 
Trimipramine 125 mg Zopiclone 7.5 mg, thioridazinel 50 mg every other day 
_Arnitriptyline 
150 mg Thioridazinel 150 mg 
Table 3.13 Details of tricyclic antidepressant (TCA) dose, and concomitant prescribed 
medications ('CYP2D6 inhibitors, 2 CYP2C19 inhibitors) for the 44 subjects for whom 
TCA level data were available 
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metaboliser range). Excluding this individual, the mean debrisoquine MR was 2.22 
(SD 2.98, range 0.21-12.28). 
3.3.4 CYP2D6 UM status and failure to respond to TCAs 
No individuals who were positive for a CYP2D6 gene duplication/amplification event 
were found amongst the non-responders, or the sample as a whole. 
3.3.5 Number of functional CYP2D6 genes and clinical response to TCAs 
The results of the linear regression analysis are given in Tables 3.14 and 3.15. 
Controlling for concomitant CYP2D6 inhibition, as expected, a significant association 
was'found between debrisoquine MR and CYP2D6 gene dosage (P = 0.006), and 
between the corrected combined TCA level and number of functional CYP2D6 genes 
(P = 0.001, Figures 3.6 and 3.7). Controlling for CYP2D6 inhibition, there was a trend 
for an association between corrected combined TCA level and clinical response to TCA 
as measured by the percentage change in HDRS (P = 0.08). However, there was no 
association between percentage change in HDRS and CYP2D6 gene dosage on linear 
regression, or between dichotornised response to TCA and CYP2D6 gene dosage on 
logistic regression analysis (P = 0.52). 
When the genotyping, was extended (by Dr Kopal Tandon) to include the CYP2D6*2 
allele, this allowed delineation of results into the following genotypic categories: 
EM/EM, EM/lM, IMAM, EM/PM, IM/PM, and PM/PM. Linear regression, controlling 
for CYP2D6 inhibition, gave a significant association between debrisoquine metabolic 
ratio and genotypic category (P = 0.003) and between corrected combined TCA level 














CYP2D6 gene dosage 
Figure 3.9 CYP2D6 gene dosage (number of functional CYP2D6 genes) versus dose 












CYP2D6 gene dosage 
Figure 3.10 CYP2D6 gene dosage (number of functional CYP2D6 genes) versus dose 
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CYP2D6 genotypic category 
Figure 3.11 CYP2D6 genotypic category versus dose corrected combined TCA level 
(pg/I per mg). The linear regression line is shown. Genotypic categories are as follows: 














CYP2D6 genotypic category 
Figure 3.12 CYP2D6 genotypic category (as in Figure 3.11) versus dose corrected 
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In Figures 3.6 - 3.9 it can be clearly seen that there is an outlier in the ]A4/PM genotypic 
category in terms of corresponding dose corrected combined TCA level. This 
individual has been genotyped as *21*4, and has since been genotyped as CYP2D6*6 
negative. She was taking cimetidine 400 mg twice daily, amoxycillin 500 mg three 
times daily, captopril 25 mg twice daily, diltiazem 60 mg three times daily, and 
zimovane 7.5 mg daily at the time that the blood sample for TCA level was taken, in 
addition to the tricyclic medication (trimipramine 75 mg). The raised dose-corrected 
combined TCA level may therefore be due to the effect of CYP inhibition (by 
cimetidine and diltiazem, British National Formulary, September 2002) on top of the 
effect of the low CYP2D6 activity (*2 only), or, alternatively, this individual may have 
an inactivating mutation in CYP2D6 not yet assayed for. DNA from this individual is 
being subjected to mutation screening using DHPLC (O'Donovan et al., 1998). 
Unfortunately, this individual did not consent to phenotyping with debrisoquine. 
3.3.6 Number of functional CYP2C19 genes and clinical response to TCAs 
No CYP2C19 poor metabolisers were found in this sample and the number of 
functional CYP2C19 genes is therefore only 1 or 2. Controlling for concomitant 
CYP2Cl9 inhibition, as expected, a significant association was found between the N- 
demethylation index and the number of functional CYP2C19 genes (P = 0.019, Table 
3.14, Figures 3.10 and 3.11). However, a novel finding was that controlling for 
CYP2C 19 inhibition, there was a significant association between number of functional 
CYP2C19 genes and percentage change in HDRS (P = 0.016). This is shown 
graphically in Figures 3.12 and 3.13. Of note, in the graphical representation, it is not 
possible to control for CYP2Cl9 inhibition, and therefore the association is less clear. 
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Figure 3.13 CYP2C19 gene dosage (number of functional CYP2C19 genes) versus 

















CYP2C 19 gene dosage 
Figure 3.14 CYP209 gene dosage (number of functional CYP2CI9 genes) versus 
clemethylation index (ratio of demethylated metabolite to parent TCA), mean values 
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Number of functional CYP2C19 genes 
Figure 3.15 Number of functional CYP2CI9 genes versus percentage change in HDRS 
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CYP2C19 gene dosage 
Figure 3.16 Number of functional CYP2CI9 genes (CYP2CI9 gene dosage) versus 
percentage change in HDRS (means with standard deviations given) 
3.3.7 Associations with adverse effects 
The associations between the total adverse effect score and the 8-item adverse effect 
score (as in Ziegler et al., 1978) and clinical and genotypic parameters are given in 
Table 3.15. For the total adverse effect score, an association was found between 
adverse effect score and presence of concomitant CYP2D6 inhibiting medication (P ý 
0.019), and with the clemethylated metabolite level (P = 0.01), and there was a trend for 
an association with the combined TCA level (P = 0.08). These effects were less 
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The association between the demethylated metabolite level and the total adverse effect 
score is shown graphically in Figure 3.17, again, without controlling for CYP2CI9 
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Figure 3.17 Demethylated metabolite level versus total adverse effect score, linear 
regression line (without controlling for CYP2C 19 inhibition) shown 
3.3.8 Investigation of possible interaction between number of functional CYP2D6 
genes and number of functional CYP2C19 genes 
The mean values of the combined CYP2D6 and CYP2CI9 index in responders and 
non-responders were 1.28 (sd 1.76) and 0.84 (sd 0.42). As the variances were not equal 
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(Levene's test for equality of variances, P=0.114), a nonparametric test (Mann- 
Whitney U test) was used to compare the values for the combined CYP2D6 and 
I 
CYP2C19 index in responders and non-responders, which gave a non-significant result 
(P = 1.0). Using lineg regression with either the simple additive model or the 
combined CYP2D6 and CYP2C 19 index, there was also no association with percentage 




No CYP2D6 UMs were found in the 13 trcatment-rcfractory subjects (as defincd by 
dichotomised response score), or indeed in the sample as a whole. Therefore, in this 
sample, a refractory response to treatment with a TCA was not associated with 
CYP2D6 UM status. However, 'the sample size is small, and therefore this does not 
exclude an association between CYP2D6 UM status and resistance to treatment with 
TCAs, as has previously been reported in. case reports (Bertilssson et al., 1993; 
Baumann et al., 1998). A larger prospective study is indicated to answer this question. 
The second hypothesis tested was that low CYP2D6 activity would be associated with 
high levels of parent TCA plus demethylated metabolite, and hence a high incidence of 
adverse effects. A significant inverse association was indeed found between number of 
functional CYP2D6 genes and dose corrected combined TCA level (P = 0.001, Figures 
3.6 and 3.7). A trend for an association was found between combined TCA level and 
total adverse effect score, controlling for CYP2D6 and CYP2C19 inhibition (P = 0.08), 
and between corrected combined TCA level and clinical response to TCA as measured 
by the percentage change in HDRS (P = 0.08). No association was found between 
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CYP2D6 gene dosage and total side effect score (P = 0.59), or between CYP2D6 gene 
dosage and antidepressant effect (P = 0.99). The failure to find a significant association 
here may be due to the sample size; a power calculation of multiple regression analysis 
shows that for the power to reach at least 0.80, the additional Rý to be contributed by 
the variable of interest must be at least 0.17 (1 variable of interest, 2 variables to be 
controlled for in the case of combined TCA level, 1 variable to be controlled for in the 
case of CYP2D6 gene dosage, if additional Rý contributed by the variables to be 
controlled is set at 0.02, sample size of 42, significance level of 0.05). For the analysis 
of combined TCA level, the Rý change contributed by the variable of interest (from the 
linear regression output) is 0.07, the Rý change contributed by the two variables 
controlled for (CYP2D6 and CYP2Cl9 inhibition) is 0.34, which gives a power of 
0.56. 
This is not the first study that has failed to find an association with CYP2D6 indices 
and antidepressant effect. in the study by Spina et al. (1997a), no significant correlation 
was found between plasma desipramine levels, or CYP2D6 phenotype as assessed by 
dextromethorphan metabolic ratio, and antidepressant effect. Moreover, in a 
retrospective study of patients taking imipramine, no correlation was found between 
CYP2D6 or CYP2CI9 phenotype and frequency or severity of side effects (Meyer et 
al., 1988), a small prospective study regarding imipramine treatment also found no 
correlation between CYP2C19 genotype and improvement rate or severity of side- 
effects (Morinobu et al., 1997), and in their, single-dose study administering 
nortriptyline, Dalen et al. (1998) found no correlation between severity of autonomic 
effects and number of functional CYP2D6 genes. One possible reason for the above 
negative results is the fact that for the hydroxylation reactions, CYP2D6 is high-affinity 
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low-capacity enzyme, with saturable kinetics (Brosen et al., 1986; Sindrup et al., 1992; 
Danish University Antidepressant Group, 1999; Aitchison et al., 2000c), and that with 
multiple-dosing, or at steady-state, CYP3A4, which is the most abundant hepatic 
cytochrome P450 (Shimada et al., 1994), may play a more major role (Olesen and 
Linnet, 1997b). Furthermore, in enzyme deficiency, the cytochromes may substitute 
for each other (Koyama et al., 1997; Venkatakrishnan et al., 1999). 
The third hypothesis was that low CYP2Cl9 activity would be associated with high 
levels of the parent TCA, low levels of the demethylated metabolite, and a consequent 
higher incidence of effects consistentwith this combination. A significant association 
(P = 0.0 19, Figures 3.10 and 3.11) was indeed found between the number of functional 
CYP2C19 genes and demethylation index (ratio of demethylated metabolite to parent 
TCA). Interestingly, a significant association was also found between CYP2C19 gene 
dosage and percentage change in HDRS (P = 0.016), with the direction of effect being 
that two functional CYP2C19 genes was associated with a poorer mean response than 
one functional CYP2C19 gene. This suggests that the parent TCA is more important in 
terms of generating clinical response than the demethylated metabolite. On the other 
hand, a significant association was also found between the level of demethylated 
metabolite and total adverse effect score (P = 0.01), suggesting that the demethylated 
metabolite is more important than the parent TCA in the generation of adverse effects. 
The demethylated metabolite in general has a relatively high noradrenaline transporter 
affinity (see below), which might be expected to be associated with adverse effects 
such as orthostatic hypotension and palpitations. (The sample size was too small to 
perform an analysis of a subdivision of the adverse effect score versus CYP2C19 
indices other than the 8-item score as in Ziegler et al., 1978. ) Interestingly, a novel 
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cytochrome found in rat brain and termed CYP2D18 is also capable of catalysing the 
demethylation of imipramine to desipramine (Kawashima et al., 1996; Thompson et al., 
1998); it may be that the associations with CYP2Cl9 indices reflect local neuronal 
metabolism rather than or as well as peripheral hepatic metabolism. 
The final hypothesis was that the combination of low CYP2D6 activity and low 
CYP2C 19 activity would render an individual particularly susceptible to TCA adverse 
effects., Analysis of the combined effect of CYP2D6 and CYP2Cl9 gene dosage did 
not reveal any association with total adverse effect or 8-item adverse effect score; the 
only variable that emerged as being significantly associated with adverse effect score in 
this analysis was CYP2D6 inhibition (by concomitant mcdication). 
Of note, the sample size for this study was small, and the P values have not been 
corrected for multiple testing. Using the Bonferonni correction for multiple testing, P 
values less than 0.005 would be significant (as approximately 10 separate association 
analyses were conducted, not counting the genotypic category analysis as separate from 
that with CYP2D6 gene dosage, or the Ziegler 8-item side effect scale analysis as 
separate from total side effect score). On this basis, there would be significant 
associations between CYP2D6 gene dosage and dose corrected combined TCA level, 
between CYP2D6 gene dosage and debrisoquine MR, between CYP2D6 inhibition and 
percentage change in HDRS, and between CYP2D6 inhibition and total side effect 
score (Tables 3.14 and 3.15). The latter two associations would suggest that higher 
levels of parent TCA plus demethylated metabolite are associated with both clinical 
response and adverse effects. 
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The parent TCA and demethylated metabolites differ in their affinities for the serotonin 
and noradrenaline transporters (Owens, 1997), in general the demethylated metabolite 
having a higher noradrenaline to serotonin transporter affinity ratio. As there are 
antidepressants in clinical use that are either predominantly serotonin reuptake 
inhibiting (e. g. citalopram) or almost exclusively noradrenaline reuptake inhibiting (e. g. 
reboxetine), inhibition of either transporter may be associated with antidepressant 
effect. Furthermore, the serotoninergic and adrenergic pathways are interconnected, 
such that action on one pathway may influence the activity of the other (Ressler & 
Nemeroff, 1999). However, there is some evidence that especially in the case of 
patients hospitalised for depression, the use of an antidepressant with combined 
serotonin and noradrenaline reuptake inhibition (so-called dual reuptake inhibitors, 
including the tertiary amine tricyclics and venlafaxine) may be more efficacious than 
employing an agent that has a high affinity for one transporter (Clerc et al., 1994; 
Leonard, 1999; Anderson, 2000; Thase et al., 2001; Nolen & Bruijn, 2002). The 
association between CYP2D6 inhibition and clinical response would be consistent with 
this. 
In conclusion, owing to the small sample size, no firm conclusions may be drawn 
bet, ween CYP2D6 or CYP2Cl9 gene dosage and clinical response as measured by 
HDRS or adverse effect ratings. However, the association with CYP2D6 inhibition, 
and the suggestions of associations between CYP2C19 gene dosage and clinical 
response and between demethylated metabolite level and adverse effect rating are 
interesting findings and warrant replication in a larger prospective study 
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3.4 Response to clozapine and CYPlA2 
3.4.1 Introduction 
The atypical antipsychotic clozapine is the drug of choice in the UK for cases of 
treatment-resistant schizophrenia or schizoaffective disorder, and is effective in 30 to 
60% of patients unresponsive to typical antipsychotics (Kane, 1992). It is metabolised 
mainly in the liver by demethylation and N-oxidation (Jann et al., 1993). Several 
cytochrome P450 enzymes including CYPIA2 have been implicated in these processes 
(Eiermann et al., 1997; Linnet and Olesen, 1997; Tugnait et al., 1999). Jerling et al. 
(1997) suggested that, since the clearance of clozapine is distributed in a similar way to 
indices of CYPIA2 activity, CYPlA2 could be the major determinant of clozapine 
clearance; this was confirmed in my study with CYPIA2-null mice (Chapter 5; 
Aitchison et al., 2000b), which was performed prior to this genetic association study. 
There is wide interindividual variation in CYPIA2 activity (Aitchison et al., 2000c), 
which in most studies is trimodally or bimodally distributed, indicating a likely genetic 
contribution to the variation in activity (Sections 1.5.3.1 and 4.6). In addition, 
CYPIA2 is subject to inhibition and induction by various agents, inducers including 
cigarette smoking. Several polymorphisms in CYPIA2 have been identified, including 
SNPs in the 5' flanking region, a G-3858A substitution (CYPIA2*IC, Nakajima et al., 
1999), a T-3591G substitution, a G-3595T substitution, and a T-3605 insertion (Chapter 4; 
Aitchison et al., 2000a); and a SNP in intron I (C-164A, CYPIA2*IF, Sachse et al., 
1999). The G-3858A was associated with a reduction in CYPIA2 activity in smokers, 
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while the C-164 variant, when present in the homozygous state, was associated with a 
higher inducibility in smokers. In transfection assays, the G-3591 substitution did not 
appear to lead to a change in CYPIA2 promoter activity (Chapter 4; Aitchison et al., 
2000a). 
In a preliminary study on the T-3591G SNP and response to clozapine, I had found a 
trend for an association between the -3591T allele and response to clozapine in 
Caucasians (Fisher exact test, 1-tailed P=0.10, OR = 3.00, exact 95% confidence 
.I 
limits 0.63-18.77; Aitchison et al., 2001b). However, owing to the low frequency of 
the -3591G variant in this sample (0.02), and the fact that my transfection studies did 
not indicate that this polymorphism was associated with a functional effect, a further 
study, investigating the association between the -164C variant and clozapine response 
was undertaken (by EM Tsapakis, under my supervision). A preliminary analysis of 
this study has been reported (Tsapakis et al., 2002b). 
3.4.2 Aim 
The C-164 variant has a relatively high allele frequency in a nonnal population (0.32, 
Sachse et al., 1999), and has been associated with functional variation in CYPlA2 
activity (altered inducibility). The aim of this study was to further investigate the 
association between polymorphism in CYPIA2 and response to clozapine. 
3.4.3 Methods 
Two hundred and forty-eight patients treated with clozapine for at least 3 months were 
rated for global level of response to the medication by their prescribing consultants, 
categorising response into I of 4 categories: improved a lot (Category 1), improved a 
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little (Category 2), showed no improvement (Category 3), and inadequate information 
available (Category 4). In addition, the following clinical information was available for 
the sample: age, sex, ethnicity, age of onset of psychosis before 19 years, family history 
of schizophrenia in a first degree relative, and reason for commencement of clozapine. 
Venous blood samples were collected from each patient and genomic DNA extracted 
by standard procedures. Genotyping for the C. 164A substitution was by PCR-RFLP 
assay, as described (Sachse et al. 1999). In brief, primers Plf (5'- 
CAACCCTGCCAATCTCAAGCAC, located in exon 1) and P4r (5'- 
AGAAGCTCTGTGGCCGAGAAGG, located in exon 2) were used to amplify up a 
370 bp region of intron 1 of CYPIA2, PCR products then being digested with Bspl201 
(MBI Fermentas). The reaction conditions and cycling parameters were as described 
by Sachse et al. (1999). 
The statistical analyses were performed using SPSS (version 8.0) and EpiInfo (version 
6.0). Data were analysed by genotype using a recessive model (C/C versus A/C or 
A/A) and by allele, and by logistic regression controlling for confounding variables. 
The recessive model was chosen as the C allele was associated with higher inducibility 
when present in the homozygous state in the study of Sachse et al. (1999). The 
genotypic distribution was tested for deviation from Hardy-Weinberg equilibrium using 
the X2 test (using the HWE programme), and a power calculation was performed using 
Solo Power Analysis. 
3.4.4 Results 
Of the 248 patients, 220 were Caucasian (85.3%), 12 African or Caribbean in origin, 10 
Asian, and 6 of mixed race. One hundred and sixty-seven (67.3%) were male, 81 
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female (32.7%). The mean age of the whole sample was 38.7 years (sd 10.1). One 
hundred and forty-seven (59.3%) were in Category I in terms of response, 86 in 
Category 2 (34.7%), and 15 in Category 3 (6%); there were none in Category 4 (all 
subjects that had been on clozapine for at least 3 months had adequate response 
information). For the purpose of the analysis, subjects in Category I were deemed to 
be "responders, " and subjects in Category 2 and 3 "non-responders. " Thirty-six 
(14.5%) had a family history of schizophrenia in a first degree relative, 163 did not 
(65.7%), and for 49 (19.8%), this information was not available. Two hundred and 
twenty-four (90.3%) were commenced on clozapine due to being refractory to 
treatment with previous antipsychotics, 11 (4.4%) due to intolerance of previous 
:,, Izi 
antipsychotics, and 12 (4.8%) due to being both treatment-refractory and treatment- 
intolerant, and for 1 (0.4%) subject this information was not available. One hundred 
ýI 'ý: '. 
and nine subjects (43.5%) had their onset of psychosis before the age of 19 years 
(43.5%), 85 (34.3%) had onset later than 19 years, and for 55 subjects (22.2%) this 
information was not available. 
The allele frequencies of the C and A allele in the whole sample were 0.31 and 0.69, in 
the Caucasians were 0.31 and 0.67, in the subjects of Afro-Caribbean origin 0.25 and 
0.75, and in the Asians 0.35 and 0.65. The allele frequencies in the Caucasians (with 
schizophrenia or schizoaffective disorder) were very similar to those previously 
reported by Sachse et al. (1999) in normal subjects (C = 0.32; A=0.68, N= 236) and 
to those reported by Basile et al. (2000) in Caucasians with schizophrenia (C = 0.34; A 
= 0.66, N= 63). Although there was a tendency for the Afro-Caribbeans (N = 12) to 
have a lower frequency of the C allele (which is in the opposite direction to that in the 
sample of 22 African-Americans reported by Basile et al. (2000), owing to the small 
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sample sizes in both of these studies, this was not deemed to be of any significance. 
There was no significant difference between the allelic distributions in the three ethnic 
groups Q2=0.56,2 degrees of freedom, P=0.76). The genotypic distribution did not 
differ from that expected by Hardy-Weinberg equilibrium for the whole sample (X2 
0.28,1 degree of freedom, P=0.30), the Caucasian subset Q2 = 1.33, P=0.12), and 
the Afro-Caribbeans (X2 = 1.33, P=0.12). For the Asians, the distribution was just 
significantly different from Hardy-Weinberg equilibrium Q2=2.90, P=0.04), which 
may be artefactual due to the very small sample size (N = 10). The sample was 
analysed as a whole, with analysis for the Caucasians (the major ethnic subset) also 
being presented separately. 
The results by genotype and by allele are shown in Tables 3.16 and 3.17. Grouping 
together responder categories 2 and 3 ("non-responders"), and analysing these versus 
category -I ("responders") by genotype, using a recessive model, genotype frequencies 
did not differ significantly between responders and non-responders to clozapine 
treatment for either the whole sample (P = 0.55), or the Caucasians (P = 0.70). 
Analysis by allele also gave non-significant results, P=0.57 for the whole sample, and 
P=0.90 for the Caucasians. 
The results of the logistic regression analysis versus dichotomised response as the 
dependent variable (Category I being "responders, " Categories 2 and 3 being "non- 
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early onset psychosis (less than 19 years), family history of schizophrenia in a first 
degree relative, and reason why the patient was treated with clozapine, are given in 
Table 3.18. This revealed no significant association between response to clozapine and 
C-164A genotype. The only factor that emerged as significant in the logistic regression 
analysis was gender (P = 0.03, odds ratio = 0.52). Logistic regression analysis on the 
Caucasian subset also revealed a significant effect of gender only (P = 0.03, odds ratio 
= 0.50), and no effect of C. 164A genotype (P = 0.94). The mean age did not differ 
significantly between subjects grouped by genotype (C/C: mean age 39.3, sd 10.08; 
C/A: mean age 38.7, sd 10.28; A/A: mean age 38.7, sd 9.98). 
Table 3: 19 shows the gender distribution in the different response categories; fifty-four 
per cent of males and sixty-nine per cent of women were responders. Chi square 
analysis (on a two by two table by combining response Categories 2 and 3) gave a 
significant effect of gender on response (P = 0.03, and OR = 0.53, exact 95% 
confidence limits 0.27-0.97), values that correlate well with the values derived from the 
logistic regression analysis (Table 3.18). This means that males are more likely to 
respond than females. Table 3.20 shows the -164C/A genotypic distribution in males 
and females, which shows that there is no significant difference between the two 
distributions (P = 0.53). This means that the effect of gender on response is not 
mediated by -164C/A genotype, which, again, is as expected from the logistic 
regression analysis. 
3.4.5 Discussion 
In a preliminary study, a trend towards an excess of the CYP I A2 G-359, allele in those 
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Table 3.19 Gender distribution in the different response categories (numbers with 
response rate for given gender per cell expressed as percentage) 
Gender 
Response category Male (N = 167) Female (N = 81) 
Improved a lot (Category 1) 91(54.5) 56(69.1) 
Improved a little (Category 2) 65(38.9) 21(25.9) 
No improvement (Category 3) 11(6.6) 4(4.9) 
Comparison of responders (Category 1) versus non-responders (Categories 2 and 3) 
gives y, 2 4.85, P=0.028, and O'R = 0.53 (exact 95% confidence limits 0.29-0.97). 
Table 3.20 Gender distribution by genotype (numbers plus percentage of given gender 
per cell) 
Gender 
CYPIA2 -164C/A genotype Male (N = 167) Female (N = 81) 
A/A 76(45.5) 53(53.0) 
A/C 73(43.7) 30(37.0) 
C/C' 18 (10.8) 8(9.9) 
Chi square analysis of gender distribution gives: X21.28,2 degrees of freedom, P 
0.53. 
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functional polymorphism in the CYPIA2 5' flanking region (Chapter 4). However, 
genotyping of the C-164A SNP in the CYPIA2 intron 1 which has been associated with a 
high inducibility phcnotypc (Sachsc et al., 1999), did not indicatc any association with 
clozapine response. Logistic regression, controlling for potential confounding factors, 
also revealed no significant association between response to clozapine and C. 164A 
genotype (P = 0.59). 
The possibility of a Type II error (false negative) has to be considered. The power 
calculation for X2, df = 1, shows that a sample size of 248, at the P=0.05 level has a 
power of 0.997 to detect a medium effect size (w = 0.30), or 0.88 to detect a slightly 
smaller effect size (w = 0.20). The corresponding values for the Caucasian subset (N = 
220) are 0.99 and 0.84. The power of the logistic regression analysis on the whole 
sample (N = 248, proportion of responders = 0.59, odds ratio set at 1.4, correlation 0.1, 
P=0.05) is 0.84, and for the Caucasian subset 0.80. However, no data on cigarette 
smoking for this sample was available, and it may be that it is essential to have data on 
this to investigate a putative association with the C-164 SNP. Furthermore, it is possible 
that clozapine itself may induce CYP 1 A2, and therefore that information on the dose of 
clozapine (again, unavailable for this sample) and controlling for this variable in the 
analysis is required. I suggest that any future studies investigating putative associations 
between CYPIA2 polymorphisms and response to clozapine should include collection 
of these clinical variables. 
It is of note that the only factor that emerged as significantly associated with response 
was gender. The association of female gender with better response found in this study 
is contrary to the findings of Lieberman et al. (1994) on 84 patients (67% male); 
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however, in the latter study, the women had a longer duration of illness prior to 
clozapine treatment, which may independently be associated with relatively poor 
response. In another study on 49 men and 12 women, there was no difference in the 
gender distribution between responders and non-responders (Honer et al., 1995). A 
poorer response in males could be due to factors such as the higher incidence of 
neurodevelopmental abnormalities in males (Castle & Murray, 1991; Murray, 1994), 
or, for example, the higher CYPIA2 activity is in males as compared to females 
(Sections 1.5.3.1 and 1.5.3.2). Consistent with this women were reported to have higher 
plasma concentrations of clozapine than men by Haring and colleagues (1989,1990), 
and in a more detailed later analysis of therapeutic monitoring data on 162 Chinese 
patients with schizophrenia (Lane et al., 1999), females had 35% higher clozapine 
levels and 36% higher norclozapine levels than males, with no sex differences being 
seen for clozapine N-oxide levels, and Jerling et al. (1997) also in a therapeutic drug 
monitoring analysis (391 samples from 241 patients) demonstrated higher clearance 
and larger volume of distribution in males as compared to females. The lower clearance 
and higher clozapine and norclozapine levels in women would be consistent with the 
lower CYPIA2 activity (see Chapter 5). This may at least partially account for the 
higher response rate in women, especially as there is a documented association between 
clozapine levels (of at least 350-420 pg/1) and response (Perry et al., 1991; Hasegawa 
et al., 1993; Kronig et al., 1995; Miller et al. 1994; Potkin et al., 1994). 
If there were a polymorphism in CYP1A2 (or its flanking regions) related to the 
differential CYPlA2 activity between males and females, then it would be expected 
that response to clozapine would be associated with such a polymorphism. The 
mechanism of the effect of oestrogens on CYPlA2 is not well understood, but by 
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analogy with the effects of other steroids on regulation of gene expression, may be 
exerted by a transcriptional effect on the CYPIA2 promoter. It is then possible that a 
CYPIA2 promoter variant which is associated with the inhibition of CYPlA2 by a 
variety of agents including oestrogens might be associated with clozapine response. 
Haring et al. (1990) reported that smoking was associated with lower clozapinc levels 
in men only, which might indicate that the mechanism of CYPlA regulation by 
smoking (involving the XRE sites) might overlap with the mechanism of CYPIA2 
regulation by oestrogens. The T-3591G SNP might be in linkage disequilibrium with 
promoter variant(s) involved in such regulation. The trinucleotide repeat region, 
(AAQ6 at -4382 to -4399 (section 4.5.2, and Figure 4.11), warrants investigation as a 
candidate for functional variation, and further mutation screening of the CYPIA2 
promoter, including the multiple putative XRE sites described by Corchero et al. 
(2001) and regions that are conserved across species and could be involved in the 
transcriptional effect of oestrogens, could yield interesting data. 
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CHAPTER FOUR 
CYPIA2 NOVEL MUTATION SCREENING AND FUNCTIONAL 
CHARACTERISATION 
4.1 Introduction 
A-1.1 Interindividual variation in CYPlA2 
There is wide interindividual variation in CYPlA2 activity (Kalow and Tang, 1991a), 
which in most studies has been demonstrated to be trimodally or bimodally distributed 
(Butler et al., 1992; Lang et al., 1994; Nakajima et al., 1994; Schrenk et al., 1998; Ou- 
Yang et aL, 2000). Butler and colleagues (1992) studied individuals from Arkansas, 
Italy, and China, and found that CYP I A2 activity was trimodally distributed, with the 
range of percentages in the 3 populations being: 12-13% slow, 51-67% intermediate, 
and 20-37% rapid metabolisers. Nakajima et al., 1994 studied 205 Japanese and found 
a bimodal distribution of CYPIA2 activity in both smokers and non-smokers, with 
13.8% of smokers and 14.3% of non-smokers being poor metabolisers (PMs), the rest 
being termed extensive metabolisers (EMs). An earlier UK study had found that 10% 
of the population was deficient in phenacetin 0-deethylase activity (Devonshire et al., 
1983), which had been subsequently shown to be CYPIA2 dependent (Distlerath et al., 
1985). Studies in monozygotic and dizygotic twins indicated a high heritability (h, = 
0.83) for an index of CYPlA2 activity (urinary excretion of 3-methylxanthine; Miller 
et al., 1984). A genetic polymorphism to account for this variability was suggested by 
an early family study in which impaired phenacetin-0-deethylation was noted in 2 
siblings (Shahidi, 1968), and Nakajima and colleagues (1994) extended this work to 
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study the pattern of CYPlA2 activity in 8 pedigrees, the results of which were 
consistent with genetic polymorphism. at a single gene locus, with autosomal 
codominant transmission. 
At least some of the interindividual variability in CYPIA2 activity is, however, 
explicable by environmental factors. The enzyme may be inhibited or induced by 
various dietary substances, drugs, and toxins (section 1.5.3.1). Nonetheless, Le 
Marchand and colleagues (1997) showed in a study of 90 subjects of various ethnic 
backgrounds in Hawaii that 73% of the variance remained unexplained after taking into 
account the major environinental contributors to the variance. In a larger study (N=786 
Caucasians), Tantcheva-Po6r et al. (1999) found that 63% of the overall variation 
remained unaccounted for after analysis for the major covariates (e. g. coffee 
consumption). This finding points to the existence of other factors, such as genetic 
polymorphisms, as contributors to the variation in indices of CYP I A2 activity. 
4.1.2 Interethnic variation in CYPlA2 
There is evidence for interethnic variation in CYPIA2 activity. Butler and colleagues 
(1992) found that the frequency of rapid metabolisers in non-smokers was 20% in 50 
Italians, and 37% in 77 individuals from Arkansas; Le Marchand et al. (1997) in their 
study found a significantly higher mean CYPIA2 activity in 15 Caucasians as 
compared with 45 Japanese; Relling et al. (1992) showed that CYPIA2 activity was 
significantly lower in a group of 63 Black subjects in comparison to a group of 246 
White subjects, and Lang et al. (1994) found African-American smokers had CYPIA2 
activity approximating that of African American or Caucasian non-smokers. 
Furthermore, a study'of clozapine levels in 162 Taiwanese found mean plasma 
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concentrations 30-50% higher than those reported in Caucasians for equivalent doses 
(Chang et al., 1997). 
4.1.3 Previous mutation screening of CYPIA2 
In their 1994 paper, Nakajima and colleagues, using PCR followed by direct 
sequencing, screened the exons, exon-intron junctions, and the 5'flanking region to - 
3470 bp in 2 non-smoking PMs, I non-smoking EM, 1 smoking PM, and I smoking 
EM and found no differences in the nucleotide sequence between each phenotype. 
Subsequent studies (see section 4.6) had not yet been performed by the time I 
performed this part of the work for my thesis. 
4.1.4 Aims of this study 
The majority of the data in this study has already been reported (Aitchison et al., 
2000a). Given the indication that factors including genetic polyrnorphism in CYPIA2 
could contribute to CYPlA2 variability and the negative finding of Nakajima et al. 
(1994), 1 decided to screen the S' flanking region of CYPIA2 further upstream than - 
I 
3470 bp'. TCDD induces the expression of CYPIAI as well as that of CYPIA2, and in 
this case, has been shown to exert this effect via its interaction with xenobiotic 
responsive elements (XREs) in the promoter sequence. Two XRE-like sequences have 
been identified in the human CYPIA2 promoter, at positions -3382 to -3400, and - 
3037 to -3055 (Quattrochi et al., 1994). These sequences were shown to lie within 
regions that contribute to the induction of CYPIA2 by 3-methylcholanthrene 
(Quattrochi et al., 1994), and in transient transfections, TCDD was found to induce the 
CYPIA2 promoter (Postlind et al., 1993). However, the fold induction is much higher 
for CYPIAl than for CYPIA2 (using a KpnI fragment of CYPIA2, -4096/-842), and 
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induction of CYPIA2 was not seen in stable transfectants (Postlind et aL, 1993). 1 
therefore decided to determine the sequence of the CYPIA2 5' flanking region that was 
further upstream than -4096, to see whether or not another XRE, polymorphism. in 
which could affect the inducibility of CYP 1 A2, could be found. 
'I have numbered the nucleotides in the CYPIA2 5' flanking region counting the start of translation as +1 (position 
2804 in GenBank sequence accession number M31664), in accordance with the international nomenclature for 
human CYPIA2 alleles, available at www. imm. ki. se/CYPalleles. 
4.2 Mutation screening of the CYPIA2 5' flanking region 
4.2.1 Study design 
Three sample groups were used for this studY: 87 Caucasians from the UK (section 
2.1.1.2), 125 Taiwanese (section 2.1.1.3), and 105 African Americans (section 2.1.1.4). 
In addition, a few Caucasians (staff of the laboratory of Dr FJ Gonzalez) were used in 
the initial mutation screening, but not included in the analysis of the frequency of the T- 
3591G SNP in different ethnic groups. The method of mutation screening was PCR- 
based resequencing, with an initial 11 Caucuasians and 8 Taiwanese being screened 
(section 4.2.3), and a total of 20 Caucasians, 31 Taiwanese, and 10 African Americans 
being sequenced in all (section 4.2.4). Sequence further upstream than the 5' flanking 
sequence of CYPIA2 that was'publicly available at the time that I commenced my 
work was obtained initially by Genome Walking (section 4.2.2), which was conducted 
at the Institute of Psychiatry (UK), and latterly by direct sequencing of BAC clones 
(section 4.5), conducted at the laboratory of Dr FJ Gonzalez (NIH, USA). 
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4.2.2 Genome walking 
The methodology for genome walking is given in section 2.2.6. Sequence from the 
second PCR product of library 2 produced sequence which aligned with the 5' flanking 
sequence of CYPIA2, and revealed the following sequence discrepancies compared 
with the published sequence: a G-3649C substitution and a T-3650 deletion. 
4.2.3 PCR sequencing 
-I 
investigated these potential polymorphisms (G-3649C andAT-3650) by PCR sequencing 
(section 2.2.7) using PCR reaction M2-M I with sequencing primers Ml and M2 (Table 
4.1 and Figure 4.1), and found the same sequence discrepancies in II Caucasians and 8 
Taiwanese samples. Furthermore, these discrepancies were found in plasmid pLlA2N 
supplied by Dr Linda Quattrochi, which is a derivative of plasmid pH4CATI, the latter 
being the plasmid that was sequenced by Quattrochi and Tukey (1989) in their original 
publication of the CYPIA2 5' Ranking sequence, and hence these sequence 
discrepancies are likely to represent errors in the original published sequence. 
However, the above PCR sequencing also revealed a T-3591G substitution in one of the 
Caucasians and one of the Taiwanese. This Caucasian was one of the Gonzalez 
laboratory staff members, and was homozygous for the T-3591G substitution (Figure 4.2 
shows the wild-type reverse sequence in this region, Figure 4.3 the reverse sequence of 
this individual). Further PCR sequencing using PCR reactions M3 -M4 or cyp I abr2-M5 
with sequencing primers Ml, M3, or M5 also revealed a second polymorphic site in 
the5' flanking region of CYP1A2, a G-3595T substitution, in one out of a further 20 
Caucasian subjects, three out of a further 31 Taiwanese subjects, and three out of 10 
I African American subjects sequenced. The Caucasian and the three Taiwanese subjects 
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were heterozygous for both of the point mutations (giving an allele frequency of 0.025 
for the G-3595T in the Caucasians, and 0.048 in the Taiwanese; Figure 4.4), while two of 
the African American subjects were homozygous for the G-3595T substitution (and wild 
type for the T-3591; Figure 4.5), and one was heterozygous for the G-3595T substitution 
(and wild type T. 3ý90. which gives an allele frequency of 0.25 for the G-3595T in this 
African American subgroup. (The numbers of samples in the 3 populations for which I 
have data on both the T. 3591G and G-3595T polymorphisms are too small to enable 
calculation of whether or not the 2 polymorphisms are in linkage disequilibrium. ) 
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TG T TTTC TTAA AACT TAA AAAA ATTI 
Figure 4.2 Sequence of 5'flanking region of CYPIA2. reverse strand. of an individual 
wild-type for both the T-3591G (i. e. A-3591 on reverse strand, sequence position 28) and 
G-3595T (i. e. C-3595, sequence position 32) SNPs. 
Figure 4.3 Sequence of 5'flanking region of CYPIA2, reverse strand, of the Caucasian 
individual homozygous for the T-3591G (i. e. C-3591 on reverse strand, sequence position 
28) and wild-type for the G-3595T (i. e. C-3595, sequence position 32) substitution 
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'I-G TT TTCTTCAAAC TTAAAAAAAT TI 




AA=AATTIwI, I, Iw i YýA GAAAAO%TTA 
20 30 40 50 
Figure 4.4 Sequence of a Taiwanese individual, forward strand, heterozygous for the T- 
3591G and for the G-3595T substitutions (sequence positions 35 and 39) 
Figure 4.5 Sequence of 5'flanking region of CYPIA2, reverse strand, of an African 
American individual wild-type for the T-3591G (i. e. A-3591 on reverse strand, position 27 




TG T TTTC T TAA AAAT TAAAAAAAT Tj 
20 30 40 
4.2.4 Further mutation identification and cloning 
For two of the African American subjects, sequence in the reverse direction was 
unambiguous at the 3' end but from point -3605 had the appearance of two sequences 
superimposed upon each other, indicating heterozygosity for a single base insertion or 
deletion at that point. This was resolved by cloning and sequencing the PCR product 
(section 2.2.8.1), which revealed aT insertion at -3605 in some clones from African 
American samples numbers 9 and 43 (Figure 4.6). For sample number 43, Mboll 
digestion showed that the T-3605 insertion and the T-3591G substitution occurred on 
different alleles. The T-3605 insertion was therefore found in heterozygous state in two 
out of 10 African Americans sequenced (giving an allele frequency of 0.10), in 0 out of 
31 Taiwanese sequenced, and in 0 out of 20 Caucasians sequenced. 
TT TC TILPAA AAC TTA AA AA AA ATTAAA 
190 200 210 
Figure 4.6 Sequence of one clone from M3-M4 PCR product of African American 
sample number 43 (reverse strand), showing an A-3605 insertion (i. e. T-360S insertion on 
forward strand) 
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4.3 Determination of the frequency of the T-3591G mutation in different ethnic 
groups 
4.3.1 Development of a PCR-RFLP assay 
In order to investigate the frequency of the T-3591G SNP in the 3 sample groups, I 
designed a PCR-RFLP assay. This involved a nested PCR, the first PCR reaction using 
primers cyplabr2 and cyplabf, the second PCR reaction using primers M2 and M3 
(Table 4.1, Figure 4.1). Products were digested with MboII (New England Biolabs) 
and separated on a 3% agarose gel (Figure 4.7; the G-3591 substitution creates an MboII 
site). I did not screen for the remaining 2 polymorphisms, as I felt this to be 
inappropriate before their functional significance was known. 
4.3.2 Results of the PCR-RFLP analysis 
DNA from all subjects that appeared to be heterozygous for the T-3591G SNP on PCR- 
RFLP analysis was sequenced using PCR reactions M3-M4 or cyplabr2-M5 and 
primers Ml, M3, or M5, in order to confirm genotype. This revealed interethnic 
variability in the frequency of the polymorphism (Table 4.2), the frequency of the G- 
359, allele being much higher (0.128) in the Taiwanese as compared to that in the 
Caucasians (0.017) or the African Americans (0.024). This difference is highly 
significant (P < 0.0001). The genotype frequencies in each population were in Hardy- 
Weinberg equilibrium Q2=0.027, P=0.43 for Caucasians; X2 = 0.063, P=0.40 for 
African Americans; X2 = 2.45, P=0.06 for Taiwanese). For the genotypic comparisons, 
I -grouped together the heterozygotes with the homozygous mutants because if the 
mutation was associated with reduced or increased promoter activity and hence reduced 
or increased enzyme activity, then, by analogy with findings of other variant alleles in 
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the cytochromes (e. g. CYP2D6, Suzuki et al., 1997), the possession of a single mutant 
allele could be associated with a degree of variation in enzyme activity (i. e. treating the 
mutant allele as dominant). Furthermore, as there were no homozygous mutants (- 
359IG/G) in either the Caucasians or the Black Americans, statistical analyses 
comparing the frequency of homozygous mutants with the frequencies of the other 











Figure 4.7 Agarose gel electrophoresis of Mboll digestion of M2-M3 PCR products. 
Subjects in lanes I and 3 are heterozygous for the T-3591G substitution; subjects in lanes 
2 and 4 are homozygous wild type; in lane 5 is aI kb ladder (Gibco BRL, bp). 
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Table 4.2 CYPIA2 T-3591G genotypes in 87 Caucasians, 104 African Americans, and 
125 Taiwanese 
Homo mut Het mut Homo wt 
Caucasian 0 3 84 
African American 0 5 99 
Taiwanese 4 24 97 
Mut, mutant, G. 3591 allele; wt, wild type, T-3sqj allele. Analysis by genotype, comparing 
homozygous mutant or heterozygous mutant versus wild type, Caucasians versus 
Taiwanese: X2 = 14.8, P=0.0001. By allele, comparing Caucasians versus Taiwanese: 
x2 16.6, P<0.0001. For Affican Americans versus Taiwanese by genotype, X2 
14.2, P 0.0001 and by allele X2 16.5, P<0.0001. For Caucasians versus African 
Americans, by genotype and by allele, Fisher's exact test gives a I-tailed P-value of 
0.46. 
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4.4 Investigation of the functional effect of the T. 3591G and G-3j95T substitutions 
4.4.1 Site-directed mutagenesis 
I decided to investigate the functional significance of the T. 3591G and G-3595T mutations 
as these were the more frequent of the mutations identified. I performed site-directed 
mutagenesis (section 2.2.8.2) to create 3 mutant plasmids: SDMI (with the T-3591G 
substitution), SDM2 (with the G-3595T substitution), and SDM3 (with both 
substitutions), the latter plasmid being created as sequencing had already identified 
samples in which both of these mutations were present, and hence the functional 
consequence of this was of interest. 
4.4.2 Transient transfections 
Transient transfections were conducted using HepG2 cells (section 2.2.9), setting up 
parallel experiments with wild-type plasmid (pLlA2N), SDMI, SDM2, and SDM3, 
and, treating 50% of the cells with a CYPlA2 inducer (TCDD). 
4.4.3 Results of transient transfections 
The results of the transient transfection experiments using HepG2 cells showing the 
constitutive (non-induced) levels of luciferase (reporter product) activity and induced 
(TCD. D-treated) levels are shown in Figure 4.8. 
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Figure 4.8 Results of transient transfections of HepG2 cells with luciferase reporter 
vectors containing the CYPIA2 promoter-I pLIA2N is the wild type promoter; SDMI, 
SDM2, and SDM3 were created by site-directed mutagenesis of pLIA2N. SDMI 
contains the T-3591G substitution, SDM2 the G-3595T substitution, and SDM3 both 
substitutions. Cells were cotransfected with a CMVP plasmid (expressing P- 
galactosiclase); results are given as relative light units (RLU) per milliunit (mU) of 0- 
galactosidase x 10-3 . The 
TCDD-treated groups were treated with 10 nM 2,3,7.8- 
tetrachlorodibenzo-p-dioxin at 40 hours post transfection for 20 hours. Mean values 
with standard deviations of 3 to 4 transfections per group, each with 6 to 12 replicate 
wells, are shown. 
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Comparing the constitutive levels of luciferase activity, Bartlett's test for homogeneity 
of variances gave a Bartlett statistic of 23.26, and a P-value of <0.0001, Le. showing 
that Ahe difference between the standard deviations of the four groups was highly 
significant. A non-parametric (Kruskal-Wallis) test was therefore used, which gave a 
Kruskal-Wallis statistic of 30.52, with three degrees of freedom, and a P-value of 
ý--0.001, Le. showing a significant difference between the median values of the four 
groups. Dunn's Multiple Comparisons Test (a post-hoc comparison), comparing the 
results of each of the other groups of transfections versus the wild type (pLlA2N) gave 
a significant difference between SDM2 (G-3595T) and wild type (P<0.05). On visual 
inspection of the data (Figure 4.8), it can be seen that the SDM2 group appears to have 
a higher mean luciferase activity than the pLlA2N group. However, the magnitude of 
this difference is small (0.72 relative light units per milliunit of P-galactosidase x 10 -3 
giving a 1.2-fold increase in the mean value for the SDM2 group as compared to the 
pLlA2N group. It is possible that this translates into a significant functional difference 
in vivo, but unlikely. 
I 
Comparing the mean fold induction for each transfection experiment performed for the 
four plasmids using the Kruskal-Wallis test, gave a Kruskal-Wallis statistic of 4.99, and 
a P-value of 0.17. This means that there is not a significant difference between the fold 
induction in the four groups (mean induction 2.6-fold). 
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4.5-BAC clone generation and sequencing 
4.5.1 Methods 
Sequencing of CYPIA2 positive BAC clones was undertaken in order to determine the 
sequence of the CYPIA2 5' flanking region further upstream than that previously 
published, in order to search for another XRE in this sequence. 
A, human bacterial artificial chromosome (BAC) library (Genome Systems Inc, St 
Louis, MO) was screened with a BamffllPstI fragment (-808/-10, in intron 1). The 
probe was labelled by random priming with DNA polymerase I, large (Klenow) 
fragment using 32 P-dCTP (Ready To Go Kit, Pharmacia Biotech Inc., Piscataway, NJ). 
Labelled probe was added to membranes at 2.0 x 106 cpm. /ml in standard hybridisation 
buffer, and hybridised at 420C overnight. Membranes were washed in O. IxSSC, 0.5% 
sodium dodecyl sulphate, and exposed to autoradiographic film overnight at -700C. 
This. procedure generated 3 positive BAC clones. These clones were then further 
probed with the following oligonucleotides: 5- 
TCTGCCATCTTCTGCCTGGTATTCTG-3' (exon 2, positions 52-77), 5'- 
TCTTCCTCTTCCTGGCCATCCTGCTAC-3' (exon 7, positions 5238-5264), and 5'- 
TGGCAGAGCTCTTCCTCATGTGTGCAG-3' (5' flanking region, positions -1217 to 
-1245). Two out of the 3 clones were positive on all 3 hybridisations and were used in 
further studies (BAC7 and BAC8). The presence of CYPIA2 in these clones was 
further confirmed by both PCR using primer pair cyplabr2-cyplabf and sequencing 
with primer MI. Clones BAC7 and BAC8 were then subject to direct sequencing using 
primer CYPIA2.5R (5'-AGCTCGATCATGTGTAGCTTG-3') and BigDye TM 
Terminator Cycle Sequencing Ready Reaction Kit (Perkin Elmer Applied Biosystems). 
/ 
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I designed a further primer, CYP I AIM (5'-CATCTTGCAGTGGTGTAAT-3') from 
the resultant sequence, and the clones were subject to direct sequencing with this 
primer. 
I 
4.5.2 Results of BAC clone sequencing 
Sequencing of the cyplabr2-cyplabf PCR product from clones BAC7 and BAC8 with 
primer MI was identical to the expected published sequence except for the G-3649C 
substitution and the T-3650 deletions already identified as above, thus confirming the 
presence of CYP1A2 in these clones. Direct sequencing of BAC7 and BAC8 with 
CYPIA2.5R and CYPlA2.5R2 produced the sequence shown in Figure 4.9. Both 
sequences differed from that published by Quattrochi and Tukey (1989) in having an A- 
4072 deletion, and a C-4093 insertion (the latter shifting the KpnI site further 5' by one 
nucleotide). I checked this region of pLlA2N (sequenced using primer M3), and found 
that this plasmid also had these sequence discrepancies compared with the original 
published sequence. The discrepancies therefore represent publication errors. I 
searched the 532 bp of novel sequence for XRE sites using MatInspector Version 2.2 
(Quandt et al., 1995), and found no XRE motif. However, blasting this sequence 
against sequence GENBANK accession number AF253322 ("Homo sapiens 
cytochrome P450 (CYPlAl) and cytochrome P450 (CYPIA2) genes, complete cds, " 
submitted 06.04.2000 by Corchero et al., and published in Corchero et al., 2001) gave 
the result shown in Figure 4.10. Of note, there is a trinucleotide repeat, (AAC)6 in my 
sequence at positions -4382 to -4399 (Figure 4.11), which is absent in the GENBANK 
sequence. This may represent a polymorphic site, or, alternatively, a sequencing error 
in the sequence reported by Corchero and colleagues, owing to the method of 
sequencing employed ("shotgun cloning"), and the likely instability of this sequence. 
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Similarly, there is a poly-T and a poly-A sequence at -4544 to -4550 and -4215 to - 
4221 respectively in my sequence (Figure 4.11), but not in the GENBANK sequence, 
which could again represent an artefact in the sequence of Corchero et al., owing to the 
qifficulty of sequencing across such regions and their method of sequencing, or these 
regions could be polymorphic. A variable length poly-T or poly-A sequence could have 
a functional consequence; there is a (TA),, repeat (n = 5-8) polymorphism in the LTDP- 
glucuronosyltransferase I (UGTIAI) gene for which there is an inverse relationship 
between the number of TA repeats and promoter activity (Beutler et al., 1998). 
Furthermore, comparison of the two sequences reveals three possible SNPs: -4597C/T, 
-4593C/A, -4583AC, and -420OA/G. None of these SNPs have been already deposited 
in dbSNP. Of these possible SNPs, as the -420OA/G site is an A in my sequence and an 
R (i. e. A/G) in the GENBANK sequence, this one may represent a true SNP. 
Interestingly, the -4072AA is confirmed in the GENBANK sequence. Further sequence 














Figure 4.9 Nucleotide sequence of the CYP1A2 5' flanking region further 5' than 
reported by Quattrochi and Tukey (1989). Sequence from -4626 to -4098 represents 
novel sequence. Discrepancies as compared with the sequence reported by Quattrochi 
and Tukey (1989) are shown: the C-4093 insertion is underlined, and the A-4072 deletion 
is illustrated. 
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Query: 30310 tggggttcaaaggattctcctgcctcagcctccctgagtagctgggactacaggcatgcg 30369 
Sbjct: I tggggttcaaaggattctcttgcatcagcctcc-tgagtagctgggactacaggcatgcg 59 
Query: 30370 ccaccatggtcggctaannnnnnngtatttttagtagagatggggttttatcatgttggc 30429 
Sbjct: 60 ccaccatggtcggctaatttttttgtatttttagtagagatggggttttatcatgttggc 119 
Query: 30430 caggctggtccagaactcctgacctcaagtgatccgcccacatcagcctcccaaagtgct 30489 
Sbjct: 120 caggctggtccagaactcctgacctcaagtgatccgcccacatcagcctcccaaagtgct 179 
Query: 30490 gagattacagatgtgagcctccacaccaggcctgagactctgtctcaannnnnnnnnnnn 30549 
Sbict: 180 gagattacagatgtgagcctccacaccaggcctgagactctgtctcaaaacaacaacaac 239 
Query: 30550 nnnnnncagaatgtatcaatattcatccacgaattgtaacaaatatattacaccactgca 30609 
Sbjct: 240 aacaaccagaatgtatcaatattcatccacgaattgtaacaaatatattacaccactgca 299 
Query: 30610 agatgttaataataggggaaactgcagagtgggggtggtaaatggccacttttacctccc 30669 
S-j- agatgttaataataggggaaactgcagagtgggggtggtaaatggccacttttacctccc 359 
Query: 30670 tcatcatactttccactcaatttttctgtgaaccaaagactgctctnnnnnnntctatta 30729 
Sbjct: 360 tcatcatactttccactcaatttttctgtgaaccaaagaCtgCtctaaaaaaatctatta 419 
Query: 30730 gctttttraaattccttggctcccctccaaaaagtgtacatatgacatgatctcatttat 30789 
sbict: 420 gctttttaaaattccttggctcccctccaaaaagtgtacatatgacatgatctcatttat 479 
Query: 30790 gtaaaatacaacaagcaaaacaaatccatgcaatagatgttggggtcatgggtacccttg 30849 
Sbict: 480 gtaaaatacaacaagcaaaacaaatccatgcaatagatgttggggtcatgggtacccttg 539 
Query: 30850 agaaaggaacacaacgggacttcttggatg 30879 
Sbjct: 540 agaaaggaacacaacgggacttcttggatg 569 
Figure 4.10 Pairwise blast ("Blast 2" from NCBI site) of gi: 13430063 (AF253322) 













Figure 4.11 My CYPIA2 5' flanking novel sequence, with possible polymorphic sites 
underlined: trinucleotide repeat, (AAQ6 at -4382 to -4399, a poly-T at -4544 to -4550 
and a poly-A at -4215 to -4221, and three possible SNPs: -4597C/T, -4593C/A, - 
4583AC, and -420OA/G (conventional wobble codes given) 
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4.6 Discussion 
I identified three novel SNPs in the CYP1A2 5' flanking region: a T. 3591G substitution, 
a G-3595T substitution, and a T-3605 insertion. A PCR-RFLP test for the T-3591G 
polymorphism was designed and used to genotype 87 Caucasians, 104 African 
Americans, and 125 Taiwanese (Table 4.2); this revealed a significantly higher 
frequency of the G-3591 allele in Taiwanese as compared to Caucasians and African 
Americans. 
The results of transfection experiments (Figure 4.8) showed that the SDM2 (G-3595T) 
group had significantly higher constitutive activity than wild type, but only by a factor 
of 1.2. This small increýse in promoter activity is unlikely to be of functional 
significance in vivo. Of note, if the G-3595T substitution were associated with increased 
promoter activity, the direction of effect would be in the opposite direction to that 
predicted by the work of Chang et al. (1997), whose data are consistent with the 
existence of a polymorphism causing reduced CYPlA2 activity present at a higher 
frequency in Taiwanese as compared with Caucasians. I performed a search for 
potential transcription factor binding sites in the region of interest using MatInspector 
Version 2.2, which showed that both the T-3591G and G-3595T polymorphisms lie within 
the putative binding site for CCAAT/enhancer binding protein P (C/EBPP, -3582 to - 
3595 on forward strand). C/EBPP is part of a family of transcription factors, that are 
widely expressed (Lekstrom-Himes and Xanthopoulos, 1998), may bind to a variety of 
sites including activating protein-1 (AP-1) sites, may heterodimerise with other 
transcription factors including c-fos, c-jun, and ATF-2, and has been shown to play a 
crucial role in the regulation of the expression of liver-specific genes (e. g. 
phosphoenolpyruvate carboxykinase, or PEPCK, Croniger et al., 1998). It is of 
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possible interest that two of the polymorphisms (T-3591G and G-3595T) that we have 
identified lie within the C/EBPP binding site, and that the third one (T-3605ins) is close. 
Comparison of the TCDD-induced activity of the CYPIA2 promoter in the four 
plasmids revealed no significant difference (mean induction 2.6-fold for the whole 
group). In the case of PEPCK regulation, C/EBP binding to a specific domain, P3(I), is 
required for the liver-specific (Le. constitutive) expression of PEPCK, whereas its 
binding to 2 other domains, the cAMP regulatory element (CRE) and the glucocorticoid 
response unit (GRU) is involved in the induced expression. By analogy, it is therefore 
possible that this upstream C/EBPP binding site is involved in the regulation of 
constitutive but not inducible CYPIA2 expression, but, again, it is my opinion that a 
rigorous interpretation of my data (Section 4.4.3) does not support this. 
I The functional significance of the T-3605 insertion was not tested. However, although 
this lies within the putative binding sequence of a human transcription factor (Octamer 
factor 6, -3601 to -3614 on the forward strand or -3597 to -3613 on reverse strand), 
the T-3605 insertion does not alter its core recognition sequence. Given this fact, and the 
fact that the other two nearby polymorphisms do not appear to cause a significant 
functional alteration in CYP1A2 promoter activity, in my opinion, it is also unlikely that 
this polymorphism, would lead to a change in CYPIA2 promoter activity. Nonetheless, 
even though these novel SNPs appear to be non-functional, they may be useful in 
disease association studies, provided that the interethnic variation in frequency is taken 
into account. 
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Genome walking and sequencing also revealed two other sequence discrepancies 
compared with the sequence published by Quattrochi and Tukey (1989): a G-3649C 
substitution and a T-3650 deletion. These sequence changes have since been reported by 
Nakajima et al. (1999). (In Fig 1 of Nakajima et al., 1999, they have incorrectly given 
aC at their position -3650 in the sequence of Quattrochi and Tukey, 1989 - this should 
be a T. ) Of note, Nakajima and colleagues also report a C-3484 deletion; I did not find 
this -deletion 
in any of the samples sequenced. It is therefore possible that this 
represents a further polymorphic site, which is present in Japanese. 
Sequencing of the BAC clone led to the description of 532 nucleotides of the 5' 
flanking region of CYPIA2 further upstream than the sequence that was available at 
that time, in the process revealing 2 further errors in the Quattrochi and Tukey (1989) 
sequence, i. e. AA-4072 and a C-4093 insertion (the latter shifting the KpnI recognition site 
upstream by one nucleotide). No XRE motif was found within the novel sequence, but 
comparison of this sequence with the GENBANK sequence in this region (AF253322) 
revealed differences between my novel sequence and the GENBANK sequence, 
including a poly-T, a poly-A, and a trinucleotide repeat sequence (all present in mine 
but not in the GENBANK sequence), and three possible SNPs. Whether or not these 
sequence discrepancies represent truly polymorphic sequence requires further 
investigation. 
Three polymorphisms in CYPIA2 which appear to be associated with a functional 
change have been reported since I performed my study: a C-164A substitution in intron 1 
of Caucasians (allele CYPlA2*]F, Macleod et al., 1998; Sachse et al., 1999), a C63G 
substitution in exon 2 of Han Taiwanese (allele CYPIA2*2, Huang et al., 1999), and a 
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G-3858A substitution in Japanese (allele CYPIA2*IC, Nakajima et al., 1999). However, 
the CYPlA2*]F allele was only associated with a slightly higher inducibility in 
smokers when present in the homozygous state; the CYP1A2*2 substitution was very 
rare in the population studied and its functional consequence was not investigated; and 
the CYPlA2*]C substitution only appeared to be associated with a reduction in 
CYPIA2 activity in smokers. In addition, a further report (Chida et al., 1999) has 
described a T-2464 deletion (allele CYPlA2*ID, frequency 0.42) and a T-74oG 
substitution in Japanese (allele CYPIA2*IE, frequency 0.082). The functional 
significance of these allelic variants has not been described. Chevalier et al. (2001) 
screened the 7 exons of CYPIA2 including the 5' and 3' splice site consensus 
sequences in samples from 100 unrelated Caucasians using a PCR-SSCP strategy 
followed by selective sequencing. They identified 6 novel rare allelic variants: 
CYPIA2*IG (-740T>G, 1545T>C, 0.5%), CYPIA2*IH (951A>C, 1545T>C, 0.5%), 
CYPIA2*3 (1042G>A, 1545T>C, 1%),, CYP1A2*4 (ll56A>T,, 0.5%), CYPIA2*5 
(1217G>A, 0.5%), CYPIA2*6 (1291C>T, 0.5%). The last four variants include 
missense mutations, of which CYPIA2*4 (1386F) encodes an amino substitution in the 
putative substrate recognition site. All of these CYPIA2 polymorphisms reported to 
date are, however, together not sufficient to account for the apparent frequency of poor 
metabolisers seen in the bimodal distributions. 
CYPlA2 phenotyping studies have varied in their conclusions as to whether the 
distributions support the existence of an underlying genetic component to CYPlA2 
variability, and, although mathematical analysis of phenotyping methodology 
(Rostami-Hodjegan et al., 1996) indicates that the ratio used by Kalow and Tang 
(1991a, b) should be the most discriminant of bimodality and independent of the renal 
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clearance of caffeine and paraxanthine, experimentally, only skewed unimodal or log 
normal distributions of this ratio have been observed (Kalow and Tang, 1991a, b; 
Vistisen et al., 1992; Tang et-al., 1994; Catteau. et al., 1995), except for the study of 
Schrenk et al. (1998), in which data best fitted by bimodal distributions in both 
smokers and non-smokers were observed.. The difference between the findings of 
Butler et al. (1992) and Kalow and Tang (1991a) on the one hand, and Chang et al. 
(1997) on the other hand may reflect failure to control for confounding variables such 
as various dietary factors (Lampe et al., 2000). 
Studies which have supported a bi- or tri-modal. population distribution of CYPlA2 
activity (Devonshire et al., 1983; Butler et al., 1992, Nakajima et al., 1994) report a 
frequency of poor metabolisers of 10-14% in non-smokers, and a bimodal distribution 
also in smokers, suggesting a significant genetic impact both upon CYPIA2 activity, 
and upon CYPIA2 inducibility. The study of Schrenk et al. (1998) notably differs in 
the reported frequency of low CYPIA2 activity: 74% in male non-smokers and 80% in 
female non-smokers. With the metabolic ratio used by Butler et al. (1992) (urinary 
[1,7-dimethylurate + 1,7-dimethylaxanthine]/caffeine), 1,7-dimethylxanthine (also 
known as paraxanthine) is both a product and a substrate of CYPlA2, and therefore the 
time of sampling is 6ritical, reproducibility for this method being optimal at 4-5 hours 
post dose (discussed by Kalow and Tang, 1993; Kadlubar et al., 1996). This ratio is 
also sensitive to the renal clearance of caffeine and paraxanthine (Rostwni-Hodjegan et 
al., 1996). If a confounding factor such as renal clearance showed multimodality in its 
distribution, then this could lead to an erroneous conclusion that CYPlA2 is 
polymorphic. Indeed, a bimodal distribution of urine flow in some populations and 
interethnic variation in the renal clearance of dimethylxanthines has been suggested 
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(Tang et al., 1994; Kalow & Tang, 1993). The ratio proposed by Fuhr and Rost (1994), 
i. e. the ratio of the plasma or salivary concentrations of paraxanthine to caffeine, is also 
subject to influence by the renal clearance of caffeine or paraxanthine, but, nonetheless, 
this ratio correlates highly (r > 0.85; 5-7 hour samples) with systemic caffeine 
clearance, and is hence regarded by Rostami-Hodjegan et aL (1996) as likely to be the 
66 , gold standard" for discrimination between CYPlA2 phenotypes, providing that there 
is enough separation between the mean enzyme activity of the different phenotypes and 
an adequate urine flow, similar in all subjects, is maintained. 
In a recent CYP1A2 phenotyping study (Tantcheva-Po6r et al., 1999), using the 
salivary paraxanthine to caffeine ratio (which correlates highly with systemic caffeine 
clearance) in 786 Caucasians, the maximum likelihood test showed that the overall 
distribution of residuals was best described by the sum of two separate normal 
distributions, with 52% of subjects lying within the first normal distribution. 
Nonetheless, this apparent polymorphism could be equally well explained by non- 
specific deviation from the normal distribution, as evidenced by minor skew seen in the 
P-P plot. (The P-P plot was a plot of the cumulative probability of ANCOVA residuals 
to be expected assuming normal distribution versus the observed cumulative 
probability of the ANCOVA residuals, the ANCOVA being based on a simplified 
paraxanthine/caffeine ratio method for calculating caffeine clearance. ) Indeed, the 
bimodal interpretation gives a poor metaboliser frequency of approximately 50%, 
substantially higher than that reported by earlier authors (Devonshire et al., 1983; 
Butler et al., 1992; Nakajima et al., 1994), although not higher than the value reported 
by Schrcnk et al. (1998). The difference between the poor metaboliser frequency in 
different studies njay again be possibly due to confounding factors. Tantcheva-P6or et 
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al. (1999) analysed the contribution to the overall variance in CYPlA2 activity by a 
variety of covariates, and found that the following covariates accounted for 37% of the 
variance (estimated change relative to arbitrarily defined basal caffeine clearance, male, 
non-smoking, German resident): coffee (1.45-fold per litre of coffee drunk daily), body 
mass index (0.99-fold per kg m2), smoking (1.22-fold, 1.47-fold, 1.66-fold, and 1.72- 
fold for 1-5,6-10,11-20, and >20 cigarettes smoked per day), oral contraceptives 
(0.72-fold), country of residence (0.81-fold and 0.74-fold for Bulgaria and Slovakia), 
and female (0.90-fold). 
As well as known environmental influences on CYPIA2 activity and intrinsic genetic 
variation, there are other possible causes of variation in CYP 1 A2 activity, such as gene- 
gene , interactions. Coordinate regulation of CYPJA2 and the LJDP- 
glucuronyltransferase UGTI. 6 has been reported (Bock el al., 1994). Macleod et al. 
(1997) reported that individuals possessing the glutathione transferase GSTMI *0 allele 
had higher CYPIA2 activity for both non-induced and induced conditions, while 
individuals having the Ile/Ile CYPIAI genotype had higher CYPIA2 activity in the 
non-induced state, but lower CYPIA2 activity in the induced state than those with the 
HeNal genotype. In their studies of the colon carcinoma cell line LS180, Li et al. 
(1998) found that the concentration-response curves for induction by TCDD or 3- 
methylcholanthrene and the time courses of induction were very similar for CyPlAl, 
CYPIA2, and CYP1131 (another enzyme of the CYPI. family, Shimada et al., 1997), 
implying that the regulation of these enzymes may occur via a common pathway. 
Indeed, each member of the CYPI family is inducible by TCDD via the 
ary1hydrocarbon receptor (AhR) mechanism (Rowlands and Gustafsson, 1997), 
whereby the inducer plus AhR translocates to the nucleus, dimerises with the AhR 
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nuclear translocator (ARNT), and interacts with cis-acting elements termed xenobiotic 
responsive elements (XREs) in the 5' flanking region of the CYPI. gene. In mice, the 
genetic difference in susceptibility of different strains to TCDD-induced toxicity has 
been shown to correlate with polymorphism of the AhR (Nebert, 1989; Chang et al., 
1993). Polymorphisms in the human AhR have been identified (Nebert et al., 1999; 
Garte and Sogawa, 1999), and it is possible that these may affect the inducibility of the 
CYPI enzymes in man. In a study of quantitative trait loci affecting caffeine 
metabolism in inbred mouse strains, 3 loci were identified: one that colocalised with 
the murine CYP I A2 locus on chromosome 9 (suggesting the presence of an expression 
polymorphism affecting this gene),, one on murine chromosome I (with a greater 
influence amongst males than females), and one on chromosome 4 (Casley et al., 
1999). This study demonstrates the possibility of genetic factors other than variation 
in CYP I A2 influencing the CYP 1 A2 activity, at least in mice. 
There are deficiencies in the studies conducted to date that have searched for functional 
polymorphisms in CYPIA2. Nakajima et al. (1994) sequenced the 7 exons, exon-intron 
junctions, and the 5' flanking region to -3470 in only 5 individuals (of different 
phenotypes); in their later paper, Nakajima et aL (1999) sequenced -3418 to -4065 in 
the same 5 individuals; Welfare et al. (1999) perfornied screening by SSCP of the 7 
1 
exons, exon-intron boundaries, and 2 upstream regions in only 19 individuals (of 
different phenotypes), and sequenced only 2; Huang et al. (1999) sequenced the exons 
of only 8 Taiwanese (Han Chinese race); Sachse et al. (1999) only investigated the 
intron I polymorphism; and our screening focused on an upstream region, sequencing 
20 Caucasians, 31 Taiwanese, and 10 African Americans. I conclude that firstly further 
phenotyping work is warranted in this field, e. g. use of the Kalow and Tang (1991a) 
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index of CYPlA2 activity in several different ethnic groups, carefully controlling for 
all possible confounding variables, and that, secondly, this should be combined with 
screening for functional polymorphisms in CYPIA2 using sensitive methods such as 
denaturing high performance liquid chromatography (DHPLC, O'Donovan et al., 
1998), followed by PCR-sequencing as indicated, in a larger. number of subjects than 
has yet been screened by this method (e. g. 50 from 3 different ethnic groups), and 
covering regions of CYPIA2 that have as yet not been screened (including intronic 
sequences, where enhancers could reside). Furthermore, a recent report has indicated 
that CYPIAI and CYPIA2 are separated by a 23 kb segment that contains no other open 
reading frames, and are orientated in opposite directions, so that the 5' flanking region 
is'in common between the two genes (Corchero et 'al., 2001, GenBank sequence 
accession number AF253322). Sequence analysis of this 5' flanking region revealed 
several XREs, in addition to the XREs previously reported (Fisher et al., 1990; Kubota 
et al., - 1991; Quattrochi & Tukey, 1989), and it is possible that polymorphism in these 
could lead to differential inducibility of CYPIA2. Investigation of the possible 
coregulation of CYPIA2 with CYP1A1, as well as the putative coregulation of CYPIA2 
with genes such as CYPIBI, the UGTs, and GSTs, should prove fruitful. 
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CHAPTER FIVE 
CLOZAPINE PHARMACOIGNETICS AND PHARMACODYNAMICS 
STUDIED WITH CYPlA2-NULL MICE 
5.1 Introduction 
5.1.1 Clozapine pharmacokineties 
Clozapine is an atypical antipsychotic that is employed in the UK in cases of treatment- 
resistant schizophrenia or schizoaffective disorder. It is effective in approximately 30 to 
60% of patients unresponsive to typical antip'sychotics (Kane et al., 1988; Kane, 1992), 
but the risk of agranulocytosis (0.7% in the first year of treatment, Atkin et al., 1996) 
means that regular haematological monitoring is necessary and limits its use in the UK 
to treatment-resistant cases. 
There is wide interindividual. variation (approximately 10- to 50-fold) in the plasma 
levels of clozapine for a given dose (Perry et al., 1991; Potkin-et al., 1994; Olesen et 
al., 1995) and several studies indicate that clozapine concentrations of at least 350-420 
ýtg/l are associated with clinical response (Perry et al., 1991; Hasegawa et al., 1993; 
Kronig et al., 1995; Miller et al., 1994; Potkin et al., 1994). Clozapine is metabolised 
mainly in the liver, with the major metabolites being desmethylclozapine (or 
norclozapine) and clozapine N-oxide (Jann et aL, 1993; Figure 5.1). There have been 
several in vitro studies investigating the roles of the hepatic cytochromes in the 
generation of these metabolites. Eiermann and colleagues (1997) concluded that 
CYPlA2 and CYP3A4 were both involved in the demethylation of clozapine, and 
CYP3A4 in the N-oxidation. However, Linnet and Olesen (1997) suggested that 
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CYP2CI9 and CYP3A4 would mediate 30% and 30-45% of clozapine metabolism 
respectively at therapeutic concentrations, with CYPlA2 mediating only about 10%. 
Tugnait et al. (1999) found that CYP I A2 and CYP3A4 both catalyse the dernethylation 
and N-oxidation of clozapine, but that CYPIA2 played a more important role in the 
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Figure 5.1 Structures of clozapine, clozapine N-oxide, and N-desmethylclozapine 
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CYPlA2 and CYP3A4 both show wide interindiVidual variation in activity (Aitchison 
et al., 2000c). Jerling et al. (1997) studied the population pharmacokinetics of 
clozapine and found that the clearance of clozapine was distributed in a similar way to 
indices of CYP 1 A2 activity, indicating that CYP 1 A2 could be the major determinant of 
clozapine, clearance. Most studies have demonstrated a trimodal or bimodal distribution 
to the pattern of CYPIA2 activity in a population (Section 4.6), with 5-14% of subjects 
in some studies (Butler et al., 1992; Lang et al., 1994; Nakajima et al., 1994; Ou-Yang 
et al., 2000), up to 50% in another (Tantcheva-Po6r et al., 1999), and up to 80% in one 
study (female non-smokers, Schrenk et al., 1998) having relatively low CYPIA2 
activity. 
5.1.2 Human and mouse CYPlA2 
Human and mouse CYP 1 A2 resemble each other closely in cDNA derived amino acid 
sequence (Kimura et al., 1984; Jaiswal et al., 1987) and in catalytic activity (Aoyama et 
al., 1989). The human and mouse mRNA sequences are shown in Figure 5.2; there is 
ý1 
79% homology between them. 
292 
Figure 5.2 Human CYP I A2 mRNA sequence (GENBANK gi 20552470, top line) 
compared to mouse CYPIA2 mRNA sequence (GENBANK gi 6753565, below), 
showing regions of identity and amino acid sequence 
95 gccacagagcttctcctggcctctgccatcttctgcctggtattctgggtgctcaagggt 154 
28 gccccagagctgctactggccactgccatcttctgtttagtgttctggatggtcagagcc 87 
10 APELLLATAIFCLVFWMV RýA 
155 ttgaggcctcgggtccccaaaggcctgaaaagtccaccagagccatggggctggcccttg 214 
1 111 11 111 11111111111111 1 HIM 1 11 1111111 HIM 
88 tcaaggacccaggttcccaaaggcctgaagaatccacccggaccctggggcttgcccttc 147 
30 SRTQVPKGLKNPPGPWGLPF 
215 ctcgggcatgtgctgaccctggggaagaacccgcacctggcactgtcaaggatgagccag 274 
1 Hill IIIIIII IIIIIIIIIIIII HIM Hill 11 11 lill III 
148 attgggcacatgctgactgtggggaagaacccacacctgtcactgacacggctgagtcag 207 
50ý IGHMLTVGKNPHLSLTRLSQ 
275 cgctacggggacgtcctgcagatccgcattggctccacgcccgtgctggtgctgagccgc 334 
.1 11 11111111 11111111111111 11111111 11 111 11111111111 11 
208 cagtatggggacgtgctgcagatccgcatcggctccactcctgtggtggtgctgagcggc 267 
70 QYGDVLQIRIGS T'P VVVLSG 
335 ctggacaccatccggcaggccctggtgcggcagggcgacgatttcaagggccggcctgan 394 
268, ctgaacaccatcaagcaggccctggtgaggcagggagatgacttcaagggccgaccag. c 32, 
90 LNTIKQALVRQGDDFKGRPD 
395 ccntnctnacancctnccaccctcatcactgatggccagagcttgaccttcagcacagac 454 
11 111 11 111 11 111111 1 111 11111 1111 1111 1 Hill 
328 ctct ---- acagctt--cacacttatcactaacggcaagagcatgactttcaacccagac 381 
110 L'YSFTLITNGKSMTFNPD 
455 tctggaccggtgtgggctgcccgccggcgcctggcccagaatgccctcaacaccttctcc 514 
382 tctggacccgtgtgggctgcccgccggcgcctggcccaggatgccctgaagagcttctcc 441 
128 SGPVWAARRRLAQDALKSFS 
515 atcgcctctgacccagcttcctcatcctcctgctacctggaggagcatgtgagcaaggag 574 
11 11111 Hill 1 11 1111111 Hill 1111111111 111111111111 
442 atagcctcggacccgacgtcagcatcctcttgctatttggaggagcacgtgagcaaggag 501 
148 '1 ASDPTSASSCYLEEHVSKE 
575 gctaaggccctgatcagcaggttgcaggagctgatggcagggcctgggcacttcgaccct 634 
Hill II IIIIII II 111 11 11111111 1 111 1111111111 
502 gctaaccatctcgtcagcaagcttcagaaggcgatggcagaggttggccacttcgaacca 561 
168 ANHLVSKLQKAMAEVGHFEP 
635 tacaatcaggtggtggtgtcagtggccaacgtcattggtgccatgtgcttcggacagcac 694 
562 gtcagccaggtggtggaatcggtggctaacgtcattggtgccatgtgctttgggaagaac 621 
188 VSQVVESVANVIGA M'C FGKN 
695 ttccctgagagtagcgatgagatgctcagcctcgtgaagaacactcatgagttcgtggag 754 
- 11111 11 Hill 11111111 11 1111111 1111 1 11 11 111111 
622 ttcccccggaagagcgaggagatgctgaacatcgtgaataacagcaaggactttgtggag 681 
208 FPRKSEEMLNIVNNSKDFVE 
293 
755 actgcctcctccgggaaccccctggacttcttccccatccttcgctacctgcctaaccct 814 
1 11 1 lill Hill I IIIIIIIIIIIII lill 11111111111 11111 
682 aatgtcacctcagggaatgcagtggacttcttcccggtcctgcgctacctgcccaacc, ý: 1 741 
228 NVTSGNAVDFFPVLRYLPNP 
1. 
815 gccctgcagaggttcaaggccttcaaccagaggttcctgtggttcctgcagaaaacagtc 874 
IIIII IIIIIII III IIIIIII II 111 11 111 11111111111 111 
742 gccctcaagaggtttaagaccttcaatgataacttcgtgctgtttctgcagaaaactgtc 801 
248 ALKRFKTFNDNFVLPLQKTV 
875 caggagcactatcaggactttgacaagaacagtgtccgggacatcacgggtgccctgttc 934 
11111111111 11 11111 11111111111 111 11111111 11111111111 
802 caggagcactaccaagacttcaacaagaacagtatccaagacatca6aagtgccctgttc 861 
268 0EHYQDFNKNSIQDITSALF 
935 aagcacagcaagaaggggcctagagccagcggcaacctcatcccacaggagaagattgtc 994 
862 aagcacagcgagaa --- ctacaaagacaatggcggtctcatccccgaggagaagattgtc 918 
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995 aaccttgtcaatgacatctttggagcaggatttgacacagtcaccacagccatctcctgg 1054 
919 aacattgtcaatgacatctttggagctggctttgacacagtcaccacagccatcacctgg 978 
307 NIVNDIFGAGFDTVTTAITW 
1055 agcctcatgtaccttgtgaccaagcctgagatacagaggaagatccagaaggagctggac 1114 
III 1 11 11111111 1111 11 11111111111111 11111111111 
979 agcattttgctacttgtgacatggcctaacgtgcagaggaagatccatgaggagctggac 1038 
327 SILLLVTWPNVQRKIHEELD 
11; 5, actgtgattggcagggagcggcggccccggctctctgacagaccccagctgccctacttg 1174 
11 111 1111111111 1111 11 11111 111111 1 11111111111 11 1 
1039 acggtggttggcagggatcggcaaccacggctttctgaccgtccccagctgccatatcta 1098 
347 TVVGRDRQPRLSDRPQLPYL 
1175 gaggccttcatcctggagaccttccgacactcctccttcttgcccttcnnaccatccccc 1234 
1099 gaggccttcatcctggagatctaccgatacacatcctttgtccccttc--accatccccc 1156 
367 'EAFILEIYRYTSFVPFTIP 
1235 acagcacaacaagggacacaacgctgaatggcttctacatccccaagaaatgctgtgtct 1294 
1111111111 11111111 1 111111111111 lill HIM I Hill III 
1157 acagcacaacgagggacacctcactgaatggcttccacattcccaaggagcgctgtatct 1216 
386 HSTTRDTSLNGFHIPXERCI 
1295 tcgtaaaccagtggcaggtcaaccatgacccagagctgtgggaggacccctctgagttcc 13S4 
1217 acataaaccagtggcaggtcaaccatgatgagaagcagtggaaagacccctttgtgttcc 1276 
406' YINQWQVNHDEKQWKDPFVF 
1355 ggcctgagcggttcctcaccgccgatggcactgccattaacaagcccttgagtgagaaga 1414 
1277 gcccagagcggtttcttaccaataacaactcggccatcgacaagacccagagcgagaagg 1336 
426 RPERFLTNNNSAIDKTQSEK 
1415 tgatgctgtttggcatgggcaagcgccggtgtatcggggaagtcctggccaagtgggaga 1474 
1111111 11 111 1111 11111111111 11 11111 111 111111111111 
1337 tgatgctcttcggcttgggaaagcgccggtgcattggggagatcccggccaagtgggamýI 1470 
446, VMLFGLGKR -R CIGEI, PAKWE 
1_475 tcttcctcttcctggccatcctgctacagcaactggagttcagcgtgccgccgggcngtg 1534 
IIIIIIIIIII I IIIIIIIIIII IIIII 11111111 11 11111 Hill III 
1397 tcttcctcttcttagccatcctgctgcagcatctggagtttagtgtgccaccggg-tgtg 1455 
466 VFLFLAILLQHLEFSVPPGV 
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1535 aaagtcgacctgacccccatctacgggctgaccatgaagcacgcccgctgtgaacatgtc 1594 
- 11 11 11111111 1111 111 111 111111111111 11 111111111 111 
1456 aaggtggacctgacacccaactatgggttgaccatgaagcccgggacctgtgaacacgtc 1515 
486 KVDLTPNYGLTMKPGTCE ji V 
1595 caggcgcggctgcgcttctcca 1616 
11 11111 111 Hill lill 
1516 caggcatggccacgcttttcca 1537 
506 QAWPRFS 
5.1.3 Aims of this study 
Given, the inconsistencies in the conclusions of the above studies regarding the 
contribution of CYPIA2 to clozapine metabolism, my aim was to use the CYPIA2 -/- 
(null) mouse in order to investigate the in vivo contribution of CYPIA2 to clozapine 
pharmacokinetics. In addition, I used the CYPIA2 -/- mouse as a model for low 
CYPIA2 activity in man, through the use of behavioural ratings aiming to draw 
conclusions regarding the pharmacodynamic effects of clozapine in individuals 
relatively deficient in CYPlA2 activity. 
5.2 Methods 
The methodology for this Chapter is given in Chapter 2: Sections 2.2.10.1 (Study 
design), 2.1.3 (Mice), 2.2.10.3 (HPLC analysis), 2.2.10.2 (Behavioural effects ratings), 
and 2.3.6 (Statistical analysis). All the data reported in this Chapter have also already 
been published (Aitchison et aL, 2000b). 
5.3 Results 
5.3.1 Pharmacokinetic parameters 
The mean weights (± standard deviations) of the wild-type (N = 4) and CYPlA2 4- 
mice (N = 4) were 23.28 g (± 3.21) and 27.06 g (± 3.27) respectively. The Mann- 
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Whitney U test revealed a 1-tailed P value of 0.17, i. e. the two groups did not differ 
significantly in their mean weights. 
Table 5.1 gives the pharmacokinetic parameters of clozapine, desmethylclozapine, and 
clozapine N-oxide in the 2 groups of mice, and Figures 5.3 to 5.5 show the 
concentrations of clozapine, desmethylclozapine, and clozapine N-oxide versus time. 
The area under the concentration-time curve (AUC) of clozapine was 2.6 times greater, 
the clearance of clozapine was 2.6 times slower, and the half-life was 1.2 times longer 
in the CYPlA2 4- mice as compared to the wild-type mice. Sixty-one percent of the 
clozapine clearance in wild-type mice is mediated by CYPIA2 (calculated by the 
formula given in Section 2.3.6). For desmethylclozapine, the AUC was 1.6 times lower 
in the CYPIA2 4- mice as compared to the wild-type mice, while for clozapine N- 
oxide, although the AUC was 1.4 times greater in the CYP I A2 4- mice, this difference 
did not quite reach statistical significance (P = 0.0571). 
5.3.2 Behavioural effects 
The behavioural effects of clozapine on the wild-type and CYPlA2 -/- mice are shown 
in Figures 5.6 and 5.7. The CYPlA2 -/- mice were significantly more drowsy and 
showed more motor impairment than the wild-type mice (P = 0.0145 in both instances, 
Mann-Whitney U test). In addition, myoclonus was noted in one wild-type mouse at 
240 min, in two CYP I A2 -/- mice at 60 min, in one CYP I A2 -/- mouse at 120 min, and 
in one CYP I A2 -/- mouse at 120 min and at 240 min. 
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Table 5.1 Pharmacokinetic parameters of clozapine, desmethylclozapine, and clozapine 
N-oxide in male wild-type and CYP I A2 -/- mice after a single 10 mg/kg intraperitoneal 
dose of clozapine (mean ± SD) 
Wild-type (n = 4) CYPIA2 -/- (n = 4) 
Clozapine AUCo., (mg min ml-') 42.9 ± 3.9 111.3 ± 11.1 ** 
Clozapine clearance/F (ml kg-1 min-') 0.234 ± 0.020 0.091 ± 0.009** 
Clozapine half-life (min) 110.1 ± 8.1 129.8 ± 3.1 ** 
Desmethylclozapine AUCO, (mg min ml-1) 11.9 ± 2.7 7.6 ± 2.2* 
Clozapine N-oxide AUCO, (mg min ml- 1)2.0 ± 0.2 2.7 ± 0.8 
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Figure 5.3 Whole blood clozapine concentration-time curves after a 10 mg/kg 
intraperitoneal dose of clozapine to male wild-type and CYPIA2 -/- mice, administered 
at time 0. Mean values + SD are given. 
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Figure 5.4 Whole blood desmethylclozapine concentration-time curves after the 
10 mg/kg intraperitoneal dose of clozapine. For the wild-type mice at 240 min, 
the mean of 2 values is reported (the other 2 values were below the limit of 
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Figure 5.5 Whole blood clozapine N-oxide concentration-time curves (mean ± SD) 
after the 10 mg/kg intraperitoneal dose of clozapine. Values beyond time= 60 min for 
both wild-type and CYP I A2 -/- mice were below the limit of detection (5.0 ng/ml). 
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Figure 5.6 Degree of drowsiness versus time after the 10 mg/kg intraperitoneal dose of 
clozapine. Mice were rated for drowsiness using the criteria given in Table 2.3. Mean 
scores + SD are given. 
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Figure 5.7 Degree of motor impairment versus time after the 10 mg/kg intraperitoneal 
dose of clozapine. Motor impairment in the mice was rated using the criteria given in 
Table 2.3. Mean scores + SD are given. 
5.4 Discussion 
My results indicate that CYPIA2 contributes significantly to the dernethylation of 
clozapine in vivo. The finding of a slightly greater AUC for clozapine N-oxide in the 
CYPIA2 -/- mice may be explained by the following: in the absence of CYPIA2. with 
a consequent higher concentration of clozapine, more clozapine was available to 
undergo N-oxidation by enzymes other than CYPIA2 (which might have included 
other enzymes, such as CYP3A4, possibly being induced by clozapine). If CYPIA2 
contributes to the N-oxidation of clozapine in mice, it must do so only to a very minor 
degree. These findings confirm the in vitro results of Eiermann el al. (1997) and are 
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consistent with those of Tupait et al. (1999). In addition, I have estimated that in 
wild-type mice, 61% of the clearance of clozapine is mediated by CYPIA2. This result 
is contrary to the estimation provided by Linnet and Olesen (1997, Section 5.1.1) but in 
accordance with the conclusion of Jerling et al. (1997) in man. In the latter study, 
therapeutic drug monitoring data were evaluated, and clozapine clearance was found to 
be similarly distributed to the indices of CYP 1 A2 activity found in other populations by 
other authors. My data can be extrapolated to man because CYPIA2 expression and 
catalytic activities are conserved between mice and humans (Figure 5.1; Kimura et al., 
1984; Jaiswal et al., 1987; Aoyama et al., 1989). 
The behavioural data show that after clozapine administration, the CYPlA2-null mice 
were significantly more drowsy, showed more motor impairment, and had more 
myoclonus than the wild-type mice. Clinical data indicate that sedation is the most 
commonly reported adverse effect of clozapine, occurring in 39% of patients 
(Safferman et al., 1991). My data predict that for a given dose of clozapine, individuals 
with relatively low CYPIA2 activity might show a greater degree of sedation than 
extensive metabolisers (EMs). Myoclonus occurs in 2% of patients on clozapine 
(Lieberman and Safferman, 1992) and may progress to generalised seizure activity 
(Berman et al., 1992; Gouzoulas et al., 1993; Meltzer and Ranjan 1994). Seizures are a 
dose-relaied adverse effect, the frequency of seizures at clozapine doses of less than 
300 mg/day, 300-600 mg/day, and above 600 mg/day being 1%, 2.7%, and 4.4% 
respectively (Devinsky et al., 1991). My data similarly indicate that CYPIA2 low 
activity individuals might be more prone to myoclonus, and therefore might be at 
greater risk of generalised seizure activity for a given dose of clozapine. The risk of 
this and other dose-related adverse effects could be minimised by titrating the dose up 
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more slowly than usual, monitoring carefully for the emergence of effects such as 
sedation. 
The fact that the CYPIA2 4- mice had significantly higher levels of clozapine would 
also imply that individuals relatively deficient in CYPlA2 would respond at lower 
doses of clozapine than those with higher CYPlA2 activity. The dose of clozapine 
employed in this study (10 mg/kg) was chosen as the results of preliminary experiments 
indicated that this dose was necessary to achieve informative data for 
desmethylclozapine and clozapine N-oxide, and would be equivalent to a dose of 
approximately 700 mg or 600 mg clozapine in an average man or woman respectively, 
as is demonstrated by the fact that the peak serum level in the wild-type mice (300-400 
ng/ml) is in the therapeutic treatment range for clozapine in man. In a study of 12,760 
clozapine recipients in the UK and Ireland, the mean clozapine dose after 12 weeks of 
treatment was 388 mg/day, the mean maximum dose was 462 mg/day, and 41% had a 
peak dose of more than 500 mg/day (Munro et al., 1999). My study indicates that daily 
doses of greater than 600-700 mg (especially as a single dose) should not be used in 
individuals with relatively low CYP 1 A2 activity. 
Parallels may be drawn between my study and studies investigating the correlation 
between adverse effects of typical antipsychotics and CYP2D6 metaboliser status. In a 
single dose pharmacokinetic study of perphenazine administered to six CYP2D6 PMs 
and six CYP2D6 EMs, the PMs reported more adverse effects, especially tiredness 
(Dahl-Puustinen et al., 1989). Similarly, in a study investigating severe adverse effects 
during the first days of treatment with a phenothiazine or haloperidol, CYP2D6 PMs 
had a higher incidence of concentration-dependent effects, such as oversedation, 
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postural hypotension and autonomic effects (Spina et al., 1992). However, 
concentration-dependent effects tend to reduce with time (Aitchison et al., 1999c); in 
the case of clozapine, patients usually develop tolerance to the sedative effects within 4 
to 6weeks of treatment (Marinkovic et al., 1994). Correlations between metaboliser 
status, and concentration-dependent effects are therefore most relevant to the initial, 
dose-finding stages of prescribing. 
Other adverse effects of clozapine, such as neutropenia and agranulocytosis, do not 
appear to be conýentration-dependent. The peak incidence of neutropenia and 
agranulocytosis occurs within the first 6-18 weeks of clozapine treatment, being 1.27% 
and 0.7% respectively, and the risk of both decreases with increases in clozapine dose 
(Munro' et al., 1999). The pathophysiological mechanism of agranulocytosis is 
uncertain, but hypotheses include a direct toxic effect on neutrophils or haemopoietic 
precursors (Veys et al., 1992; Gerson et al., 1994, Deliliers el al., 1998), and an 
immunological basis (Pisciottta. et al., 1992), the latter with a possible genetic 
predisposition (Corzo, et al., 1995; Lieberman et al., 1990). Desmethylclozapine at 
high concentrations has been seen to have a toxic effect on the precursors of both 
myeloid and erythroid lineages (Gerson et al., 1994), and the 
desmethylclozapine/clozapine ratio has been seen to be inversely correlated with 
neutrophil count in patients treated with clozapine (Mauri et al., 1998). If the 
formation of desmethylclozapine is primarily CYPlA2-dependent, then the 
desmethylclozapine/clozapine ratio should reflect CYPIA2 activity. This would imply 
that individuals with relatively high CYPIA2 activity could be at greater risk of 
clozapine-induced neutropenia and agranulocytosis. However, other studies have failed 
to , find an association between desmethylclozapine levels or 
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desmethylclozapine/clozapine ratio and granulocyte counts (Hasegawa et al., 1994; 
Combs et al., 1997). 
Another hypothesis regarding the mechanism of agranulocytosis is that it involves 
metabolic activation of clozapine with the formation of free radicals which are able to 
bind covalently to neutrophil or bone marrow proteins, then leading to agranulocytosis 
either by a direct toxic (analagous to the covalent binding of acetaminophen in the 
liver, Purnford and Halmes, 1997) or an immunological route (Fischer et al., 1991; 
Pirmohamed et al., 1995; Liu and Uetrecht 1995; Maggs et al., 1995; Gardner et al., 
1998a and 1998b). Chemically reactive metabolites of clozapine may be formed by 
neutrophil myeloperoxidase (Gardner et al., 1998a) or by cytochrome P450s CYP3A, 
CYP2C9, and C, YP2EI (Pirmohamed et al., 1995). Cytochrome P450 isoforms appear 
to be expressed not only in the liver, but also in neutrophils and bone marrow stem cells 
(Murray et al., 1988; Gonzalez, 1992). The formation of the reactive metabolites 
catalysed by the P450s is reversible (Pirmohamed et al., 1995); under conditions of 
relatively low CYPIA2 activity, the increase in clozapine concentration would be 
expected to lead to an increase in the proportion of clozapine passing down the 
pathway of reactive metabolite formation. If this hypothesis were correct, then 
relatively low CYPIA2 activity might be expected to be associated with 
agranulocytosis. However, agranulocytosis and CYPIA2 activity do not show the 
same ethnic stratification, Le. agranulocytosis occurs at a greater frequency in Asians 
but not Orientals or African-Caribbeans compared with Caucasians (Munro et al., 
1999), while CYPIA2 activity appears to be lower in Orientals and Blacks (Le 
Marchand et al., 1997; Relling et al., 1992; Chang et al., 1997). Nonetheless, it is 
possible that combined enzyme deficiency (e. g. relative deficiency in CYPIA2 
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combined with a glutathione S-transferase deficiency) 'could fuTther incTease an 
individual's risk for the formation of potentially harmful reactive intermediates. This 
theory is supported by the analagous finding of Rojas and colleagues (1998) that 
smokers with combined CYPIAl and glutathione S-transferase Ml (GSTM1) 
deficiency showed significantly higher levels of activated covalently bound metabolites 
than individuals with CYP IA1 or GSTM I deficiency alone. 
Although the CYPIA2 alleles identified thus far (Section 4.6) would appear not to 
account for the bi- or trimodality of CYPlA2 activity in a population, it is possible that 
genetic determinants of variable CYPIA2 activity will be identified. Pre-prescribing 
genotyping for CYPIA2 activity would then become feasible, and could lead to the 
1, judicious use of particularly low doses, of clozapine and other drugs that are 
metabolised by CYP I A2. Furthermore, in combination with assays for polymorphisms 
in other drug metabolising enzymes such as the glutathione transferases, genotyping for 
CYPIA2 activity could yield useful information regarding genetic susceptibility to 
idiosyncratic drug reactions such as agranulocytosis. In the mean time, as it is known 
that CYPIA2 activity is lower in Orientals and Blacks (Aitchison et al., 2000c), my 
data suggest that in these groups it would be wise to commence with particularly low 
doses of clozapine and other CYPIA2-metabolised drugs, and to use a slow dose 
escalation procedure, monitoring carefully for the emergence of concentration- 




6.1 Overview of findings and their relevance 
In chapter 2,1 describe a novel long-PCR assay, developed for the identification of 
CYP2D6 ultrarapid metabolisers (UMs). This assay was the first assay to be developed 
for this purpose, has been validated by comparison of results with a subsequently 
developed assay, and has the potential to provide an estimate of the number of extra 
copies of the CYP2D6 coding sequence in UMs. 
In. Chapter 3,1 describe two genotype-phenotype correlation studies, one in French 
subjects (mainly Caucasians), and one in elderly British Caucasians. The French study 
showed that it is necessary to genotype for the CYP2D6*6 allele in French Caucasians 
I 
in order to predict CYP2D6 PM status with a high degree of accuracy. This had 
previously been shown for German Caucasians (Sachse et al., 1997), but not for French 
Caucasians. In the study of elderly British Caucasians, there was one individual with 
genotype-phenotype discrepancy (*11*5 genotype, but PM phenotype), which has since 
been subjected to mutation screening by Dr K Tandon under my supervision. The 
mean debrisoquine MR (5.67) in the elderly sample is higher than the mean 
debrisoquine MRs in two previous sets of data on Caucasian volunteers (Daly et al., 
1991, mean debrisoquine MR less than 1.0 for N= 73 volunteers; Sachse et al., 1997, 
mean debrisoquine MR 3.54 for 133 debrisoquine-phenotyped German Caucasians). 
Moreover, the mean MR for subjects with one functional CYP2D6 gene was higher 
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than that in previous studies (Sachse et al., 1997; Leathart et al., 2000). The relatively 
high overall mean debrisoquine MR may therefore be due to the relatively high mean 
MR for sUbjects with CYP2D6 gene dosage of one; this may in turn was hypothesised 
to reflect the presence of an intermediate metabolising allele (e. g. CYP2D6*2) in the 
elderly cases with relatively high frequency (CYP2D6*2 has since been shown not to 
be in excess, Tandon et al., unpublished data), or reduced CYP2D6 activity in the 
heterozygous state due to a degree of age-related reduction in CYP2D6 hepatic 
capacity. 
The next section of Chapter 3 reports genetic association studies between CYP2D6 
metaboliser status and clinical response to typical antipsychotics including 
extrapyramidal adverse effects. In a relatively large sample size of treatment-refractory 
individuals (N = 235), 1 demonstrated that ultrarapid hydroxylation by CYP2D6 of TAs 
'is not a major cause of failure to respond to treatment with these agents, this being the 
only study published to date on this topic. A suggestive association between CYP2D6 
PM or IM status and a high incidence of adverse effects was shown in a sib pair and a 
twin pair. A case control study, however, revealed no association between CYP2D6 
gene dosage and intolerance to TAs, or drug-induced parkinsonism, and a trend for a 
positive association (i. e. in the opposite direction to that of previous investigators) 
between the number of functional CYP2D6 genes and tardive dyskinesia. This study 
indicated that CYP2D6 PM status or CYP2D6 gene dosage need not be, in isolation, a 
risk factor for intolerance to typical antipsychotics (particularly in the case of 
haloperidol), or specifically DIP or TD. Differences between my findings and those of 
previous investigators were discussed. It is possible that my finding of a trend for an 
association with number of functional CYP2D6 genes and TD, direction of effect the 
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opposite to that of other investigators, may indicate that there is a real association at 
this locus with TD, the association being with an element of the locus as yet untested 
for association with TD (e. g. a promoter polymorphism) in linkage disequilibrium with 
CYP2D6 metaboliser status, or a nearby locus in linkage disequilibrium with CYP2D6. 
This latter explanation would be analogous to the hypothesis proposed by Lerer & 
Macciardi (2002) to explain the discrepancies in direction of effect (short versus long 
allele) between the results of different allelic association studies between a serotonin 
transporter promoter polymorphism (5-HYTLPR) and response to antidepressants. 
The fact that both the treatment-refractory study and the treatment-intolerant study 
yielded results in the opposite direction from that predicted may reflect the relatively 
high proportion of subjects prescribed haloperidol in these studies, and the fact that the 
precise steps in haloperidol metabolism that CYP2D6 is involved with are at present 
ý. , unclear, but may include the oxidation of reduced haloperidol back to haloperidol, with 
an inverse correlation between reduced haloperidol levels and clinical response 
(Bareggi et al., 1990). Moreover, owing to the more potent inhibition of CYP2D6 by 
phenothiazine antipsychotics as compared to haloperidol (Spina et al., 1991), 
associations between reduced CYP2D6 activity and antipsychotic adverse effects may 
be more likely to be found in the case of the phenothiazines than in the case of 
haloperidol. I suggest that -future studies investigating the association between 
CYP2D6 metaboliser status or gene dosage and adverse effects include the nature and 
dose of the typical antipsychotic as confounding variables in the analysis. 
The next section of Chapter 3 reports a genetic association study of CYP2D6 and 
CYP2C]9 genotypes and response to TCAs. Contrary to previous case reports, in this 
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relatively small sample, a refractory response to treatment with a TCA was not 
associated with CYP2D6 UM status. A larger prospective study is indicated to further 
investigate this association, particularly in the case of UMs who have more than 3 
functional copies of CYP2D6. A significant association was found between the 
corrected combined TCA level and CYP2D6 gene dosage (P = 0.001), and, controlling 
for CYP2D6 inhibition, there was a trend for an association between corrected 
combined TCA level and clinical response to TCA as measured by the percentage 
change in HDRS (P = 0.08). Controlling for CYP2Cl9 inhibition, there was a 
significant association between number of functional CYP2C19 genes and percentage 
change in HDRS (P = 0.016), and between the level of dernethylated metabolite and 
total adverse effect score (P = 0.01). There was also a significant association between 
adverse effect score and CYP2D6 inhibition (P < 0.005). CYP2D6 inhibition (by 
.I concomitant medication) was significantly associated with both response and adverse 
effects., The association with CYP2D6 inhibition, and the suggestions of associations 
between CYP2C19 gene dosage and clinical . response and between demethylated 
metabolite level and adverse effect ratings warrant replication in a larger prospective 
study. If replicated, genotyping for CYP2D6 (including for the CYP2D6*2 allele) and 
for CYP2C19 common variants might assist clinicians in choosing an appropriate dose 
titration regime and in predicting clinical response to TCAs. This would be consistent 
with the recommendations of Kirchheiner et al. (2001), suggesting dose reductions of 
approximately 50% fbrýpoor metabolisers of CYP2D6 or CYP2Cl9 in the case of 
TCAs. 
The next section of Chapter 3 reports a trend towards an excess of the CYPIA2 G-3591 
allele in those with a poor response to clozapine, but no association with the CYPIA2 
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intron 1 polymorphism. Although no data on cigarette smoking for this sample was 
available, and an early report (Sachse et al., 1999) indicated an association between the 
intron 1 C-1 64 SNP and CYP 1 A2 inducibility by smoking, a more recent report indicates 
that this polymorphism does not appear to influence the effect of smoking on clozapine 
levels (van der Weide et al., 2003). It is, however, possible that clozapine itself may 
induce CYPlA2, and therefore that information on the dose of clozapine and 
controlling for this variable in the analysis is required. I suggest that any future studies 
investigating putative associations between CYPIA2 polymorphisms, and response to 
clozapine should include collection of information on the dose of clozapine, duration of 
treatment, concomitant medication, and level of smoking, as well as genotyping for 
other CYP1A2 polymorphisms. The only factor that emerged as significantly associated 
with response was gender, consistent with the higher CYPIA2 activity in males as 
compared to females. The mechanism of the effect of oestrogens on CYPlA2 is not 
well understood, but by analogy with the effects of other steroids on regulation of gene 
expression, may be exerted by a transcriptional effect on the CYPIA2 promoter. It is 
then possible that a CYP1A2 promoter variant that is associated with the inhibition of 
il 
CYPlA2 by a variety of agents including oestrogens might be associated with 
clozapine response. The T-3591G SNP might be in linkage disequilibrium with such a 
I 
variant. The trinucleotide repeat region that I have identified, (AAQ6 at -4382 to - 
4399, warrants investigation as a candidate for functional variation, and further 
mutation screening of the CYPIA2 promoter, including the XREs and regions that are 
conserved across species, and could be involved in the transcriptional effect of 
oestrogens, could yield interesting data. 
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Chapter 4 describes mutation screening of part of the CYPIA2 5' flanking region, and 
the identification of a T-3591G substitution, a G-3595T substitution, and a T-3605 insertion 
(Aitchison et al., 2000a). Genotyping revealed a significantly higher frequency of the 
G-3591 allele in Taiwanese as compared to Caucasians and African Americans. 
Functional characterisation of the G. 359, and T-3595 variants, and the combination of the 
two, was undertaken, which revealed that the T-3595 variant was associated with a 
s ightly higher constitutive CYPIA2 promoter activity. However, this was only by a 
factor of 1.2, which is unlikely to be of significance in vivo. There did not seem to be 
any functional consequence in terms of TCDD-induced activity for the mutations 
tested. Therefore, although novel variants in the 5' flanking region were identified, 
they did not appear to have a functional consequence. 
Genome walking with sequencing, and sequencing of a BAC clone revealed sequence 
discrepancies compared with the sequence published by Quattrochi & Tukey (1989) 
and my 532 bp novel 5' flanking CYPIA2 sequence. Comparison versus GENBANK 
sequence AF253322 revealed the presence of a trinucleotide repeat, (AAC)6, and a 
poly-T and a poly-A sequence in my sequence versus the GENBANK sequence, and 
three possible SNPs. These may represent polymorphic, sites, or, alternatively, 
sequencing errors in the GENBANK sequence owing to the method employed 
I 
("shotgun cloning! '), and the likely instability of the microsatellite and poly-T and poly- 
A sequences. Further sequence analysis across this region is required to confinn these 
potentially polymorphic sites, followed by functional studies as indicated. 
Chapter 5 describes a study of clozapine pharmacokinetics and pharmacodynmnics in 
CYPlA2-null mice, which showed that CYPIA2 contributes significantly to the 
demethylation of clozapine in vivo, with CYPIA2 being the major determinant of 
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clozapine clearance in wild-type mice. After clozapine administration, the CYPlA2- 
null mice were significantly more drowsy, showed more motor impairment, and had 
more myoclonus than the wild-type mice. This suggests that in patient groups in which 
CYPIA2 is relatively low in activity (Orientals, Blacks, female non-smokers) that it 
would be wise to use a slow dose titration procedure for clozapine and other CYPlA2- 
metabolised drugs, monitoring carefully for the emergence of concentration-depen4ent 
adverse effects. 
6.2 Methodological issues in pharmacogenetics research 
,_ Much of the world-wide research effort in pharmacogenetics has so far been 
disappointing, and in this respect, the results of some of my studies (e. g. investigating 
the number of functional CYP2D6 genes and response to typical antipsychotics) are not 
unusual. There are a number of methodological issues that may have contributed to 
this, as has been discussed by various authors (Hodge 1994; Elston 1998; Malhotra and 
Goldman 1999; Paterson et al., 1999; Veenstra-VanderWeele et al., 2000), and include 
heterogeneity in clinical, genetic, and statistical methodology employed by different 
research groups, and the complexity of the phenotype of drug response. All of these 
issues are well illustrated by studies on the pharmacogenetics of extrapyramidal side 
effects (EPS) including tardive dyskinesia (Lerer et al., 2002), and also by studies on 
the pharmacogenetics of clozapine response (discussed in Aitchison & Gill, 2002). 
6.2.1 Heterogeneity in clinical methodology 
Heterogeneity in clinical methodology between different studies refers to the variation 
in diagnostic criteria employed, clinical scales used, length of washout periods, qtc. 
For example, Vandel et al. (1999) and Chou et al. (2000), and my studies on TA 
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adverse effects including DIP and TD differed in that the samples of Vandel et al. and 
Chou et al. were mixed in terms of diagnosis and drug (including non-psychotic 
illnesses and e. g. antidepressants as well as antipsychotics), and the clinical ratings 
(EPS assessment using the Simpson-Angus scale plus clinical examination and 
interview to diagnose dystonia or akathisia according to the Leo (1996) criteria for 
Vandel et al., Simpson Angus Scale for Chou et al., Webster's Rating Scale for 
Parkinsonism and the AIMS for TD for my sample). The mixed nature of the samples 
might well be relevant to the difference in findings, as the association between adverse 
drug events and CYP2D6 gene dosage may be stronger in the case of antidepressants 
than in the case of antipsychotics (Chen et al., . 1996). Similarly, Armstrong et al. 
(1997) and Scordo et al. (2000) studied a variety of movement disorders, including 
parkinsonism and dyskinesia in the case of the former, and dystonia, parkinsonism, and 
TD in, the latter, whereas I separated out DIP and TD cases for the purpose of the 
analysis. There is also the issue of whether or not the diagnosis of TD was made by 
more than one assessment; two sequential clinical assessments, at least three months 
apart are necessary to fulfil the Schooler & Kane (1982) criteria for persistent TD, and 
few studies (e. g. Kapitany et al., 1998; Andreassen et al., 1997) have complied with 
this, most assessing at one time point only, which can give only a diagnosis of RDC 
probable TD. Finally, there is the issue of heterogeneity in terms of which 
antipsychotics were prescribed, which could in fact be the most important factor in 
accounting for discrepancies in findings (sections 3.2.3.3 and 3.2.4.2.3). 
6.2.2 Heterogeneity in genetic methodology 
Examples of heterogeneity in genetic methodology include the use of phenotyping (e. g. 




-5 and gene amplification by RFLP analysis in Arthur et al., investigated (CYP2D6*3 
(1995); CYP2D6*3-5 in Armstrong et al. (1997); CYP2D6*3-7 in that of Andreassen et 
al. (1997); CYP2D6*3-5 in that of Kapitany et al. (1998); CYP2D6*3-4, and *10 in 
Ohmori et al., 1998; wild-type, reduced activity, and non-functional alleles including 
CYP2D6*2-6 and *9-10 in Vandel et al. (1999); CYP2D6*10 only in Lam et al. (2001); 
and CYP2D6*2 in Ohmori et al. (1999); CYP2D6*3-6 and gene amplification in 
Scordo et al. (2000); CYP2D6*3-5 and gene amplification in my study). My study and 
those of Arthur et al. (1995) and Scordo et al. (2000) are the only studies to date to 
have included assaying for CYP2D6 gene amplification events. Of note, in Scordo et 
al. 's study, no difference in the distribution of homozygous EM, heterozygous EM, and 
UM were found between those with and without EPS. Although in their study all 4 
(out of a total N of 119) PMs had a history of EPS, they acknowledged that concluding 
that there was an association between PM status and EPS was premature, owing to the 
I 
small number of PMs. Of note, the 3 PMs in my study (N = 72) had neither DIP nor 
TD., The apparent association between PM status and EPS in Scordo et al. (2000) 
study and the absence of such an association in my study could then have occurred by 
chance, owing to the small numbers of PMs in both studies. 
6.2.3 Heterogeneity in statistical methodology 
Heterogeneity in statistical methodology refers to, for example, whether a parametric 
(using e. g. total AIMS score) or categorical analysis (e. g. using presence or absence of 
TD, defined as probable or persistent) is conducted, and whether or not effort is made 
to control for confounding variables. Most groups (Andreassen et al., 1997; Kapitany 
ft al., 1998; Ohmori et al., 1998 and 1999; Lam et al., 2001; my study) have conducted 
a categorical analysis (mostly using RDC probable TD); some (Arthur et al., 1995; 
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Ohmori et al., 1998 and 1999; my study) have employed parametric analysis using total 
AIMS score, or, in the case of Kapitany et al. (1998), total Tardive Dyskinesia Rating 
Scale score; others (my study and Ohmori et al., 1998) have additionally used an AIMS 
score of at least 6, or mean AIMS score in different genotyping categories (Andreassen 
et al., 1997; Ohmori et al., 1998 and 1999; Scordo et al., 2000), or AIMS score of at 
least 4 (Armstrong et al., 1997). For those studies that have included an analysis by 
AIMS score, three have been negative (Arthur et al., 1995; Ohmori et al., 1999; my 
study), and only one positive (Ohmori et al., 1998). As to controlling for confounding 
variables, this was performed using logistic regression and/or linear regression analysis 
by Ohmori et al. (1998,1999), and my study, but not by other investigators. These 
differences in statistical approach may have contributed to the different conclusions 
reached (see Section 3.2.4.2.3. ). 
A further statistical issue is the question of power: the power of my sample to test the 
hypothesis by logistic regression was 0.999 for the 72 subjects rated for probable TD 
(using values from the data of- affected proportion 0.18, odds ratio 4.86, Rý = 0.0469, cc 
= 0.05), and 0.96 for the 66 subjects rated for persistent TD (affected proportion = 0.17, 
odds ratio = 3.49, Rý = 0.0348, cc = 0.05; calculations performed using NCSS 2000). 
Comparable sample sizes were used by Andreassen et al. (1997; N= 100), Ohmori et 
al. (1998,1999; N= 100), and Scordo et al. (2000; N= 119,15 affected with TD), but 
relatively small samples were used by Arthur et al. (1995; N= 16 affected with tardive 
dyskinesia only), Kapitany et al. (N = 45), and Lam et al. (N = 38 affected with TD, 38 
without TD). It would appear that none of the samples studied to date had sufficient 
power to adequately address the question of the possible contribution of CYP2D6 
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variants to the genesis of EPS including TD, especially if consideration is also to be 
made regarding a possible interactive effect of CYP2D6 with other loci. 
6.2.4 The complexity of the phenotype 
Apart from heterogeneity in methodology in the studies of the pharmacogenetics of 
EPS including TD, the inconsistent nature of the findings may well be related to the 
complex nature of the phenotypes being addressed. Subtypes of EPS include DIP, 
dystonia, akathisia, and TD, and different groups have included different subtypes as 
discussed above. Furthermore, within subtypes, there may be subdivisions; for 
example, for TD, risk factors include high. lifetime antipsychotic exposure, presence of 
a movement disorder, negative symptoms, cognitive impairment, diabetes, alcohol or 
drug abuse, female gender, smoking, age (in most studies), and, in some studies, 
affective disorder (Kane & Smith, 1982; Kane, 1992; Yassa & Jeste, 1992; Wolf et al., 
1983; Kane et al., 1986; Woemer et al., 1991; Caliguiri et al., 1991; Waddington 
1995a; van Os et al., 1997; Muscettola et al., 1993 and 1999; Sections 3.2.1 and 
3.2.4.2.3). Different candidate genes can be postulated to be contributing to different 
subtypes of TD, Le. TD may be genetically heterogeneous. Thus, for example, it may 
well be that the TD associated with movement disorder, cognitive impairment, and 
negative symptoms should be subjected to a separate pharmacogenetic analysis from 
that associated with, for example, smoking. Polymorphisms in different candidate 
genes may interact, each contributing a small proportion to the total variance observed 
in the phenotype (i. e. polygenic inheritance), which may lead to false negative findings 
(type I errors). Furthermore, Quinn et al. (2001) report that the prevalence of 
involuntary movements approaches 100% over a lifetim6 trajectory for individuals with 
schizophrenia chronically medicated with TAs. The point at which one samples 
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subjects for a pharmacogenetic association study of TD then becomes crucial: too early 
and not enough individuals may have passed through the age of association of risk with 
the particular genetic risk factor(s) being investigated, and too late and the number of 
affected individuals becomes so great that association with any putative genetic risk 
factors is masked. 
6.3 The pharmacogenetics of the future: pharmacogenomics 
With the advent of the "new genetics, " the term pharmacogenomics has arisen, which 
has been variously defined (Housman & Ledley, 1998; Persidis, 1998; Regalado, 1999; 
Rioux, 2000; Masellis et al., 2000; Aitchison & Gill, 2002), but encompasses the 
application of genomics to the study of pharmacogenetics, or pharmacogenetics in a 
postgenomic era (i. e. after the availability of the draft sequence of the human genome). 
Although the two terms are often used interchangeably, it may be useful to try and 
retain the distinction between the two. 
Pharmacogenetics is the study of the relationship between definable genetic factors 
(polymorphisms or mutations) and clinical drug response endophenotypes, with the aim 
of generating information that may lead to rational drug prescribing, based on 
individual genetic profile. Pharmacogenomics may be considered a branch of 
functional genomics. The availability of the draft sequence of the human genome and 
recent advances in molecular genetics means that there is now an unprecedented 
opportunity to study all genes in the human genome, including genes encoding drug 
metabolising enzymes, drug targets, regulatory mechanisms, and post-receptor 
messenger machinery in relation to drug safety and efficacy (Ozdemir, Shear, & 
Kalow, 2001). Pharmacogenomics includes the utilisation. of techniques such as high 
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throughput genotyping of genome-wide markers in order to identify genomic 
"hotspots" corresponding to susceptibility loci contributing to response or adverse 
effect profiles by linkage and/or association. It also includes bioinformatic analysis of 
- the wealth of sequence data now available, in order to 
identify novel sequence variants 
I in or near candidate genes, followed by experimental confirmation of such variants, 
with functional characterisation (for example of variants in promoter sequences, 5' or 
3' untranslated regions, or intronic sequence and their impact on levels of gene 
expression / mRNA splicing). More recently, it has been shown that gene expression 
microarrays can be used to correlat6 patterns of gene expression (upregulation or 
downregulation) with drug effect or toxicity - this has been termed "transcriptome 
profiling, " and has been employed with some promising results (Alen, 2001). 
The short-term goal of pharmacogenomics is the same as pharmacogenetics, that is, to 
elucidate how individual genetic make-up influences the response to or side-effects of a 
particular drug (Masellis et al., 2000). A methodological difference between the two 
fields is that pharmacogenetics is hypothesis driven, requiring a priori knowledge of 
drug.,, phannacology, whereas (e. g. in the search for genomic - "hotspots"), 
pharmacogenomics may not be. The long-term vision of pharmacogenomics is that the 
discovery of genetic influences on drug action will lead to the development of new 
diagnostic procedures and therapeutic products that enable drugs to be prescribed 
selectively to patients for whom they will be effectiveý and safe (Housman & Ledley, 
1998). In the US, in 1994, adverse drug reactions (ADRs) were between the fourth 
and sixth leading cause of death amongst hospitalised patients (Lazarou et al., 1998). 
The expectation of pharmacogenomics is that subgroups of patient populations might 
be identifiable - those who are likely to respond better to a given drug than the rest of 
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the population, and those who are less likely to. have an ADR - and that drugs will then 
be able to be selectively marketed to those patient groups (population segmentation or 
stratification by genetic profile). This could lead to significant cost savings, both in the 
cost of drug development, and costs to the individual and to the health care provider. 
Clinical trial design might become more efficient and drugs might reach the market 
faster, and stay there'longer (Spallone & Wilkie, 1999). If a patient could be identified 
as being unlikely to respond well to a given drug, then the cost of months of ineffective 
treatment - costs both personal and economic - could be avoided. Similarly, those at 
high risk of an ADR for a given drug could be saved resulting morbidity or even- 
mortality. Pharmaceutical companies might even resurrect drugs that have been taken 
off the market, if subgroups of patients who were at risk of the particular offending 
ADR could be identified and excluded. from, the prescribing license. For example, 
consider the ADR of agranulocytosis on clozapine treatment (section 5.4), which has 
the consequence of prescription in the USA and UK under a restricted license, with 
strict haematological monitoring., If the subgroup of patients likely to be at high risk of 
agranulocytosis could be identified, then this patient group could be excluded from the 
prescribing license, with the result that haernatological monitoring might not be 
required for the rest of the population prescribed clozapine, or be required at a lower 
monitoring frequency. This, of course, would require a test for susceptibility to 
agranulocytosis with a high level of sensitivity and specificity. 
6.4 Suggestions for future directions in pharmacogenetics/genomics 
- 6.4.1 Study design. 
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From consideration of the methodological issues, a number of recommendations may 
be made regarding future pharmacogenetics and pharmacogenomics studies. Firstly, 
the design of the clinical data set is crucial. Prospective studies that are specifically 
designed for pharmacogenetic or pharmacogenomic analysis and include the power and 
rigor of design necessary to test phannacogenetic hypotheses are most likely to yield 
informative data (Pickar and Rubinow, 2001; Masellis et al., 2000). Ideally, 
standardised diagnostic interviews should be used, a clearly defined washout period 
should be employed, with prior treatment response and baseline symptom level 
recordings, and prospective recordings of clinical response and adverse effects using 
standardised rating instruments should be made at predefined, theoretically justifiable 
time points. In addition, the drug dose and plasma drug levels (both serially, at 
,- different response times) should be determined, and details of standard demographic 
variables (age, sex, and ethnicity), other clinical variables (e. g. age at onset of 
diagnosis, comorbid diagnosis, family history, symptom complex), and any others 
pertinent to the psychotropic drug being evaluated should be detennined. Exclusion 
criteria should be defined a priori, as should the criteria for clinical response (e. g. mean 
change in clinical score over time, controlling for baseline, Basile el al., 1999). 
6.4.2 Statistical issues 
Secondly, some recommendations regarding statistical issues may be made. In the case 
of pharmacogenetic studies, calculations of sample size required for adequate power 
should also be conducted a priori, taking into consideration allele frequencies for the 
specific polymorphisms to be examined, and the number of candidate genes to be tested 
(Masellis et al., 2000). This may not, however, be possible for pharmacogenomics 
studies, in which e. g. marker allele frequencies (particularly in disease populations) 
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may not be known. Similarly, it may be appropriate to define a priori an appropriate 
significance level given the number of candidate loci and hypotheses to be tested. 
Finally, in the data analysis, the relative effect size contributed by each candidate gene 
polymorphism should be estimated (Masellis et al., 2000). 
In order to control for population stratification, methods such as the Transmission 
Disequilibrium Test (TDT; Spielman & Ewens, 1996), or "Genomic Control" (GC; 
Bacanu et al., 2000), or the method of Pritchard and colleagues (Pritchard & 
Rosenberg, 1999; Pritchard et al., 2000) may be used. The TDT has been extended for 
use with quantitative traits (and response to drug treatment measured on a linear scale 
may be viewed as a quantitative trait), is resistant to confounding (Allison, 1997; 
,,, Rabinowitz et al., 1997), and has particularly high power if the most extreme 20% of 
the phenotypic distribution is selectively sampled. However, adequate sample sizes 
may be difficult to attain, given that it can be difficult or impossible to collect clinical 
information and DNA from parents of relatively old affected individuals, and also, with 
TDT, only heterozygous parents are informative. Whenever parents are homozygous, 
- the genotyping data are effectively useless, with consequent loss of study power. An 
alternative TDT approach to the standard parent-child trio uses samples of sibling pairs 
to test for association (Spielman & Ewens, , 
1998). 
The analysis may also be improved by genotyping for a number of different 
polymorphic sites at loci of interest, so that haplotypes may be constructed. Some high 
throughput genotyping strategies (especially those' involving pooling) may not 
automatically yield haplotype data, but using haplotype estimation maximization 
algorithms (Long et al., 1995), it is possible to assign haplotypes. Usually haplotype 
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analysis provides the benefit of more information about the likelihood that a particular 
gene is associated with the phenotype of interest, and has been perfort-ned with success 
(e. g. haplotype analysis of the P2-adrenergic, receptor gene and response to 
bronchodilators, Drysdale et aL, 2000). The power and validity of haplotype-based 
analysis is increased by the grouping of haplotypes according to their most likely 
common origin (Templeton et al., 1987). A detailed haplotype analysis of the exon 3 
VNTR of the DRD4 (dopamine D4 receptor) gene has been provided (Ding et al., 
2002). 
"Genomic Control" refers to the use of 20-60 SNPs spread throughout the genome 
(Devlin & Roeder, 1999); Bacanu et al., 2000), in order to generate an estimate of the 
degree of population stratification in an apparently homogeneous population. The 
method of Pritchard and colleagues (Pritchard & Rosenberg, 1999; Pritchard et al., 
2000) is similar, but uses 15-20 unlinked microsatellite markers, in a method that has 
greater power to detect stratification than biallelic markers such as SNPs- 
6.4.3 Candidate pathway analysis 
Thirdly, there are recommendations to be made in regard to the candidate genes chosen 
for analysis. Both pharmacokinetic and pharmacodynamic genetic factors should be 
investigated, as well as genes that appear to be of aetiological significance in the 
relevant disease process. An illustration of this is candidate pathway analysis (Craig & 
McClay, 2002), in which, for example for a pharmacogenetic analysis of response to 
proserotonergic antidepressants, one might include the genes involved in serotonin 
synthesis and breakdown, in addition to the serotonin transporter and regulators of 
serotonin transporter response (e. g. the presynaptic 5HTIA-receptor, Smeraldi et al., 
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1998; Kelsoe et al., 1998). This suggestion, though, may lead to the inclusion of a 
large number of candidate genes (e. g. BDNF, Stahl, 2000; third messenger systems 
such as kinases; other neurotransmitter systems functionally connected to the 
serotonergic system, Schafer, 1999; etc. ), and a balance may have to be struck between 
what is desirable to investigate and what is practical, given the sample size and power 
considerations. If possible, a hierarchy of which genes are presumed to be "better 
candidates" than others should be constructed, using the existing literature, which will 
not be easy unless pilot phannacogenetic studies have been conducted. 
6.4.4 Open system approaches 
Some of the most interesting results to date (reviewed in Chen et al., 2001; Wang et al., 
2001; Rohlff, 2001) in the field of pharmacogenornics have come from the use of open 
system approaches, and it may be that significant effort should be expended in the 
employment of these. "Opený' system approaches are "open" rather than "closed" in 
that they are not hypothesis-driven, and hence have greater potential for truly novel 
discoveries regarding the mechanisms of psychotropic drug action. Such open system 
approaches include genome-wide scans, differential gene expression studies, and 
proteomic approaches. 
1 
6.4.4.1 Genome-wide scans 
In pharmacogenomic genome-wide scans, all potential genes are evaluated for 
association with a psychotropic phenotype, using markers spaced throughout the 
genome. These markers may be microsatellite markers (historically used e. g. for 
linkage analysis, and previously at a spacing that gave incomplete coverage of the 
gcnome), or singlc nuclcotidc polymorphisms (SNPs). SNPs arc the most common 
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genetic variant in man (Schork et al., 2000), occurring at a density of approximately I 
per, 1000 bp when comparing two unrelated individuals; a genome-wide, map of SNPs 
has been published (International SNP Map Working Group, 2001), and is continuously 
being updated. It has been estimated that approximately 30,000 SNPs are sufficient to 
undertake a genome-wide scan (Collins et al.,, 1999); however, this view has been 
questioned (Weiss & Terwilliger, 2000). The density of SNP markers required depends 
on the average degree of linkage disequilibriurn extending from each SNP. The work of 
Reich et al. (2001) suggested that linkage disequilibrium extended 60 kb from common 
alleles in a sample of subjects of Northern European descent in the United States, and 
was similar in a Swedish sample, but a much smaller degree of linkage disequilibrium 
(LD) was found in a Nigerian sample. ý This paper has, however, been criticised by 
Weiss & Clark (2002), who commented that the LD estimate for the Nigerian sample 
was inaccurate due to inequality in sample size between this and the Caucasian 
samples, degree of inbreeding, and method of SNP ascertainment. 
6.4.4.2 Differential gene expression studies 
In open differential gene expression studies, all the genes expressed in a system such as 
a cell or a specific brain region (transcriptome) may be profiled. Two methods have 
been used to date for such studies: differential display polymerase chain reaction (DD- 
PCR), and expression microarrays. Most of the studies to date have been conducted in 
animals. 
DD-PCR provides a comprehensive approach to identifying genes that are differentially 
expressed at the mRNA level, especially when relatively small changes in gene 
expression are expected. In this technique, total RNA is reverse-transcribed to cDNA 
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using an 'anchored' oligo(dT) primer (Liang et al., 1994). The cDNA is then amplified 
. and radiolabelled 
in a series of reactions, each using one 3' anchored primer and an 
arbitrary oligonuclcotidc as the second primer. The use of an arbitrary, rather than 
specific primer, results in the amplification of as many different mRNA species as 
possible. Matching reactions (i. e. generated with the same set of primers for all 
experimental RNA samples, in duplicate) are then run sidc-by-sidc on a denaturing gcl, 
and the bands analysed. Bands exhibiting different intensities between experimental 
treatment groups (e. g. samples treated with a specific psychotropic agent versus 
untreated) represent candidate transcripts with altered expression levels, which are then 
subjected to further analysis. Findings are then validated by performing e. g. real-time 
PCR and in situ hybridisation, and further integrative studies may be conducted in 
order to establish the relationship between the molecular/cellular changes and facets of 
the therapeutic response being studied (Ikonomov & Manji, 1999). 
DD-PCR has been used by several laboratories to study the effects of mood stabilisers 
(such as lithium and valproate) on gene expression (Chen et aL 1999a, 1999b, 2001; 
Hua et al., 2000; Wang et al., 1996,1999a, 1999b), which has led to interesting results, 
including the identification of a novel lithium-regulated gene (Wang et al., 1999b) and 
unexpected targets of the long-term actions of mood stabiliser genes, such as the 
cytoprotective protein human B-cell lymphoma protein-2 (bcl-2; Chen et al., 1999b). 
There are now available expression microarrays (Affymetrix, Santa Clara, CA, 
GeneChip R Human Genome U133 set), that cover most of the human transcriptome 
(over 106 oligonucleotides, covering more than 39,000 transcript variants, representing 
more than 33,000 human genes). These high density microarrays, with at least 300,000 
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polydeoxynucleotides per array (Lipshutz et al., 1999), allow the analysis of large 
numbers of human expressed sequence tags (ESTs), each EST being represented by 16- 
20 pairs of specific 25-mer oligonucleotides (each probe pair containing a perfect 
match and a mismatched oligonucleotide). Total RNA is reverse-transcribed into 
cDNA, then transcribed into cRNA in the presence of fluorescent label, which is 
hybridised to two identical microarrays, and the signal patterns analysed (Strakhova & 
Skolnick, 2001). The employment of multiple probe pairs is to improve the specificity 
of the experiment, more than half of the perfect-match probes having to produce a 
hybridisation signal in order for the hybridisation to a particular gene sequence to be 
considered real. The presence of mismatched oligonucleotides facilitates efficient 
subtraction of non-specific hybridisation and background signal. It is generally 
accepted that the GeneChip arrays; are able to detect changes in mRNA expression of at 
least 2-fold (Strakhova & Skolnick, 2001), although it is possible that sensitivity may 
extend down to 1.4-fold with modification of the method of analysis Q DeBellaroche, 
presentation at Davos, February 2002). Therefore, while microarray technology 
presents an attractive alternative to labour- and time-consuming DD techniques, its 
application to finding unknown sequences and modest changes in gene expression 
levels (1.5-fold or less) is likely to be problematic (Strýkhova & Skolnick, 2001). 
Nonetheless, if used as a complement to DD, it may reveal genes that are coregulated 
with those identified by DD. Indeed, this technique has been successfully used to show 
that genes coding for a particular system or pathway (e. g. a neurotransmitter pathway) 
are differentially expressed in concert (Hakak et al., 2001; Mimics et al., 2000). In the 
field of neuropharmacology, it has identified genes differentially expressed in the rat 
brain following treatment with the antidepressant sertraline (Yamada et al., 2000), and 
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on exposure to Aý-tetrahydrocannabinol (the primary psychoactive agent in cannabis) 
(Kittler et al., 2000). There is evidence that the brain is the organ that exhibits the 
greatest degree of complexity of gene expression (Colantuoni et al., 2000), and hence 
pharmacogenomics studies using differential gene expression methodologies hold great 
promise. 
6.4.4.3 Proteomics and neuropsychopharmacology 
A review of the application of proteornics to the study of neuropsychiatric disorders has 
been provided recently (Rolff, 2001). Proteomics describes techniques that aim. to 
profile all proteins expressed in a particular system (e. g. a cell, body fluid, or tissue). 
The gene expression profile in terms of transcripts may not equate to the proteomic 
profile because gene transcription and protein expression are often not unambiguously 
linked and may be regulated separately (Guygi et al., 1999), including e. g. post- 
translational protein modifications, and also,, in the case of postmortem samples, 
postmortem delay in human brain tissue affects mRNA more than protein (Edgar et al., 
1999). Current proteomic approaches include 2-dimensional gel electrophoresis, mass 
spectrometry, and protein chip arrays (Senior, 1999; Parekh & Lyall, 2000). In 
neuropsychopharmacology, these may be applied to the study of cerebrospinal fluid 
(CSF) proteins (Sharma et al., 1997; Thompson et al., 1999), plasma (Milller et al., 
1997), and CNS tissues (Davidsson et al., 1999; Greber et al., 1999; Johnston-Wilson 
et, al., 2000). However, to date most of these applications have been studies related to 
neuropsychiatric, disease , aetiology rather than to psychotropic drug response. 
Proteomics is at present under-explored in neuropsychopharmacology, but is predicted 
to lead to more selective and efficacious treatments (Lieberman, 2000), including the 
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development of both novel therapeutics and second-generation compounds derived 
ýorn an improved understanding of the mechanisms of action of existing therapies. 
6.5 Projects arising from work conducted in this thesis 
Mutation screening of CYP2D6 by DHPLC in samples with genotype-phenotype 
discrepancy from my studies is being undertaken. So far this has revealed two subjects 
with an IlelO9Val amino acid substitution, which would appear to be associated with 
reduced CYP2D6 activity (Tandon et al., 2002a). 
I have extended my study on the pharmacogenetics of antidepressant response to 
include subjects on other antidepressants, and pharmacodynamic candidate genes, as 
well as drug metabolising enzymes. I am also involved in a proposal for funding under 
- the European Framework 6 Programme (FP6), which proposes to use functional 
,. . -,. , genomics and proteomics 
in order to - identify genomic loci and their functional 
t, correlates corresponding to clinical response to antidepressants. 
A large sample (N>250) individuals chronically treated with typical antipsychotics, 
who have been rated for TD using the AIMS (Abnormal Involuntary Movements Scale) 
according to the Schooler and Kane criteria (1982), is being amassed through 
collaborations. Using this sample, Dr Tsapakis, under my supervision, will be 
extending the pharmacogenetic association study of tardive dyskinesia to include other 
relevant phannacodynamic and drug metabolising candidates. 
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Failure to respond to treatment with typical antipsychotics is not 
associated with CYP2136 ultrarapid hydroxylation 
Katherine J. Aitchison, ' Janet Munro, ' Padraig Wright, 2 Shulabade Smith, 2 Andrew J. Makoff, ' 
22 Christoph Sachse, 3 Pak C. Sham, Robin M. Murray, David A. Collier' & Robert W. Kerwin' 
I Section Clinical Neurophannacoloqy, 2 Department of PsycholqqicalAtedicine. Institute of Psychiatry, De Cresp(qny Park, Denmark, Hill, 
London SE5 8AF and 3 Institute oý Clinical Phannacology. University Clinic Chariti, Humboldt University tf Berlin, Berlin 
Aims To investigate whether or not there is a correlation between failure to respond 
to typical antipsychotics and CYP2136 ultrarapid metaboliser status. I 
Methods CYP2D6 phenotype (metaboliser status) was assigned following genotyping 
for gene duplication, as well as for the CYP2D6*3, CYP2D6*4, and CYP2D6*5 
null alleles in 235 treatment-refractory patients and 73 nonrefractory patients. 
Results Four (1.7%) of the 235 treatment-refractory subjects were positive on the 
duplication assay, but, of these, two were found to represent duplications of a null 
allele (CYP2D6*4), therefore leaving only two (0.85%) positive for duplication of 
a wild type allele (ultrarapid metabolisers). Three (4.1%) of the nonrefractory subjects 
had a genotype consistent with ultrarapid metaboliser status. Fisher's exact test gave 
a two-tailed P value of 0.09 1, i. e. a trend towards an excess of ultrarapid metabolisers 
in the nonrefractory group, which was in the opposite direction to that predicted 
by our hypothesis. 
Conclusions Although the results show a trend towards an excess of ultrarapid 
metabolisers in the nonrefractory group, the percentages in the two groups of 
patients are both within the range for ultrarapid metabolisers in Caucasian 
populations. Our data are not consistent with ultrarapid metaboliser status being a 
major cause of failure to respond to typical antipsychotics. 
Keyipords: CYP2136, genotype, metabolism, pharmacokinetics. treatmctit-rcfractory. 
typical antipsychotics 
Introduction 
The cytochrome P450 enzyme CYP2D6 is a polymorphic 
enzyme which contributes significantly to the pharmaco- 
kinetics of most typical antipsychotics 111. Between 0.5% 
and 7% of Caucasians have very high enzyme activity 12, 
31 and are known as ultrarapid metabolisers, or UMs- 
This high enzyme activity is due to the presence of 2 or 
more copies of a functional CYP2D6 allele existing in 
tandem on the same chromosome [2,4-61. At the other 
end of the metabolic spectrum are individuals who are 
homozygous for null alleles (poor metabolisers or PMs), 
representing about 7-9% of most Caucasian populations. 
The remainder of the population (excluding PMs and 
UMs) arc known as extensive metabolisers (or EMs). 
Two patients with ultrarapid metaboliser status have 
Correspondence: Dr K. Aitchison. Section Clinical Neuropharmacology, Institute 
of Psychiatrlý De Crespigryy Park. Denmark Hill. London SES BAF 
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been described for whom tricyclic antidepressants at doses 
beyond the usual therapeutic range were required in 
order to achieve a therapeutic response 141. Up to 30% 
of patients with schizophrenia who arc prescribed typical 
antipsychotics arc treatment-resistant 171. The tcrm 
trcatment-rcsistant includes those who are treatment- 
refractory (show inadequate clinical response) and those 
who are treatment-intolerant (exhibit adverse responses). 
We hypothesized that patients with schizophrenia who 
were refractory to treatment with typical antipsychorics 
would be more likely to be ultrarapid mctabolisers, as 
compared with patients who responded to typical 
antipsychotics. If the hypothesis were confirmed, it could 
form the rationale for a prcprescribing genotyping assay 
to predict patients who would be less likely to rcsponý 
well to typical antipsychotics at standard doses, and 
therefore assist the process of clinical dose finding and/or 
the more rapid progression of such patients on to an 
atpyical antipsychotic not subject to the CYP2D6 
polymorphism. 
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Methods 
Our 235 treatment-refractory subjects came from a 
sample of 246 patients treated with clozapine in the 
United Kingdom (UK). All of these patients were resistant 
to treatment with typical antipsychotics, and had a 
diagnosis of schizophrenia or schizoaffective disorder 
(clozapine prescribing restrictions in the UK, UK Clozaril 
Patient Monitoring Service). Prescribing consultants pro- 
vided dam regarding whether their patients were refractory 
to typical antipsychotics, intolerant of typical antipsy- 
chotics, or both refractory and intolerant of typical 
antipsychotics. Out of the 246 patients on clozapine there 
were a total of 235 who were refractory, or refractory 
and intolerant to typical neuroleptics. The standard 
definition of treatment-refractory schizophrenia has been 
provided by Kane et al. [71: (1) at least three periods of 
treatment in the preceding 5 years with antipsychotics 
(from at least two different chemical classes) at doses 
equivalent to or greater than 1000 mg day- I of chlorpro- 
mazine for a period of 6 weeks, each without significant 
symptomatic relief, and (2) no period of good functioning 
within the preceding 3 years. Data regarding which 
typical antipsychotics had been prescribed were not 
available. However, the most commonly prescribed 
typical antipsychotic prior to switching to cIozapine 
in the UK for the period during which our sample 
was collected was haloperidol (Novartis, personal 
communication). 
Our comparison group, nonrefractory to typical anti- 
psychotics, comprised 73 patients from the Maudsley and 
Bethlem, Royal Hospitals NHS Trust. Sixty-six of these 
had been treated with various antipsychotics, mostly 
haloperidol (approximately 60%) or fluphenazine, at doses 
equivalent to at least 100 mg -chlorpromazine daily for at 
least 12 months prior to assessment and had DSM-IIIR 
schizophrenia. Information regarding duration of treat- 
mcnt was not available for the remaining seven subjects, 
but six had been treated with the equivalent of at least 
100 mg chlorpromazine daily, while the remaining patient 
received 15 mg flupenthixol decanoate by depot injection 
fortnightly, the equivalent of 75 mg chlorpromazine daily. 
Six of these seven subjects had a clinical diagnosis of 
schizophrenia; one had a diagnosis of affective psychosis. 
As the patients were treated with a variety of antipsy- 
chotics, we converted all the prescriptions to chlorproma- 
zine equivalents according to British National Formulary 
guidelines, in order to assess whether or not there was a 
relationship between the magnitude of the dose and the 
CYP2D6 genotype. 
Ethics Committee approval was obtained for the study 
on all subjects, and, as there were insufficient numbers of 
non-Caucasians in the sample for the analysis to be 
informative, all non-Caucasians were exclude4. 
DNA was extracted from blood collected in EDTA 
tubes using the Nucleon 11 kit (Nucleon Biosciences, 
UK). CYP2D6 gene duplication was detected by the 
long-PCR method of Lovlie and colleagues 181, using 
the Expand Long Template PCR System (Bochringer 
Mannheim, UK), and primers 5-TCCCCCACTGAC 
CCAACTCT-3' and 5ý-CACGTGCAGGGCAC 
CTAGAT-Y. The PCR was performed in a final volume 
of 25 P including 2.5 [LI Bochringer buffer 1,4.5 V1 of a 
2 mm solution of each dNTP, 0.5 iil of each primer 
(10 I. Lm solutions), and 0.25 ul of Boehringer enzyme mix 
(Taq/Pwo). Boehringer buffer I contains 20 mjA Tris- 
HCI PH 7.5,100 mm KCI, 1 mm dithiothreitol, 0.1 mAl 
EDTA, 0.5% (v/v) Tweenik 20,0.5% (v/v) Nonidetp, 
P40,50% glycerol (v/v), and 1.75 mm MgCl,. Cycling 
conditions were modified as foHows: initial denaturation 
for 2 min at 94' C, 35 cycles of 93* C for 10 s, 60" C 
for 30 s and 68* C for 5 rrdn, followed by an elongation 
step of 68* C for 7 min. 
As cases have been described in which there arc extra 
copies of a nonfiinctional or null CYP2D6 allele 18-101, 
it is necessary to assay for nonfunctional CYP2D6 alleles 
as weH as for the presencc of a duplication event in order 
to confirm ultrarapid metaboliser status. We therefore 
assayed for the CYP2D6*3, CYP2D6*4, and CYP2D6*5 
null alleles. CYP2D6*4 and CYP2D6*5 are the most 
common and next most common null alleles, respectively-, 
analysis for CYP2D6*4, CYP2D6*5, and CYP2D6*3 
should detect 90-95% of null allcles in a European 
Caucasian population 111-131. 
The CYP2D6*3 and CYP2D6*4 point mutation alleles 
were detected by PCR. followed by restriction enzyme 
digestion as in the method of Smith et al. [141, with 
rninor modifications. For the CYP2D6*3 assav , primers 
5'-ATGAGCTGCTAACTGAGCCC-3' and 5'-CCGA 
GAGCATACTCGGGAC-3'were used in a total reaction 
volume of 25 ýd containing 10 mm Tris-HCI pH 8.3, 
50 mm KCI, 0.001% (w/v) gelatin, 3 mm MgCl,, 0.2 mm 
each dNTP, 0.25 tim each primer, and 1.25 U AmpliTaq 
(Perkin-Elmer, UK). Cycling conditions were: initial 
denaturation at 94 "C for 3 min, 30 cycles at 95' C for 
I min, 60' C for 30 s, and 72' C for I n-dn. followed by 
final elongation at 72* C for 10 min. PCR, products 
were digested using Hpall, and anal- 
ysed on a 3% agarose gel, together with a lkb ladder 
(Gibco BRQ. For the CYP2D6*4 assav, we used 
primers 5-GCCTTCGCCAACCACTCCG-3' and 
5ý-AAATCCTGCTCTTCCGAGGC-3' and the same 
conditions as for CYP2D6*3, except a MgCl, conccn- 
tration of 1.5 mm. PCR products were digestcd with 
BstNI and analysed on a 3% agarose gel as above. 
The CYP2D6*5 gene deletion allele was assayed by 
long-PC& using the GeneAmp XL PCR kit (Perkin 
Elmer, UK) by the method of Steen and colleagues 1151, 
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using primers 5'-ACCGGGCACCTGTACTCCTCA-Y 
and 5ý-GCATGAGCTAAGGCACCCAGAC-3'. PCR 
was performed according to the manufacturer's instruc- 
tions using Ampliwax8 beads to facilitate a hot start and 
a 100-0 reaction volume with 200 ng genomic DNA, 
1 xXL reaction buffer, 0.2 mm each dNTP, 0.3 [Lm each 
primer, 1.1 mm Mg(OAc)2 and 2U of the rTth/Vent8 
DNA polymerase mixture. The XL reaction buffer 
contains Tricine, K(OAc), glycerol, and DMSO (concen- 
trations not given by the supplier). Cycling conditions 
were: initial denaturation at 93* C for Imin, 35 cycles at 
93" C for I min, 65" C for 30 s, 68" C for 5 min, and a 
final elongation at 72' C for 10 min. 
Two casei were positive on both the CYP2D6*4 and 
the duplication assays. These were further tested to 
determine whether the null or the wild type allele was 
duplicated as described by Sachsc et al. [101: a further 
duplication assay was performed with primers as described 
by Johansson et al. [161, giving a 10kb amplicon in 
cases positive for a duplication, which was then subjected 
to a nested PCR followed by digestion with Hphl. 
The primers for the Johansson et al. assay 
were 5ý-GCCACCATGGTGTCTTTGCTTTC-3' and 
5'-ACCGGATTCCAGCTGGGAAATG-3', and we 
modified the conditions by perforn-dng the assay with the 
Expand Long Template PCR System (Boehringer 
Mannheim, UK), using a total reaction volume of 25 VI 
with 2.5 1A of Boehringer buffer 1,4.5 ýd of a2 mm 
solution of each dNTP, 0.5 ýLl of each primer (10 ýLm 
solutions), 0.37 0 of the Taq/Pwo enzyme mix, and 
200 ng of genomic DNA. Cycling conditions were: initial 
elongation of 94* C for 2 min; 10 cycles of 93" C for 
10 s, 60* C for 30 s, 68" C for 12 n-dn; 20 cycles of 93* C 
for 10 s, 60* C for 30 s, and 68' C for 12 min with a 15 s 
increment per cycle; and a terminal elongation step of 
68" C for 7 min. The product of this reaction was then 
diluted 1 :5 and subjected to nested PCR using primers 5'- 
TCAACACAGCAGGTTCA-3' and 5-CTGTGGT 
TTCACCCACC-3'. The reaction volume was 65 ýJ, 
containing 10 mm Tris-HCl pH 8.3,50 mm KCI, 1.5 mm 
MgCl,, 0.16 mm each dNTP, 0.1 [tm each primer, and 
0.2 U ArnpliTaq. The cycling conditions were: initial 
elongation at 94'C for 2 min, 25 cycles of 94'C for 30 s, 
58*C for 10 s, 720C for 1 min, and a final elongation 
step of 72'C for 7 min. The products were digested with 
Hphl and separated on a 3% agarosc gel. 
The results were analysed using SPSS for Windows 
and Epilnfo Version 6 (Centers for Disease Control and 
Prevention, USA and World Health Organization, 
Switzerland). 
Results 
CYP2D6 genotype and deduced phenotype for the 235 
subjects refractory to treatment with typical antipsychotics 
390 
vs the 73 responsive to typical antipsychotics are given 
in Table 1. Of the 235 treatment-refractory subjects, four 
(1.7%) cases were positive on the duplication assay. 
However, two cases yielded a CYP2D6*41wt result with 
the CYP2D6*4 assay and a positive result with the 
duplication assay; these cases were found to represent 
duplications of the CYP2D6*4 allele. As these cases 
possessed only one functional copy of CYP2D6, they 
were deduced to be phenotypically equivalent to hetero- 
zygous null cases and hence extensive metabolisers, not 
ultrarapid metabolisers. Therefore only two out of 235 
cases (0.9%) were positive for duplication of a wild type 
allele. In contrast, of the sample of 73 nonrcftactory 
patients, 3 (4.1%) were positive for the duplication assay, 
of which none was positive for the null alleles tested. 
The results were therefore in the opposite direction to 
that predicted by our hypothesis, but they did not reach 
significance: Fisher's exact test was performed, comparing 
the presence or absence of UM status in the two clinical 
groups, which gave a two-tailed P value of 0.091. (Chi 
square was not appropriate here, with the number of 
cases being less than 5; with Fisher's exact test the one- 
tailed and two-tailed values were identical, but the value 
is reported as two-tailed as the results were in the 
opposite direction to that predicted by the hypothesis). 
Table 2 shows the distribution of the alleles with allele 
frequencies in the two clinical groups, with the results 
being reported under the assumption that the duplication 
allele is present in the heterozy ous state. If this allele .9 
were present in a homozygous state in all cases in which 
it was found, then the frequencies of the wild type and 
null alleles in the treatment-refractory group would be 
unchanged, while that of the duplication allele would be 
doubled at 0.0085; the frequencies of the wild type, null, 
and duplication alleles in the nonrefractory group would 
be 0.71,0.25, and 0.041, respectively. However, as in 
the paper by Johansson et al. none of their cases with 
a duplication allele was homozy ous for this variant, we .9 have assumed that all of our cases are heterozygous. The 
frequencies of the CYP2D6*4, CYP2D6*5, * and 
CYP2D6*3 alleles, respectivelv, in the sample of 235 and 
73 were: 0.223,0.024, and 0.018 (in the sample of 233), 
and 0.219,0.02, and 0.02 (in the sample of 73). 
Comparing the presence or absence of the duplication 
allele in the two groups, Fisher's exact test gave a two- 
tailed P value of 0.10 (Table 2). 
Discussion 
We did not find an excess of ultrarapid metabolisers in 
subjects refractory to treatment with typical antipsychotics. 
On the contrary, only two out of 235 (0.9%) treatment- 
refractory cases were positive for duplication ofa wild- 
type allele, while three out of 73 (4.1%) nonrefractory 
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CYP2D6 duplication and typical antipsychotic resistance 
Table I CYP2D6 genotype and 
deduced phenotype in subjects refi-actory EM PM UM 
to treatment with typical antipsychotics (wt/wt) or (Wt/mut) (Mut/Mut) (dup f -t) 
and nonrefractory to treatment with 
typical antipsychotics; numbers of cases Pic-fractory to TAs (n - 235) 220(93.6) 13(5.5) 2 (0.9)* 
given with percentages in parentheses. Non-rcfractory to TAs (Ps=73) 67(91.8) 3(4.1) 3 (4.1)* 
TAs, typical antipsychotics, wt, wild type, mut, nonfunctional mutant or null allclc (includes 2 
duplications of mut in the EM group), dup of wt, duplication of wild type allcle. *Two-tailcd 
P-value for presence or absence of UM status in refractory vs nonrcfractory group= 0.09 
(Fisher's exact test); odds ratio-0.2,95% confidence limits 0.02-1.80. 
Table 2 Distribution of CYP2D6 alleles in the treatrnent- - 
refractory and nonrefractory groups; allele numbers given, with 
frequencies in p*arentheses. The CYP2D6*4 x2 allele is included 
in the null alleles. 
Duplication of 
Wild type Ivull u4ld type 
Refractory to 343 (0.73) 97 (0.26) 2(0.0043) 
TAs 
Non-refractory 103(0.72) 37(0.26) 3 (0.021)* 
to TAs 
TAs, typical antipsychotics. *Two-tailcd P-value for presence or 
absence of duplication allele in refractory Ps nonrefractory groups= 
0.10 (Fisher's exact test); odds ratio - 0.21,95% confidence limits 
0.02-1.88. 
cases were genotyped as ultrarapid metabolisers. This 
gives a trend (P=0.091, Fisher's exact test) towards an 
excess of ultrarapid metabolisers in the nonrefractory 
group of patients. However, both percentages are within 
the range for ultrarapid metabolisers in Caucasian popu- 
lations 12,3,6,10]. Two cases of CYP2D6*4 duplications 
were found, which is the second time this has been 
reported in Caucasians, Sachse and colleagues [101 having 
provided the first report. 
The results demonstrate that ultrarapid hydroxylation 
by CYP2D6 of typical antipsychotics is not a major cause 
of failure to respond to treatment with these agents. 
There are at least five possible explanations for this 
surprising result. Firstly, we could have failed to find a 
significant result when there is in fact a significant 
association of ultrarapid hydroxylation either with treat- 
ment-refactory status (the direction of the original hypoth- 
esis), or with treatment nonrefractory status (the direction 
of the trend found). The odds ratio (OPQ for UM status, 
counting the treatment-refractory group as the 'diseased 
state' and the nonrefmctory group as the 'nondiseased 
state', was 0.2, with exact lower and upper 95% confidence 
limits of 0.02 and 1.8, respectively (Table 1). This means 
that ultrarapid metaboliser status is less associated with 
being treatment-refractory than with being nonrcfmctory, 
with the range extending to being more associated with 
treatment-refmctory. Of note the two patient sample 
groups are unequal in size; if we had had as many in the 
treatment nonrefractory group and the percentage of 
ultrarapid metabolisers in this group had remained the 
same as in our current findings, then we would have 
found 10 ultrarapid mctabolisers in the nonrefractory 
group, which would have given a chi square of 5.47, a 
P value of 0.019, and an OR of 0.19, with exact lower 
and upper limits of 0.02 and 0.92, respectively. In this 
scenario a significant result in the opposite direction to 
our original hypothesis would have been found. 
Secondly, in both of our groups of subjects, the dose 
of antipsychotic was titrated by the prescribing consultants 
according to clinical ' effect. 
This could obscure any 
pharmacogenctic effects, i. e. ultrarapid metabolisers could 
be receiving doses above or at the upper end of the 
normal prescribed range, and then respond as if they were 
extensive metabolisers. However, for the nonrefractory 
group one of the patients with CYP2D6 duplication was 
on only 30 mg flupenthixol decanoate 2 weekly (equival- 
ent to 150 mg chlorpromazine daily, i. e. a low dose). 
Thirdly, although CYP2136 is known to contribute to 
the phan-nacokinetics of many typical antipsychotics I 11, 
the specific contribution is different for different antipsy- 
chorics, and other cytochromes are involved. CYP266 
is involved in the first pass metabolism and systemic 
elimination of perphenazine [171, and the systemic 
elimination of zuclopenthixol [181. For these drugs, high 
CYP2D6 activity would be expected to lead to lower 
serum levels of the drugs, and hence possible therapeutic 
resistance. Although inhibition studies demonstrated that 
CYP2D6 is likely to be involved in the metabolism of 
chlorpromazine [19,201, Muralidhan and colleagues [211 
showed that CYP2D6 makes a relatively minor contri- 
bution to the large interindividual variability seen in 
plasma chlorpromazine levels. 
The systemic elimination of haloperidol has been 
shown by Llerena and colleagues to be dependent on 
CYP2D6 activity [221, and although early reports showed 
that CYP2136 catalysed the oxidation of reduced haloperi- 
dol back to haloperidol [23,241, other work was not 
consistent with this [251, and recent reports [26,271 have 
demonstrated that CYP3A4 is the primary enzyme 
involved in this step in the metabolic pathway. The steps 
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in the metabolism of haloperidol in which CYP2D6 
is involved are at present unclear, but, consistent with 
the results of Llercna and colleagues 1221, Nyberg et al. 
showed that a CYP2136 poor metaboliscr had higher 
concentrations of plasma haloperidol throughout a 4-week 
treatment period with haloperidol decanoate as Compared 
with 7 CYP2D6 extensive meEabolisers [281. Although 
none of the subjects in the study of Nyberg et al. was an 
ultrarapid metaboliser, it would be logical to assume that 
a UM would haye low plasma haloperidol levels. Suzuki 
and colleagues [291 studied the correlation between 
CYP2136 genotype and steady-state plasma concentrations 
(C. ) of haloperidol and reduced haloperidol in a group 
of 50 Japan6se patients with schizophrenia. They found 
that the mean C,, of halopcridol was significantly higher 
(P<0.05) in the patients with I Mutant allcle compared 
with those with no mutant alleles, and that the mean C,, 
of reduced haloperidol was significantly higher (P<0.05) 
in the patients with I or 2 mutant alleles compared with 
those with no mutant alleles. They therefore suggested 
that the C,, of reduced haloperidol was more dependent 
upon CYP2D6 activity than the C,, of haloperidol. 
Howeýer, although they did not find a significant 
difference between the mean Cý, of haloperidol in patients 
with 2 mutant allcles compared to those with no mutant 
alleles, it is of note that in this study the patients with 2 
mutant afleles were either homozygous for the 
CYP2D6*10 allele (n=4), which is associated with 
reduced but not absent CYP2D6 activity, or were 
compound heterozygotes for the CYP2D6*10 and 
CYP2D6*5 alleles (n=2). Hence no patient actuafly had 
2 CYP2D6 null alleles. Lane et al. [301 examined the 
relationship between CYP2D6 phenotype (as measured 
by dextromethorphan/dextrorphan metabolic ratio) and 
haloperidol disposition in 18 newly hospitalized Chinese 
patients with schizophrenia. Despite the fact that no PMs 
were found in this study, significant correlations between 
the metabolic ratio and plasma h2loperidol concentration, 
reduced haloperidol concentration, and reduced haloperi- 
dol/haloperidol ratios were found. In a preliminary report 
of a larger study, Schmider et al. 1311 investigated 
therapeutic drug monitoring data in 178 patients Ps 
CYP2D6 genotype and found that PMs had significantly 
higher reduced haloperidol but not h2loperidol concen- 
trations compared with patients with one or no mutant 
alleles. The suggestion of Suzuki et al. 1291 that CYP2D6 
affects reduced haloeperidol levels at steady-state to a 
greater extent than haloperidol levels might therefore be 
correct. However, Suzuki et al. also suggested, based on 
the work of Tyndale and colleagues [241, that CYP2D6 
catalyses the oxidation of reduced h2lOperidol back to 
haloperidol. As already outlined above, more recent work 
is not consistent with this [25-271, although the precise 
step in the metabolism of reduced haloperidol in which 
CYI112D6 is involved is at present unclear. Young et al. 
125] showed that reduced haloperidol was the preferred 
form in the plasma after the administration of a single 
dose of either haloperidol or reduced haloperidol to 
healthy volunteers. A negative correlation between clinical 
response and reduced haloperidol levels or reduced 
haloperidol/halopcridol ratios has been observed [321; it 
is possible that ultrarapid metabolisers of CYP2D6 could 
have lower reduced haloperidol levels and hence a better 
clinical response. This would be consistent with the trend 
that we have found for an excess of UMs in the 
nonrefractory group. However, Lane et al. [301 -did not 
find a correlation between response and reduced haloperi- 
dol levels, reduced haloperidol/haloperidol ratios, or 
haloperidol levels. This is consistent with analyses by 
other authors [33,341. 
In the case of thioridazine, CYP2D6 catalyses the 
formation of mesoridazine, a metabolite with antipsychotic 
activity [351, and may be involved in the generation of 
another active metabolite, sulphoridazinc. Extensive 
metabolisers have been shown to have higher peak levels 
of mesoridazine and sulphoridazinc than poor metabolisers 
after a single oral dose, with lower levels of thioridazine 
[351. The total serum concentrations of substances with 
antipsychotic activity at steady state will be determined 
by the relative magnitudes oi the equilibrium constants 
of all the reactions in the metabolic pathway; these 
equilibrium constants and the relative antipsychoric 
potencies of the different active metabolites are unknown. 
It is therefore difficult to predict the effect of ultrarapid 
metaboliscr status on clinical response to thioridazine. 
Both of our groups of patients had been treated with 
various typical antipsychotics; it is therefore possible that 
we failed to show a correlation in one direction or the 
other as effects with some anripsychotics vs other 
antipsychotics cancelled each other out. Furthermore, it 
is possible that some patients in the treatment-refractory 
group were treated with agents whose levels are not 
significantly affected by CYP2D6 genotype (such as 
chlorpromazine). However, we would emphasize that a 
significant result would be unlikely to be obscured by 
either of the above possibilities as the numbers of 
individuals with duplications is very low in both the 
treatment-refractory and nonrefractory groups. It is also 
of note that the subject on zuclopenthixol who is an 
ultrarapid metaboliser is clinically stable on a low dose. 
Fourthly, several of the above studies (especially those 
on normal volunteers) were single-dose pharmacokinedc 
analyses; single dose effects may differ markedly from 
those seen at steady state in a situation of pharmacological 
adaptation 1361. However, the work of Nyberg ct al. 
[281, Suzuki et al. 1291, Lane et al. 1301, and Schmider 
et al. [311 was conducted on patients at steady-state. 
Furthermore, jerling et al. 1371 conducted a study on 
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patients during continuous treatment and CYP2D6 
genotype was shown to predict significantly the oral 
clearance of pcrphcnazine and zuclopcnthixol (patients 
with 2 CYP2D6 null alleles having a significantly lower 
clearance than those with one or no mutant alleles). 
Finally, other factors may contribute towards nonre- 
sponse to medication, including noncompliance, pharma- 
codynamic factors, other biological factors, and 
psychosocial factors. Non-compliance occurs in up to 
50% of patients on neuroleptics [381. Pharmacodynamic 
factors have been implicated in the clinical response to 
clozapine, an atypical antipsychotic [391; it may be that 
other pharmacodynamic factors (e. g. 132-receptor variants) 
are involved in the response to typical antipsychotics. 
Lieberman and colleagues [401 and Van Os et al. [411 
have reviewed predictors of outcome in psychotic illness 
and concluded that factors such as longer duration of 
untreated illness, and structural brain abnormality on CT 
or MR1 predict unfavourable outcome, while living in a 
low 'expressed emotion' environment is one of the 
predictors of a favourable outcome. 
We have not found an association between ul=rapid 
metaboliscr status and being treatment-refractory to 
typical antipsychotics. On the con=rv, we found a trend 
towards an association between ultrarapid metaboliser 
status and being nonrefiractory to typical antipsychotics, 
which could have reached significance had our nonrefrac- 
tory group been equal in size to our refractory group. 
Nonetheless, we have not excluded the possibility that 
ultrarapid metaboliser status could lead to failure to 
respond to a standard dose of some typical antipsychorics. 
But as only 0.5% to 7% of Caucasians are ul=rapid 
metabolisers, unless ultrarapid metaboliser status were 
associated with the psychotic illnesses for which the 
antipsychotics were prescribed (in this study, mainly 
schizophrenia), then as treatment resistance occurs in up 
to 30% of cases of schizophrenia, this factor would be 
unlikely to account for the majority of cases of treatment 
resistance. In summary, our data are not consistent with 
ultrarapid metaboliser status being a major cause of failure 
to respond to typical antipsychotics, and are consistent 
with ul=rapid metaboliser status being weakly associated 
with response to typical antipsychotics, especially in the 
case of halopcridol. 
We thank Dr A. K. Daly for the provision of a CYP2D6*5 positive 
control. Katherine J. Aitchison is a Wellcome Trust Clinical 
Training Fellow. Christoph Sachse is supported by BMBF grant 
OlEC9408. 
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CYPIA2 activity has been demonstrated to be bimodally or trimodally distributed In several 
populations, consistent with a codominant or recessive functional genetic polymorphism. 
However, studies aimed at identifying polymorphisms in CYPIA2 have not yet adequately 
accounted for this distribution pattern. To search for functional polymorphisms, we 
performed gcnome-walking, polymerase chain reaction (PCR) sequencing, and cloning, and 
Identified three novel polymorphisms in the 5' flanking region of CYPIA2: a T-3591G 
substitution, a G-3s9ST substitution, and a T-3605 Insertion. The frequency of the T-359IG 
substitution was determined by a PCR-rcstriction fragment length polymorphism assay, and 
found to be significantly higher (P < 0.0001) In Taiwanese (allele frequency 0.128, n= 125) 
compared to Caucasians (0.017, n= 87) or African Americans (0.024, n= 104). The 
functional consequence of the T-3591G and the G-3sgsT substitutions was determined by site- 
directed mutagenesis followed by transient transfection experiments. The T-359IG mutation 
was shown to be nonfunctional, while although the G-3sgsT mutation appeared to result In 
an Increase in promoter activity, this was only to a small degree and therefore unlikely to be 
Important In vivo. In addition, we report 532 bases of 5' flanking sequence further upstream 
than that reported to date, and four sequence discrepancies compared to the original 
published sequence (G-3649CP AT-36so, AA-4072, and C-4093 Ins). Pharinacogenetics 10: 695-704 (D 2MO 
Uppincott W1111ims & Wilkins 
Keywords: cytochrome P450, CYPlA2, promoter, pharmacogenetics, genotype. 
Introduction 
The cytochrome P450 enzyme CYPIA2 plays a 
major role in the metabolism of many commonly 
used drugs, including chlorpromazine, trifluopera- 
zine. clozapine, olanzapine, tricyclic antidepressants, 
zopiclone, tacrine, paracetamol, xanthines including 
Correspondence to Katherine j Aitchison. Clinical Neuropharmacology, I 
Windsor Walk, Denmark Hill, 1, ondon, SE5 RAF, UK 
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Throughout this paper, nucleolides are numbered with the start of translation 
as +1 (position 2804 In GenBnnk accesssion number M31664) in accordance 
with the International nomenclature for human LNPIA2 alleles. available at 
www. lmm. kI. se/LYPalleles. 
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caffeine, and lignocaine (Imaoka et al., 1990; 
Aitchison et al., 2000). It is also involved in the 
metabolism of the neurotoxin 1-methyl-4-phenyl- 
1,2,3,6-tetrahydropyridine (MPTP), which produces 
a parkinsonian syndrome in man (Coleman et al., 
1996), and in the activation of arylamines and 
heterocyclic amines implicated in the genesis of colon 
and bladder cancer (McManus et al., 1990; Boobis et 
al., 1994; Eaton et al., 1995; Hammons et al., 1997). 
There is wide interindividual variation in CYP1A2 
activity (Kalow & Tang, 1991a) which, in most 
studies, has been demonstrated to be trimodally or 
bimodally distributed (Butler et al.. 1992, Lang et al., 
1994; Nakajima et al., 1994; Schrenk et al., 1998; 
0960-314X 31 2000 Lippincott Williams & Wilkins 
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Ou-Yang et al., 2000). Butler et al. (1992) studied 
individuals from Arkansas, Italy, and China, and 
found that CYP1A2 activity was trimodally distrib- 
uted, with the range of percentages in the three 
populations being: 12-13% slow, 51-67% intermedi- 
ate, and 20-37% rapid metabolizers. Nakajima et al. 
(1994) studied the pattern of CYP1A2 activity in 
eight pedigrees, the results of which were consistent 
with genetic polymorphism at a single gene locus, 
with autosomal codominant transmission. At least 
some of the interindividual variability in CYP1A2 
activity is, however, explicable by environmental 
factors. The enzyme is inducible by various dietary 
substances, drugs, and toxins, and including crucifer- 
ous vegetables, heterocyclic amines, polycyclic aro- 
matic hydrocarbons (e. g. 3-methylcholanthrene), and 
heterocyclic aromatic hydrocarbons (including 
2,3,7,8-tetrachlorodibenzo-p-dioxin, or TCDD), caf- 
feine, cigarettes, paracetamol, omeprazole, and carba- 
mazepine (Rost et al., 1994; Parker et al., 1998; 
Aitchison et al., 2000). CYPIA2 may be inhibited by 
lutein (found in leafy green vegetables, Le Marchand 
et al., 1997), grapefruit juice (Fuhr et al., 1993), 
oestrogens and pregnancy (Knutti et al., 1981; 
Rietveld et al., 1984; Abernethy & Todd, 1985; 
Vistisen et al., 1992; Le Marchand et al., 1997), 
quinolone antibiotics (Fuhr et al., 1992), fluvoxamine 
(Brosen et al., 1993), and, in smokers, heavy ethanol 
consumption (Rizzo et al., 1997). Nonetheless, in a 
study of CYP1A2 activity in 786 Caucasians, 
Tantcheva-Po6r et al. (1999) found that 63% of the 
overall variation remained unaccounted for after 
analysis for the major covariates (e. g. coffee con- 
sumption). This finding points to the existence of 
other factors, such as genetic polymorphisms, as 
contributors to the variation in CYP1A2 activity. 
There is evidence for interethnic variation in 
CYPIA2 activity. Butler et al. (1992) found that the 
frequency of rapid metabolizers in nonsmokers was 
20% in 50 Italians and 37%) in 77 individuals from 
Arkansas. Le Marchand et al. (1997) found a sig- 
niflcantly higher mean CYP1A2 activity in 15 Cau- 
casians compared to 45 Japanese. Relling et al. 
(1992) showed that CYPIA2 activity was signifi- 
cantly lower in a group of 63 black subjects in 
comparison to a group of 246 white subjects. Lang et 
al. (1994) found African American smokers had 
CYP1A2 activity approximating that of African 
American or Caucasian non-smokers. Furthermore, a 
study of clozapine levels in 162 Taiwanese found 
mean plasma concentrations 30-50%, higher than 
those reported in Caucasians for equivalent doses 
(Chang et al., 1997). 
Nakajima ct al. (1994), using polymerase chain 
reaction (PCR) followed by direct sequencing, 
Aitchison et al. 
screened the exons, exon-intron junctions, and the 
5' flanking region to -3470 bp in two non-smoking 
poor metabolizers, I non-smoking extensive metabo- 
lizer, 1 smoking poor metabolizer, and 1 smoking 
extensive metabolizer and found no differences in the 
nucleotide sequence between each phenotype. Given 
the indication that factors including genetic poly- 
morphism in CYPIA2 could contribute to CYP1A2 
variability and this negative finding, we decided to 
screen the 5' flanking region of CYPIA2 further 
upstream than -3470 bp. TCDD induces the expres- 
sion of CYPIAI as well as that of CYP1A2, and in 
this case, has been shown to exert this effect via its 
interaction with xenobiotic responsive elements 
(XREs) in the promoter sequence. Two XRE-like 
sequences have been identified in the human 
CYPIA2 promoter, at positions -3382 to -3400, 
and -3037 to -3055 (Quattrochi et al., 1994). 
These sequences were shown to lie within regions 
that contribute to the induction of CYPIA2 by 3- 
methylcholanthrene (Quattrochi et al., 1994). and in 
transient transfections, TCDD was found to induce 
the CYP1A2 promoter (Postlind et al., 1993). How- 
ever, the fold induction is much higher for CYP1AI 
than for CYPIA2 (using a KpnI fragment of CYPIA2, 
-4096/-842), and induction of CYP1A2 was not 
seen in stable transfectants (Postlind et al., 1993). 
We therefore decided to determine the sequence of 
the CYPIA2 5' flanking region that was further 
upstream than -4096, to see whether or not an- 
other XRE could be found. 
Materials and methods 
Study design 
Three sample groups were used for this study. The 
first was 87 Caucasians from the UK. The second 
was 125 Taiwanese, the third was 104 African 
American subjects', the DNA from both of these latter 
groups has been described previously (Wei et al., 
1998). Approval for the study was obtained from the 
Maudsley and Bethlem Royal Hospitals/Institute of 
Psychiatry and King's College Hospital, London (UK) 
Ethical Committees. 
Genome walking 
As the original aim of the study was to search for 
functional mutations in the 5' flanking region of 
CYPIA2 beyond -2.6 kb, primers were designed for 
use with the Genome Walker Kit (Clontech Labora- 
tories Inc., CA, USA). Gene-specific primers cyplabrl 
and cyplabr2 (Table 1) were used together with the 
supplied adaptor primers, according to the manufac- 
turer's instructions in the primary and secondary 
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PCR reactions on the five 'libraries' of uncloned, 
-0 .0 rýj co tv adaptor-ligated genomic DNA fragments. (These five 
'libraries' are produced by digestion of genomic DNA 
with five different enzymes: EcoRV, ScaI, DraI, PvuII, 
Z0-t-- and Sspl. ) The secondary PCR products were purified 
using QlAquick PCR purification (Qiagen Ltd, Craw- 
C0 E2 E ley, West Sussex, UK), and sequenced directly using ZMZ 11 rn -4 ro en -4 -4 1114 Uq 60-90 ng of purified PCR product, standard cycle U0 tj U ýj U ý.; UU 
cu 11 11 11 
5i ... sequencing with primer cypIabr2, ABI PRISM Dye Uý in " Ln M rn Ln in U*) S tn M in U11 Ln Ln Ln M Terminator Cycle Sequencing Ready Reaction Kit 
(Applied Biosytems, UK), and an ABI 377 DNA 
'? sequencer. 
U 
U U PCR sequencing 
DNA was extracted from whole blood samples using 
standard procedures. Primers M1 and M2 (Table 1) 
were used in a final volume of 100 pl with 10 mm 
UU Tris-HCI pH 8.3.50 mm KCI, 0.001% (w/v) gelatin, 
1-5 MM MgC12,0.2 mm each dNTP, 0.5 [tM each 
Ul< primer, and 2.5U AmpliTaq (Perkin-Elmer Applied UU QU Biosystems, Foster City, CA, USA). PCR products were 
purified using a Wizard PCR purification kit (Pro- 
mega Corporation, Madison, WI, USA), and subjected 
to cycle sequencing using primer M1. Sequence com- 
parison was undertaken with the program MacVector Ul (Oxford Molecular Limited, Oxford, UK). 
U U Further mutation identification and cloning 
U 
E-4 US The PCR product of reaction cyplabr2-M5 of African UU American sample number 9 was cloned using the TA U E. 
E- -eý <<UU, U Cloning Kit (Invitrogen Corporation, Carlsbad, CA, UU<UUE- HU U<UUt <t 
U<UU 
USA) with the vector pCR2.1. The protocol for colony 
UUU<UU lysis and PCR was then followed from the PCR-Trap UUU 
Eu E- E-4 manual 
(GenHunter Corporation, Nashville, TN. HUUý 
UUE. U '_1 0U USA), using primers M13R (5'-CAGGAAACAGCTAT UU U< < ut U 1ý GAC-3') and T7 (5'-TAATACGACTCACTATAGGG- UUUU E-0 E-4 
UUU 
V) with annealing at 50 T for 30 s. Clones positive E_ UY E-4 
yYU for the insert were subjected to sequencing using T7. 5 
1-? Yý 1ý 
Cý Zn Zn Zn Ln ZM Zil U-1 Zn Zn ZM ZM Zn Zn Zn The PCR product of reaction M3-M4 of African 
American sample number 43 was also cloned using 
-4 ý. c a C4 (). s r4 %ýo r-4 -z ýD t-ý t-ý NN the TA cloning kit as above. Because sample 43 had 
-4 N ID a*, t" N Ln 1.4 14 NNNN en 00 Ln 00 "N %0 -Z ý. o ý0 %0 'D %. 0 already been shown to be heterozygous for the M rn rn rn en en en rn MMMM rn rn IIIIIIIIIIIII1 T-3591G substitution, we screened PCR products from 
TTITIITITTTTTT the clones using Moll digestion, and sequenced 
NN 00 Ln C: ) ýc en 00 00 rn MM en products that did and did not digest using T7. 00 (71, C1% 114 00 0M ý0 %0 00 00 00 00 MNN in 00 ZV K ýD U-1 tn U-1 Ln Un Ln V, i en rn rn rn rn fln en MM rn M en en PCR-restriction fragment length polymorphism (RFLP) 
test 
A PCR-RFLP test for the T-3591G substitution was 
designed. This involved a nested PCR, the first PCR 
reaction using primers cyplabr2 and cyplabf, the 
second PCR reaction using primers M2 and M3 WW ; 14 (Table 1). Products were digested with Mboll (New -4 (-4 4 -4 
-4 ry) tn England Biolabs, Beverly, MA, USA) and separated EV) CV551 5_ný 601 toý a on a 3% agarose gel. 
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Site-directed mutagenesis 
To investigate the functional significance of the 
T-3591G and G-359sT substitutions, site-directed mu- 
tagenesis was performed using the QuikChange Site- 
directed mutagenesis kit (Stratagene Inc., La Jolla, 
CA, USA) on the pL1A2N plasmid that had already 
been constructed by LQ. This plasmid is approxi- 
mately 10 kb in length, and contains a KpnI frag- 
ment of CYPIA2 (-4096/-842) proximal to a 
luciferase reporter gene (Postlind et al., 1993). 
Site-directed mutagenesis to create the T-3591G 
mutation was performed with primers SDM1F and 
SDM1R (Table 1). Products were digested with DpnI, 
and Epicurian Blue cells transformed. Cells were plated 
on to CircleGrow (BIO 101 Inc., Vista, CA, USA) agar 
plates with ampicillin at 50 ng/ml, the pUC18 control 
reaction being plated in NZY+ broth. Plasmid was 
harvested from cultures grown from single colonies 
using QIAGEN-tips 500 (QIAGEN Inc., Santa Clarita, 
CA, USA). DNA was quantified using a spectrophot- 
ometer. The mutant plasmid was subjected to sequen- 
cing using primer M3, which confirmed correct 
introduction of the mutation, and absence of any 
other differences in DNA sequence from the parent 
plasmid (data not shown). Sequence comparison was 
undertaken with the programme Hitachi MacDNASIS 
Pro version 3.4 (Novex, San Diego, CA, USA). This 
plasmid was then termed SDM1. 
Site-directed mutagenesis to create the G-3s95T 
mutation was performed in a similar manner to the 
above, using primers SDM2F and SDM2R, and the 
resultant plasmid was designated SDM2. A third site- 
directed mutagenesis reaction was performed in order 
to create a double mutant, with both the T-3591G 
and the G-3595T substitutions, using primers SDM3F 
and SDM3R, the resultant mutated plasmid being 
designated SDM3. 
Transient transfections 
HepG2 cells were seeded at 1.25 X 105/ml in 6-well 
plates in complete growth medium with 10% serum. 
The complete growth medium consisted of Dulbecco's 
Modified Eagle Medium and F-12 Nutrient Mix in a 
1: 1 ratio (DMEM/F12,1: 1, GIBCO BRL, Life Tech- 
noIogies Inc., Gaithersburg, MD, USA), with 10 mm 
Hepes, 100 U/ml penicillin, and 100 pg/ml strepto- 
mycin. Cells were grown up for 24h at 37T under 
5% C02, and transfected the next day with 2 pg 
plasmid and 0.5 Rg CMVP (ClonTcch Laboratories 
Inc., Palo Alto, CA, USA), using lipofectamine re- 
agent (Life Technologies), with a1: 8 ratio (mass: - 
mass) of DNA: lipofectamine and OPTI-MEM I (Life 
Technologies) as the serum-free medium. The CMVP 
plasmid expresses P-galactosidase from the human 
Aitchison et al. 
cytomegalovirus immediate early gene promoter. At 
40 h post transfection, one 6-well plate for each 
plasmid was treated with 10 nm TCDD. Sixty hours 
post transfection, the cells were harvested for lucifer- 
ase activity, using a Luciferase Assay System with 
Reporter Lysis Buffer (Promega Corporation, Madi- 
son, WI, USA). The lysates were cleared by centrifu- 
gation for 2 min at 4 *C, and 20 V1 of cleared lysate 
was then assayed for luciferase activity using a 
Lumat LB9501 luminometer (Berthoid, Sci West, 
Arvada, CO, USA). Lysates (50 ýd) were assayed in 
duplicate for P-galactosidase activity using the P- 
galactosidase Enzyme Assay System with Reporter 
Lysis Buffer (Promega Corporation, Madison, WL 
USA). 
BAC clone generation and sequencing 
A human bacterial artificial chromosome (BAC) 
library (Genome Systems Inc., St Louis, MO, USA) 
was screened with a BarnHI/PstI fragment (-808/- 
10, in intron 1). The probe was labelled by random 
priming with DNA polymerase I, large (Klenow) 
fragment using 32P-dCTP (Ready To Go Kit, Pharm- 
acia Biotech Inc., Piscataway, NJ, USA). Labelled 
probe was added to membranes at 2.0 X 106 C. p. M. / 
ml in standard hybridization buffer, and hybridized at 
42 OC overnight. Membranes were washed in 
0.1 X SSC, 0.5% sodium dodecyl sulphate, and ex- 
posed to autoradiographic film overnight at -70'C. 
This procedure generated three positive BAC clones. 
These clones were then further probed with the 
following oligonucleotides: 5-TCTGCCATCTTCTG 
CCTGGTATTCTG-3' (exon 2, positions 52-77), 5'- 
TCTTCCTCTTCCTGGCCATCCTGCTAC-3' (exon 7. po- 
sitions 5238-5264), and 5'-TGGCAGAGCTCTTCCT 
CATGTGTGCAG-3' (5' flanking region, positions 
-1217 to -1245). Two out of the three clones were 
positive on all three hybridizations and were used in 
further studies (BAC7 and BAC8). The presence of 
CYPIA2 in these clones was further confirmed by 
both PCR using primer pair cyplabr2-cyplabf and 
sequencing with primer M1. Clones BAC7 and BAC8 
were then subject to direct sequencing using primer 
CYP1A2.5R (5'-AGCTCGATCATGTGTAGCTTG-3') 
and BigDye Terminator Cycle Sequencing Ready 
Reaction Kit (Perkin-Elmer Applied Biosystems). A 
further primer, CYPIA2.5112 (5'-CATCTTG 
CAGTGGTGTAAT-3'), was designed from the resul- 
tant sequence, and the clones were subject to direct 
sequencing with this primer. 
Statistical analysis 
The results for the T-3591G polymorphism in the 
three ethnic groups were analysed by EpiInfo Version 
6 (Centers for Disease Control and Prevention, USA. 
CYP I A2 pollilmorphism and interetlillic variatioll 
and World Health ort gaiiization, Switzerland). The 
transfection dala HIMINISCLI U. Sing SigillilStilt 2.0 
(SPSS Inc.., Chicago. H, PSA). 
Results 
Genoi ne- walkii ill, PCR svipiciicinli, and cloiiing 
Sequence 1rom ill(- secmidar\, 11CR product of' the Scal 
'library' ol'the Gcnonic Walker kit produced sequence 
which aligned xvidi ill(- 5' flanking sequence of' 
CYPIA2, and reve; ilud the l'ollowing sequence dis- 
crepancies compared with the published sequence: it 
G, "(, ý,, )C Slihstitillioll and ýI T ! (,, (I deletion. We investigated these polcillial polymorphisills by PCR 
sequencing using PCR reactions M2-M ý with se- 
quencing primers NI I and N12, and I'Mind the sanic 
sequence discrepancies ill II CilLICdSiMIS Mid eight 
, raiwanese samples. itirthernmr,, tiesc, discrepancies 
were found ill plasmid pl. lA2N supplied by IA 
which is a dcrival ive oI, plasillid pf 1-1 CAT I, t lie latter 
being the plasmid diat kvýis sequenced by Quattrochi 
and Tuke 
-v( 
1989). and liclice these Sequence dis- 
crepancies are likelv to represent publication errors. 
However, the above IICR sequencing also revealed 
T 
- ýS, )IG SLlhStitllliOlI ill olle of' the 
Caucasians and 
One 01' tile T; fiWilllCSL-. l"UrtIlCr PCR SC(JLlClIClllg Using 
PCR reactions MI XI-I or cyp I ahi-2-Nlý with sequcn- 
cing primers M I, M 1, or MS also reveilled a second 
polymorphic sitc ill the ý' thinking region oF 
CYPI112, a (; ;,, )jT stillstitutioll, ill One 0111 of' a 
l'urther 20 Coucasimis suhiects, 1111-CC OLIt ol' a I'm-ther 
31 Taiwanese subjects, and three out of 10 Afi-ican 
American subjects sequenced. The Caucasian and the 
three Taiwanese subjects were licterozvgous for both 
of' the point mutations (giving an allclc fi-ccluency of' 
0.025 in Ilic Caucasians, and 0.04S in tile I kli- 
wallese), while two of' ille 2\1'ricall Allicricall subjects 
were homozygous for the G substitution (and 
wild-type Ior the T ý,, )I 1. Mid one was liclerozygous 
f'or the G, 
- stihshtution tand wild type 
T- Iýql ). 
WhiCh giVCS M] illICIC I'l-C(IlIC1101 01' 0.25 ill this 
subgroup. The numbers of' samples in the three 
popil lilt ion s for which we have dala oil hoth file 
T- ý5')J G (Ind G I)o1villorphisnis are too small to 
enable calculation of' whether or not tile two I)ol\, - 
morphisnis are in linkage discquilihi-imn. 
Vor two of' tile Atrican Alll(TiCilll SllbjCCIS, SC(ILICIIC(' 
ill the rcverse direction WilS LIM1111higLICIIIS ill tile )" 
elid but From point - ))ooý had tile j1ppe'll-jillee of' txl, () 
scqLICIICeS SllpCTilllJ)oSCd ul)oll each ()tilcl-. ill(lieilling 
heterozygosity for a single hilse insertion or (1cletioll 
ilt that point. This was resolved hV clolling and 
SC(ILICII('illg the PCR prodUCt. whjell I-eVeille(I ii '1' 
insertion at - 160i ill S0111C ClOlICS fi-0111 Af'rican 
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American samples numbers 9 and 43. For sample 
number 43, Alboll digestion showe(I tililt tile, 
insertion and the substitution OCCUrred oil 
diff, cTellt i11101M TIIC T- 1,60i insertion was theref'orc 
I, oulld ill licterozygous State ill two Out 01' 10 Afi-icall 
Americans scqLICIICCd (giving an allele 1requencN, of' 
ill () Out 01,31 Taiwanese Sequenced, and ill 
OLIt 01' 20 CdlICilSiMl. S SC(Illenced. 
PCR-RFI. P Icsting 
We used a PCII-RFIT test to determine the 1recluency 
of' the. T ýý, ), G, substitution in 87 Caucasians. 125 
Taiwanese and 104 At'rican Americans (Fig. 1). 
(These included 12 of' the Caucasians sequenced ; is 
above. and all of' the seque. nced Taiwanese and 
At'rican Americans. ) DNA frorn all subjects that 
appeared to be licterozygous lor the 'r- SLlbStitU- 
tion on PCR-RFLP analysis was sequenced using IICR 
rcactions MI-M4 or cYpIabr2-M5 and primers N/11. 
M3, or M5. in order to confirm genotype. This 
revealed interctlinic variability in the Il-cquency of' 
the polymorphism (Table 2), the 1requency of' the 
G, 
-ý5, ), allele 
being 1111-1ch higher (0.128) in the 
Taiwanese as compared to that in the Caucasians 
(0.017) or the Al'rican Americans (0.024). This 
ditlerence is highly significant The 
genotype 1'requencies ill cach POI)LIliltiOn Were ill 
liardy-Weinberg C(ILlilibl'iLlill. Screening [or the re- 
maining two polyniorphisms was felt to be inap- 
propriate bel'ore their l'unctional significance was 
known. 
'Apo" 
Fig. 1. Aý L, II gar-W gel Cl-ti-OPIMI-Csis ol' Alboll ch, C'stio, () 
X12--NI 1 PCR products. Subjects in lanes I and I are 
IICICFOZN'i eI g011S I01- HIC T ýj, )IG, SUbStillItiOll: All)! CIS il 
lanes 2 and 4 MT IIOIIIOZ. VgOLIS IA'dd-tN'j)C: ill IMIC i iS il 
I kb ladder. 
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Tahle2. (TPIA2 T gcnotypes in Caucasians, 
104 African Amvricans, and 12 ý Taiwanese 
Ib )I IIi)IIII It I let Inut I /mIlo lx, t 
Caucasian 84 
African American 99 
Taiwanese -1 2.1 9-1 
Milt, 111111ant, G ý"', afldc: wi. wild-vvp(" T ; ýqj illIcle. 
Analysis by geiiotvl)(-. compariog IIOIIIOZVgOIIS 1111,11iint 01- 
heterozygous 1111LIU1111 VOI-SUS Wild-IVIA', CMICilSiMIS VVI-Su, " 
Taiwanese: 7.2 1 11 Bv allcle, coniparilig 
Caucasimis versics Faiwaiiesc: 10.0.1) - 0.000 1. For 
African Americims VVI-SLIS gVlIOfVpC, 
Z2= 14.2. P 0.000 1 aild 1) Xý2 16. S, 
1) < 0.000I. For Calwasums vvi-stis African Americans, I)v 
genotype and bý' illIVIL'. FI. SIICl-'S VXiICI ICS1 giXTS it one- 
tailed 11-value of 0.40. 
Transient translections 
We chose to investigate the I'Linctional significance of' 
the T ý,, jj(; and G. mutations ; is diesc %vere 
the more 1'requent A' the mutations identified. The 
results ol'the tnursient Innist'C-clion experiments using 
HepG-) cells showing the cmistitutive (non-induced) 
ICVeIS 01' IUCilcl-ýISC (ITI)ON(T IWOdUCH i1CtiVitV ; 111(1 
induced CIVIM-treatc(l) levels arc shown in Fig. ). 
Comparing Ihe constitutive levvIs ol' luciterase 
ilCti%lity, ILINICH'S test I01- l)()HWgCHCitN' ol' variances 
gave a Bartlett statistic 01,2 ý. 20, and 1) -A 
non-paranictric (Kruskal Wallis) tCS1 was therclore 
used. which gave a Kruskill -Wallis statistic of' W. 5 ). 
with three degrees ot' 1'recdom, and 11 -- 0.00I. ix. 
showing a Significmit dit'lcl-clice between tile Inediall 
Value's of' Illc 1,0111- groups. Dunn's Multiple Compari- 
sons TCSt. COMIMI-ing 111C I-CSHIIS 01' Vildl (4 tile Olliff 
grOUI)S of' trallsk-ctions vel-sus II le Wild-type 
(pI, IA2N) gave a significant dill'Crelicc between 
SDm2 W, and wild-tYpe (P- 0.0i). On visual 
inspection ol' tile (Ijjj; j (J. 'ig. 2), it cini J)e seen tIjjjj tile, 
SDM2 group appcars to have a higher mean lucif, (. 11' 
ase activity than the pI, IA2N gi-OLIJ). HOWCVC1ý. file 
magnitude of' this dillercnce is small (0-72 relative 
light units per millimiii ()I' 1; -galactosidase x to 
ý), 
giving a 1.24old increasc in the nican value for tile 
SDM2 group compared to 1he pI, IA2N group. It is 
possible that this irmislates into a significant l'unc- 
tional dilTerenCC ill but unlikel V. 
Comparing the nican fold induction I'or cach trans- 
I. ection experiment pt-1-torined 1,01- the lour plas'linds 
using the Krusk; d Wallis lest, gave a Kruskal-Wallis 
StiltktiC 01' 4.99. i1nd il P-VýIIHC of' (). 17. This invans 
that there is 1101 a significant (fil'I'LI-ence between tile 










Fig. 2. Results of' transient transt , ections of' lIcp(; 2 cells 
with luciferase reporter ýFeCtol-S (Iollt'lillillg tjIe C')`111,12 
promoter: pIAA2N is the wild-tvpe promoter; SDXII, 
SDM2, and SIAI I were created by sile-directed inutagen- 
esis ol' pI. 1A2N. SIMI conlains the T jj,, jG, substitution. 
SIA12 IIIC G SLII). StilLItiOll, Mid SIAH b0d) HIC 
and the G j;, )jT substitutions. Colls were coli-alls- 
Fected with a CNAV(i plasmid (expressing Ii-galaclosidase): 
results are given as relalive light units (RLIJ) I)CI- 111111il-illit 
(11111) of' j, )_giIlijC(oSi(IijSe X 1() 
1 FlIlle I1(, I)I)_II_eijIe(j g I_OLIPS 
treated will) M mi 2. '). 7.8-teti-iictilot-o(lit)(ýiizo- p- 
dioxin al 40 1) post transi'ection tor 20 h. Mean values 
with standard deviations of' 1-4 translections per group, 
each wit 11 6- 12 replicate wells, are shown. 
fold induction in the four grOLIPS (111CM1 ill(ILICtiOll 
2.6401d). 
Sequencill'(1 o. 1 13AC clones 
Sequencing of' (TPIA2 positive BAC clones was 
undertaken in order to determine the sequence ofthe 
CYPIA2 5' Ilanking region further upstream than 
that previously published. in order to search tor 
another XRF, in this sequence. Scquencing of the 
cN, plabi-2-cyplabf ITR product from clones BAC7 
and BAC8 with primer MI %vas identical to the 
CXpCCtVd pUbliShCd Se(]IICIICC CXCCpt I'01' the G ý(,. Iq(' 
substitution and the deletions already idCIIIi- 
lied as above. thus confirming the presence of 
CYPIA2 in these clones. Oirect sequencing of BAC7 
and BAC8 xvith CYPIA2.5R and CYPIA2.5R2 pro- 
duced the sequence shown in Fig. 3). Both sequences 
differed from that published by Quattrochi and Tukey 
(ITS9) in having an A -, ()72 
deletion, and aC 4(), ), 
insertion (the latter shifting the Kpid 'site FL11-11ICT 5' 
[IV One 1111cleotide). We cliecked this region of 
pl, lA2N (scquenced using primer N/I 1ý. and lound 
that this plasillid also had these sequence discrepan- 
cies compared with the original published sequence. 
The discrepancies therefore represent publication 
errors. We searched the 5 32 bp of novel sequence for 
; ýý Sf)%l I [)%IP 
CYPlA2 polymorphisin and interethnic variation 











Fig. 3. Nucleotide sequence of the CYPIA2 5' flanking 
region further 5' than that yet reported. Sequence from 
-4626 to -4098 represents novel sequence. Discrepan- 
cies ý as compared with the sequence reported by 
Quattrochi & Tukey (1989) are shown: the C-4093 inser- 
tion is underlined, and the A-4072 deletion Is Illustrated. 
XRE sites using MatInspector Version 2.2 (Quandt et 
aL, 1995), and found no XRE motif. 
Discussion 
We have found three novel polymorphisms in the 
CYP1A2 5' flanking region: a T-3591G substitution, a 
G-359ST substitution, and a T-3605 insertion. A PCR- 
RFLP test for the T_3591G polymorphism was used to 
genotype 87 Caucasians, 104 African Americans, 
and 125 Taiwanese (Table 2); this revealed a sig- 
nificantly higher frequency of the G-3591 allele in 
Taiwanese compared to Caucasians and African 
Americans. 
The results of transfection experiments (Fig. 2) 
showed that the SDM2 (G-3595T) group had signifi- 
cantly higher constitutive activity than wild-type, but 
only by a factor of 1.2. This small Increase in 
promoter activity is unlikely to be of functional 
significance in vivo. Of note, if the G-3595T substitu- 
, 
tion were associated with Increased promoter activ- 
ity, 'the direction of effect would be in the opposite 
direction to that predicted by the work of Chang et 
al. (1997), whose data are consistent with the 
existence of a polymorphism causing reduced 
CYP1A2 activity present at a higher frequency in 
Taiwanese compared to Caucasians. We performed a 
search for potential transcription factor binding sites 
in the region of interest using MatInspector Version 
2.2 (Quandt et al., 1995). which showed that both 
the T-3591G and G-3595T polymorphisms lie within 
the putative binding site for CCAAT/enhancer bind- 
ing protein P (C/EBPP, -3582 to -3595 on forward 
strand). C/EBPP Is part of a family of transcription 
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factors, that arc widely expressed (L-ekstrom-Himes & 
Xanthopoulos, 1998), may bind to a variety of sites 
including activating protein-1 sites, may hetero- 
dimerise with other transcription factors including c- 
fos, c-jun, and ATF-2, and has been shown to play a 
crucial role in the regulation of the expression of 
liver-specific genes (e. g. phosphoenolpyruvate carboxy- 
kinase or PEPCK-, Croniger et aL, 1998). It is of 
possible interest that two of the polymorphisms 
(T-359, G and G-3595T) that we have identified lie 
within the C/EBPP binding site, and that the third 
one (T-3605ins) is close. 
Comparison of the TCDD-induced activity of the 
CYPIA2 promoter in the four plasmids revealed no 
significant difference (mean induction 2.6-fold for the 
whole group). In the case of PEPCK regulation, C/ 
EBP binding to a speciflc domain, P3(l), is required 
for the liver-specific (i. e. constitutive) expression of 
PEPCK, whereas its binding to two other domains, 
the cAMP regulatory element (CRE) and the gluco- 
corticoid response unit (GRU) is involved in the 
induced expression. By analogy, it is therefore possi- 
ble that this upstream C/EBPP binding site is involved 
in the regulation of constitutive but not inducible 
CYPIA2 expression, but, again, we feel that a 
rigorous interpretation of our data does not support 
this. 
The functional significance of the T-3605 insertion 
was not tested. However, although this lies within 
the putative binding sequence of a human transcrip- 
tion factor (octamer factor 6, -3601 to -3614 on 
the forward strand or -3597 to -3613 on reverse 
strand), the T-3605 insertion does not alter its core 
recognition sequence. Taken together with the fact 
that the other two nearby polymorphisms do not 
appear to cause a significant functional alteration in 
CYPIA2 promoter activity, we feel that it is also 
unlikely that this polymorphism would lead to a 
change in CYPIA2 promoter activity. Nonetheless. 
even though our polymorphisms appear to be non- 
functional, they may be useful in disease association 
studies, provided that the interethnic variation in 
frequency is taken into account. 
Genome walking and sequencing also revealed two 
other sequence discrepancies compared with the 
sequence published by Quattrochi and Tukey (1989): 
a G-3649C substitution and a T-365() deletion. These 
sequence changes have since been reported by 
Nakajima et a]. (1999). [In Figure 1 of Nakajima et 
al. (1999), they have incorrectly given aC at their 
position -3650 in the sequence of Quattrochi & 
Tukey (1989) when this should be a Tj Of note, 
Nakajima and colleagues also report a C-3484 del- 
etion; we did not find this deletion in any of our 
samples sequenced. It is therefore possible that this 
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represents a further polymorphic site, which is pres- 
ent in Japanese. 
Three polymorphisms in CYP1A2 which appear to 
be associated with a functional change have been 
recently reported; a C-164A substitution In intron 1 
of Caucasians [allele CYP1A2*1F, Macleod et al. 
(1998); Sachse et al. (1999)], a C63G substitution in 
exon 2 of Han Taiwanese [allele CYPIA2*2, Huang 
et al. (1999)], and a G-38s8A substitution in Japanese 
[allele CYPIA2*IC, Nakajima et al. (1999)]. How- 
ever, the CYP I A2 *IF allele was only associated with 
a slightly higher inducibility in smokers when pres- 
ent in the homozygous state; the CYPIA2*2 substi- 
tution was very rare In the population studied and its 
functional consequence was not investigated; and the 
CYPIA2*IC substitution only appeared to be asso- 
ciated with a reduction in CYP1A2 activity in 
smokers. In addition, a recent report (Chida et al., 
1999) has described a T-2464 deletion (allele CY- 
PIA2* ID, frequency 0.42) and a T-740G substitution 
in Japanese (allele CYPIA2*113, frequency 0.082). 
The functional significance of these latter allelic 
variants has not been described. CYPIA2 phenotyp- 
Ing studies have varied in their conclusions as to 
whether the distributions support the existence of an 
underlying genetic component to CYP1A2 variability 
and, although mathematical analysis of phenotyping 
methodology (Rostami-Hodjegan et al., 1996) indi- 
cates that the ratio used by Kalow and Tang 
(1991a, b) should be the most discriminant of bimod- 
ality and independent of the renal clearance of 
caffeine and paraxanthine, experimentally, only 
skewed unimodal or log normal distributions of this 
ratio have been observed (Kalow & Tang, 1991a. b; 
Vistisen et al., 1992; Tang et al., 1994). This may be 
because these studies have been performed mainly in 
Caucasians, and other work (Relling et al., 1992; 
Chang et al., 1997) indicates that there may be a 
higher frequency of CYPIA2 poor metabolizers or a 
lower population mean CYP1A2 activity in other 
ethnic groups. Studies which have supported a 
bimodal or trimodal population distribution of 
CYP1A2 activity (Devonshire et al., 1983: Butler et 
al., 1992: Nakajima et al.. 1994) report a frequency 
of poor metabolizers of 10-14%, in both smokers and 
non-smokers. The CYPIA2 polymorphisms: reported 
to date are not sufficient to account for this apparent 
frequency of poor metabolizers. 
In a recent CYP1A2 phenotyping study 
(Tantcheva-Po6r et al., 1999). using the salivary 
paraxanthine to caffeine ratio (which correlates 
highly with systemic caffeine clearance) In 786 
Caucasians, the maximum likelihood test showed 
that the overall distribution of residuals was best 
described by the sum of two separate normal distribu- 
Aitchison et al. 
tions, with 52% of subjects lying within the first 
normal distribution. Nonetheless, this apparent poly- 
morphism could be equally well explained by non- 
specific deviation from the normal distribution, as 
evidenced by minor skew seen in the P-P plot. 
Indeed, as the bimodal interpretation gives a poor 
metabolizer frequency substantially higher than that 
reported by earlier authors (Devonshire et al., 1983; 
Butler et al., 1992; Nakajima et al., 1994), we 
conclude that this study does not support the ex- 
istence of polymorphism in CYPIA2 in the studied 
population. 
As well as known environmental influences on 
CYP1A2 activity and intrinsic genetic variation, 
there are other possible causes of variation in 
CYP1A2 activity, such as gene-gene interactions. 
Coordinate regulation of CYPIA2 and the UDP- 
glucuronyltransferase UGTI. 6 has been reported 
(Bock et al., 1994). Macleod et al. (1997) reported 
that individuals possessing the glutathione transfer- 
ase GSTMI*O allele had higher CYP1A2 activity for 
both non-induced and induced conditions, while 
individuals having the Ile/Ile CYP1A1 genotype had 
higher CYP1A2 activity in the non-induced state, but 
lower CYP1A2 activity in the induced state than 
those with the Ile/Val genotype. In their studies of 
the colon carcinoma cell line LS180, Li et al. (1998) 
found that the concentration-response curves for 
induction by TCDD or 3-methylcholanthrene and the 
time courses of induction were very similar for 
CYP1A1, CYP1A2, and CYP1B1 [another enzyme of 
the CYP1 family; Shimada et al. (1997)], implying 
that the regulation of these enzymes may occur via a 
common pathway. Indeed, each member of the CYP1 
family is inducible by TCDD via the ary1hydrocarbon 
receptor (AhR) mechanism (Rowlands & Gustafsson, 
1997). In mice, the genetic difference in susceptibility 
of different strains to TCDD-induced toxicity has been 
shown to correlate with polymorphism of the AhR 
(Nebert, 1989; Chang et al., 1993). Polymorphisms 
in the human AhR have been identifled (Garte & 
Sogawa, 1999; Nebert et al., 1999), and it is possible 
that these may affect the inducibility of the CYP1 
enzymes in man. 
There are deficiencies in the studies conducted to 
date that have searched for functional polymorph- 
isms in CYP1A2. Nakajima et al. (1994) sequenced 
the seven exons, exon-intron junctions, and the 5' 
flanking region to -3470 in only five individuals (of 
different phenotypes); in their later paper, Nakajima 
et al. (1999) sequenced -3418 to -4065 in the same five individuals; Welfare et al. (1999) performed 
screening by SSCP of the seven exons, exon-intron 
boundaries, and two upstream regions in only 19 
individuals (of different phenotypes), and sequenced 
CYPlA2 polymorphisin and interethnic variation 
only two; Huang et a]. (1999) sequenced the exons of 
only eight Taiwanese; Sachse et al. (1999) only 
investigated the intron 1 polymorphism. and our 
screening focused on an upstream region, sequencing 
20 Caucasians, 31 Taiwanese, and 10 African Amer- 
icans. We conclude that, first, further phenotyping 
work is warranted in this field, e. g. use of the Kalow 
and Tang (1991a) index of CYP1A2 activity in 
several different ethnic groups, carefully controlling 
for all possible confounding variables and, second, 
this should be combined with screening for func- 
tional polymorphisms In CYPIA2 using reliable 
methods such as PCR-scquencing In a larger number 
of subjects than has been screened by this method to 
date (e. g. 50 from three different ethnic groups), and 
covering regions of CYPIA2 that have not been 
screened. Finally, characterization of the positions of 
CYPIAI and CYPIA2 on chromosome 15 and 
investigation of their possible coregulation, as well as 
the putative coregulation of CYPIA2 with genes such 
as CYPIBI, the UGTs, and GSTs, should prove 
fruitful. 
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Clozapine pharmacokinetics and pharmacodynamics studied with 
CYPlA2-null mice 
Katherine J. Aitchisonl, Michael W. Jann3, Jing Hua Zhao2, Takafumi Sakai4, Hani 
Zaher4, Kim WolfP, David A. Collierl, Robert W. KerwinI and Frank J. GonzaleZ4 
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The aim of this study was to use the CYPIA2-null mouse to investigate the in-vivo contribution of CYPIA2 to 
clozapine pharmacokinetics and pharmacodynamics. An intraperitoneal injection of 10 mg/kg clozapine was 
administered to four male CYPIA2 -/- mice and four male wild-type mice. Clozapine, desmethylelozapine, 
and clozapine N-oxide concentrations in sequential tail blood samples were measured by HPLC with UV 
detection. Behavioural parameters were recorded at each time point. The area under the curve (AUC) of 
clozapine was 2.6 times greater, the clearance of clozapine was 2.6 times slower, and the half-life was 1.2 
times longer in the CYP1A2 -/- mice (p = 0.0143) as compared to the wild-type mice. Sixty-one percent of the 
clozapine clearance in wild-type mice was calculated to be mediated by CYP1A2. The AUC of 
desmethylelozapine was 1.6 times lower in the CYP1A2 -/- mice compared to the wild-type mice (p = 0.0286), 
while there was a trend for the AUC of clozapine N-oxide to be greater in the CYPJA2 -4- mice (p = 0.0571). 
The CYPlA2 -/- mice were significantly more drowsy and showed more motor impairment (p = 0.0145) and 
myoclonus than the wild-type mice. Our results indicate that, in vivo, CYPJA2 is the major determinant of 
clozapine clearance, contributes significantly to the demethylation of clozapine, and has a negligible 
contribution to the N-oxidation. Our data also indicate that CYPIA2 poor metabolizers might be more 
susceptible than extensive metabolizers to dose-related adverse effects of clozapine, such as sedation, 
myoclonus and seizures. 
Key words: clozapine; CYP1A2; cytochrome P450; knockout; metabolism; pharmacodynamics; pharmacoldneties 
Introduction 
Clozapine is an atypical antipsychotic that is employed in the UK in 
cases of treatment-resistant schizophrenia or schizoaffective disorder. 
It is effective in approximately 30-601/a of patients unresponsive to 
typical antipsychotics (YAne el at, 1988; Kane, 1992), but the risk 
of agranulocytosis (0.7% in the first year of treatment, Atkin et al., 
1996) means that regular haernatological monitoring is necessary 
and limits its use to treatment-resistant cases. 
There is wide intcrindividual variation (approximately 10- to 
50-fold) in the plasma levels of clozapine for a given dose (Perry et 
at, 1991; Potkin et at, 1994; Olesen et at. 1995) and several 
studies indicate that clozapine concentrations of at least 
350-420 gg/l arc associated with clinical response (Perry et al., 
1991. Hasegawa et at, 1993; Miller et at, 1994; Potkin et at. 
1994; Kronig el al, 1995). Clozapine is metabo 
' 
lized mainly in the 
liver, with the major metabolites being dc-, mcthylclozapine (or 
norclozapine) and clozapine N-oxide (Jann et at, 1993). There 
have been several in-vitro studies investigating the Toles of the 
hepatic cytochromcs in the generation of these metabolites. 
Eiermann etaL (1997) concluded that CYPIA2 and CYP3A4 were 
both involved in the demethylation of clozapine, and CYP3A4 in 
the N-oxidation. However, Linnet and Olesen (1997) suggested that 
CYP2CI9 and CYP3A4 would each mediate approximately 35% 
of clozapine metabolism at therapeutic concentrations. with 
CYP I A2 mediating only approximately 10%. Tugnait et al. (1999) 
found that CYP I A2 and CYP3A4 both catalyse the demethylation 
and N-oxidation of clozapine, but that CYPIA2 played a more 
important role in the former and CYP3A4 in the latter. 
CYP I A2 and CYP3A4 both show wide intcrindividual variation 
in activity (Aitchison et al., 2000a). Jerling el al. (1997) studied the 
population pharmacokinetics of clozapine and found that the 
clearance of clozapine was distributed in a similar way to indices 
of CYPIA2 activity, indicating that CYPIA2 coui-d be the major 
determinant of clozapine clearance. Most studies have 
demonstrated a trimodal or bimodal distribution to the pattern of 
CYPlA2 activity in a population (Butler et aL, 1992; Lang et al., 
1994; Nakajima el al., 1994; Schrenk el al., 1998; Tantcheva-Po6r 
et al., 1999), with 12-14% of the population being CYP I A2 poor 
mctabolizers. 
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Human and mouse CYPIA2 rescmble each other closely in 
cDNA derived amino acid sequence (Kimura et A, 1984; Jaiswal 
el A, 1987) and in catalytic activity (Aoyama et aL. 1989). Given 
the inconsistencies in the conclusions of the above studies 
regarding the contribution of CYPIA2 to clozapine metabolism, 
we aimed to use the CYPIA2 -4- (null) mouse in order to 
investigate the in-vivo contribution of CYPIA2 to clozapine 
pharmacokinetics. In addition, we used the CYP I A2 -4- mouse as 
a model for CYPIA2 poor mciabolizers, through the use of 
bchavioural ratings aiming to draw conclusions regarding the 
pharmacodynamic effects of clozapine in CYPIA2 poor 
metabolizers. 
Materials and methods 
Materials 
Clozapinc was purchased from Sigma Chemicals Co. (St Louis, 
MO, USA). and dcsmcthylclozapine and clozapinc N-oxidc from 
Research Biochemicals International (Natick, MA, USA). All other 
chemicals were of analytical-grade. available from corrunercial 
sources. 
Animals 
A line of CYP I A2 --/- mice were produced as described (Pincau et 
at, 1995. Buters et at, 1996). The wild-type mice were of the 
same (129/SV) genetic background. These two strains have been 
prcviously characterized in detail (Butcrs et at, 1996). All mice 
were kept in a barrier facility with 2 p. p. m. chlorinated water, 
autoclaved food, and bedding under a 12 h light--dark cycle, 40% 
humidity, with free access to food and water. The animals were 
fasted for 12 It prior to dosing and for the duration of the 
experiment. but allowed water ad libitum throughout. Four male 
CYP I A2 --/- and four male wild-type animals were used. All mice 
had been bom 81 days prior to the day ofthc pharmacokinctic 
study. The study protocol was approved by the Animal Care and 
Use Committee of the National Cancer Institute (National 
Institutes of I Icalth, Bethesda, MD, USA). 
Study design 
A clozapinc solution of I mg/ml was made (clozapine powder was 
dissolved in 0.1 M HCI, neutralized to pH 5-6 with Im NaOl J, and 
made up to I mg/mI with dcionized distilled water). All mice were 
weighed. and at time - 0, a dose of 10 mg/kg clozapine was given 
intraperitoneally. Eight sequential blood samples (each 
approximately 50 pl) per mouse were then taken by tail blood 
sampling at 5,15,30,60,120,240,360, and 480 min post injection 
(the injection times of the mice were approximately 20 min apart 
for case of sampling). The method of tail blood sampling was by 
sequential clipping of the tail (2-3 nun of tail being cut at each 
interval), followed by cauterization to stop bleeding. The blood 
was collected in heparinized tubes (Sarstedt Ltd, Leicester. UK), 
and stored at -80 *C until analysis. Behavioural parameters (degree 
of drowsiness. motor incoordination) were recorded at each time 
point. After the last sample had been taken, the mice were killed by 
carbon dioxide asphyxiation. 
IlPLC analysis 
Clozapine, desmethylclozapinc, and clozapine N-oxide in the 
blood samples were analysed by HPLC with UV detection at 
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254 nm as described (Volpiccili et at, 1993). The recovcry from 
control rat serum at 500 ng/mI of clozapinc, 500 ng/nil of 
dcsmethylclozapine, and 100 ngl; pl of clozapine N-oxide was 78%, 
84%, and 62%, respectively (n =6 samples). A standard assay 
curve was completed and repeated six times using seven data 
points for clozapine of known concentrations in the range 10 ng/mI 
to 1000 ng/mI (r2 = 0.996). The lower limit of detection was 
5.0 ng/ml for clozapine, desmethylclozapine, and clozapine N- 
oxide, and the interassay and intra-assay coefficients of variation 
(CV) were 8.2% and 5.0%, respectively, for all three substances. 
Pharmacokinetic data were calculated using the equation: 
Cl =Dx F/AUC in which CI is whole blood clearance. D is doses 
of clozapine, AUC is the area under the curve, and F is the fraction 
absorbed or bioavailability (model independent pharmacokinetics). 
The AUC was calculated using the linear trapezoidal rule using 
C (concentration) =0 and t (time) =0 and was extrapolated to 
infinity using Axum 5.0 (MathSoft, Inc, Cambridge, MA, USA). 
The half-life of clozapine in blood was calculated by linear 
regression of the In transformed blood concentrations. The percent- 
age of the clozapine clearance mediated by CYP I A2 (O/OCtCYP I AD 
in wild-type mice was estimated by The following relationship: 
I/OCICYPIA2 ý (Clwl a 
in which Clw, is the wild-type clozapine clearance and CL4_ is the 
clozapine clearance in the CYPIA2 -4- mice. This simple 
relationship was used as it had already been established that the 
CYPIA2 -I- and wild-type mice lines did not differ from each 
other in paramcters (such as liver function) that could affect the 
pharmacokinetics of clozapine (Buters et aL, 1996). 
Behavioural effects ratings 
In pilot studies. it was noted that clozapine at the dose administered 
caused drowsiness and motor impairment in the micc. A scale for 
the rating of these effects was therefore devised (Table 1). Mice 
were scored at each time point, just before tail blood sampling. 
Statistical analysis 
Statistical analyses were conducted using SPSS version 8.0 for 
Windows (SPSS, Chicago. IL, USA). 
Table I Scale for rating behavioural effects of clozapine in mice 
Clozapme behavioural cffects ratings in mice 
Drowsiness 
0 Fully alert 
I Eyes half closed at rest 
2 Eyes closed at rest, but easily rousable 
3 Eyes closed at rest, difficult to rouse 
Motor Impairment 
0 Normal posture at rest, move normally in cage on handling 
I Mild splaying of legs at rest, movements slowed and jerky. mild 
reduction in struggle on handling 
2 Moderate splaying of legs at rest, little movement in cage. moderate 
reduction in struggle on handling 
3 Prominent splaying of legs at rest (sprawled), no movement in cage. 
minimal struggle on handling 











Figure I Whole blood clozapine concentration-tinic curves after a 
10 mg/kg intrapcritoncal close of clozapine to male wild-type and 
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Figure 2 Whole blood desmethylclozapine concentration-time curves after 
the 10 mg/kg intraperitoneal dose of clozapine. For the wild-type mice 
at 240 min. the mean of two values is reported (the other two values 
were below the limit of detection, i. e. less than 5.0 ng/ml), otherwise 
the data are mean of four values * SDs 
Results 
The mean weights (with standard deviations) of the wild-type and 
CYPIA2 -/- mice were 23.28 g (3.21) and 27.06 g (3.27), 
respectively. The Mann-Whitney U-test revealed a one-tailed P- 
value of 0.17, i. e. the two groups did not differ significantly in their 
mean weights. (Although mice weight and all the other parameters 
measured would be expected to show a normal distribution in the 
two groups, because there are only four mice per group, we 
consider that nonparamctric testing is more appropriate and more 
stringent than parametric in this instance, and have hence used 
nonparametric testing throughout our analyses. ) 
Table 2 gives the pharmacokinctic parameters of clozapinc, 
desinetliylclozapine, and clozapine N-oxide in the two groups of 
mice, and Figs 1-3 show the concentrati6ns of clozapinc, 
dcsmcthylclozapine. and clozapine N-oxide versus time. The AUC 
of clozapine was 2.6 times greater. the clearance of clozapine was 
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Figure 3 Whole blood clozapine jV-oxidc concentration-timc curves 
(mcan :k SD) after the 10 mg/k& intrapcritoncal dose of clozapinc. 
Values beyond t= 60 min for both wild-type and CYPA2 4- mice were 
below the limit of detection (5.0 ng/ml) 
Table 2 Pharmacokinctic parameters of clozapinc, dcsmcthyl- 
clozapine. and clozapine N-oxidc in male wild-type and 
CYP I A--/- mice after a single 10 mg/kg intraperitoneal dose of 
clozapine (mean ± SD) 
Wild-type 
(n - 4) 
CYPIA2-4- 
(n 4) 
Clozapine AUCO-., ()() (mg/min/ml) 42.9*3.9 111.3 11.1** 
Clozapinc clearance/F (mVkg/min) 0.234 * 0.020 0.091 0.009** 
Clozapine half-life (min) 110.1 * 8.1 129.8 * 3.1 ** 
DesmcthylclozapincAUCO-., Oo(mg/min/ml ) 11.9: k2.7 7.6 A: 2.2* 
ClozapincN-oxideAUCO-. W(mg/min/ml) 2.0+0.2 2.7 ± 0.8 
*One-tailcd P- 0.0286. ** onc-tailcd P-0.0143 (Mann-Whitncy U-test). 
CYPIA2 -/- mice as compared to the wild-type mice. Sixty-onc 
percent of the clozapine clearance in wild-type mice is mediated by 
CYP I A2. For dcsmethylclozapine, the AUC was 1.6 times lower in 
the CYP I A2 -/- mi ce as compared to the wild-type mice, while for 
clozapine N-oxide, although the AUC was 1.4 times greater in the 
CYPIA2 -4- mice, this difference did not quite reach statistical 
significance Q) = 0.057 1). 
The bchavioural effects of clozapine on the wild-typc and 
CYPIA2 -/- mice are shown in Figs 4 and 5. The CYPIA2 -/- 
mice were significantly more drowsy and showed more motor 
impairment than the wild-type mice (p - 0.0145 in both instances, 
Mann-Whitney U-test). In addition, myoclonus was noted in one 
wild-type mouse at t- 240 min, in two CYPIA2 -/- mice at 
t= 60 min, in one CYP I A2 -/- mouse at t= 120 min, and in one 
CYPIA2-/-mouse at t= 120minand att=240min. 
Discussion 
Our results indicate CYPIA2 contributes significantly to the 
demethylation of clozapine in vivo. The finding of a slightly greater 
AUC for clozapine N-oxide in the CYPIA2 -4- mice may be 
explained by the following: in the absence of CYPIA2, with a 
consequent higher concentration of clozapine, more clozapine was 
available to undergo N-oxidation by enzymes other than CYP I A2. 
If CYPIA2 contributes to the N-oxidation of clozapine in mice, it 







Tw" j. 1n) 
" 4(N"4) 
" CP1A2. I. K. (N4) 
T. m (mm) 
Figure 4 Degree of drowsiness versus time after the 10 mgtkg Figure 5 Degree of motor impairmcnt vs. time after the 10 mg/lcg 
intrapcritoncal dose of clozapine. Mice were rated for drowsiness using intrupcritoneal dose of clozapinc. Motor impairment in the mice was 
the criteria given in Table 1. Mean scores * SD are given rated using the critcriu given in Table 1. Mean scores ± SD are given 
must do so only to a very minor degree. These findings confirm the 
in vitry) results of Eicimann et at (1997) and are consistent with 
those of Tugnait et at (1999). In addition, we have estimated that 
in wild-type mice. 61% of the clearance of clozapine is mediated 
by CYPIA2. This result is contrary to the estimation provided by 
Linnet and Olesen (1997), but in accordance with the conclusion of 
Jerling et al. (1997) in man. Our data can be extrapolated to man 
because CYP I A2 expression and catalytic activities are conserved 
between mice and humans (Kimura et al., 1984; Jaiswal et al., 
1987. Aoyama eta/., 1989). 
The bebavioural data show that after clozapine adminstration, 
the CYPIA2-null mice were significantly more drowsy, showed 
more motor impairment, and had more myoclonus than the wild- 
type mice. Clinical data indicate that sedation is the most 
commonly reported adverse effect of clozapinc, occurring in 39% 
of patients (Safferman et al.. 1991). Our data indicate that for a 
given dose or clozapine, CYP I A2 poor metabolizets might show a 
greater degree of sedation than extensive nictabolizers. Myoclonus 
-occurs in 2% of patients on clozapine (Lieberman and Safferman. 
1992) and may progress to generalized seizure activity (Berman et 
al., 1992; Gouzoulas et al., 1993; Meltzer and Ranjan, 1994). 
Seizures are a dose-related adverse effect, the frequency of seizures 
at clozapine doses of less than 300 mg/day, 300-600 mg/day, and 
above 600 mg/day being 1%, 2.7%, and 4.4%, respectively 
(Devinsky et al., 1991). Our data similarly indicate that CYPIA2 
poor metabolizers might be more prone to myoclonus, and 
therefore might be at greater risk of generalized seizure activity for 
a given dose of clozapine. The risk of this and other dose-rclated 
adverse effects could be minimized by titrating the dose up more 
slowly than usual. monitoring carefully for the emergence of 
effects such as, sedation. The fact that the CYPIA2 -/- mice had 
significantly higher levels of clozapine would also imply that 
CYPIA2 poor metabolizers would respond at lower doses of 
clozapinc than extensive nictabolizers. The dose of clozapinc 
employed in this study (10 mg/kg) was chosen as the results of 
preliminary experiments indicated that this dose was necessary to 
achieve informative data for desmcthylclozapine and clozapine N- 
oxide. and would be equivalent to a dose of approximately 700 mg 
or 600 mg clozapine in an average man or woman, respectively. In 
a study of 12 760 clozapine recipients in the UK and Ireland, the 
mean clozapine dose after 12 weeks of treatment was 388 mg/day, 
the mean maximum dose was 462 mg/day, and 41% had a peak 
dose of more than 500 mg/day (Munro et at, 1999). Our study 
indicates that daily doses of greater than 600-700 ing (especially as 
a single dose) should not be used in CYP I A2 poor metabolizers. 
Parallels may be drawn between our study and studies 
investigating the correlation between adverse effects of typical 
antipsychotics and CYP2D6 metabolizer status. In a single dose 
pharmacokinetic study of perphenazine administered to six 
CYP2D6 poor nictabolizers and six CYP2D6 extensive 
metabolizers. the poor metabolizers; reported more adverse cffects, 
especially tiredness (Dahl-Puustinen et at, 1989). Similarly, in a 
study investigating severe adverse effects during the first days of 
treatment with a phenothiazine or haloperidol, CYP2D6 poor 
metabolizers bad a higher incidence or concentration-dependent 
effects, such is oversedation, postural hypotension and autonomic 
effects (Spina et at, 1992). However, concentration-depcndent 
effects tend to reduce with time (Aitchison et at, 1999); in the case 
of clozapinc, patients usually develop tolerance to the sedative 
effects within 4-6 weeks of treatment (Marinkovic et at, 1994). 
Correlations between metabolizer status and concentration- 
dependent effects are therefore most relevant to the initial, dose- 
finding stages of prescribing. 
Other adverse effects or clozapine, such as ncutropenia and 
agranulocytosis. do not appear to be concentration-dependent. Ile 
peak incidence of neutropenia and agranulocytosis occurs within 
the first 6-18 weeks of clozapine treatment, being 1.27% and 
0.7%, respectively, and the risk of both decreases with increases in 
clozapine dose (Munro et at., 1999). The pathophysiological 
mechanism of agramilocyotosis is uncertain, but hypotheses 
include a direct toxic effect on neutrophils or haernopoictic 
precursors (Veys; el al., 1992; Gerson et at, 1994; Deliliers et at, 
1998), and an immunological basis (Pisciottta et at, 1992), the 
latter with a possible genetic predisposition (Lieberman et al., 
1990, Corzo et al., 1995). Desinethylclozapine at high 
concentrations has been seen to have a toxic cffect on the 
precursors of both mycloid and crythroid lineages (Gerson et al., 
1994), and the desmcthylclozapine/clozapine ratio has been seen to 
be inversely correlated with neutropbil count in patients treated 
with clozapine (Mauri el al., 1998). If the fori-nation of 
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dcsmcthylclozapine is primarily CYPIA2-dcpcndcnt. then the 
desmethylclozapine/clozapine ratio should reflect CYPIA2 
activity. This would imply that individuals with relatively high 
CYPIA2 activity could be at greater risk of clozapine-induccd 
neutropenia and agranulocytosis. However, other studies have 
failed to rind an association between desmcthylclozapitie levels or 
dcsmcthylclozapine/clozapine ratio and granulocyte counts 
(Hasegawa el at. 1994; Combs et at, 1997). 
Another hypothesis regarding the mechanism of 
agramilocytosis is that it involves metabolic activation of clozapinc 
with the formation of free radicals which are able to bind 
covalcmlY to neutrophil or bone marrow protein. % then leading to 
agranulocytosis either by a direct toxic (analagous to the covalent 
binding of acetaminophen in the liver, Purnford and Halmes, 1997) 
or an immunological route (rischer et at, 1991; Liu and Uetrecht, 
1995: Maggs et al., 1995, Pirmohamcd el al.. 1995, Gardner et al., 
1998a. b). Chemically reactive metabolites of clozapine may be 
formed by neutrophil mycloperoxidase (Gardner et at, 1998a) or 
by 
, cytochrome 
P450s CYP3A, CYP2C9, and CYP2EI 
(Pirmohamed et al., 1995). The formation of the reactive 
metabolites catalysed by the P450s is reversible (Pirmohamcd et 
at, 1995); under conditions of relatively low CYP I A2 activity, the 
increase in clozapine concentration would be expected to lead to an 
increase in the proportion of clozapine passing down the pathway 
of reactive metabolite formation. If this hypothesis were correct. 
then CYPIA2 poor metabolizer status would be expected to be 
associated with agranulocytosis. However, agramilocytosis and 
CYPIA2 activity do not show the same ethnic stratification. i. e. 
agranulocytosis occurs at a greater frequency in Asians but not 
Orientals or African-Caribbeans compared to Caucasians (Munro 
et at, 1999). while CYPIA2 activity appears to be lower in 
Orientals and Blacks (Relling et al., 1992; Chang et al.. 1997; Le 
Marchand el at. 1997). Nonetheless, it is possible that combined 
enzyme deficiency (e. g. CYPIA2 poor metabolizer status 
combined with a glutathionc S-transferase deficiency) could further 
increase an itidividual's risk for the formation of potentially 
harmful reactive intermediates. This theory is supported by the 
analagous finding of Rojas et at (1998) that smokers with 
combined CYPIAI and glutathione S-transferase MI (GSTMO 
deficiency showed significantly higher levels of activated 
covalently bound metabolites than individuals with CYPIAI or 
GSTM I deficiency alone. 
An allelic variant of CYPIA2. CYPIA2*]C (-3858G to A) 
occurring at an allcle frequency of 0.23 in Japanese (Nikajima et 
at. 1999), which appears to be associated with reduced CYPIA2 
activity in smokers, has recently been identified. Other allelic 
variants, whose functional consequences have not been described. 
have also been reported: CYPIA201D (-2464delT, frequency 0.42 
in Japanese, Chida et at, 1999), CYPIA2*]E (-740T -4 G, 
frequency 0.082 in Japanese, Chida et at, 1999), and CYPIA2*2 
(63C -4 G, frequency < 0.0 1 in Chinese, Huang et at, 1999). In 
addition, three rurther polymorphisms in the CYPIA2 S' flanking 
region have been identified (Aitchison et at, 2000b). Although the 
alleles identified to date would appear not to account for the bi- or 
trimodality of CYPIA2 activity in a population. it is likely that in 
the near future the CYPIA2 allcles responsible for the poor or rapid 
metabolizer phenotypes will be identified. Pre-prescribing 
gcnotyping for CYP I A2 activity would then become feasible. and 
could lead to the judicious use of particularly low doses of 
clozapine and other drugs that are metabolized by CYPIA2. 
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Furthermore, in combination with assays for polymorphisms in 
other drug metabolizing enzymes such as the glutathione 
transferases, genotyping for CYPLA2 activity could yield useful 
information regarding genetic susceptibility to idiosyncratic drug 
reactions such as agranulocytosis. In the mean time. since it is 
known that CYPIA2 activity is lower in Orientals and Blacks 
(Aitchison et at, 2000a), we would suggest that in these groups it 
would be wise to commence with particularly low doses of 
clozapine and other CYP I A2-metabolized drugs, and to use a slow 
dose escalation procedure, monitoring carefully for the emergence 
of conccntration-dcpcndent adverse cffects such as sedation and 
myoclonus. 
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SUMMARY 
Interethnic variation amongst the drug metabolising enzymes 
relevant to the treatment of psychosis is revie,, N-ed. The frequency of 
genetically determined variants at the extremes of enzyme activity is 
seen to vary considerably between different ethnic groups; in addition, 
a shift in the frequency distribution giving an overall lower population 
mean activity may occur. The role of dietary and other environmental 
influences in the generation of interethnic variation in cytochrome 
activity is also discussed. Clinical studies pertinent to this variation are 
reviewed. It is suggested that the reason for conflicting data from 
some clinical studies is the existence of overlapping substrate 
specificity, so that one cytochrome is able to substitute for another. 
Individuals deficient for more than one cytochrome would be likely to 
show much more pronounced clinical effects than those showing 
single cytochrome deficiency. 
KEY WORDS 
ethnicity, pharmacogenetics, metabolism, v. 1ochrome P450, anti- 
psychotics 
INTRODUCTION 
The term pharmacogenetics was coined when adverse drug 
reactions were first attributed to genetic factors /I/. Genetic factors 
affect both drug metabolism (pharmacokinetics) and drug response at 
the level of the target organ (pharmacodynamics). With respect to 
interethnic variation affecting the treatment of psychosis, pharmaco- 
kinetic genetic factors, encoding the drug metabolising enzymes (or 
DMEs), have been far more extensively investigated than interethnic 
variation affecting pharmacodynamic genetic factors. This review will 
therefore focus mainly on the DMEs. 
An important subset of the DMEs is the group of cýlochrome P450 
enzymes (CYPs), or haem-thiolate proteins. These enzymes metab- 
olise not only drugs, but also endogenous compounds (e. g. steroids), 
plant products, and man-made environmental toxins. Three members 
of this family of enzymes have been described to be involved in the 
metabolism of antipsychotics: CYP2D6, CYP3A4, and CYPIA2. 
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Other enzymes in this family, including members of the CYP2C 
subfamily, should also be considered, especially with regard to drug- 
drug interactions. 
1. CYP2D6 
1.1 Genetic variation in CYP2D6 
Four different levels of activity of CYP2D6 have been identified, 
through the use of probe drugs which are metabolised by the enzyme. 
An individual may be termed an ultrarapid metaboliser (UM), extens- 
ive metaboliser (EM), intermediate metaboliser (1, M). or poor metab- 
oliser (PM). This variation in enzymatic activity is due to multiple 
allelic variants of CYP2D6 (the gene encoding the protein), the 
frequencies of which differ in different ethnic groups /2.33 
In Caucasian populations, the frequency of PINIs is 5-10% /4/, 
while in Black Africans the frequency is 0-8% /5-T. in African- 
Americans the frequency is 3.7% /8/, and in Orientals (Chinese, 
Japanese, and Koreans having been studied) the frequency is 
approximately 1% /9-14/. In addition, a lower population mean 
enzyme activity has been observed in Chinese, Zimbabweans, and 
Ghanaians as compared to Caucasians. The low P1114 frequency in 
Orientals is caused mainly by the very low frequency of the 
CYP2D6*4 mutant allele, an allele which is associated with absent 
enzyme activity and accounts for about 66% of PX1 alleles in 
Caucasians /3/. The lower population mean enzyme activity has been 
attributed to the relatively high frequency of CYP2D6*10 in the 
Chinese, and of CYP2D6*17 in the Ghanaians and Zimbabweans, 
both of which alleles being associated with diminished CYP2D6 
activity /15-18/. The CYP2D6*17 allele also occurs at a greater fre- 
quency in African-Americans /8/. Dahl et aL /19/ compared findings 
in a pilot study on Koreans, Chinese, and Japanese, and found that the 
frequency of CYP2D6*10A and CYP2D6*]OB was somewhat lower 
among the Koreans than among the Chinese or Japanese. Therefore 
findings from one ethnic group may not be applicable to another 
geographically close and apparently similar ethnic group. Canadian 
Native Indians are descendants of North Asian populations, and have 
been found to resemble Chinese in terms of PM frequency, but to lack 
the shift towards a lower mean enzyme activity (Fig. 1) /20/. This was 
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Fig. 1: Frequency distributions of dextromethorphan 0-demethylation ratios in 
Caucasian, Canadian Native Indian (central graph. n=I 15), and Chinese 
populations. Dextromethorphan is metabolised by CYP2D6, and the 0- 
demethylation ratio (ODMR) is a measure of Cý1`21)6 enzyme activity, 
where the higher the ratio, the lower the enzyme activity. (From: Nowak 
MP, Tyndale RF, Sellers EM. CYP2D6 phenotype and genotype in a 
Canadian Native Indian population. Pharmacogenetics 1997; 7: 147, with 
permission. ) 
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seen to be due to a lower frequency of the CYP2D6*. )' and CIT2D6*4 
mutant alleles relative to Caucasians, and a lower frequency of 
CYP2D6*10 compared with the Chinese. Similarly. a relatively low 
frequency of CYP2D6*10 has been found in the South-Amerindian 
population of Chile /21/. This genetic drift has been interpreted as 
possibly due to a founder effect, mitochondrial DNA -sequence vari- 
ations revealing that these two groups of Amerindians were derived 
from a small number of maternal lineages /22/, or due to genetic 
selection pressures by dietary or other environmental factors. Middle 
Eastern populations show a very low frequency of CYP2D6 PMs, 
resembling Orientals rather than Caucasians in phenon. ping studies 
(reviewed in /233ý. 
A further factor to be considered amongst individuals of lower 
CYP2D6 activity is that in Black African populations. individuals who 
appear to be PNIs when tested with one drug may not be PMs when 
tested with another drug, the two drugs both beinz metabolised z. 
similarly by CYP2D6 in Caucasians /5,24-26/. This has been sug- 
gested to be due either to the presence of an as yet unidentified 
CYP2D6 variant with differential substrate specificIty. or to inter- 
ethnic variations in conjugation and/or renal tubular transport. 
At the other end of the spectrum of en2: yme activity. the frequency 
of UMs also differs markedly between different ethnýc groups, being 
0.8-2% in Danes or Swedes /27,28/, 3.6% in Germans /29/, less than 
5% in Black Zimbabweans /7,3 )0/, 7% in Spaniards /3 1'. 20% in Saudi 
Arabians /32/, and 29% in Ethiopians /33/. 
1.2 Clinical relevance 
It has been suggested that PMs and Elvis might show a tendency 
towards higher serum levels of drugs metabolised by CYP2D6 for a 
given dose, and might therefore be more susceptible to adverse effects 
(Le. be treatment-intolerant), whereas UNIs might show particularly 
low serum levels at standard doses and might therefore appear to be 
treatment-refractory. In accordance with this, in studies on normal 
volunteers, PMs were shown to have significantly higher serum levels 
of perphenazine /34/ and zuclophenthixol /35/, while the oral clear- 
ance of perphenazine and zuclopenthixol in patients on continuous 
treatment was shown to be significantly predicted by CYP2D6 geno- 
type /36/. 
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CYP2D6 is also involved in the metabolism of haloperidol, flu- 
phenazine, and trifluperidol /37/. Case reports support in association 
between PM status and a higher susceptibility to adverse effects 
/38,39/. A trend towards an excess of mutant CI'P-'D6 alleles has been 
seen in schizophrenics with movement disorders '401. However, 
another study has not found an excess of PMs amongst schizophrenics 
intolerant of typical antipsychotics (Aitchison er al.. unpublished 
data). 
Haloperidol concentrations have been found to be elevated in 
Chinese patients suffering from schizophrenia '41 . Although this 
could also be due to interethnic variations in CYP-', A4 activity (see 
below), it would be consistent with the lower mean CYP2D6 activity 
seen in Chinese. Nyberg et al. /42/ showed that a PM of CYP2D6 had 
higher concentrations of plasma haloperidol throughout a 4-week 
treatment period with haloperidol decanoate compared with 7 EMs of 
CYP2D6. Suzuki et al. /433/ studied 50 Japanese schizophrenic 
patients, and found a higher mean steady-state plasma haloperidol 
concentration in patients with one mutant allele (mainly CYP2D6*10) 
as compared with patients with no mutant alleles, and a higher mean 
steady-state plasma reduced haloperidol concentration in patients with 
I or 2 mutant alleles as compared with patients with no mutant alleles. 
However, Lin et al. /44/ found that on a fixed dose weight-adjusted 
regime, Oriental patients had only a slightly increased mean 
haloperidol plasma level. Nonetheless, they had a significantly higher 
rating for extra pyramidal symptoms (EPS), and also higher 
concentrations of prolactin in response to haloperidol 1451. This could 
be due to a pharmacodynamic interethnic difference, e. g due to 
variability in the dopamine D2 receptor, or to interethnic differences in 
CYP3A4 (see below). 
With regard to UM status, two patients have been described for 
whom particularly high doses of tricyclic antidepressants metabolised 
by CYP2D6 were required in order to achieve a therapeutic response 
/46/. However, in a study comparing 73 patients who were treated 
with typical antipsychotics and found not to be treatment-refractory 
with 235 treatment-r&actory patients, an excess of UMs was not 
found in the refractory group /47/. On the contrary, a trend towards an 
excess of UMs was found in the non-refractory group, although the 
numbers of UNIs were very low in both groups (2 and 33 in the 
refractory and non-refractory groups, respectively). This argues against 
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ultrarapid hydroxylation by CYP2D6 of typical antipsychotics being a 
major cause of failure to respond to treatment with these agents. 
Risperidone and sertindole are metabolised by CYP2D6 to 9-OH- 
risperidone and dehydrosertindole respectively. Although 9-OH-ris- 
peridone has antipsychotic activity, and the combineel plasma concen- 
trations of risperidone and this metabolite would be expected to be 
similar for individuals with different ends of the spectrum of CYP2D6 
activity, it differs somewhat from risperidone in its in vitro receptor 
profiles and protein- and brain-binding characteristics 48/. The anti- 
psychotic activity of dehydrosertindole appears to be less than sertin- 
dole, with the mean serum levels of sertindole being up to 3-fold 
higher in PMs than in EMs. However, trials to date do not show a 
clear relationship between sertindole concentrations and therapeutic 
effect, and sertindole has a significant alternative pathway via 
CYP3A4. In vitro work reported a role for CYP2D6 in clozapine 
metabolism /49/; however, no association has been found between 
CYP2D6 genotype and clozapine response 1501. This is consistent 
with later work that has shown that the predominant enzymes in 
clozapine metabolism are CYPIA2 and CYP3A4 /5F. Nonetheless, 
the inhibitory effect of the selective serotonin reuptake inhibitors 
(SSRIs) paroxetine, fluoxetine, and sertraline on clozapine metabol- 
ism may be partly accounted for by CYP2D6-mediated interactions 
/52/. 
In summary, the clinical data regarding CYP2D6 metaboliser status 
and response are confusing. It is possible that in certain individuals, 
CYP2D6 plays a factor in either the generation of adverse effects or 
lack of therapeutic response, but that when studies are conducted on 
patient populations, other factors, such as the overlapping substrate 
specificities of CYP enzymes, or pharmacodynamic factors cloud the 
pictur& so that the results seen in case reports are not replicated in 
larger studies. 
2. CYP3A4 
2.1 Variability in CY"P3A4 activity 
CYP3A4 is present in the liver and small intestine, and plays a role 
in the metabolism of many typical antipsychotics, sertindole, and 
clozapine /48/. This enyzme can be induced, inhibited, or inactivated 
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by drugs as well as environmental factors including food substances. 
Interpopulation variation in activity may therefore arise not only 
secondary to intrinsic variation in enzyme activity. but also secondary 
to the effect of environmental agents. 
Nifedipine is a cardiovascular drug that is metabolised by CYP3A4 
and has been used as a probe drug to investigate CYP3A4 activity in 
different populations. It has been shown that South Asians (from the 
Indian subcontinent) oxidise nifedipine at a significantly slower rate 
than Caucasians (Fig. 2) /53,54/, resulting in sustained haemodynamic 
changes. In the first study by Ahsan and colleagues. the South Asians 
had retained their original dietary practices, whereas the Caucasians 
consumed a typical Western diet. The effect of diet was studied in six 
Caucasians by giving them an Indian diet for 3) days prior to the 
administration of nifedipine; no significant difference in any of the 4D 
pharmacokinetic parameters was detected. 
Similarly, the N-demethylation of codeine, which is catalysed by 
an enzyme of the CYP3A subfamily, occurs at a significantly slower 
rate in Chinese as compared to Caucasians 1551. Interestingly, Chinese 
have also been shown to have a significantly lower mean codeine N- 
demethylation activity as compared to Japanese 1561. 
Recently an A-4G point mutation has been found in the nifedipine 
specific element (NFSE) at position -289 in the 5' flanking region of 
the CYP3A4 gene /57/. This mutation has been further analvsed in 59 
Taiwanese, 59 Finnish, and 75 African-American subjects, and found 
to show an allelic frequency of 0%, 4.2%, and, 66.7% in these 
populations, respectively (Sata, personal communication). Functional 
studies have not yet been performed, but it could well be the case that 
this mutation is the primary mutation responsible for interethnic 
variations in CYP3A4 activity. 
2.2 Clinical considerations for CYP3A4 
Drugs and food substances may act on the CYP3A4 present in the 
small intestine as well as that present in the liver. Indeed, the effect of 
a given agent on the two CYP3A4s may differ. For example, con- 
sumption of some furanocourmarins present in grapefruit juice can 
cause inactivation of enterocyte CYP3A4 while having no detectable 
effect on liver CYP3A4 activity /58/. Conversely, some oral drug 
regimens have been shown to increase liver CYP3A4 activity while 
having no effect on small bowel CYP3A4. It appears that some drugs 
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Fig. 2: Plasma concentration-time curves for nifedipine after 20 mg capsules were 
administered to Caucasian subjects (open circles; n=27) and South Asians 
(solid circles; n=30). Data are mean values with standard errors shown as 
vertical bars. (From: Ahsan CH, Renwick AG, Waller DG, Challenor VF, 
George CF, Amanullah M. The influences of dose and ethnic origins on 
the pharmacokinetics of nifedipine. Clin Pharmacol Ther 1993; 54: 333, 
with permission. ) 
(including benzodiazepines) undergo substantial first pass metabolism 
by enterocyte CYP3A (CYP3A4 and sometimes CYP3A5). 
Recent work has shown that CYP3A4 is the responsible for the 
back oxidation of reduced-haloperidol to haloperidol and also for the 
N-dealkylation of haloperidol /59,60/. A negative correlation between 
clinical response and reduced-haloperidol levels or reduced-halo- 
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peridol/haloperidol ratios has been observed /61/. hence individuals 
with higher CYP3A4 activity could respond better to haloperidol than 
those with lower CYP3A4 activity. In a study on newly hospitalised 
Chinese patients with schizophrenia, Lane and colleagues found that 
those who experienced EPS had significantly higher reduced haloper- 
idol concentrations and reduced-haloperidol/haloperidol ratios than 
the other patients /62/. A trend towards higher haloperidol concen- 
trations was also found in the EPS group. This would be consistent 
with individuals with lower CYP3A4 activity being more vulnerable 
to EPS. 
CYP3A4 is readily induced by carbamazepine: for most typical 
antipsychotics twice as much antipsychotic is required to achieve the 
same plasma concentration in the presence of carbamazepine as in the 
absence of carbarnazepine /48/. This interaction is relevant for the 
treatment of schizoaffective psychoses. Other substances inhibit 
metabolism by the CYP3A enzymes (Table 1, modified from /63/). 
Clozapine toxicity has been reported after the coadministration of 
erythromycin /64/. Individuals who are CYP2D6 poor metabolisers or 
who are in receipt of drugs that inhibit CYP2D6 metabolism would be 
expected to be at increased risk of effects secondary to drug inter- 
actions at CYP3A4, and vice versa. 
TABLE I 
CYP3A inhibitors (modified from /63 )/) 
SSRIs (fluoxetine, fluvoxamine), SNRls (venlaflaxine, nefazodone) 
Steroids (oral contraceptives, prednisolone, tamoxifen, etc. ) 
Antibiotics (erythromycin, troleandomycin, clarithromycin, isoniazid) 
Antifun-als (ketoconazole, itraconazole) 0 
AntiHIV drugs (ritanovir, zidovudine) 
Analgesics (e. g. dextropropoxyphene) 
Anaesthetics (e. g. lidocaine) 
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3. CYPIA2 
3.1 Variation in CYPIA-1 activity 
CYPIA2 is involved in the metabolism of many typical anti- 
psNchotics, clozapine. and olanzapine. A preliminary study showed 
evidence of interethnic variation, with Japanese showinQ an increased 
maximum plasma concentration of olanzapine after a given dose. and 
a mean half-life of '34 hours as compared with 24 hours in Caucasians 
,,, 4S/. Le Marchand et aL /65/ also showed significantly lower CYPIA2 
activity in a group of 45 Japanese as compared with I; Caucasians 
living in Hawaii. Nakajima et aL /66/ showed that CYPIA2 activity as 
measured by caffeine _' 3-demethylation was bimodally distributed 
in a 
group of 205 Japanese. with 14.1% being poor metabolisers. Other 
groups have also shov. -n a multimodal distribution of CYP I A2 activity 
in most /67-70/, but not all /67,69/ populations. Relling et aL /71/ 
showed that C YP I A2 activity was significantly lower in a group of 63 
Black subjects as compared with a group of 246 White subjects (p 
0.036). 
This enzyme is also involved in the metabolism of aromatic and 
heterocyclic amines, and in most populations is found to be induced 
by smoking /66-70,77'. The effect of smoking appears to be absent in 
Chinese /68/, which has been proposed to be secondary to the lower 
level of smoking in this ethnic group. Oral contraceptives. postmeno- 
pausal replacement oestrogens, and pregnancy appear to reduce 
CYP I A2 activity /65,73,74/. The lower CYP I A2 activity in women as 
compared to men appears to be explained by the effect of oestrogens 
1651. Le Marchand and colleagues /65/ also found that lutein (which is 
found in green leafy vegetables) inhibits CYPIA2 activity. Caffeine 
and paracetamol (acetaminophen) intake increases CYPIA2 activity, 
as does the. consumption of cruciferous vegetables (cabbage, broccoli, 
Brussels sprouts and ývatercress). However, the amount of cruciferous 
vegetable (e. g. 500 g broccoli daily for 10 days) required to increase 
CYP I A2 activity is considerably higher than that commonly present in 
a norinal diet. Intake of meat cooked rapidly at a high temperature has 
also been shown to increase CYP I A2 activity /75/. 
Although environmental factors such as the above are important in 
contributing towards variability in CYP I A2 activity, Le Marchand and 
colleagues 165/ found that 73% of the variability remained unexplain- 
ed after taking into account the major environmental contributors to 
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the variance in 90 subjects of various ethnic backgrounds in Hawaii. A 
significant contributor to the variance may be genetic in origin, as 
suggested by work with inbred mice /76/. A mutation in the promotor 
region of CYPIA2 has recently been found (Aitchison et aL, unpub- 
lished data). This mutation shows significant interethnic variation: the 
frequencies of individuals heterozygous and homozygous for the 
mutation was found to be 2.3% and 1.1% resrectivelv in 176 
Caucasians and 24.4% and 4.1% respectively in 123 
ýaiwanese. 
3.2 Clinical relevance of variations in CYPIA2 activir. % 
The metabolism of clozapine in vivo appears w correlate with 
CYPIA2 activity, although CYP3A4, CYP2CI9, and CYP2D6 are 
also involved /77,78/. Levels of clozapine of at least 350 to 420 ng/ml 
are associated with therapeutic response /79/, while the incidence of 
seizures and EEG abnormalities also appears to increase with dose. 
Elevated plasma clozapine concentrations in Chinese patients have 
been described (mean steady-state plasma clozapine concentration 60- 
100% higher than that found in Caucasians, /800. At the opposite end 
of the spectrum, very low plasma clozapine levels despite high doses 
and compliance have been described, in association with very high 
CYPIA2 activitv /81/. It is therefore possible that, analogous to the 
situation with CYP2D6, there exist individuals with ultrarapid 
CYP I A2 metaboliser status. 
The most important pathways for olanzapine metabolism are 
CYPIA2, flavin-containing monoxygenase 3, and N-glucuronidation, 
with minor pathways including CYP2D6 and CYPZý19 /48/. Olan- 
zapine clearance is increased in males (by about 30%) and in smokers, 
and decreased in the elderly, all of which are consistent with the 
involvement of CYP I A2. Evidence for the contribution of CYP I A2 to 
the pharmacokinetics of typical antipsychotics includes the effect of 
smoking: smoking increases the clearance of fluphenazine and halo- 
peridol by 100% and at least 50% respectively in an affected 
population. 
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4. CYl". C ENZYMES 
4.1 CYPIC ctnctics 
Four members of the human CYP2C subfamil%- have been 
identified: CYP2C8. CYPZC9, CYP2CI8, and CYP2611) /821. their 
genes form a cluster at chromosome I0q24. Of these. the role of 
C%'P2CI9 in the metabolism of psychotropic drugs has been most 
extensi%cly studied. Relevant substances include amirriptyline. imi- 
rraminc. clomipramine. moclobemide, citalopram, diazeparn ar. 1 des- 
mcthyidiazcpam /831, as well as clozapine, olanzapine. propranolol, 
and phen)ioin to lesser extents. Four SSRIs (fluoexetire. sertraline, 
raroxctine, and citalopram) are all able to inhibit CYPX19 and may 
also be metabolised by this enzyme. CYNCIS lies distal to CYPX19 
on chromosome 10, is 85.7% homologous to CYP2C19. and shows 
similar substrate specificity towards diazeparn /841, phenytoin /S.;. 36/` 
and omeprazole /87/. Furthermore. Nlamiya ef aL /SS/ found cosegreg- 
ation of poor metaboliser mutations of CYP2C19 and CYP-'CI8, 
indicating that CYP2CI8 may not be able to take over from CYP_C19 
in individuals deficient in CYP2C19. CYP2C9 was shown by 
I lashimoto and colleagues /89/ to play a greater role than CYP. X19 in 
the metabolism of phcn)-toin, and the Leu 339 allele, which is present in 
the hetcrozygous state in 3.40,1* of Ilan Chinese subjects 90/, was seen 
to be associated with a 40% reduction in the V.. for phenvtoin. 
The incidence of poor metaboliscrs (PNls) of CYP2CI9 in different 
populations has been reviewed /23,91-93/. There is substantial inter- 
ethnic variation: the frequency of P. 1vIs is 2-5% in Caucasians, :% in 
Saudi Arabians. 4116 in Black Zimbabwcans, 51,11a in Ethiopians, 13% in 
Koreans. 15-17% in Chinese, 21% in Indians, and 18-23% in Japan- 
csc. Indeed, %%hen the square root of the PM frequency (representing 
the total frequency of mutant CYP2C19 alleles) was plotted versus 
longitude. an increase in this value versus longitude was seen, with a 
step in the value occurring somewhere between Saudi Arabia and 
Bombay (Fig. 3). 
There are two mild-type C`YP2C19 allelcs (CYP2C]9*]A and 
CYNC1901D), and seven defective alleles which are responsible for 
the PNI phenotype /93/. The most common defective allele is CYP2 
C19014 (a G6&1A substitution in exon 5, which creates an aberrant 
splice site. previous name for this alle1c, ml). A variant of this allele. 
CYPX1902B, contains a G276C substition in exon 2 which creates a 
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Fig. 3: Estimates of q. the total frequency of mutant CYP2CN alleles, with 95% 
confidence limits in relation to longitude. (From: Price Evans DAP, Krahn 
P. Narayanan N. The mcphcn)ioin (c)iochrome P450 X19) and dextro- 
methorphan (c)tchrome P450 2136) polymorphisms in Saudi Arabians and 
Filipinos. Pharmacogenctics 1995.5: 70. with permission. ) 
GIU92Asp change; this allele comprises 15% of the CYP209*2 allele 
in Caucasians, but was not observed in 53 Japanese CYP2C19*2 
alleles studied. The two CYP2CI9*2 alleles account for 86% of PM 
alleles in Caucasians and 69-87% in Orientals. The second major 
defectivc allele is CYP2CI9*3 (a G636A mutation in exon 4, which 
creates a premature stop codon, Frevious name for this allele, m2); this 
comprises 13-3 1110 of PNI alleles in Oriental populations and 1.5% in 
Caucasians. A third PNI allele, C)P2C]9*4 (an A-+G mutation in the 
initiation codon). accounts for 3% of Caucasian PM alleles. CYP2 
C19*5 (a C1297T mutation in exon 9 which results in an Arg433Trp 
change in the haern binding region) accounts for 1.5% of Caucasian 
PNI alleles and is rare in Orientals. CYP209*6 (a G395A base sub- 
stitution resulting in an ArgI32GIn coding change in exon 3) and 
CYP20907 (a GT-+GA mutation in the donor splice site of intron 5) 
each account for a further 1.5% of Caucasian P. M alleles. CYP2C19*8 
(a T35&C substitution resulting in a Trp12GArg change in exon 3) is a 
newly characterised, rare defective allele. The products of CYP2- 
C19*6 and CYP209*3 show reduced catalytic activity (2% and 9% 
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of wild-typc S-mcphcn)ioin hydroxylase activity, respectively); the 
other mutants are associated %%ith failure to express active CYP2C19. 
CYP2C19*2A and CYP2C19*J have both been identified in an 
Ethiopian population, and found to account for all the PNI alleles in 
the 114 individuals studied /92/. 
4.2 Clinical studies of CYP2Cl9 
Omeprazole has been used as a probe drug in studies of CYP2C 19 
activity. In singic-dose studies the clearance of omeprazole has been 
found to be higher in CYP2CI9 EMs than MvIs in Caucasians, 
Chinese, and Koreans, with the clearance in Caucasian ENIs being 
significantly higher than that in both Chinese and Korean ExIs . -'91/. 
Aner multiple doses of omeprazole, the mean areas under the plasma 
conccntration-time curve for the parent drug indicated that hetero- 
zýgous individuals had a reduced rate of metabolism as compared to 
homozygous E, %ls- It has therefore been h)pothesised that the differ- 
ence in clearance bct%%ccn Caucasians and Orientals is due to the 
relatively high proportion of heterozygous EMs among Orientals as 
compared with Caucasians. 
In the case of diazepam, the clearance is significantly lower in 
Caucasian and Korean CYP2CI9 PMs than ENIs /91/. However, in 
Chinese. no significant difference between the elimination half-life of 
eight EMs and eight PNIs was found, and the mean clearance in the 
%%; olc group was relatively low as compared to Caucasians. It has 
been suggested that among the eight Chinese ENls, seven with a 
relatively low diazeparn clearance might be hetcrozygous, which 
\%ould explain the low overall clearance and the lack of significant 
difference between the EM and PM groups. Alternatively, differences 
in the contribution of CYP3A4 to diazepam pharmacokinetics in the 
different ethnic groups could explain the different findings. Like 
CYP2D6, CYP2CI9 often functions as a high-affinity, low capacity 
enzyme. which is more important at low drug doses. With higher 
doses, muldpic-dosing, or in the case of CYP2CI9 deficiency, 
CYP3A4, which has a relatively high capacity and often shows 
relatively low substrate affinity, increases in its contribution to overall 
drug clearance. Schmider et al /94/ have calculated that even %ith 
single doses, approximately 60% of diazepam clearance is CYP3A4- 
dependent. The relatively high incidence of low CYP3A4 activity in 
Chinese may therefore contribute to the low mean diazepam clearance, 
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and. if polymorphisms in CYP3A4 and CYP2CI9 do not cosegregate, 
could contribute towards the lack of a significant difference between 
diazcparn clearance in S-mcphenytoin PNIs and EXIs. It has been 
noted that "many Hong Kong physicians routinely prescriýe smaller 
diazcparn doses for Chinese than for white Caucasians- 95/; this 
tradition is consistent with the lower clearance fourd experimentally. 
5. DRUG-DRUG INTERACTIONS 
When prescribing psychotropic drugs that are sub * 
ject to interethnic 
variations in metabolism. it is important to rememýcr that interactions 
%%ith non-psychotropic drugs at these sites may occur. A summary of 
substrates metabolised by the enzymes discussed above is listed in 
Table 2. Many cnzý-mes show overlapping substrate- specificity, and 
only the major routes of metabolism are sho%vri. It should also be 
remembered that substances may exert considerable inhibitory effect 
at a given route. %%ithout being metabolised by that enzý'Me (e. g. 
quinidinc in the case of CYP2D6). An individual %%ho is a NIVI of a 
particular CYP enzyme %vill tend to be more susceptible to drug-drug 
interactions at the other c)iochromes. 
6. CONCLUSIONS 
There is considerable interethnic variability in the activity of the 
DMEs. Although some studies aiming to show correlations between 
the activity of a single DME and clinical effects have yielded con- 
flicting results, this may be because of the existence of alternative 
metabolic pathways using other DMEs. For example, in the case of 
CYP2D6 or CYP_4C 19 deficiency, CYP3A4 will often be able to play 
a substitutive role. Individuals who have a relativelv low C1T2D6 or 
CYP2CI9 activity will therefore be more susceptibie to the effects of 
CYP3A4 inhibitors. Furthermore, it would be loeical to h. -Pothesise 
that while the clinical effects of single enzyme deficiency might not be 
consistent, the effects of dericiency of mor6 than one enz)-me might 
well be significant. This hypothesis is supported by the analagous 
finding of Rojas and colleagues /97/ that smokers with combined 
CYPIAI and Slutathione S-transferase Nil (GSTIMI) dericiency 
showed significantly higher levels of activated DNA-bound potentially 
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carcinogenic metabolites than individuals with CYPIAI or GSTMI 
deficiency alone. We have noted that there is a lo%%c. - population mean 
CYP2D6 activity, lower CYPIA2 activity, and higýer incidence of 
CYP2C19 poor metabolisers in Japanese as compar. -J to Caucasians. 
Similarly. a lower population mean CYPZD6 actvity and a much 
higher incidence of a mutation in the promotor of CYP3A4 has been 
found in Black subjects, while impaired CYP3A4 acývity and a high 
frequency of CYPZC19 poor metabolisers has been found in indiv- 
iduals from the Indian subcontinent. We would ther. -: 10re suggest that 
future studies focussing on the relevance of ethr: c influences in 
pharm: icogcnctics to the treatment of psychosis s. -Cluld encompass 
methodology that is capable of analysing tlýe variation in activity of all 
the DNIEs (including the role of dietary and otýer environmental 
factors such as smoking) relevant to the population being studied. 
There is a paucity of studies addressing ethnic varia-zon in pharmaco- 
dynamic factors; this issue should also be addressed in future work. 
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